Nothing Special   »   [go: up one dir, main page]

WO2015057659A1 - Selectively substituted quinoline compounds - Google Patents

Selectively substituted quinoline compounds Download PDF

Info

Publication number
WO2015057659A1
WO2015057659A1 PCT/US2014/060418 US2014060418W WO2015057659A1 WO 2015057659 A1 WO2015057659 A1 WO 2015057659A1 US 2014060418 W US2014060418 W US 2014060418W WO 2015057659 A1 WO2015057659 A1 WO 2015057659A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
carbonitrile
quinoline
mmol
cyanoquinolin
Prior art date
Application number
PCT/US2014/060418
Other languages
French (fr)
Inventor
Lynn Hawkins
Eric Carlson
Hans Hansen
Matthew MACKEY
Shawn Schiller
Chikako OGAWA
Heather Davis
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI201431479T priority Critical patent/SI3057964T1/en
Priority to EP19194302.6A priority patent/EP3626717A1/en
Priority to DK14790937.8T priority patent/DK3057964T3/en
Priority to MA39034A priority patent/MA39034B1/en
Priority to KR1020187002263A priority patent/KR102103256B1/en
Priority to EP14790937.8A priority patent/EP3057964B1/en
Priority to PL14790937T priority patent/PL3057964T3/en
Priority to NZ720129A priority patent/NZ720129B2/en
Priority to EP21193428.6A priority patent/EP3995495A1/en
Priority to CA2927510A priority patent/CA2927510C/en
Priority to KR1020167012593A priority patent/KR101823488B1/en
Priority to LTEP14790937.8T priority patent/LT3057964T/en
Priority to MDA20160052A priority patent/MD4635C1/en
Priority to MYPI2016000624A priority patent/MY192489A/en
Priority to CN201480066535.7A priority patent/CN106414432B/en
Priority to RU2016118619A priority patent/RU2679622C2/en
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Priority to CN201910424442.1A priority patent/CN110105346B/en
Priority to MX2016004632A priority patent/MX364657B/en
Priority to UAA201605195A priority patent/UA120039C2/en
Priority to ES14790937T priority patent/ES2773303T3/en
Priority to BR112016008359-8A priority patent/BR112016008359B1/en
Priority to SG11201602818TA priority patent/SG11201602818TA/en
Priority to RS20200164A priority patent/RS59911B1/en
Priority to JP2016523329A priority patent/JP6223563B2/en
Priority to AU2014334554A priority patent/AU2014334554B2/en
Publication of WO2015057659A1 publication Critical patent/WO2015057659A1/en
Priority to ZA2016/01882A priority patent/ZA201601882B/en
Priority to PH12016500642A priority patent/PH12016500642A1/en
Priority to IL245131A priority patent/IL245131B/en
Priority to HK16111184.5A priority patent/HK1223092A1/en
Priority to IL26297018A priority patent/IL262970B/en
Priority to AU2018264036A priority patent/AU2018264036B2/en
Priority to HRP20200147TT priority patent/HRP20200147T1/en
Priority to CY20201100129T priority patent/CY1122776T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • Embodiments of the disclosure relate to selectively substituted quinoline compounds and pharmaceutical agents comprising one or more of those compounds as active ingredient(s). More particularly, embodiments of the disclosure relate to those compounds that act as an antagonist or inhibitor for Toll-like receptors (TLR) 7 and 8, and their use in a pharmaceutical composition effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
  • TLR Toll-like receptors
  • SLE Systemic lupus erythematosus
  • lupus nephritis are autoimmune diseases characterized by inflammation and tissue damage.
  • SLE may cause damage to the skin, liver, kidneys, joints, lungs, and central nervous system.
  • SLE sufferers may experience general symptoms such as extreme fatigue, painful and swollen joints, unexplained fever, skin rash, and kidney dysfunction. Because organ involvement differs amongst patients, symptoms may vary.
  • SLE is predominantly a disease of younger women, with peak onset between 15-40 years of age and an approximate 10-fold higher prevalence in women vs. men.
  • Embodiments of the disclosure provide compounds and methods of use for preventing or treating diseases or conditions characterized by Toll-like receptor 7 or 8 activation in patients.
  • One embodiment features a compound of formula (I):
  • Ri and R 2 is -H, methyl, or ethyl, and the other is
  • Ci-C 6 alkyl that is optionally substituted with:
  • Ri and R 2 together with the nitrogen atom to which they are attached, form an 8 to 11 member spirodiamine, an 8 member bicyclodiamine, a 7 member spiroxamine, a piperidinyl optionally substituted with ethyl, or a four to six member cycloalkyl, optionally substituted with at least one of carboxamidyl, aminomethyl, methyl, (ethylamino)methyl, (dimethylamino)methyl, dimethylamino, (methylamino)methyl, and amino; and wherein R 3 is -H or methyl.
  • the compound is a compound of Formula (I), having the stereochemistry set forth in one of Formula (la), (lb), (Ic), or (Id), having the same substituent options as set forth above for Formula (la): [0009]
  • a further embodiment provides a compound of Formula (Ie) (relative stereochemistry indicated):
  • the compound is a compound of Formula (II):
  • R is -H or methyl
  • R 5 is Ci-Cs alkyl that is saturated, partially saturated, or unsaturated, and that is optionally substituted with:
  • Ci-C 6 alkyl methylphenyl, methylcyclohexyl, pyridinyl, diazinyl, or phenyl optionally substituted with -F or methyl,
  • C 2 -C alkyl that is linear, branched, or cyclic, saturated or unsaturated, and optionally substituted with oxo-, phenyl, methyl, or -OH,
  • pyridinyl optionally substituted with methyl, methoxy, phenyl, or amino, diazinyl optionally substituted with ethyl, benzoimidazolyl, methylphenyl, phenylpyrazolyl, naphthyridyl, phenyl optionally substituted with -F, methyl, ethyl, or ethoxy, imidazolidin l optionally substituted with methyl
  • R 5 is , wherein n is 1-3, and wherein the cyclic amine is optionally substituted with
  • Ci-C 3 alkyl optionally substituted with
  • Ci-Cs alkyl phenyl, pyridinyl, fluorophenyl, methylsulfonyl, fluorobenzenesulfonyl, dimethyl pyrazole sulfonyl, or
  • piperidinyl optionally substituted with -C(0)CH 3 , -C(0)CH 2 CH 3 , methyl, oxo-,
  • n 1 or 2
  • the cyclic diamine is optionally substituted on at least one carbon atom with
  • piperidinyl optionally substituted with methyl, -C(0)CH 3 , -C(0)CH(CH 3 ) 2 , -C(0)Ph, or -C(0)OC(CH 3 ) 3 , and
  • a further embodiment provides a compound of Formula (III):
  • Rn is H or methyl
  • Rio is H or, when both R 14 and R are H, is methyl- 1, 4 '-bipiperidinyl;
  • R9 is -H or is -CH 2 - substituted by 1,4 '-bipiperidinyl, oxo-, hydroxyl, methylpyridinyl, or piperidinyl optionally substituted with hydroxyl, -N(CH 3 ) 2 , or piperidinyl.
  • the compound is selected from ⁇ - ⁇ 2R, ⁇ i?)-4-(8- cyanoquinolin-5-yl)-N-((5i? ⁇ 5)-4-fluoiOpyrrolidin-3-yl)-6-methylmorpholine-2-carboxamide hydrochloride, (2R, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l -methylpiperidin-4- yl)morpholine-2-carboxamide, 5-((25', (5i?)-2-([l,4'-bipiperidin]- -ylmethyl)-6- methylmoipholino)quinoline-8-carbonitrile, and 5-((2R, 7i?)-2-(hydroxymethyl)-7-methyl- l,4-oxazepan-4-yl)quinoline-8-carbonitrile.
  • the compound or pharmaceutically effective salt thereof of the preceding paragraph has an IC50 less than or equal to 20 nM against human TLR7 receptors expressed in a HEK-293 cell line. In a further embodiment the compound or pharmaceutically effective salt thereof of the preceding paragraph of this disclosure has an IC50 less than or equal to 100 nM against human TLR7 receptors expressed in a HEK-293 cell line.
  • the IC50 against human TLR7 receptors expressed in a HEK-293 cell line is measured by (1) plating cells of the HEK-293 cell line stably expressing TLR7 in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum at a density of 2.22X105 cells/ml into a 384-well plate and incubating for 2 days at 37 °C, 5 % CO2; (2) adding the compound or pharmaceutically acceptable salt thereof and incubating the cells for 30 minutes; (3) adding CL097 (InvivoGen) at 3ug/ml and incubating the cells for approximately 20 hours; and (4) quantifying NF-kappaB dependent reporter activation by measuring luminescence.
  • CL097 InvivoGen
  • compounds have an IC50 against human TLR7 receptors expressed in a HEK-293 cell line less than or equal to 200 nM, less than or equal to 180 nM, less than or equal to 160 nM, less than or equal to 140 nM, less than or equal to 120 nM, less than or equal to 100 nM, less than or equal to 80 nM, less than or equal to 60 nM, less than or equal to 40 nM, or less than or equal to 20 nM.
  • compounds have an IC50 against human TLR7 receptors expressed in a HEK-293 cell line from 10 nM to 30 nM, from 10 nM to 50 nM, from 10 nM to 100 nM, from 30 nM to 50 nM, from 30 nM to 100 nM, or from 50 nM to 100 nM.
  • the IC50 against human TLR7 receptors expressed in a HEK-293 cell line is measured by (1) plating cells of the HEK-293 cell line stably expressing TLR7 in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum at a density of 2.22X105 cells/ml into a 384-well plate and incubating for 2 days at 37 °C, 5 % C0 2 ; (2) adding the compound or pharmaceutically acceptable salt thereof and incubating the cells for 30 minutes; (3) adding CL097 (InvivoGen) at 3ug/ml and incubating the cells for approximately 20 hours; and (4) quantifying NF-kappaB dependent reporter activation by measuring luminescence.
  • CL097 InvivoGen
  • Further embodiments provide methods for treatment of lupus, including but not limited to treatment of systemic lupus erythematosus, cutaneous lupus, neuropsychiatric lupus, fetal heart block, and antiphospholipid syndrome, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
  • Further embodiments provide methods for antagonizing TLR7, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
  • Further embodiments provide methods for antagonizing TLR8, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
  • compositions comprising at least one compound or pharmaceutically acceptable salt of the disclosure and at least one pharmaceutically acceptable carrier.
  • Further embodiments provide methods for treatment of systemic lupus erythematosus or lupus, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure. [0020] Further embodiments provide methods for antagonizing TLR7, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
  • Further embodiments provide methods for antagonizing TLR8, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
  • compositions comprising at least one compound or pharmaceutically acceptable salt of the disclosure and at least one pharmaceutically acceptable carrier.
  • the term "optionally substituted,” as used herein, means that the subject structure may include, but is not required to include, one or more substituents independently selected from lower alkyl, methoxy-, -OH, -N3 ⁇ 4, -CH 2 -NH-CH 2 , -OCH 2 CH 2 C3 ⁇ 4, or - OCH(CH 3 ) 2 . If the optionally substituted moiety is cyclic, then the optional substitution may be a methyl bridge between two atoms in the ring.
  • lower alkyl refers to straight, or, in the case of three- and four-carbon groups, straight, branched, or cyclic saturated hydrocarbons having between one and four carbon atoms.
  • the term "attached through a nitrogen" when referring to a heterocyclic moiety including nitrogen, means that a point of attachment of the moiety to another structure is through a nitrogen that is part of the heterocycle.
  • TLR7/8 means "TLR7 and TLR8" or "TLR7 or
  • TLR8 or "TLR7 and/or TLR8.”
  • TLR7/8 the particular meaning can be understood by a person skilled in the art based upon the context in which "TLR7/8" appears.
  • Heterocyclic moieties recited herein include azetidinyl, pyrrolidinyl, piperidinyl, methylazetidinyl, pyrazolyl, piperazinyl, morpholinyl, thiazolyl, pyrrolopyrrolyl, imidazolidinyl, and isothiazolyl.
  • a heterocyclic group is mentioned, unless otherwise indicated it will be understood that the heterocyclic atom(s) in the group may be at any position in the group. It will further be understood that imidazolyl, pyrazolyl, thiazolyl, and pyrrolyl may be unsaturated or partially unsaturated.
  • An embodiment of the disclosure may include a pharmaceutical composition that includes one or more compounds of the disclosure with a pharmaceutically acceptable excipient.
  • These pharmaceutical compositions may be used to treat or prevent a disease or condition characterized by TLR7/8 activation in a patient, typically a human patient, who has or is predisposed to have such a condition or disease.
  • diseases or conditions characterized by TLR7/8 activation include systemic lupus erythematosus (SLE) and lupus nephritis.
  • effective amount of a compound of an embodiment of the disclosure is effective amount of the above-identified compounds in an amount sufficient to treat or prevent SLE and lupus nephritis.
  • Embodiments presented herein may include asymmetric or chiral centers.
  • Embodiments include the various stereoisomers and mixtures thereof.
  • Individual stereoisomers of compounds of embodiments of the disclosure may be prepared synthetically from commercially available starting materials that contain asymmetric or chiral centers, or by preparation of mixtures of enantiomeric compounds followed by resolution of those compounds. Suitable methods of resolution include attachment of a racemic mixture of enantiomers, designated (+/-), to a chiral auxiliary, separation of the resulting diastereomer by chromatography or recrystallization and separation of the optically pure product from the auxiliary; or direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
  • Embodiments of the disclosure also include a pharmaceutical composition including any compound of the disclosure as well as a pharmaceutically acceptable excipient.
  • the pharmaceutical compositions can be used to treat or prevent SLE and lupus nephritis. Therefore, embodiments of the disclosure may also feature a method for treating or preventing SLE or lupus nephritis in a human patient having or predisposed to having lupus nephritis or SLE.
  • Embodiments of the disclosure include pharmaceutically acceptable salts of the compounds presented herein.
  • pharmaceutically acceptable salt refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic response.
  • Pharmaceutically acceptable salts are well laiown in the art. For example, S. M. Berge, et al, describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences 66: 1-19, 1977. Salts can be prepared in situ during final isolation and purification of a compound or separately by reacting a free base group with a suitable organic acid.
  • Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, monomaleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pam
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
  • esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic, and alkanedioic acids, in which each alkyl or alkenyl group typically has not more than 6 carbon atoms.
  • esters include formates, acetates, propionates, butyates, acrylates, and ethylsuccinates.
  • enantiomers are designated by the symbols "R " or "5"' or are drawn by conventional means with a bolded line defining a substituent above the plane of the page in three-dimensional space and a hashed or dashed line defining a substituent beneath the plane of the printed page in three-dimensional space. If no stereochemical designation is made, then the structure definition includes both stereochemical options. If a structure or chemical name includes “REL” or “rel” then that structure is understood to show relative stereochemistry.
  • FIG. 1A and FIG. IB show short-term in vivo suppression of the TLR7 pathway in mouse by compounds ER-899742 and ER-899464.
  • FIG. 1A ER-899742 and ER-899464 were tested side by side in a single experiment.
  • FIG. IB A repeat experiment was done with ER-899742 examining all three doses at all three timepoints.
  • FIG. 2A through FIG. 2C show results of testing ER-899742 in the
  • NZBxNZW strain (abbreviated hereafter as NZBWF1/J or NZB/W) lupus disease model.
  • NZBWF1/J mice Female NZBWF1/J mice were received at 5 weeks of age, baseline bleeds were performed, and mice were monitored for disease progression by following anti-dsDNA titers. At 27 weeks of age, mice were randomized into groups with equivalent median anti- dsDNA titers and treated at 29 weeks of age with Vehicle (Veh; 0.5% methyl-cellulose) alone or 33, 100, or 300mg/kg once-a-day orally (QD PO). At 46 weeks of age after 17 weeks of treatment mice were bled and tested for anti-dsDNA titers.
  • Vehicle Vehicle
  • FIG. 2 A Just prior to termination at 50 weeks of age (following 21 weeks of treatment), urine was collected from individual mice, and the Urinary Albumin Creatinine Ratio (UACR, proteinuria) was determined for each animal as an indirect measure of kidney function.
  • FIG. 2B Timecourse of mortality observed in this study for the highest and lowest dose groups. No mortality was seen with compound treatment. Further, no mortality was observed in the middle dose group (not shown).
  • FIG. 2C Impact of treatment on anti-dsDNA titers after 17 weeks of dosing, at 46 weeks of age. No statistically significant effect was observed.
  • FIG. 3 A through FIG. 3E show results of testing compound ER-899742 in the
  • Pristane DBA/1 strain lupus disease model.
  • Female DBA/1 mice at 9 weeks of age were given an intraperitoneal injection of 0.5ml pristane or PBS. At 9 weeks post- pristane animals were bled for auto-antibody titers.
  • Vehicle Vehicle (Veh; 0.5% methyl-cellulose) or 33 mg/kg, 100 mg/kg, or 300 mg/kg of ER-899742 was begun 10 weeks after pristane injection and continued for 13 weeks of treatment. Mice were euthanized after 13 weeks of compound treatment, and anti-dsDNA (FIG. 3 A), anti- Sm/nRNP (FIG. 3B), anti-histone (FIG.
  • FIG. 3C 3C
  • FIG. 3D anti-RiboP titers were measured in blood plasma samples by ELISA (statistical significance of treatment versus vehicle determined by ANOVA with Dunnett's post-test).
  • FIG. 3E The expression of IFN- regulated genes in whole blood was measured by a qPCR panel after 13 weeks of treatment with 300 mg/kg of ER-899742, and an IFN gene signature score was calculated (see Pharmacology Materials and Methods section for details regarding IFN score calculation).
  • the table shows the full list of genes significantly upregulated by pristane treatment vs. PBS controls. When interferon scores were calculated, no significant difference was seen between treated and vehicle-treated animals. However six genes were significantly reduced by compound treatment vs. vehicle treatment (Student's t-test) and are marked in the table.
  • FIG. 4A through FIG. 4C show results of testing E -899464 in the NZB/W disease model in the same experiment as FIG. 2 A.
  • FIG. 4B Summary of mortality observed in this study for the highest and lowest dose groups. No mortality was seen in the middle dose group (not shown).
  • FIG. 5C Impact of treatment on anti-dsDNA titers after 17 weeks of dosing, at 46 weeks of age. No statistically significant effect was observed.
  • FIG. 5A through FIG. 5D show results of testing ER-899464 in the Pristane disease model in the same experiment as that shown in FIG. 3A through FIG. 3E.
  • FIG. 6 shows structures and corresponding chemical names according to various embodiments presented herein.
  • "ER-Number” is a reference number assigned to each compound. Where available, activity against a HEK cell line stably expressing human TLR7, activity against a HEK cell line stably expressing human TLR9, 1H NMR data, and mass spectrometry data are also included.
  • FIG. 7A through FIG. 7G show the effect of dosing with ER-899742 in
  • Pristane-induced disease in DBA/1J mice Female DBA/1 mice at 9 weeks of age were given an intraperitoneal injection of 0.5ml pristane or PBS. At 10 weeks post- pristane animals were bled for auto-antibody titers. Once-a-day oral dosing with Vehicle (Veh; 0.5% methyl-cellulose) or 33 mg/kg, or 300 mg/kg of ER-899742 was begun 11 weeks after pristane injection and continued for 14 weeks of treatment. Mice were euthanized after 14 weeks of compound treatment, and anti-dsDNA (FIG. 7A), anti-RiboP (FIG. 7B), anti- Sm/nRNP (FIG.
  • FIG. 7F Scores were summed for the two hind paws assessed on each animal, and graphed in FIG. 7F with statistical assessment as for ELISA titers above. Dose-dependent statistically significant suppression was observed. When interferon scores were calculated, no significant difference was seen between treated and vehicle-treated animals. However FIG. 7G demonstrates the downregulation of five out of 28 disease-related interferon-modulated genes upon treatment with ER-899742.
  • FIG. 8 contains the result of treating for a month with ER-899742 in Pristane- induced disease in DBA/1 J mice with advanced disease, after development of high levels of autoantibody.
  • DBA/1 J mice were injected i.p. with pristane at 10 weeks of age. Three months later anti-RiboP and anti-dsDNA titers were taken, and animals randomized into groups with matching mean titers. Groups were sacrificed after one, two or four weeks of oral dosing with ER-899742, and RiboP titers measured in serum.
  • FIG. 8 demonstrates no statistically significant reversal of anti-RiboP or DNA titers after 28 days of dosing, although dosing was associated with lack of increase in titers.
  • FIG.. 9 is an ORTEP plot of the crystal structure of ER-899742 as a HC1 salt.
  • TLR7 can be activated by single-stranded RNA (ssRNA) derived from both mammalian and viral sources
  • TLR9 can be activated by DNA derived from mammalian, viral, and bacterial sources.
  • Lupus is characterized by auto-antibodies reactive against double-stranded
  • dsDNA DNA
  • associated proteins histones
  • RNA-associated proteins such as Ro, La, Smith (Sm), and Ul snR P. Kirou, K.A., et al.
  • Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
  • IFNs type-1 interferons
  • PBMC PBMC
  • type-1 IFN gene signature a major source of IFN in the blood is a specialized immunocyte called a plasmacytoid dendritic cell (pDC), which constitutively expresses both TLR7 and TLR9.
  • pDC plasmacytoid dendritic cell
  • TLR7 X-linked Toll-like receptor 7
  • MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLOS Genetics, 2013. el003336.
  • lupus standard-of-care (SOC) anti-malarial drugs such as chloroquine disrupt endosomal TLR7/9 signaling and inhibit PBMC and/or pDC IFNalpha production induced by ssRNA- ribonucleoprotein complexes or lupus patient serum.
  • TLR7 As a critical determinant of autoimmunity, transgenic overexpression of TLR7 alone leads to spontaneous anti-RNA auto-reactivity and nephritis in the normally disease-resistant C57BL/6 strain. Deane, supra.
  • mice 7/8- and 7/9-dual gene deficient mice are immune-compromised to the extent that infection by opportunistic pathogens is observed.
  • SOC anti-malarials are thought to be largely safe and effective for long-term use in humans to control lupus disease flare at doses predicted to at least partially inhibit TLR7/9 signaling.
  • TLR7 in particular is a well-validated target in the context of mouse pre-clinical SLE models.
  • Both genetic and functional human studies support the hypothesis that antagonism of the TLR7 and/or TLR8 pathways will afford therapeutic benefit to lupus patients.
  • both mouse TLR gene deletion studies and the long-term use of anti-malarials in humans suggest that pharmacological TLR7, 8 and/or 9 suppression can be undertaken without significantly compromising host defense.
  • a compound that suppresses TLR7, TLR8, or both TLR7 and TLR8 may therefore be expected to act as a therapeutic or prophylactic agent for SLE or lupus nephritis.
  • the present inventors have found compounds that suppress TLR 7 and/or 8 and are therefore expected to have a prophylactic or therapeutic effect on SLE or lupus nephritis. Compounds and methods of the disclosure are described herein.
  • Dosage levels of active ingredients in the pharmaceutical compositions of the disclosure may be varied to obtain an amount of the active compound(s) that achieves the desired therapeutic response for a particular patient, composition, and mode of administration.
  • the selected dosage level depends upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. Doses are determined for each particular case using standard methods in accordance with factors unique to the patient, including age, weight, general state of health, and other factors that can influence the efficacy of the compound(s) of the disclosure.
  • the compound according to the present disclosure or a pharmaceutically acceptable salt thereof is administered at a dose of approximately 30 ⁇ g to 100 ⁇ g, a dose of 30 ⁇ g to 500 ⁇ g, a dose of 30 ⁇ g to 10 g, a dose of 100 ⁇ g to 5 g, or a dose of 100 ⁇ g to 1 g per adult per day.
  • a dose is administered once or divided over several administrations.
  • Dosage may be simulated, for example, using the Simcyp® program.
  • administration of a compound of the disclosure to a mammal, including humans be limited to a particular mode of administration, dosage, or frequency of dosing.
  • the present disclosure contemplates all modes of administration, including oral, intraperitoneal, intramuscular, intravenous, intraarticular, intralesional, subcutaneous, or any other route sufficient to provide a dose adequate to prevent or treat SLE or lupus nephritis.
  • One or more compounds of the disclosure may be administered to a mammal in a single dose or multiple doses.
  • the doses may be separated from one another by, for example, several hours, one day, one week, one month, or one year. It is to be understood that, for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of a pharmaceutical composition that includes a compound of the disclosure.
  • a compound of the present disclosure may generally be administered intravenously, subcutaneously, intramuscularly, colonically, nasally, intraperitoneally, rectally, buccally, or orally.
  • Compositions containing at least one compound of the disclosure that is suitable for use in human or veterinary medicine may be presented in forms permitting administration by a suitable route.
  • These compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients.
  • the adjuvants comprise, inter alia, diluents, sterile aqueous media, and various non-toxic organic solvents.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988, 1999, Marcel Dekker, New York.
  • compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs, or syrups, and the compositions may optionally contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, and stabilizers to obtain pharmaceutically acceptable preparations.
  • excipients such as lactose, sodium citrate, calcium carbonate, and dicalcium phosphate and disintegrating agents such as starch, alginic acids, and certain complex silicates combined with lubricants (e.g., magnesium stearate, sodium lauryl sulfate, and talc) may be used for preparing tablets.
  • lubricants e.g., magnesium stearate, sodium lauryl sulfate, and talc
  • lactose and high molecular weight polyethylene glycols When aqueous suspensions are used, they may contain emulsifying agents that facilitate suspension.
  • Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol, chloroform, or mixtures thereof may also be used.
  • emulsions, suspensions, or solutions of the compositions of the disclosure in vegetable oil e.g., sesame oil, groundnut oil, or olive oil
  • aqueous-organic solutions e.g., water and propylene glycol
  • injectable organic esters e.g., ethyl oleate
  • sterile aqueous solutions of the pharmaceutically acceptable salts are used.
  • the solutions of the salts of the compositions of the disclosure are especially useful for administration by intramuscular or subcutaneous injection.
  • Aqueous solutions that include solutions of the salts in pure distilled water may be used for intravenous administration with the proviso that (i) their pH is adjusted suitably, (ii) they are appropriately buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride, and (iii) they are sterilized by heating, irradiation, or microfiltration.
  • Suitable compositions containing a compound of the disclosure may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid canier for use in a dry powder inhaler.
  • Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the disclosure.
  • Dosage formulations of a compound of the disclosure to be used for therapeutic administration should be sterile. Sterility is readily accomplished by filtration through sterile membranes (e.g., 0.2 micron membranes) or by other conventional methods. Formulations typically are stored in lyophilized form or as an aqueous solution.
  • the pH of the compositions of this disclosure in some embodiments, for example, may be between 3 and 11, may be between 5 and 9, or may be between 7 and 8, inclusive.
  • compositions may be administered subcutaneously, intravenously, intramuscularly, colonically, rectally, nasally, or intraperitoneally in a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations, and topical formulations such as ointments, drops, and dermal patches.
  • Compounds of embodiments of the disclosure may be incorporated into shaped articles such as implants, including but not limited to valves, stents, tubing, and prostheses, which may employ inert materials such as synthetic polymers or silicones, (e.g., Silastic® compositions, silicone rubber, or other commercially available polymers).
  • inert materials such as synthetic polymers or silicones, (e.g., Silastic® compositions, silicone rubber, or other commercially available polymers).
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy- propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide- polylysine substituted with palmitoyl residues.
  • a compound of the disclosure may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross linked or amphipathic block copolymers of hydro gels.
  • biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross linked or amphipathic block copolymers of hydro gels.
  • a compound of the disclosure may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine, or phosphatidylcholines.
  • a compound of the disclosure may also be delivered using antibodies, antibody fragments, growth factors, hormones, or other targeting moieties to which the compound molecules are coupled (e.g., see Remington: The Science and Practice of Pharmacy, vide supra), including in vivo conjugation to blood components of a compound of an embodiment of the disclosure.
  • Microwave heating was done using a Biotage® Emrys Liberator or Initiator microwave reactor.
  • Column chromatography was carried out using Biotage® SP4 flash chromatography system.
  • Solvent removal was carried out using either a Biichii rotary evaporator or a Genevac® centrifugal evaporator.
  • NMR spectra were recorded at 400 MHz on a Varian Unity® spectrometer using deuterated solvents. Chemical shifts are reported relative to residual protonated solvent.
  • Thin layer chromatography was performed on Whatman® glass plates precoated with a 0.25 mm layer of silica gel using various ratios of one or more of the following solvents: EtOAc, heptane, dichloromethane or MeOH.
  • Analytical LC/MS was performed for many examples on a Waters AcquityTM system using an XBridgeTM CI 8 1.7 ⁇ 2.1 ⁇ 50mm column.
  • Solvents A and B are Water w/ 0.1% formic acid and Acetonitrile w/ 0.1% formic acid, respectively. 5 minute total method time with 5% B to 99% B over 4 minutes with a flow rate of 0.3 ml/min.
  • Mass spectral data were acquired on a Waters SQD from 100-2000 amu in electrospray positive mode.
  • Solvents A and B are water w/ 0.1% formic acid and Acetonitrile w/ 0.1% formic acid, respectively. 12 minute total method time with 30% B to 95% B over 10 minutes with a flow rate of 20 ml/min. Mass spectral data were acquired on a Micromass ZQTM from 130-1000 amu in electrospray positive mode.
  • DIPEA N,N-diisopropylethylamine
  • dsDNA double-stranded DNA
  • HATU N.N.N'.N'-Tetramethyl-O-CT-azabenzotriazol-l-yl) hexafluoropho sphate
  • IFN interferon
  • IP A isopropyl alcohol or isopropanol
  • MgS0 4 magnesium sulfate (anhydrous)
  • NBS N-bromosuccinimide
  • PBMC peripheral blood mononuclear cell
  • PBS phosphate buffered saline
  • PhNTf 2 N-phenyltrifluoromethanesulfonimide
  • ssRNA single-stranded RNA
  • T3P Propylphosphonic anhydride
  • THF tetrahydrofuran
  • TLDA Taqman® Low Density Array
  • TLR Toll-like receptor
  • the commercially available protected epoxide 6 is condensed with aqueous ammonia to provide the amino alcohol 23 which in turn is condensed with the chiral chloropropinate 24 to form the enantiomerically pure amide 25.
  • Ether formation using a strong base such as sodium hydride provides lactam 26, which can be converted to intermediate 11 by amide reduction to the cyclic amine.
  • ether examples are prepared by two possible methods: (1) the displacement of activated group on an alkyl, alkenyl or aryl functional group using base and compound 11 from Scheme 4; or using the activated alcohol 14 or 36 with phenols or alkyl alcohols in the presences of an appropriate base. Both methods to provide examples with the general chemical structure 42 are shown in Scheme 12.
  • Key intermediate 13 may also be oxidized to form an aldehyde 43 followed by condensation with various alkyl and aryl coupling reagents to provide examples 44 or 46 as depicted in Scheme 13.
  • a final set of examples are prepared by the use of Scheme 14. Using the same synthetic methodology to prepare compound 13 in Scheme 4, one can prepare the desired seven-membered heterocycle 68 replacing allyl amine with l-amino-3-butente 62. 68 can then be activated and then condensed with various substituted amines to generate additional analogs in a similar manner as shown in several the schemes depicted above.
  • ER-880369 (8.2 mg, 0.031 mmol, 48.4 % yield) was produced in a similar manner to ER-878952 using 3 (15 mg, 0.064 mmol) and 2-ethylmorpholine (22.2 mg, 0.191 mmol). The separation of the enantiomers was not performed.
  • ER-885618 385.2 mg, 1.032 mmol, 60.7 % yield was produced in a similar manner to ER-878952 using 3 (400 mg, 1.716 mmol) and 11 (398.1 mg, 1.799 mmol) from Scheme 4.
  • ER-879484 3.0 mg, 0.010 mmol
  • ER-879569 1.0 mg, 0.004 mmol
  • ER-879570 1.0 mg, 0.004mmol
  • ER-879739 (12 mg, 0.047 mmol, 73.6 % yield) was produced in a similar manner to ER-879484 starting using 3 (15 mg, 0.064 mmol) and 2-methylmorpholine (19.5 mg, 0.195 mmol). Separation of the enantiomers was not performed.
  • ER-880191 (9.5 mg, 0.036 mmol, 23.7 % yield) was produced in a similar manner to ER-879484 starting using 3 (35 mg, 0.150 mmol) and (2S,6S)-2,6- dimethylmorpholine (741 mg, 6.434 mmol).
  • the cw-isomer ER-878952 (15.2 mg, 0.057 mmol, 37.9 % yield) was also isolated. TEA was not used in this preparation.
  • ER-885160 ER-878952 (85.6 mg, 0.320 mmol) was dissolved in 1,2- ethanediol (1 mL) followed by the addition of potassium hydroxide (60 mg, 1.069 mmol). The reaction mixture was micro waved at 120 °C for 10 h after which time, it was filtered then directly injected onto a C-18 reverse-phase preparative HPLC for purification (Water's X- Bridge C18 19 x 100 mm column, eluting with 10-100 % acetonitrile in water with 0.05 % TFA).
  • Compound 8 To a stirred suspension of sodium bicarbonate (1180 g, 14.0 mol) in water (7.2 L) at 10-11 °C was added a solution of o-nitrobenzenesulfonyl chloride (1038 g, 4.684 mol) in DCM (3100 mL) followed by warming the resultant biphasic mixture to 20 °C. A solution of 7 (ca. 1037 g, 4.684 mol assumed) in DCM (4100 mL) was added over 3 h while maintaining-T-internal between 20-23 °C and vigorous stirring was continued overnight. The mixture was diluted with water (4100 mL) with stirring followed by separation of the layers.
  • the aqueous layer was extracted with MTBE (4100 mL).
  • the combined organic layers were diluted with ⁇ -heptane (4100 mL), sequentially washed with 1.0 M HCl (4700 mL), saturated NaHC0 3 (2.0 kg), water (4100 mL), concentrated, and azeotroped with MTBE (5200 mL x 3) to dry to provide (i?)-N-allyl-N-(3-(benzyloxy)-2- hydroxypropyl)-2-nitrobenzenesulfonamide, 8 (1.855 kg, 4.56 mol, 97% yield) as brownish green oil after drying for 3 days in vacuo.
  • the completed reaction was diluted with pre-chilled ⁇ -heptane (8.74 L at -10 °C) then poured into pre- chilled NaOH solution (NaOH: 890 g, 22.3 mol in water: 8.7 L at 5 °C) while controlling T- internal ⁇ 15 °C (over 1 h) followed by rinsing the reactor rinsed with MTBE (3.5 L).
  • the mixture was diluted with MTBE (5.2 L) and the layers separated.
  • the organic layer was sequentially washed with: water (8.7 L), 30 wt % NaCl (3.5 kg) in water, water (5.2 L), treated with Celite 545 (175 g) and filtered.
  • the work-up vessel and filter cake were rinsed with MTBE (1.75 L) and the combined filtrates were concentrated under vacuum to approx. 3.5 L, azeotroped with ⁇ -heptane (8.7 L) and concentrated to approx. 5 L.
  • the tan precipitates were collected by filtration, rinsed with -heptane (3.5 L) and dried under N 2 /vacuum for 1 h. 1.65 kg of the resultant solid was combined with 353 g solid obtained from a separate batch and suspended in «-heptane/EtOAc 1 :1 (8.0 L).
  • the mixture was heated to 61-63 °C to achieve complete dissolution, cooled down to 23-25 °C over 1 h, diluted with heptane (4 L) and further cooled down to 10-12 °C over 30 min. Stirring was continued at this temperature for 30 min.
  • Resultant mixture was vigorously stirred for 10 min followed by separation of the layers.
  • the organic layer was extracted with water (0.24 L) with rinsing with ⁇ -heptane (0.24 L). All aqueous layers were combined and washed with ⁇ -heptane (3.60 L) followed by the addition of NaCl (240 g) with stilling.
  • the aqueous mixture was rendered basic with 5.0 M of NaOH (165 mL) followed by extraction two times with DCM (3.60 L & 2.40 L each).
  • the resulting mixture was filtered through a pad of Celite 545 (260g) and the layers separated.
  • the aqueous layer was extracted with EtOAc (1.31 L) followed by combining the organic layers washing two times with 5% NaCl (1.0 kg, each) and concentrated to give black solid.
  • the solid was dissolved in DCM (1 L), diluted with n- heptane (520 mL) followed by the addition of silica gel (196 g) and MgS0 4 (130 g).
  • the resultant slurry was stirred at 20 °C for 30 min, filtered and eluted with isopropyl acetate (2.09 L).
  • Precipitates were collected by filtration and rinsed with pre-chilled water (500 ml), then «-heptane/MTBE 7: 1 (400 ml) followed by drying under vacuum (40 °C) overnight to 5-((2i?, ⁇ 5R)-2- (hydroxymethyl)-6-methylmoi-pholino)quinoline-8-carbonitrile, 13 or ER-885493 (127.2g, 0.45 mol, 100%) yield) as tan powder.
  • ER-886604 (7.8 mg, 0.021 mmol, 73 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-4- methylbenzene (0.030 mL, 0.290 mmol) using a microwave at 180 °C for 15 min.
  • ER- 886604 was purified by reverse-phase HPLC (Water's X-Bridge C18 19 x l00 mm column, eluting with 10 % acetonitrile in water containing 0.05 % TFA).
  • ER-886608 (8.2 mg, 0.019 mmol, 67 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5-Amino-l,2- dimethylbenzimidazole dihydrochloride (30 mg, 0.128 mmol) along with TEA (0.040 mL, 0.290 mmol).
  • ER-886609 (7.4 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5-amino-l- ethyl-2-methylbenzimidazole (30 mg, 0.171 mmol).
  • ER-886611 (9.2 mg, 0.027 mmol, 88 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1- aminocyclohexane (30 mg, 0.171 mmol).
  • ER-886787 (4.5 mg, 0.012 mmol, 43.9 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- aminopyrimidine (24.7 mg, 0.263 mmol).
  • ER-886788 (5.2 mg, 0.014 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- aminopyridine (24.4 mg, 0.263 mmol).
  • ER-886789 (4.5 mg, 0.012 mmol, 42 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-6- methylpyridine (28.1 mg, 0.263 mmol).
  • ER-886790 (4.6 mg, 0.012 mmol, 43 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-5- methylpyridine (28.1 mg, 0.263 mmol).
  • ER-886814 (4.2 mg, 0.012 mmol, 40.4 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and D-prolinol (26.2 mg, 0.263 mmol).
  • ER-886815 (4.0 mg, 0.011 mmol, 38.2 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2,2- dimetylpyrrolidine (14.2 mg, 0.145 mmol).
  • ER-886816 (6.0 mg, 0.016 mmol, 60 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- isopropylpyiTolidine (29.4 mg, 0.263 mmol).
  • ER-886817 (4.2 mg, 0.012 mmol, 62 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-2- methylpyrrolidine (22.1 mg, 0.263 mmol).
  • ER-886818 (4.2 mg, 0.010 mmol, 35.2 % yield) was prepared by a similar method described for ER-890604 starting with 14 (12.5 mg, 0.029 mmol) and (S) 3- phenylpyrrolidine (38.2 mg, 0.263 mmol).
  • ER-886819 (5.2 mg, 0.015 mmol, 52 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-3- methylpyrrolidine (22.1 mg, 0.263 mmol).
  • ER-886820 (6.2 mg, 0.018 mmol, 62 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S)-3- hydroxypyrrolidine (22.6 mg, 0.263 mmol).
  • ER-886853 (6.2 mg, 0.017 mmol, 58 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-4- methylpyridine (28.1 mg, 0.263 mmol).
  • ER-886854 (2.9 mg, 0.007 mmol, 25 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3- phenylpyrrolidine hydrochloride (47.7 mg, 0.263 mmol).
  • ER-886855 (4.9 mg, 0.013 mmol, 44 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-5- methoxypyridine (32.2 mg, 0.263 mmol).
  • ER-886856 (7.8 mg, 0.022 mmol, 78 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and S -2- methylpyiTolidine (22.1 mg, 0.263 mmol).
  • ER-886857 (5.6 mg, 0.015 mmol, 54 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2,5- dimethylpyiTolidine (25.7 mg, 0.263 mmol).
  • ER-886858 (3.6 mg, 0.009 mmol, 32 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-4- methoxypyridine (32.2 mg, 0.263 mmol).
  • ER-886859 (2 mg, 0.005 mmol, 20 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-6- methoxypyridine (32.2 mg, 0.263 mmol).
  • ER-886860 (2.5 mg, 0.006 mmol, 21 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5 -amino- 1 - phenylpyrazole (41.3 mg, 0.263 mmol).
  • ER-886866 (8.2 mg, 0.022 mmol, 78 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and L-prolinol (22.1 mg, 0.263 mmol).
  • ER-886867 (4.5 mg, 0.013 mmol, 45 % yield) was prepared by a similar method described for ER-886604 stalling with 14 (12.5 mg, 0.029 mmol) and (R)-3- hydroxypyrrolidine (22.6 mg, 0.263 mmol).
  • ER-886868 (6.5 mg, 0.019 mmol, 65 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S 3- methylpyiTolidine (22.1 mg, 0.263 mmol).
  • ER-886869 (5.3 mg, 0.015 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3,3- dimetylpyrrolidine (25.7 mg, 0.263 mmol).
  • ER-886948 (6.2 mg, 0.016 mmol, 56 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- methoxypyridine (32.2 mg, 0.263 mmol).
  • ER-886949 (4.8 mg, 0.013 mmol, 46 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-3- hydiOxypiperidine (26.2 mg, 0.263 mmol).
  • ER-886950 (5.0 mg, 0.013 mmol, 46 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R, S)-2,6- dimethylpiperidine (29.4 mg, 0.263 mmol).
  • ER-886951 (3.2 mg, 0.009 mmol, 31 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S)-3- hydroxypiperidine (26.2 mg, 0.263 mmol).
  • ER-886953 (5.8 mg, 0.016 mmol, 55 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- hydroxypiperidine (26.2 mg, 0.263 mmol).
  • ER-886955 (7.5 mg, 0.020 mmol, 69 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- hydroxymethylpiperidine (29.9 mg, 0.263 mmol).
  • ER-887137 (4.5 mg, 0.012 mmol, 42 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2,3 dimethylpiperazine (29.6 mg, 0.263 mmol).
  • ER-887138 (5.9 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3- aminopyridine (24.4 mg, 0.263 mmol).
  • ER-887139 (6.5 mg, 0.018 mmol, 63 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3- aminopyridine (24.4 mg, 0.263 mmol).
  • ER-887141 (5.2 mg, 0.014 mmol, 50 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- methylpiperidine (25.7 mg, 0.263 mmol).
  • ER-887142 (4.5 mg, 0.012 mmol, 41 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4,4- diffuroropiperidine (31.4 mg, 0.263 mmol).
  • ER-887143 (4.7 mg, 0.011 mmol, 38 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- phenylpiperidine (41.8 mg, 0.263 mmol).
  • ER-887144 (6.2 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- fluroiOpiperidine (26.8 mg, 0.263 mmol).
  • ER-887145 (6.5 mg, 0.019 mmol, 65 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1- aminocyclopentane (22.1 mg, 0.263 mmol).
  • ER-887146 (7 mg, 0.018 mmol, 60 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-3- methylcyclohexane (29.4 mg, 0.263 mmol).
  • ER-887177 (5.3 mg, 0.014 mmol, 49 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- methylpyridine (20 mg, 0.145 mmol).
  • ER-887253 (10.2 mg, 0.029 mmol, 60 % yield) was prepared by a similar method described for ER-886604 starting with 14 (20 mg, 0.046 mmol) and piperazine (40 mg, 0.460 mmol).
  • ER-887442 (6.2 mg, 0.016 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.2 mg, 0.028 mmol) and l-amino-4- methylcyclohexane (30 mg, 0.265 mmol).
  • ER-887443 (4.5 mg, 0.013 mmol, 47 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1-amino- cyclobutane (10 mg, 0.141 mmol).
  • ER-887444 (7.7 mg, 0.020 mmol, 70.7 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1 -amino- cycloheptane (20 mg, 0.177 mmol).
  • ER-887526 (6.2 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-4- hydroxycyclohexane (30 mg, 0.260 mmol).
  • ER-887528 (5.4 mg, 0.015 mmol, 51.2 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1 -amino-2- hydroxycyclopentane (30 mg, 0.297 mmol).
  • ER-887539 (5.3 mg, 0.014 mmol, 49 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-2- methylcyclohexane (30 mg, 0.265 mmol).
  • ER-887538 (6.5 mg, 0.014 mmol, 51.8 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-5- phenylpyridine (50 mg, 0.294 mmol).
  • ER-887540 (6.1 mg, 0.014 mmol, 49 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- phenylpyridine (50 mg, 0.294 mmol).
  • ER-887586 (6.2 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S.R)-l- amino-2-hydroxypyrrolidine (10 mg, 0.099 mmol).
  • ER-887587 (7.5 mg, 0.019 mmol, 65 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- ethoxylpyridine (40 mg, 0.290 mmol).
  • ER-887588 (5.6 mg, 0.013 mmol, 45 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4-amino-2- phenylpyridine (20 mg, 0.118 mmol).
  • ER-887589 (2.4 mg, 0.006 mmol, 19 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino ⁇ 6- pheny .pyridine (20 mg, 0.118 mmol).
  • ER-887722 (3.5 mg, 0.009 mmol, 32 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5- methylpiperazin-2-one (20 mg, 0.175 mmol).
  • ER-887723 (6.2 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1-JV- methylpiperazine (10 mg, 0.100 mmol).
  • ER-887724 (6.2 mg, 0.016 mmol, 55 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1-N- propylpiperazine (40 mg, 0.138 mmol).
  • ER-887725 (7.2 mg, 0.018 mmol, 64 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- (dimethylamino)-piperidine (20 mg, 0.156 mmol).
  • ER-887927 (10.2 mg, 0.024 mmol, 82.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1,4'- bipiperidine (20 mg, 0.119 mmol).
  • ER-887928 (3.2 mg, 0.009 mmol, 31 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-Iert -butyl piperidin-3-ylcarbamate (30 mg, 0.150 mmol).
  • ER-888070 (4.5 mg, 0.012 mmol, 43 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and tert-butyl piperidin-4-ylcarbamate (30 mg, 0.150 mmol).
  • ER-888202 (6.2 mg, 0.018 mmol, 62 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and piperidine (0.034 niL, 0.348 mmol).
  • ER-888203 (7.2 mg, 0.020 mmol, 58 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and morpholine (0.030 niL, 0.350 mmol).
  • ER-888204 (6.2 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (2S, 6R)-2,6- dimethylmorpholine (0.070 mL, 0.580 mmol).
  • ER-888205 (4.6 mg, 0.012 mmol, 41 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and ((2R, 6R)-6- methylmorpholin-2-yl)melhanol or ER-885491 (40 mg, 0.305 mmol).
  • ER-888285 (8.6 mg, 0.020 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and N-(2- pyridyl)piperazine (30 mg, 0.184 mmol).
  • ER-888286 (10.2 mg, 0.020 mmol, 71.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (14.6 mg, 0.033 mmol) and 7V-(4- pyridyl)piperazine (30 mg, 0.184 mmol).
  • ER-888288 (7.2 mg, 0.016 mmol, 52 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and N-(piperidin-4- yl)acetamide (20 mg, 0.141 mmol).
  • the HCl salt is formed by procedures previously described.
  • ER-888289 (16.2 mg, 0.039 mmol, 21.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (80 mg, 0.183 mmol) and 1 ,8- naphthyridin-2-amine (100 mg, 0.689 mmol).
  • ER-888320 (5.8 mg, 0.015 mmol, 42 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and piperidine-4- carboxamide (20 mg, 0.156 mmol).
  • ER-888321 (6.2 mg, 0.013 mmol, 37 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and N-(piperidin-4- yl)benzamide (40 mg, 0.196 mmol).
  • ER-888322 (10.5 mg, 0.027 mmol, 75.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and 1- isopropylpiperazine (20 mg, 0.156 mmol).
  • ER-888330 (4.2 mg, 0.011 mmol, 30 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and piperazine-1- carboxamide (20 mg, 0.155 mmol).
  • ER-888479 (7.6 mg, 0.018 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 4- cyclohexylpiperidine (30 mg, 0.179 mmol).
  • ER-888480 (8.3 mg, 0.020 mmol, 58 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 4-(pyrrolidin-l- yl)piperidine (30 mg, 0.194 mmol).
  • ER-888838 (6.2 mg, 0.015 mmol, 45 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 3,5- dimethylpyridine-2,6-diamine (20 mg, 0.146 mmol).
  • ER-888977 (1.2 mg, 0.003 mmol, 1 1 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1,3-dimethyl- lH-pyrazol-5-amine (28.8 mg, 0.259 mmol).
  • ER-889448 (8.2 mg, 0.022 mmol, 63 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 1- ethylpiperazine (0.020 mL, 0.136 mmol).
  • ER-889469 (6.5 mg, 0.018 mmol, 52 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and l-(azetidin-3- yl)pyrrolidine (20 mg, 0.158 mmol).
  • ER-889470 (7.2 mg, 0.017 mmol, 48 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and l-(azetidin-3- yl)piperidine (20 mg, 0.158 mmol).
  • ER-889557 (7.7 mg, 0.020 mmol, 58.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and pipcridin-4- ylmethanol (20 mg, 0.174 mmol).
  • ER-889571 (3.2 mg, 0.008 mmol, 23 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and (R)-l,3'- bipyiTolidine (20 mg, 0.143 mmol).
  • ER-889572 (1.1 mg, 0.003 mmol, 7.7 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and (R)- ⁇ - (pyrrolidin-3-yl)piperidine (20 mg, 0.130 mmol).
  • ER-889601 (6.7 mg, 0.018 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 1 -methyl- 1 ,4- diazepane (20 mg, 0.175 mmol).
  • ER-889602 (10.2 mg, 0.022 mmol, 65.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and phenyl(piperazin-l-yl)methanone (30 mg, 0.158 mmol).
  • ER-891084 (7.2 mg, 0.016 mmol, 47 % yield) was prepared by a similar method described for ER-886608 starting with 14 (15 mg, 0.034 mmol) and l-(piperidin-4- yl)azepane (30 mg, 0.165 mmol).
  • ER-890108 (15.2 mg, 0.036 mmol, 58.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (27 mg, 0.062 mmol) and l-(azetidin-3- yl)-4-methylpiperazine (90.2 mg, 0.581 mmol). Triethylamine (0.008 mL, 0.062 mmol) was also added to the reaction.
  • ER-890112 (296.5 mg, 0.683 mmol, 74.7 % yield) was prepared by a similar method described for ER-886604 starting with 14 (400.6 mg, 0.916 mmol) and 4,4'- bipiperidine (290 mg, 1.723 mmol).
  • ER-886507 (4.2 mg, 0.013 mmol, 51.9 % yield) was prepared by a similar method described for ER-886604 starting with 14 (10.6 mg, 0.024 mmol) and pyrrolidine (0.022 mL, 0.257 mmol) using toluene (1 mL) instead of DMA as solvent. Boc-deprotection was not required.
  • ER-886508 (3.3 mg, 0.010 mmol, 38.9 % yield) was prepared by a similar method described for ER-890507 starting with 14 (10.8 mg, 0.025 mmol) and N,N- diethylamine (0.027 mL, 0.262 mmol).
  • ER-886509 (4.8 mg, 0.013 mmol, 44.9 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and benzylamine (0.028 mL, 0.263 mmol).
  • ER-88660 (6.6 mg, 0.018 mmol, 64.2 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and phenylamine (0.008 mL, 0.087 mmol).
  • ER-886602 (6.4 mg, 0.017 mmol, 60.1 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and l -amino-3- methylbenzene (0.028 mL, 0.263 mmol).
  • ER-887104 (2.1 mg, 0.005 mmol, 17.9 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and (S')-2- (trifluoiOmethyl)pyrrolidine (36.1 mg, 0.260 mmol).
  • ER-886603 (7.6 mg, 0.020 mmol, 71 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-2- methylbenzene (0.030 mL, 0.290 mmol) using NMP(1 mL) instead of toluene as a solvent.
  • ER-886957 (4.7 mg, 0.013 mmol, 45 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2- methylpiperidine (25.7 mg, 0.263 mmol).
  • ER-886958 (6.2 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2- ethylpiperidine (29.3 mg, 0.263 mmol).
  • ER-887139 (2.1 mg, 0.005 mmol, 18 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and (S)-2- trifluoromethypyrrolidine (36.1 mg, 0.263 mmol).
  • ER-887252 (2.6 mg, 0.006 mmol, 21 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-4- phenylpyridine (20 mg, 0.145 mmol).
  • ER-887258 (4.2 mg, 0.010 mmol, 34 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and N-phenyl piperazine (0.040 mL, 0.290 mmol) in toluene (0.5 mL).
  • ER-887259 (3.2 mg, 0.009 mmol, 30 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2,6- dimethylpyridine (30 mg, 0.290 mmol).
  • ER-887260 (3.3 mg, 0.009 mmol, 30.1 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and (S,S)-2,5- dimethylpiperazine (29.6 mg, 0.263 mmol).
  • ER-887261 (4.2 mg, 0.011 mmol, 39 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12 mg, 0.027 mmol) and N-acetyl piperazine (40 mg, 0.274 mmol).
  • ER-887262 (2.4 mg, 0.006 mmol, 22 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 4-(R)- hydiOxy-2-(5 -hydroxymethylpyrrolidine (30.4 mg, 0.263 mmol).
  • ER-887268 (9.3 mg, 0.017 mmol, 10 % yield) was prepared by a similar method described for ER-886608 starting with 14 (50 mg, 0.114 mmol) and (R)-tert-b tyi 3- methylpiperazine-l-carboxylate (100 mg, 0.570 mmol) using toluene (1 mL). Boc- deprotection was required as described for Boc-protected ER-890963 above.
  • ER-887268 was purified by reverse-phase HPLC (Water's X-Bridge C18 19 x 100 mm column, eluting with 10 - 40 % acetonitrile in water with 0.05% TFA) followed by neutralization as described for ER-886608.
  • ER-887269 (6.2 mg, 0.025 mmol, 21.4 % yield) was prepared by a similar method described for ER-887268 starting with 14 (51.8 mg, 0.118 mmol) and (R)-tert-butyl 2-methylpiperazine-l-carboxylate (100 mg, 0.570 mmol).
  • ER-887270 (12.2 mg, 0.033 mmol, 30 % yield) was prepared by a similar method described for ER-887268 starting with 14 (50 mg, 0.114 mmol) and S)-ter t-b tyl 2- methylpiperazine-l-carboxylate (200 mg, 1.14 mmol).
  • ER-887271 (2.3 mg, 0.006 mmol, 5.5 % yield) was prepared by a similar method described for ER-887268 starting with 14 (48.2 mg, 0.110 mmol) and (llR)-iert- butyl 2,5-dimethylpiperazine-l-carboxylate hydrochloride (100 mg, 0.399 mmol) and DIPEA (0.10 mL, 0.55 mmol).
  • ER-887272 (3.2 mg, 0.008 mmol, 7.1 % yield) was prepared by a similar method described for ER-887268 starting with 14 (52.7 mg, 0.120 mmol) and (S,R)-tert- butyl 2,5-dimethylpiperazine-l-carboxylate (100 mg, 0.467 mmol).
  • ER-890119 (256.2 mg, 0.630 mmol, 58.6 % yield) was prepared by a similar method described for ER-890963 starting with 14 (450 mg, 1.029 mmol) and /e/7-butyl 4- (azetidin-3-yl)piperazine-l-carboxylate (314.2 mg, 1.302 mmol).
  • Triethylamine (0.172 mL, 1.23 mmol) was also added to the reaction.
  • Dioxane (2 mL) was used instead of DMA. Deprotection of a Boc-group with TFA was required followed by neutralization of the final product as described previously.
  • ER-892253 (152.3 mg, 0.362 mmol, 4.0 % overall yield) was prepared by a similar method described for ER-890119 starting with 14 (4.0 g, 9.1 mmol) and /e/7-butyl (l -(azetidin-3-yl)piperidin-4-yl)carbamate (2.52 g, 9.9 mmol).
  • ER-888605 (7.6 mg, 0.017 mmol, 5.0 % yield) was prepared by a similar method described for ER-890119 starting with 14 (150 mg, 0.343 mmol) and [1,4'- bipiperidin]-2-one hydrochloride (82.5 mg, 0.377 mmol). Boc-group deprotection was not required.
  • ER-888605 (7.6 mg, 0.017 mmol, 5.0 % yield) was prepared by a similar method described for ER-890119 starting with 14 (150 mg, 0.343 mmol) and [1 ,4'- bipiperidin]-2-one hydrochloride (82.5 mg, 0.377 mmol). Boc-group deprotection was not required.
  • ER-890093 (15.2 mg, 0.035 mmol, 45.4 % yield) was prepared by a similar method described for ER-890119 starting with 14 (33.6 mg, 0.077 mmol) and 4-(piperidin- 4-yl)morpholine (52 mg, 0.305 mmol). Boc-group deprotection was not required.
  • ER-890104 (569 mg, 1.06 mmol, 42.6 % yield) was prepared by a similar method described for ER-890119 starting with 14 (1.08 g, 2.5 mmol) and tert-butyl 4- (piperidin-4-yl)piperazine-l-carboxylate (1.00 g, 3.7 mmol). Boc-group deprotection of ER- 890104 (21 mg, 0.039 mmol) was performed as described above to provide ER-890106 (12.4 mg, 0.029 mmol, 73.2 % yield).
  • ER-89010S (65 mg, 0.122 mmol, 1 1.3 % yield) was prepared by a similar method described for ER-890119 starting with 14 (1.08 g, 2.5 mmol) and tert-bntyl 4- (piperidin-4-yl)piperazine-l-carboxylate (1.00 g, 3.7 mmol). DIPEA (0.65 mL, 3.7 mmol) was also added to the reaction mixture. Boc-group deprotection of ER-890105 (60 mg, 0.112 mmol) was performed as described above to provide ER-890107 (11.3 mg, 0.026 mmol, 23.2 % yield).
  • ER-890311 (4.5 mg, 0.01 1 mmol, 31 % yield) was prepared by a similar method described for ER-886608 starting with 14 (15 mg, 0.034 mmol) and (S)-l- (pyrrolidin-3-yl)piperidine dihydrochloride (30 mg, 0.108 mmol) replacing DMA with acetonitrile (1 mL). Triethylamine (0.014 mL, 0.102 mmol) was also added to the reaction. The dihydrochloride salt of the product was produced according to processes described previously.
  • ER-890342 (41.3 mg, 0.101 mmol, 1 1 % yield) was prepared by a similar method described for ER-890311 starting with 14 (150.2 mg, 0.916 mmol) and 4-(azetidin-3- yl)morpholine (221.6 mg, 1.030 mmol).
  • ER-890343 (25.2 mg, 0.062 mmol, 77.2 % yield yield) was prepared by a similar method described for ER-890311 starting with 14 (35.2 mg, 0.080 mmol) and 1- (azetidin-3-yl)-4-methylpiperazine (40.3 mg, 0.0201 mmol).
  • ER-890344 (21.4 mg, 0.059 mmol, 73.8 %) was prepared by a similar method described for ER-890311 starting with 14 (35.2 mg, 0.080 mmol) and (S)-tert-butyl 3- methylpiperazine-l-carboxylate (28.2 mg, 0.201 mmol). Deprotection of the Boc-group with TFA followed by neutralization was performed.
  • ER-890963 (685.2 mg, 1.806 mmol, 86 %) was prepared by a similar method described for ER-890344 starting with 14 (919 mg, 2.101 mmol) and (S)-ter t-b tyl 2- ethylpiperazine-l-carboxylate (500 mg, 2.333 mmol).
  • the dihydrochloride salt of the product was produced according to processes described previously.
  • ER-891090 (54.2 mg, 0.133 mmol, 46.8 % yield) was prepared by a similar method described for ER-890311 starting with 14 (137.5 mg, 0.314 mmol) and (£)-1,3'- bipyiTolidine dihydrochloride (30 mg, 0.165 mmol). Boc-group deprotection was not required.
  • ER-895204 (35.2 mg, 0.084 mmol, 73.1 % yield) was prepared by a similar method described for ER-890311 starting with 14 (50 mg, 0.114 mmol) and N- ethylpiperidine-4-carboxamide (21.4 mg, 0.137 mmol).
  • the hydrochloride salt of the product was produced according to processes described previously.
  • ER-885211 (4 mg, 0.016 mmol, 24.7 % yield) was prepared in a similar manner to ER-886849 starting with Compound 3 (15 mg, 0.064 mmol) and (R)-2- methylmoipholine (22 mg, 0.160 mmol).
  • TEA 0.05 mL, 0.359 mmol
  • the completed reaction mixture was cooled to 18 °C followed by the addition of di-tert-butyl dicarbonate (262.1 g, 1.201 mol) maintaining the temperature between 18 and 21°C.
  • the mixture was stirred at rt overnight after which time the completed mixture was washed two times with heptane (2000 mL).
  • the aqueous layer was acidified with 20 wt% citric acid (270 g) and extracted three times with EtOAc (2000 mL & 2 x 1000 mL).
  • the aqueous layer was extracted with MTBE (1100 mL) followed by combining the organic layers and washing them with 20 wt % NaCl (270 g) and concentrated to dry. The residue was dissolved in toluene (1100 mL), filtered, concentrated, azeotroped to dry with toluene (1100 mL), and then dissolved in DCM (1200 ml). The mixture was cooled to -72 °C and triethylsilane (0.200 L, 1.25 mol) was added followed by trimethylsilyl trifluoromethanesulfonate (151 mL, 0.836 mol) over 45-min period while maintaining the temperature at ⁇ -68 °C.
  • the tan solid was suspended in DCM (11 ml), diluted with ??-heptane (110 ml), filtered, rinsed with /7-heptane/DCM 10:1 (121 ml), and dried under vacuum to provide ((2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2- yl)methyl trifluoromethanesulfonate, 36 (15.20 g, 36.6 mmol, 94% yield) as light tan solid.
  • N-Heptane (10 mL) and MTBE (10 mL) were added and the mixture was partially concentrated upon which time a brownish solid thus formed was collected by filtration, rinsed with: (1) water (15 mL) and (2) ⁇ -heptane (15 mL), and dried under vacuum overnight.
  • the dried solid was dissolved in ⁇ -heptane (10 mL, 0.2 mol), diluted with acetonitrile (5.0 mL, 0.096 mol) then treated with Florisil (0.50 g) at rt for 10 min.
  • ER-893881 (15.2 mg, 0.037 rnmol, 51.6 % yield) was prepared by a similar method described for ER-887927 starting with 36 (30 mg, 0.072 rnmol) and (5)-1,3'- bipyrrolidine dihydrochloride (20.5 mg, 0.144 rnmol) using TEA (0.020 mL, 0.141 rnmol) instead of K 2 C0 3 .
  • ER-894483 (30 mg, 0.079 rnmol, 32.8 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and (R)-3- methylpiperazin-2-one (54.9 mg, 0.481 rnmol).
  • ER-894484 (30 mg, 0.079 rnmol, 32.8 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and (S)-3- methylpiperazin-2-one (54.9 mg, 0.481 rnmol).
  • ER-894504 (30 mg, 0.076 rnmol, 31.5 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and (2S,5R)-2,5- dimethylpiperazine (54.9 mg, 0.481 rnmol).
  • ER-894505 (30 mg, 0.076 rnmol, 31.5 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and 2,3- dimethylpiperazine (54.9 mg, 0.481 mmol).
  • ER-894655 (140 mg, 0.309 mmol, 64.2 % yield) was prepared by a similar method described for ER-893881 starting with 36 (200 mg, 0.482 mmol) and tert-butyl 2,2- dimethylpiperazine-l-carboxylate (206 mg, 0.961 mmol).
  • the Boc-protecting group was hydrolyzed using 4 N HCl dioxane followed by isolation of the desired product by azeotroping to dry with toluene and drying under vacuo.
  • ER-894151 (1.066 g, 3.16 mmol, 65.4 % yield) was prepared by a similar method described for ER-893881 starting with 36 (2.0 g, 4.81 mmol) and tert-biityl azetidin- 3-ylcarbamate (0.995 g, 5.78 mmol).
  • the Boc-protected intermediate was deprotected using TFA (3 mL) in DCM (3 mL). The reaction was allowed to stir for 30 m, after which time the reaction was concentrated to dry with azeotroping three times with toluene (5 mL each). The residue was diluted with DCM (10 mL), washed two times with sat. NaHC0 3 (5 mL), water (5 mL), brine (5 mL), dried over MgS0 4 , filtered, concentrated and dried in vacuo to provide the desired product.
  • ER-890250 To a cooled stirring solution of ER-887927 (50 mg, 0.1 15 mmol) in THF (1 mL) at - 78 °C was added 1.6 M methyl lithium-lithium bromide complex in ethyl ether (0.15 mL, 0.24 mmol) whereupon the pale yellow solution was changed to bright red/orange. The reaction mixture was stirred for 1.5 h at - 78 °C after which time it was quenched with aqueous ammonium hydroxide (2 mL) followed by slowly warming to rt. The reaction was extracted three times with DCM (5 mL) and the combined organic layers were dried over , filtered and concentrated to dry.
  • the crude intermediate was dissolved in acetone (1 mL) followed by a solution of eerie ammonium nitrate (300 mg, 0.547 mmol) in water (1.5 mL). The reaction mixture was stirred for 30 min after which time the reaction mixture was concentrated to a crude solid. The solid was suspended in acetone 5 mL, stirred for 5 min, filtered and the solid filter pad eluted three times with acetone (5 mL each). The combined filtrates were concentrated in then purified by reverse-phase HPLC (X-Bridge C18 19 x 100 mm column using a acetonitrile/water gradient containing 0.1 % formic acid).
  • ER-884884 To a stirred solution of 37 (0.545 g, 2.126 mmol) in MeOH (5 mL) was added 5 % palladium on activated carbon (250 mg) followed by charging the flask several times with hydrogen gas. The reaction was maintaining under a hydrogen atmosphere (balloon pressure) at rt and stirred for 12 h, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with EtOH (2 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo.
  • reaction mixture was warmed to 140 °C and stirred for lh after which time the completed reaction was cooled to rt and directly injected onto a preparative reverse-phase HPLC column (after filtering) to provide ER-884884 (12.1 mg, 0.043 mmol, 19.7 % yield) after concentration of the desired combined fractions and drying under vacuo.
  • reaction mixture was stirred at rt for 3 h after which time the completed reaction was concentrated, filtered, and purified directly via preparative reverse-phase HPLC (Water's X-Bridge C18 19xl00mm column; eluted with a gradient of acetonitrile in water containing 0.05 % TFA) to provide ER-879713 (20.5 mg, 0.056 mmol, 52.3 % yield) after concentration of the desired combined fractions and drying under vacuo.
  • preparative reverse-phase HPLC Water's X-Bridge C18 19xl00mm column; eluted with a gradient of acetonitrile in water containing 0.05 % TFA
  • ER-886432 (10.2 mg, 0.023 mmol, 52.7 % yield) was obtained using a similar process to ER-879713 starting with ER-884884 (50 mg, 0.177 mmol) and 1 - phenylcyclobutanecarbonyl chloride (8.5 mg, 0.044 mmol).
  • ER-886563 (3.6 mg, 0.023 mmol, 20.3 % yield) was obtained using a similar process to ER-879713 starting with ER-884884 (12.4 mg, 0.044 mmol) and benzeneacetyl chloride (0.007 mL, 0.053 mmol). .
  • ER-888137 To a stirred solution of ER-884884 (30.2 mg, 0.107 mmol) in
  • ER-888701 (12.2 mg, 0.031 mmol, 17.7% yield) was prepared in a similar manner to ER-888137 starting with ER-884884 (50 mg, 0.177 mmol) and 2-chloro-5- ethylpyrimidine (150 mg, 1.052 mmol).
  • ER-888896 (3.0 mg, 0.008 mmol, 23.1 % yield) was prepared in a similar manner to ER-888137 starting with ER-884884 (10.1 mg, 0.036 mmol) and 2- chloropyrazine (30 mg, 0.261 mmol).
  • ER-888603 To stirred solution of 37 (58.1 mg, 0.227 mmol) and cyclohexylacetylene (0.026 mL, 0.200 mmol) in tert-butyl alcohol (0.08 mL) and water (0.07 mL) was added sodium bicarbonate (2.5 mg, 0.030 mmol) followed by copper(II) sulfate pentahydrate (2.5 mg, 0.010 mmol) and sodium ascorbate (7.8 mg, 0.039 mmol). The reaction mixture was stirred at rt for 14 h after which time DCM (5 mL) and saturated sodium bicarbonate (5 mL) was added and stirred an additional 10 min.
  • the mixture was microwaved at 150 °C for 30 min after which time the cooled reaction was directly injected onto a preparative, C-18 reverse phase HPLC column (Water's X-Bridge C18 19 x l00 mm column; eluting with a gradient of 10 - 40 % acetonitrile in water containing 0.05 % TFA).
  • the desired collected fractions were concentrated and dried in vacuo to provide ER-888603 (3.3 mg, 0.008 mmol, 23.3 % yield or a 3.9 % overall yield).
  • ER-888604 (5.2 mg, 0.013 mmol, 6.5 % overall yield) was prepared in a similar manner to ER-888603 starting with 37 (58.1 mg, 0.227 mmol), phenylacetylene (0.022 mL, 0.200 mmol) and 3 (7.85 mg, 0.034 mmol).
  • ER-889556 To a stirred suspension of ER-887268 (140.3 mg, 0.384 mmol) in water (1.5 mL) was added formaldehyde (1 mL) and formic acid (0.55 mL) after which time the reaction mixture was micro waved at 110 °C for 1.5 h. The completed reaction was cooled and directly injected onto a preparative, C-18 reverse phase HPLC column eluting with a gradient of 10 - 40 % acetonitrile in water containing 0.1 % TFA.
  • ER-890114 (75.9 mg, 0.170 mmol, 40.5 % yield) was prepared in a similar manner to ER-889556 starting with ER-890112 (182 mg, 0.420 mmol).
  • ER-890108 (72.1 mg, 0.171 mmol, 40.7 % yield) was prepared in a similar manner to ER-889556 starting with ER-890119 (170.6 mg, 0.420 mmol).
  • ER-890345 (43.5 mg, 0.115 mmol, 38 % yield) was prepared in a similar manner to ER-889556 starting with ER-890344 (110.2 mg, 0.302 mmol).
  • ER-890346 (52.6 mg, 0.139 mmol, 73.3 % yield) was prepared in a similar manner to ER-889556 starting with ER-887269 (69 mg, 0.189 mmol).
  • ER-890831 (85.2 mg, 0.225 mmol, 74.5 % yield) was prepared in a similar manner to ER-889556 starting with ER-887270 (110.2 mg, 0.302 mmol).
  • ER-890964 (506.2 mg, 1.286 mmol, 71.2 % yield) was prepared in a similar mamier to ER-889556 starting with ER-890963 (685.2 mg, 1.806 mmol).
  • ER-890186 (10.2 mg, 0.023 mmol, 20.7 % yield) was prepared in a similar manner to ER-889556 starting with ER-890107 (48 mg, 0.111 mmol).
  • ER-890223 35 mg, 0.078 mmol, 42.9 % yield was prepared in a similar mamier to ER-889556 starting with ER-890106 (100 mg, 0.182 mmol) as the TFA salt.
  • ER-894656 (31.7 mg, 0.068 mmol, 61.5 % yield) was prepared in a similar manner to ER-889556 starting with ER-894655 (50 mg, 0.1 1 1 mmol) as the dihydrochloride salt.
  • ER-889728 To a stirred solution of ER-888070 (12.5 mg, 0.034 mmol) in
  • ER-889729 (8.2 mg, 0.017 mmol, 51.3 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and isonicotinoyl chloride (10 mg, 0.071 mmol).
  • ER-889734 (8.6 mg, 0.018 mmol, 52.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and picolinoyl chloride (10 mg, 0.071 mmol).
  • ER-889744 (12 mg, 0.028 mmol, 80.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and hexanoyl chloride (9 mg, 0.067 mmol).
  • ER-889745 (8 mg, 0.018 mmol, 54 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and isobutyryl chloride (7 mg, 0.066 mmol).
  • ER-889746 (7.6 mg, 0.017 mmol, 50 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and 2,2- dimethylpropanoyl chloride (8 mg, 0.066 mmol).
  • ER-890113 (25.6 mg, 0.054 mmol, 66.7 % yield) was prepared in a similar manner to ER-889728 starting with ER-890112 (35.2 mg, 0.081 mmol) and acetic anhydride (0.093 mL, 0.984 mmol).
  • ER-890120 (20.3 mg, 0.045 mmol, 54.2 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (33.7 mg, 0.083 mmol) and acetic anhydride (0.012 mL, 0.127 mmol).
  • ER-890122 (35.2 mg, 0.069 mmol, 43.1 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (65.2 mg, 0.160 mmol) and benzoyl chloride (0.037 mL, 0.318 mmol).
  • ER-890142 (45.2 mg, 0.084 mmol, 53.1 % yield) was prepared in a similar manner to ER-889728 starting with ER-890112 (68.5 mg, 0.158 mmol) and benzoyl chloride (0.037 mL, 0.318 mmol).
  • ER-890187 (9.4 mg, 0.020 mmol, 18.0 % yield) was prepared in a similar manner to ER-889728 starting with ER-890107 (48 mg, 0.11 1 mmol) and acetic anhydride (0.125 mL, 1.3 mmol).
  • ER-890188 (8.9 mg, 0.018 mmol, 16.0 % yield) was prepared in a similar manner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) and isobutyryl chloride (0.051 mL, 0.487 mmol).
  • ER-890189 (10 mg, 0.019 mmol, 16.7 % yield) was prepared in a similar manner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) and benzoyl chloride (0.056 mL, 0.482 mmol).
  • ER-890190 (6.5 mg, 0.014 mmol, 36.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (15.6 mg, 0.038 mmol) and isobutyryl chloride (0.006 mL, 0.058 mmol).
  • ER-890219 (32.0 mg, 0.067 mmol, 91.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-890106 (40.2 mg, 0.073 mmol) as the TFA salt, TEA (0.20 mL, 1.43 mmol) and acetic anhydride (0.10 mL, 1.06 mmol).
  • ER-890221 (28.2 mg, 0.056 mmol, 76.7 % yield) was prepared in a similar manner to ER-890219 starting with ER-890106 (40.2 mg, 0.073 mmol) as the TFA salt and isobutyryl chloride (0.080 mL, 0.764 mmol).
  • ER-890222 (30.1 mg, 0.056 mmol, 76.7 % yield) was prepared in a similar manner to ER-890219 starting with ER-890106 (40.5 mg, 0.074 mmol) as the TFA salt and benzoyl chloride (0.20 mL, 1.723 mmol).
  • ER-892254 (24.2 mg, 0.0.52 mmol, 67.5 % yield) was prepared in a similar manner to ER-889728 starting with ER-892253 (32.2 mg, 0.077 mmol) and acetic anhydride (0.015 mL, 0.151 mmol). Acetonitrile (0.5 mL) was added to the reaction mixture.
  • ER-892256 (25.2 mg, 0.052 mmol, 41.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (50.2 mg, 0.124 mmol) and methanesulfonyl chloride (0.011 mL, 0.142 mmol).
  • ER-893926 (124.2 mg, 0.255 mmol, 51.7 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (180.2 mg, 0.493 mmol) and 1,3-dimethyl- iH-pyrazole-4-carbonyl chloride (93.8 mg, 0.592 mmol).
  • ER-893927 (45.2 mg, 0.0.83 mmol, 57.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-892253 (60.5 mg, 0.144 mmol) and 1 ,3-dimcthyl- yH-pyrazole-4-carbonyl chloride (27.4 mg, 0.173 mmol).
  • ER-893948 (65.3 mg, 0.147 mmol, 29.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (180.2 mg, 0.493 mmol) and methanesulfonyl chloride (68 mg, 0.593 mmol).
  • ER-894149 (67.2 mg, 0.133 mmol, 80.6 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (60.2 mg, 0.165 mmol) and benzenesulfonyl chloride (0.023 mL, 0.180 mmol).
  • ER-894150 (58.2 mg, 0.11 1 mmol, 69.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (58.2 mg, 0.159 mmol) and 4- fluorobenze esulfonyl chloride (0.025 mL, 0.188 mmol).
  • ER-894152 (36.2 mg, 0.095 mmol, 63.6 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.6 mg, 0.150 mmol) and acetic anhydride (0.014 mL, 0.135 mmol).
  • ER-894153 (5.4 mg, 0.012 mmol, 7.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (52.2 mg, 0.155 mmol) and 4- fluorobenzenzoyl chloride (25 mg, 0.158 mmol).
  • ER-894154 (38.5 mg, 0.093 mmol, 62.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.4 mg, 0.149 mmol) and methanesulfonyl chloride (0.012 mL, 0.146 mmol).
  • ER-894155 (42.1 mg, 0.085 mmol, 57.1 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.3 mg, 0.149 mmol) and 4- fluorobenzenesulfonyl chloride (29 mg, 0.149 mmol).
  • ER-894159 (20.4 mg, 0.041 mmol, 27.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.5 mg, 0.150 mmol) and 1,3-dimethyl- iH-pyrazole-4-sulfonyl chloride (29 mg, 0.149 mmol).
  • ER-894160 (47.2 mg, 0.0.90 mmol, 65.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (50.1 mg, 0.137 mmol) and 1,3-dimethyl- 7H-pyrazole-4-sulfonyl chloride (27 mg, 0.139 mmol).
  • ER-894206 (1 1.3 mg, 0.029 mmol, 19 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.6 mg, 0.150 mmol) and isobutyryl chloride (16. mg, 0.150 mmol).
  • ER-894594 (215 mg, 0.487 mmol, 46.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (354 mg, 1.049 mmol) and benzoic anhydride (407 mg, 1.81 mmol). Acetonitrile (2 mL) was used instead of DCM.
  • ER-890252 (120.3 mg, 0.306 mmol, 71.2 % yield) was prepared in a similar manner to ER-890222 starting with 5-((2S, 6R)-2-(((R)-3 -aminopyrrolidin- 1 -yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and acetic anhydride (0.80 mL, 8.46 mmol).
  • ER-890253 (146.5 mg, 0.348 mmol, 80.8% yield) was prepared in a similar manner to ER-890122 starting with 5 -((2$ 6 ⁇ )-2-((( ⁇ )-3 -aminopyrrolidin- 1 -yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and isobutyryl chloride (0.50 mL, 4.77 mmol).
  • ER-894544 (103.6 mg, 0.227 mmol, 52.9 % yield) was prepared in a similar manner to ER-890122 starting with 5-((2S, 6.fl)-2-(((/ -3 -aminopyrrolidin- 1 -yl)methyl)-6- methylmoipholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and benzoyl chloride (0.50 mL, 4.31 mmol).
  • ER-894546 (96.7 mg, 0.214 mmol, 49.8 % yield) was prepared in a similar manner to ER-890222 starting with 5-((2»S , , ⁇ )-2-(((5)-3-aminopynOlidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and acetic anhydride (0.80 mL, 8.46 mmol).
  • ER-894547 (120.8 mg, 0.287 mmol, 66.7 % yield) was prepared in a similar manner to ER-894546 starting with 5-((25 , , ⁇ 5i?)-2-(((5 -3-aminopyiTolidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and isobutyric anhydride (0.70 mL, 4.22 mmol).
  • ER-894548 (1 10.4 mg, 0.242 mmol, 56.4 % yield) was prepared in a similar manner to ER-894546 starting with 5-((2 l S , , (ii?)-2-((( 1 S)-3-aminopyiTolidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and benzoic anhydride (0.50 g, 2.21 mmol).
  • ER-894545 (32 mg, 0.084 mmol, 19.6 % yield) was prepared in a similar manner to ER-889556 starting with 5-((25 , , 5i?)-2-(((i?)-3-aminopyrrolidin-l-yl)methyl)-6- methylmoipholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA.
  • ER-894549 (103.8 mg, 0.274 mmol, 63.6 % yield) was prepared in a similar manner to ER-889556 starting with 5-((2S, 6 ?)-2-((( l S')-3-aminopynOlidin- 1 -yl)methyl)-6- methylmoipholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA.
  • the pH of the quenched reaction was adjusted to pH 9 by the slow addition of 1M sodium hydroxide in water while maintaining the temperature at ⁇ 25 °C.
  • the stining layers were separated and the organic layer was washed with water (560 mL).
  • 1-Butanol (2.31 L) was added to the combined aqueous layers after which time the mixture was cooled to 10 - 15 °C followed by the slow addition of 5 M sulfuric acid (231 mL) maintaining the temperature at ⁇ 25 °C to obtain an approximate pH 5.
  • the resultant layers were separated and the aqueous layer was extracted 3 times with 1-butanol (2.31 L) while maintaining the pH of the aqueous layer approximately pH 5 between extractions.
  • the resultant mixture was stirred at 2-3 °C for 1 h, warmed up to 17-18 °C over lh, and stirred at this temperature for 16 h.
  • 20 wt% Na 2 S0 4 (5 g) was added followed by EtOAc (30 ml) after which time the resultant mixture was stirred vigorously for 10 min and filtered through a pad of Celite (2 g).
  • Organic layer was separated, washed with 20 wt% sodium sulfite (5 g), 20 wt% NaCl (5 g) and concentrated to give light purple/gray oil.
  • MC2-1130-120-1) was dissolved in 0.5mL IP A and 0.3mL H 2 0.
  • the vial containing the solution was capped and stored at room temperature for a day.
  • the crystal structure was solved with a final i?-factor of 0.0606 and a Flack parameter of -0.01.
  • the structure of ER-899742-01 was determined as (2R, 6i?)-4-(8- cyanoquinolin-5-yl)-/V-[(3S', 4i?)-4-fluoiOpyn lidin-3-yl]-6-methylmoi"pholine-2- carboxamide hydrochloride. See FIG. 8 for ORTEP drawing.
  • reaction mixture was passed over silica gel plug (3 g, eluting with heptane- EtOAc 1 :3), and then further purified by preparative TLC (ft-heptane/EtOAc 1 :4) to provide (3S, 4S)-tert-buty ⁇ 3-((2R, i5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholine-2-carboxamido)- 4-fluoiOpyrrolidine-l-carboxylate, 85 (14.2 mg, 0.029 mmol, 47% yield in 2 steps) as yellow/green oil.
  • ER-899745-HCL (62.3 mg, 0.148 mmol, 96% yield) was obtained using the same equivalents of reagents as for ER-899742-HC1, starting with compound 79 (75 mg, 0.155 mmol).
  • ER-894550 (5.3 mg, 0.016 mmol, 18.4 % yield) was prepared in a similar manner to ER- 899742 starting with 38 (25.9 mg, 0.087 mmol) and ethyl amine hydrochloride (206 mg, .962 mmol). DMF (0.5 mL) was used instead of DCM.
  • the ER-894550 was purified by reverse- phase HPLC (X-Bridge C18 19 x 100 mm column; eluting with a gradient of increasing acetonitrile in water containing 0.1 % formic acid) followed by combining the desired fractions, concentration and drying in vacuo.
  • ER-895473 (103 mg, 0.261 mmol, 27.1 % yield) was prepared in a similar manner to ER-899742 starting with 38 (286 mg, 0.962 mmol) and (S)-tert-butyl 2- ethylpiperazine-l-carboxylate (206 mg, .962 mmol).
  • DMF (3 mL) was used instead of DCM for the amide forming reaction and 2.0 M HC1 in ethyl ether (1.3 mL, 2.6 mmol) was used in the Boc-deprotection process using acetonitrile (1 mL) as a solvent.
  • ER-895473 was purified by reverse-phase HPLC (X-Bridge CI 8 19 x 100 mm column; eluting with a gradient of increasing acetonitrile in water containing 0.1 % fomiic acid). The product fractions were combined and concentrated to dry followed by dilution in MeOH (1 mL), passed through as basic silica gel plug (Biotage S1CO 3 , 1 g, eluting with MeOH (ImL)), concentrated and dried in vacuo.
  • ER-895474 (6.3 mg, 0.015 mmol, 19.6 % yield) was prepared in a similar manner to ER-899742 starting with 38 (22.5 mg, 0.076 mmol) and (3,4- difluorophenyl)methanamine (10.83 mg, .076 mmol). Boc-deprotection was not required.
  • ER-895475 (16.2 mg, 0.044 mmol, 71.5 % yield) was prepared in a similar to
  • ER-895476 (14.0 mg, 0.042 mmol, 28.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (43.0 mg, 0.145 mmol) and azetidine hydrochloride (13.53 mg, .145 mmol).
  • ER-895477 (26.1 mg, 0.058 mmol, 32.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (54.0 mg, 0.182 mmol) and l,4'-bipiperidine (30.6 mg, .182 mmol).
  • ER-895478 (15.9 mg, 0.047 mmol, 29.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (48.4 mg, 0.163 mmol) and cyclopropanamine (11.42 ⁇ , .163 mmol).
  • ER-895479 (14.9 mg, 0.042 mmol, 23.7 % yield) was prepared in a similar manner to ER-895473 starting with 38 (53.2 mg, 0.179 mmol) and ferf-butyl azetidin-3- ylcarbamate (30.8 mg, .179 mmol).
  • ER-897922 (15.1 mg, 0.041 mmol, 48.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and l -aminobutan-2-ol (13.0 mg, 0.146 mmol).
  • ER-897923 (13.9 mg, 0.038 mmol, 44.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-ethoxyethanamine (13.0 mg, 0.146 mmol).
  • ER-897924 (17.0 mg, 0.046 mmol, 54.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-2-aminobutan-l-ol (14.0 mg, 0.157 mmol).
  • ER-897925 (4.5 mg, 0.012 mmol, 14.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-aminopropane- 1 ,3-diol (14.0 mg, 0.154 mmol).
  • ER-897926 (7.6 mg, 0.021 mmol, 24.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 3-aminopropane-l,2-diol (15.0 mg, 0.165 mmol).
  • ER-897927 (15.0 mg, 0.039 mmol, 46.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-(tetrahydrofuran-2- yl)methanamine (15.0 mg, 0.148 mmol).
  • ER-897928 (14.9 mg, 0.039 mmol, 46.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (tetrahydrofuran-2- yl)methanamine (16.0 mg, 0.158 mmol).
  • ER-897929 (10.3 mg, 0.027 mmol, 32.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-propoxyethanamine (16.0 mg, 0.155 mmol).
  • ER-897930 (12.8 mg, 0.033 mmol, 39.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-2-aminopentan-l-ol (16.0 mg, 0.155 mmol).
  • ER-897931 (11.1 mg, 0.029 mmol, 34.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-isopropoxyethanamine (15.0 mg, 0.145 mmol).
  • ER-897932 (10.0 mg, 0.026 mmol, 31.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 1 -methoxybutan-2-amine (0.0160 g, 0.155 mmol).
  • ER-897933 (9.0 mg, 0.021 mmol, 24.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-amino-l-(2- fluorophenyl)ethanol (23.0 mg, 0.148 mmol).
  • ER-897934 (13.3 mg, 0.035 mmol, 41.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (5 f )-2-amino-3-methylbutan- l-ol (15.0 mg, 0.145 mmol).
  • ER-897935 (15.7 mg, 0.041 mmol, 48.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2,2-dimethoxyethanamine (15.0 mg, 0.143 mmol).
  • ER-897936 (10.4 mg, 0.027 mmol, 32.2 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-(2-aminoethoxy)ethanol (16.0 mg, 0.152 mmol).
  • ER-897937 (12.1 mg, 0.031 mmol, 36.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (lS S)-2- aminocyclohexanol (23.0 mg, 0.200 mmol).
  • ER-897938 (8.5 mg, 0.022 mmol, 25.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-aminocyclohexanol (17.0 mg, 0.148 mmol).
  • ER-897939 (10.1 mg, 0.025 mmol, 30.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-aminohexan-l-ol (18.3 mg, 0.156 mmol).
  • ER-897940 (10.3 mg, 0.026 mmol, 30.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and ( ⁇ S 2-amino-3,3- dimethylbutan-l-ol (19.0 mg, 0.162 mmol).
  • ER-897941 (14.0 mg, 0.035 mmol, 42.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (,S> 2-aminohexan- 1 -ol (19.0 mg, 0.162 mmol).
  • ER-897942 (9.9 mg, 0.025 mmol, 29.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (2£35 2-amino-3- methylpentan-l-ol (18.0 mg, 0.154 mmol).
  • ER-897943 (11.1 mg, 0.028 mmol, 33.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (>S)-2-amino-4- methylpentan-l-ol (18.0 mg, 0.154 mmol).
  • ER-897944 (10.9 mg, 0.027 mmol, 32.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-2-amino-4- methylpentan-l-ol (18.0 mg, 0.154 mmol).
  • ER-897945 (13.2 mg, 0.032 mmol, 38.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (4-methylmorpholin-2- yl)methanamine (20.0 mg, 0.154 mmol).
  • ER-897946 (16.1 mg, 0.035 mmol, 42.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (,S 2-amino-4- (methylthio)butan-l-ol (20.0 mg, 0.148 mmol).
  • ER-897947 (12.0 mg, 0.029 mmol, 34.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-phenoxyethanamine (21.0 mg, 0.153 mmol).
  • ER-897948 (12.0 mg, 0.028 mmol, 33.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (S)-2-amino-3- phenylpropan-l-ol (24.0 mg, 0.159 mmol).
  • ER-897949 (11.7 mg, 0.027 mmol, 32.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-phenoxypropan-l -amine (29.0 mg, 0.192 mmol).
  • ER-897950 (11.7 mg, 0.027 mmol, 32.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and l-amino-3-phenylpropan-2- ol (23.0 mg, 0.152 mmol).
  • ER-897952 (14.0 mg, 0.032 mmol, 38.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-(pyridin-3-yloxy)propan- 1-amine (24.0 mg, 0.158 mmol).
  • ER-897955 (8.2 mg, 0.019 mmol, 22.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-(4- fluorophenoxy)ethanamine (23.0 mg, 0.148 mmol).
  • ER-897956 (11.2 mg, 0.026 mmol, 26 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-amino-l-(3- fluorophenyl)ethanol (24.0 mg, 0.155 mmol).
  • ER-897957 (9.8 mg, 0.022 mmol, 26.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (S)-2-amino-3- cyclohexylpropan-l-ol (30.0 mg, 0.191 mmol).
  • ER-897958 (13.6 mg, 0.031 mmol, 36.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and isochroman-1- ylmethanamine (24.0 mg, 0.147 mmol).
  • ER-897960 13.0 mg, 0.029 mmol, 34.6 % yield was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and l-amino-3-phenoxypropan- 2-ol (25.0 mg, 0.150 mmol).
  • ER-897961 (9.7 mg, 0.022 mmol, 25.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 4-((lS, 2R)-2-anam.o-l- hydroxypropyl)phenol (32.0 mg, 0.191 mmol).
  • ER-897962 (17.8 mg, 0.040 mmol, 47.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (AS;25 2-amino-l- phenylpropane-l,3-diol (26.0 mg, 0.155 mmol).
  • ER-897963 (3.1 mg, 0.007 mmol, 8.4 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl 4-(3-amino-2- hydi xypropyl)piperazine-l-carboxylate (40.0 mg, 0.154 mmol).
  • ER-897964 (12.7 mg, 0.036 mmol, 21.5 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl 3-aminoazetidine- 1-carboxylate (27.0 mg, 0.157 mmol).
  • ER-897965 (0.4 mg, 0.001 mmol, 1.3 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (S)-tert-butyl 3- aminopyrrolidine-l-carboxylate (29.0 mg, 0.156 mmol).
  • ER-897966 (0.4 mg, 0.001 mmol, 1.3 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (R)-tert-buty ⁇ 3- aminopyiTolidine-l-carboxylate (29.0 mg, 0.156 mmol).
  • ER-897967 (0.3 mg, 0.001 mmol, 0.9 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (.S /er/-butyl 3- aminopiperidine-l-carboxylate (30.0 mg, 0.150 mmol).
  • ER-897968 (0.4 mg, 0.001 mmol, 1.3 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (R)-tert-buty ⁇ 3- aminopiperidine-l-carboxylate (30.0 mg, 0.150 mmol).
  • ER-897969 (0.2 mg, 0.001 mmol, 0.6 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (S)-tert-buty ⁇ 2- (aminomethyl)pyrrolidine-l-carboxylate (30.0 mg, 0.150 mmol).
  • ER-897970 (3.4 mg, 0.008 mmol, 9.4 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl (2- aminoethyl)(benzyl)carbamate (38.0 mg, 0.152 mmol).
  • ER-898560 (11.2 mg, 0.030 mmol, 30.9 % yield) was prepared in a similar manner to ER-895473 starting with 38 (28.8 mg, 0.097 mmol) and pyridin-2-amine (9.12 mg, .097 mmol).
  • ER-898561 (12.8 mg, 0.033 mmol, 44.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (22.1 mg, 0.074 mmol) and 6-methylpyridin-2-amine (8.04 mg, .074 mmol).
  • ER-898562 (7.4 mg, 0.020 mmol, 18.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (31.2 mg, 0.105 mmol) and 5-methylisoxazol-3-amine (10.30 mg, .105 mmol).
  • ER-898563 (6.5 mg, 0.017 mmol, 16.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30.7 mg, 0.103 mmol) and 2,2,2-trifhioroethanamine hydrochloride (13.99 mg, .103 mmol).
  • ER-898564 (1.4 mg, 0.004 mmol, 3.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and 2,2-difluoroethanamine (8.18 mg, .101 mmol).
  • ER-898565 (3.0 mg, 0.008 mmol, 7.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30.2 mg, 0.102 mmol) and 3,3,3-trifluoropropan-l - amine (1 1.49 mg, .102 mmol).
  • ER-898566 (14.6 mg, 0.037 mmol, 20.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (53.7 mg, 0.181 mmol) and N2,N2,2- trimethylpropane-l ,2-diamine (20.99 mg, .181 mmol).
  • ER-898914 (31.6 mg, 0.092 mmol, 28.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (95.2 mg, 0.320 mmol) and 2-fluoroethanamine hydrochloride (31.9 mg, .32 mmol).
  • ER-898915 (19.1 mg, 0.054 mmol, 19.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (82.3 mg, 0.277 mmol) and 3-fluorapropan- 1 -amine hydrochloride (31.4 mg, .277 mmol).
  • ER-898916 (14.6 mg, 0.037 mmol, 21.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (51.4 mg, 0.173 mmol) and (R)- 1 , 1 , 1 -trifluoropropan- 2-amine (20 mg, .177 mmol).
  • ER-898917 (27.6 mg, 0.066 mmol, 20.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (95.7 mg, 0.322 mmol) and (R)- 1 ,1 ,1 -trifluoro-3- methylbutan-2-amine (45.4 mg, .322 mmol).
  • ER-898918 (15.0 mg, 0.038 mmol, 19.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (59.2 mg, 0.199 mmol) and 1,3-dimethyl-iH-pyrazol- 5-amine (22.13 mg, .199 mmol).
  • ER-898919 (13.1 mg, 0.035 mmol, 10.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (98.1 mg, 0.33 mmol) and l-methyl-iH-pyrazol-5- amine (32.0 mg, .33 mmol).
  • ER-898920 (20.1 mg, 0.060 mmol, 21.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (83.3 mg, 0.280 mmol) and 2-aminoacetonitrile hydrochloride (25.9 mg, .28 mmol).
  • ER-898921 (11.4 mg, 0.032 mmol, 12.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (73.1 mg, 0.246 mmol) and cyclopropanecarbonitrile hydrochloride (25.5 mg, .246 mmol).
  • ER-898922 (25.4 mg, 0.067 mmol, 33.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (59.0 mg, 0.198 mmol) and l,2,4-thiadiazol-5-amine (20.07 mg, .198 mmol).
  • ER-898923 (12.6 mg, 0.032 mmol, 16.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (57.6 mg, 0.194 mmol) and 3 -methyl- 1,2,4-thiadiazol- 5-amine (22.31 mg, .194 mmol).
  • ER-899017-HC1 (328 mg, 0.769 mmol, 65.3 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (350 mg, 1.177 mmol) and /ert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate (250 mg, 1.177 mmol).
  • ER-899019-HC1 (26 mg, 0.059 mmol, 58.2 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and ferf-butyl 4- (aminomethyl)-4-fluoropiperidine-l-carboxylate (23.4 mg, .101 mmol).
  • ER-899020-HC1 (25 mg, 0.062 mmol, 61.4 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) fert-butyl 3- (aminomethyl)azetidine-l-carboxylate (18.8 mg, .101 mmol).
  • ER-899023-HC1 (25.5 mg, 0.060 mmol, 59.4 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and / ⁇ ?/ -butyl 1,6- diazaspiro[3.4]octane-6-carboxylate (21.4 mg, .101 mmol).
  • ER-899024-HC1 (30.1 mg, 0.068 mmol, 67.5 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and /e/v-butyl 1,7- diazaspiro[4.4]nonane-l-carboxylate (22.8 mg, .101 mmol).
  • ER-899025-HC1 (32.1 mg, 0.077 mmol, 76 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and 4-amino-l -methyl- ///- pyrazole-3-carboxamide (14.1 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899031-HC1 (30.1 mg, 0.079 mmol, 78 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (3-methyloxetan-3- yl)methanamine (10.2 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899032-HC1 (28.7 mg, 0.079 mmol, 78 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and 2-oxo-6- azasprio[3.3]helptane (10.0 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899033-HC1 (32.8 mg, 0.093 mmol, 92 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and oxetane-3-amine (7.4 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899034-HC1 (26.4 mg, 0.067 mmol, 66.2 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and oxetane-3,3- diyldimethanamine dihydrochloride (19.1 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899035-HC1 (25.9 mg, 0.071 mmol, 70.1 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and oxetan-2- ylmethanamine (8.8 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899036-HC1 (33.1 mg, 0.082 mmol, 82 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl piperazine-1- carboxylate (18.8 mg, .101 mmol).
  • ER-899191-HC1 (30.7 mg, 0.081 mmol, 80 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and azetidine-3- carboxamide (10.1 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899192-HC1 (34.4 mg, 0.078 mmol, 77 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 2,7- diazaspiro[4.4]nonane-2-carboxylate (22.8 mg, .101 mmol).
  • ER-899193-HC1 (38.1 mg, 0.081 mmol, 80 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 3,9- diazaspiro[5.5]undecane-3-carboxylate (25.7 mg, .101 mmol).
  • ER-899196-HC1 (23.7 mg, 0.057 mmol, 56.4 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and 4- aminonicotinamide (13.84 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899282-HC1 (29.6 mg, 0.079 mmol, 79 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and pyridin-4-amine (9.5 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899283-HC1 (31.1 mg, 0.083 mmol, 83 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and pyridin-3 -amine (9.5 mg, .101 mmol). Boc-deprotection was not required.
  • ER-899285-HC1 (28.5 mg, 0.059 mmol, 58.6 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-buXyl 4-(4- amino-lH-pyrazol-l-yl)piperidine-l-carboxylate (26.9 mg, .101 mmol).
  • ER-899286-HC1 (31.7 mg, 0.070 mmol, 69.2 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and te/7-butyl 3-(4- amino-lH-pyrazol-l-yl)azetidine-l-carboxylate (24.0 mg, .101 mmol).
  • ER-899287 (29.7 mg, 0.079 mmol, 78 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (iH-pyrazol-5- yl)methanamine (9.80 mg, .101 mmol).
  • ER-899288 (20.7 mg, 0.057 mmol, 56.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and iH-pyrazol-4-amine (8.38 mg, .101 mmol).
  • ER-899289 (35.5 mg, 0.078 mmol, 77 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (3-(trifluoromethyl)pyridin- 2-yl)methanamine (17.77 mg, .101 mmol).
  • ER-899290 (15.0 mg, 0.034 mmol, 33.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and l-(pyridin-2-yl)ethanamine (12.33 mg, .101 mmol).
  • ER-899291 (26.1 mg, 0.067 mmol, 66.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and pyridin-2-ylmethanamine (10.91 mg, .101 mmol).
  • ER-899292 (31.0 mg, 0.077.2 mmol, 76.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (6-methylpyridin-2- yl)methanamine (12.3 mg, .101 mmol).
  • ER-899293 (32.0 mg, 0.079 mmol, 77.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (l-methylpiperidin-2- yl)methanamine (12.9 mg, .101 mmol).
  • ER-899294 (32.2 mg, 0.080 mmol, 79 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (3-methylpyridin-2- yl)methanamine (12.3 mg, .101 mmol).
  • ER-899334 (51.3 mg, 0.140 mmol, 11.7 % yield) was prepared in a similar manner to ER-895473 starting with 38 (357.2 mg, 1.201 mmol) and (R)-tert-buly ⁇ 2- (aminomethyl)pyrrolidine-l-carboxylate (224 mg, 1.201 mmol).
  • ER-899414-HCI (31.1 mg, 0.075 mmol, 74.1 % yield) was prepared in a similar mamier to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (7?)-to7-butyl 2-(aminomethyl)pyiTolidine-l-carboxylate (20.2 mg, .101 mmol).
  • ER-899415-HC1 (30.5 mg, 0.071 mmol, 70.3 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (S)-tert-butyl 2-(aminomethyl)piperidine-l-carboxylate (21.6 mg, .101 mmol).
  • ER-899416-HC1 (24.2 mg, 0.055 mmol, 54.3 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 3- amino-8-azabicyclo[3.2.1]octane-8-carboxylate (22.84 mg, .101 mmol).
  • ER-899417-HC1 (32.8 mg, 0.076 mmol, 76 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 4- aminoazepane-l-carboxylate (21.62 mg, .101 mmol).
  • ER-899418-HCI (29.6 mg, 0.072 mmol, 70.9 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (lR,5S,6S)-tert- butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate (20.0 mg, .101 mmol).
  • ER-899476-HC1 (31.0 mg, 0.068 mmol, 67.4 % yield) or the diastereomeric mixture of ER-899742 and ER-899745 was prepared in a similar manner to ER-899742-I 1C1 starting with 38 (30 mg, 0.101 mmol) and a 1 : 1 mixture of (3R,4S)-tert-butyl 3-amino-4- fluoropyrrolidine-l-carboxylate and ' (3 S,4R)-ter t-butyl 3-amino-4-fluoi pyrrolidine-l- carboxylate (20.6 mg, .101 mmol).
  • ER-899477-HCI (25.5 mg, 0.059 mmol, 58.2 % yield) as a diaslcreomer mixture was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and a 1 :1 mixture of (3 R,4S)-ter t-butyl 3-amino-4-fluoiOpiperidine-l-carboxylate and (3S, 4 R)-ter t-butyl 3-amino-4-fluoiOpiperidine-l-carboxylate (22.02 mg, .101 mmol).
  • ER-899479-IIC1 (30.5 mg, 0.071 mmol, 70.6 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 6- amino-2-azaspiro[3.3]heptane-2-carboxylate (21.42 mg, .101 mmol).
  • ER-897383 (14.2 mg, 0.017 mmol, 14.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (35.2 mg, 0.1 18 mmol) and 2-aminoethanol (10.9 mg, 0.178 mmol). DMF (1 mL) was used instead of DMAC.
  • ER-897385 (14.2 mg, 0.017 mmol, 14.1 % yield) was prepared in a similar manner to ER-897383 starting with 38 (35 mg, 0.118 mmol) and 2-methoxyethanamine (13.7 mg, 0.178 mmol).
  • ER-897445 (87 mg, 0.245 mmol, 72.9 % overall yield) was prepared in a similar manner to ER-897383 starting with 38 (100 mg, 0.336 mmol) and (R)-2-((tert- butyldiphenylsilyl)oxy)propan-l -amine (158 mg, 0.505 mmol) followed by the removal of the tert-butyldiphenylsilyl-protecting group using 1 M TBAF in THF (0.43 mL, 0.43 mmol) in DCM (1.1 mL) stilling for 1 h at rt. The desired product was purified over silica gel (eluted with 80 - 100 % EtOAc in heptane).
  • ER-897446 (67 mg, 0.189 mmol, 75 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (75 mg, 0.252 mmol) and (S)- ⁇ -((tert- butyldiphenylsilyl)oxy)propan-2-amme (103 mg, 0.329 mmol).
  • ER-897447 (78 mg, 0.220 mmol, 65.5 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (100 mg, 0.336 mmol) and (R)- l -((ter(- butyldiphenylsilyl)oxy)propan-2-amine (158 mg, 0.505 mmol).
  • ER-897827 (48.2 mg, 0.131 mmol, 64.9 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (S)- ⁇ -((tert- butyldiphenylsilyl)oxy)butan-2-amine (90 mg, 0.303 mmol).
  • ER-897828 (49.4 mg, 0.129 mmol, 64 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (S)-l-((tert- butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (103 mg, 0.303 mmol).
  • ER-897829 (65.2 mg, 0.157 mmol, 77.7 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (S)-2-((tert- butyldiphenylsilyl)oxy)-l -phenyl ethanamine (1 14 mg, 0.303 mmol).
  • ER-897830 (60.2 mg, 0.145 mmol, 71.8 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (R)-2-((tert- butyldiphenylsilyl)oxy)-l-phenylethanamine (114 mg, 0.303 mmol).
  • ER-899722 (79 mg, 0.215 mmol, 25.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (250 mg, 0.841 mmol) and 2-methylpropane-l ,2- diamine (0.09 mL, 0.841 mmol). DCM (2 mL) was used instead of DMAC. [0537] ER-899295 (27.5 mg, 0.0.71 mmol, 70.4 % yield) was prepared in a similar manner to ER-899722 starting with 38 (30 mg, 0.101 mmol) and 3-amino-/H-pyrazole-4- carbonitrile (10.9 mg, 0.101 mmol) .
  • ER-898946 38 (50 mg, 0.168 mmol), HATU (128 mg, 0.336 mmol) and
  • the completed reaction was concentrated to dry and the crude product was purified by chromatography (25 g Silica gel) eluting with 10% acetonitrile in DCM to give pure Boc protected product.
  • the Boc-protected product was dissolved in DCM(4 ml)/TFA (0.5 ml) and stirred at rt for 3 h after which time the solvent was removed under reduced pressure, the residue was dissolved in MeOH (10 mL) and 0.3 g of MP-carbonate was added (pH>7).
  • ER-898694-2 HC1 (67 mg, 0.155 mmol, 46.1 % yield) was prepared in a similar manner to ER-898946 starting with 38 (100 mg, 0.336 mmol) and (S)-fert-butyl 2- (aminomethyl)moipholine-4-carboxylate (95 mg, .437 mmol) followed by the addition of 3N HC1 in dioxane (31 uL) to provide the dihydrochloride salt after concentration and high vacuum to dryness.
  • ER-899742 free base can be obtained by dissolving the TFA salt in MeOH and adding Amberlite IRA 400 hydroxide form and stimng for 10 min or once a neutral pH is obtained. The resultant suspension is filtered, washed with MeOH two times with MeOH of equal volumes, and concentration of the combined filtrates to paste. The paste is azeotroped two times with toluene to provide ER-899742 in the free base form in quantitative yield. The HC1 salt form can be then be generated as described above.
  • ER-899742 -I lCl salt may be obtained directly from 78 by treatment with 5.5
  • N HCL in isopropanol to provide desired product in quantitative yield after stimng for 2 h at if followed by azeotroping to dry 3 times with toluene and high vacuum drying as 1.5 molecules of HC1 to one molecule of ER-899742 demonstrated by mass spectra analyses.
  • ER-899464 (44.9 g, 114 mmol, 67.9% yield).
  • the HC1 salt is obtained by dissolving ER-899464 (22.8 g, 57.9 mmol) in 10 volumes of isopropanol and 1 volume of water followed by the addition of 1 equivalent of 5.5 N HC1 in isopropanol to provide a white precipitate.
  • the solid is filtered and washed with isopropanol (2 vol) followed by drying in a vacuo to provide ER-899464.HC1 (20.3 g, 47.2 mmol, 81.5%).
  • ER-899477 (78 mg, 0.196 mmol, 58.3% yield) was prepared in a similar manner to ER-899464 starting with 38 (100 mg, 0.336 mmol) and (3S,4R)-tert-butyl 3- amino-4-fluoiOpiperidine-l-carboxylate (220 mg, 1.009 mmol).
  • ER-897968 (475 mg, 1.252 mmol, 37.2 % yield) was prepared in a similar manner to ER-899464 starting with 38 (1.00 g, 3.364 mmol) and (R)-teH-butyl 3- aminopiperidine-l-carboxylate (2.021 g, 10.091 mmol).
  • ER-899018 (370 mg, 0.975 mmol, 58.0 % yield) was prepared in a similar manner to ER-899464 starting with 38 (500 mg, 1.682 mmol) and te -butyl (azetidin-3- ylmethyl)(methyl)carbamate (500 mg, 2.497 mmol).
  • ER-899819 (62 mg, 0.158 mmol, 31.3 % yield) was prepared in a similar manner to ER-899464 starting with 38 (150 mg, 0.505 mmol) and tert-butyl 3- aminoazepane-l-carboxylate (324 mg, 1.514 mmol).
  • ER-899416-HC1 (53 mg, 0.120 mmol, 35.7 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and (!R S S)- tert-bntyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (76 mg, .336 mmol).
  • ER-899417-HC1 (56 mg, 0.130 mmol, 38.7 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and tert-butyl 4- aminoazepane-l-carboxylate (144 mg, .673 mmol).
  • ER-899285-HC1 (52 mg, 0.108 mmol, 32.1 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and /e/7-butyl 4- (4-amino-iH-pyrazol-l-yl)piperidine-l-carboxylate (179 mg, .673 mmol)
  • ER-899021-HC1 (62 mg, 0.140 mmol, 41.7 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and tert-butyl 2,6- diazaspiro[3.5]nonane-6-carboxylate (152 mg, .673 mmol).
  • ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and (5 -tert-butyl 3- (methylamino)piperidine-l-carboxylate (216 mg, 1.009 mmol).
  • ER-899616-HC1 (21 mg, 0.049 mmol, % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and (fl)-tert-butyl 3- (methylamino)piperidine-l -carboxylate (216 mg, 1.009 mmol).
  • ER-898566-HC1 (272 mg, 0.630 mmol, 37.5 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (500 mg, 1.682 mmol) and N2,N2,2- trimethylpropane-l,2-diamine (586 mg, 5.045 mmol).
  • ER-899618-HC1 (4.8 mg, 0.011 mmol, 3.2 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (500 mg, 1.682 mmol) and 4-aminopicolinamide (138 mg, 1.009 mmol).
  • ER-899477 (78 mg, 0.196 mmol, 58.3 % yield as a diastereomeric mixture) was prepared in a similar manner to ER-899464 starting with 38 (100 mg, 0.336 mmol) and a racemic mixture of (3S,4R)-tert- vXy ⁇ 3-amino-4-fluoropiperidine-l-carboxylate and (3R,4S)- fert-butyl 3-amino-4-fluoropiperidine-l-carboxylate (220 mg, 1.009 mmol).
  • ER-895415 as an example for Compound 41 in Scheme 11: To a stirred solution of 38 (1.10 g, 3.70 mmol) in DCM ( 5 mL) at 0 °C was added oxalyl chloride (1.0 mL, 11.42 mmol) dropwise over 2 min. The reaction mixture was allowed to warm to rt and stir for 1 h after which time the reaction was concentrated and dried in vacuo. The dried syrup was cooled to 0 °C followed by the slow addition of MeOH (5 mL) with stirring.
  • the completed reaction was concentrated to dry, diluted with DCM (10 mL), washed with saturated sodium sulfite (3 mL), brine (3 mL) and then dried over Na 2 S0 4 , filtered and concentrated to dry.
  • the crude product was purified over silica gel (eluting w a 0 - 50 % EtOAc in heptane gradient) to provide ER-895415 (894 mg, 2.81 mmol, 76 % yield) after combining the desired fractions, concentrating and drying in vacuo.
  • ER-899457 (50 mg, 0.117 mmol, 97 % yield) was prepared in a similar manner to ER-899332 starting with ER-89933 (50 mg, 0.122 mmol) .
  • ER-899836 A stirred solution of ER-899477 (76 mg, .191 mmol) in solution of 37 % formaldehyde in water (0.5 g, 16.652 mmol) and formic acid (0.5 ml, 13.036 mmol) was warmed to 80 °C for 3 h after which time the completed reaction is cooled to rt. The mixture was azeotroped to dryness four times with toluene (2 mL each) and the resultant residue was dissolved in MeOH (5 mL) followed by the addition of Amberlite IRA400 hydroxide form (2 g) and stirred for 10 min.
  • ER-899836 50 mg, 0.124 mmol was dissolved in acctonitrilc (1 mL) followed by the addition of 2 M HC1 in diethyl ether (0.062 ml, 0.124 mmol) and stirred at rt for 30 min. The resultant orange solution was concentrated to dryness and placed under high vacuum overnight to provide ER-899836-HC1 in quantitative yield.
  • ER-899688-HC1 (381 mg, 0.886 mmol, 88.4 % yield) was prepared in a similar manner to ER-899836-HC1 starting with ER-897968 (600 mg, 1.58 mmol) .
  • ER-899820-HC1 (45 mg, 0.110 mmol, 69.9 % yield) was prepared in a similar manner to ER-899836-HC1 starting with ER-899819 (62 mg, 0.158 mmol) .
  • ER-899337 (35.6 mg, 0.087 mmol, 24. % yield) was similarly prepared in a similar manner to ER-899836 starting with ER-897968 (142 mg, 0.361 mmol) as a free base.
  • ER-899835 (29 mg, 0.071 mmol, 81. % yield) was similarly prepared in a similar manner to ER-899836 starting with ER-899718 (34 mg, 0.086 mmol) as a free base.
  • ER-899837 (35.6 mg, 0.087 mmol, 24.2 % yield) was similarly prepared in a similar manner to ER-899836 starting with ER-899417 (142 mg, 0.361 mmol) as a free base.
  • ER-898707-formate (17 mg, 0.0.36 mmol, 78. % yield) was prepared in a similar manner to ER-899836 starting with ER-898694 (20 mg, 0.046 mmol) maintaining as the formate salt instead of conversion to the HC1 salt as above.
  • ER-895472 To a cooled solution of 38 (22.7 mg, .076 mmol) and TEA (12.8 ⁇ , .092 mmol) in THF at - 15 °C was added ethyl chloroformate (8.1 ⁇ , .084 mmol). After stirring 1.5 hr, ammonium hydroxide (6.0 ⁇ , .153 mmol) was added after which time stilling continued for an additional 2 hr at -10 °C. The reaction was allowed to warm to rt and stirred an additional 2 h. The completed reaction was quenched by addition of sat. NaHC0 3 (5 mL) followed by the extraction of the aqueous phase 3 times with EtOAc (5 mL each).
  • ER-899122 To a cooled solution of 38 (80 mg, .24 mmol) and 4- methylmorpholine (32 ⁇ , .288 mmol) in THF (4 mL) at 0 °C was added isopropyl chloroformate (38 ⁇ , .084 mmol). After stilling 30 min, Tetrahydro-pyran-4-ylamine (29.1 mg, .288 mmol) was added after which time stirring continued for an additional 2 hr at -10 °C. The reaction was allowed to warm to rt and stirred an additional 16 h. The completed reaction was quenched by addition of sat.
  • ER-899121 (40 mg, 0.104 mmol, 43.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 3-aminomethyl-oxctane (25.06 mg, .288 mmol).
  • ER-899123 (40 mg, 0.109 mmol, 45.5 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 3-aminotetrahydrofuran (25.06 mg, .288 mmol).
  • ER-899140 (20 mg, 0.051 mmol, 21.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and tert-butyl (2- aminoethyl)(methyl)carbamate (50.1 mg, .288 mmol) after removal of the Boc group using TFA and neutralizing with MP-carbonate as described.
  • ER-899153 (32 mg, 0.083 mmol, 34.4 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and glycine methyl ester hydrochloride (36.1 mg, .288 mmol).
  • ER-899154 (16 mg, 0.041 mmol, 17.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and dimethylethylenediamine (31.6 ⁇ , .288 mmol).
  • ER-899161 13 mg, 0.031 mmol, 12.9 % yield was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 4,4,4-tri ITuorobutanc- 1 ,3- diamine dihydrochloride (61.9 mg, .288 mmol) as a diastereomeric mixture.
  • ER-899152 (9 mg, 0.024 mmol, 37.0 % yield) was prepared by dissolving
  • ER-899278 (20 mg, 0.051 mmol, 33.8 % yield) was prepared in a similar manner to ER-899140 starting with 38 (50 mg, 0.15 mmol) and (R)-te/7-butyl 2- (aminomethyl)moipholine-4-carboxylate (48.6 mg, .225 mmol).
  • ER-899366 (70 mg, 0.171 mmol, 42.4 % yield) was prepared in a similar manner to ER-899140 starting with 38 (120 mg, 0.404 mmol) and (2S, 6R)-tert-b tyl 2-
  • ER-899367 (40 mg, 0.102mmol, 38 % yield) was prepared in a similar manner to ER-899140 starting with 38 (80 mg, 0.269 mmol) and tert-butyl hexahydropyiTolo[3,4-c]pyrrole-2(7H)-carboxylate (68.5 mg, .373 mmol).
  • ER-899459 (30 mg, 0.074 mmol, 31.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (70 mg, 0.235 mmol) and N, N-di mcthy lpipcridin-4- amine (36.2 mg, .283 mmol).
  • ER-899464 (20 mg, 0.051 mmol, 18.9 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.269 mmol) and l-methylpiperidin-4-amine (36.9 mg, .323 mmol).
  • ER-899588 (40 mg, 0.105 mmol, 44.8 % yield) was prepared in a similar manner to ER-899140 starting with 38 (70 mg, 0.235 mmol) and tert-butyl piperidin-4- ylcarbamate (56.6 mg, .283 mmol).
  • ER-899608 (40 mg, 0.102 mmol, 37.8 % yield) was prepared in a similar manner to ER-899140 starting with 38 (70 mg, 0.235 mmol) and /e/7-butyl (4- methylpiperidin-4-yl)carbamate (63.4 mg, .296 mmol).
  • ER-899680 (40 mg, 0.098 mmol, 19.2 % yield) was prepared in a similar manner to ER-899122 starting with 38 (100 mg, 0.336 mmol) and l-ethylpiperidin-3 -amine (43.1 mg, .336 mmol).
  • ER-899431 (53 mg, 0.103 mmol, 51.3 % yield) was prepared in a similar mamier to ER-899122 starting with 38 (99 mg, 0.333 mmol) and methylamine (2M in THF) (1.50 mL, 3.00 mmol).
  • ER-899626 (29 mg, 0.071 mmol, 35.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (60 mg, 0.202 mmol) and 4-amino-l -ethyl piperidine (25.9 mg, .202 mmol).
  • ER-899718 (32 mg, 0.081 mmol, 40.1 % yield) was prepared in a similar manner to ER-899140 starting with 38 (60 mg, 0.202 mmol) and /e/7-butyl 4-amino-4- methylpiperidine-l-carboxylate (47.6 mg, .222 mmol).
  • the crude product was purified over silica gel (50 g, eluting with a 40 -100% EtO Ac in heptane, 20 column volumes) to provide 86 (58.5 mg, , 0.118 mmol, 56.2 % yield) as a pale yellow solid.
  • the crude product was purified over silica gel (25 g, eluting with a 40 - 100% gradient of EtO Ac in heptane, 20 column volumes) to provide 87 (42.9 mg, 0.084 mmol, 71.0 %) as a pale yellow solid.
  • ER-8999335 To a stirred solution 38 (357.2 mg, 1.201 mmol) and HBTU
  • the crude product was purified over silica gel (40 g, eluting with a 50-100%) EtO Ac/heptane, 20 column volumes) to provide 88 (181.6 mg, 0.390 mmol, 32.5 % yield) of pale yellow solid.
  • the combined organic phases were dried over anhydrous Na 2 S0 4 , filtered and concentrated to dryness.
  • the crude product was purified over silica gel (25 g, eluting with 70 -100% EtOAc in heptane, 20 column volumes) to provide the Boc-protected intermediate which was used in the next step.
  • the Boc was removed by dissolving the intermediate in EtOAc (1 mL) and adding TFA (0.5 mL) followed by stirring for 1 h.
  • ER-899336 To a stirred solution of ER-899334 (35.4 mg, .097 mmol) and iodomethane (0.013 mL, .213 mmol) in DMF (1 mL) at 0 °C was added 60% sodium hydride (9.69 mg, .242 mmol) after which time the reaction was warmed to rt and stirred overnight. The completed reaction was cooled to 0 °C and quenched by the slow addition of saturated NH 4 C1 (5 mL) followed by dilution with water (5 mL) and extraction two times with EtOAc (10 mL each).
  • ER-899481 To a stirred solution of ER-898946 (60 mg, .158 mmol) in acetonitrile (10 niL) was added K 2 C0 3 (87 mg, .632 mmol) and 2-bromoacetamide (43.6 mg, .316 mmol). The reaction mixture was warmed to 60 °C and stirred for 16 h, after which time the completed reaction was filtered.
  • ER-885612 as an example of Compound 42, Scheme 12: To a cooled, stirred solution of 13 (25 mg, 0.088 mmol) in DMF (0.5 mL) at 0 °C was added NaH (3.5 mg, 0.088 mmol, 60% oil dispersion) followed by methyl iodide (16.5 uL, 0.265 mmol). The reaction was stirred an additional 20 min after which time water (1 mL) was slowly added. The quenched reaction was extracted two times with DCM (2 mL each), dried over MgS0 4 , filtered and concentrated to dry.
  • ER-885807 (15.2 mg, 0.049 mmol, 55.7 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and iodoethane (20.6 mg, .132 mmol).
  • ER-885808 (8.2 mg, 0.025 mmol, 28.6 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and isopropyl iodide (22.5 mg, .132 mmol).
  • ER-885892 (3.1 mg, 0.009 mmol, 10.4 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and 1 -iodo-2-methylpropane (15.2 uL, .132 mmol).
  • ER-885929 (17.5 mg, 0.048 mmol, 54.6 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and 1 -iodohcxanc (37.4 mg, .176 mmol).
  • ER-885930 (7.9 mg, 0.021 mmol, 23.7 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and cyclohexylmethyl bromide (31.3 mg, .177 mmol).
  • ER-895324 (35.2 mg, 0.098 mmol, 54.7 % yield) was prepared in a similar manner to ER-885612 starting with 13 (50.6 mg, 0.179 mmol) and 2-bromopyridine (20.4 uL, .214 mmol). THF (1 mL) was used instead of DMF.
  • ER-895325 (54.2 mg, 0.150 mmol, 83.8 % yield) was prepared in a similar manner to ER-893324 starting with 13 (50.6 mg, 0.179 mmol) and 2-bromopyrimidine (57 mg, .359 mmol).
  • ER-894552 (5 mg, 0.014 mmol, 19.2 % yield) was prepared in a similar manner to ER-893324 starting with 13 (20.4 mg, 0.072 mmol) and 2-chloropyrazine (8.3 mg, .0.072 mmol).
  • the reaction mixture was micro waved at 110 °C for 12 h after which time the mixture was directly injected on a reverse-phase preparative HPLC column (Water's X-Bridge C18 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA) for purification eluting with, providing a crude product.
  • the crude product was purified over silica gel (Biotage eluting with a gradient from 25 % EtOAc in heptane to 100 % EtOAc) to provide ER-886137 (12.1 mg, 0.031 mmol, 17.6% yield) after combining the desired collected fractions, concentration and drying in vacuo.
  • ER-886514 To a stirred suspension of 14 (10.5 mg, 0.024 mmol) and potassium carbonate (30 mg, 0.217 mmol) in toluene (1 mL) was added phenol (24.4 mg, 0.259 mmol).
  • the reaction mixture was microwaved at 150 °C for 5 h after which time the crude mixture was filtered and directly injected on a reverse-phase preparative HPLC column (Water's X-Bridge C18 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA) to provide ER-886514 (4.5 mg, 0.013 mmol, 54.1 % yield) after combining the desired collected fractions, concentration and drying in vacuo.
  • a reverse-phase preparative HPLC column Water's X-Bridge C18 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA
  • ER-886515 (3.2 mg, 0.009 mmol, 37.6 % yield) was prepared in a similar manner to ER-886514 starting with 14 (10.6 mg, 0.024 mmol) and 3-methylphenol (28.1 mg, 0.260 mmol).
  • ER-886516 (4.7 mg, 0.013 mmol, 52.4 % yield) was prepared in a similar manner to ER-886514 starting with 14 (10.6 mg, 0.024 mmol) and 4-methylphenol (28.1 mg, 0.260 mmol).
  • ER-886605 (7.9 mg, 0.020 mmol, 85.1 % yield) was prepared in a similar manner to ER-886514 starting with 14 (10.3 mg, 0.024 mmol) and 3,4-diflurorphenol (20 mg, 0.154 mmol). 1-Methylpyrrolidinone (1 mL) was used instead of toluene in this preparation.
  • ER-886606 (7.2 mg, 0.019 mmol, 81.2 % yield) was prepared in a similar manner to ER-886605 starting with 14 (10.3 mg, 0.024 mmol) and 3-flurorphenol (13.2 mg, 0.118 mmol).
  • ER-886624 (5.1 mg, 0.014 mmol, 59 % yield) was prepared in a similar manner to ER-886605 starting with 14 (10 mg, 0.023 mmol) and 2-flurorphenol (10 mg, 0.089 mmol).
  • ER-886786 (8.2 mg, 0.022 mmol, 76.9 % yield) was prepared in a similar manner to ER-886605 starting with 14 (12.5 mg, 0.029 mmol) and 2-methylphenol (28.1 mg, 0.260 mmol).
  • ER-885621 To a stirred solution of bis(2-methoxyethyl)aminosulfur trifluoride (24.4 uL, 0.132 mmol) in DCM (0.1 mL) cooled to - 78 °C under a N 2 atmosphere was added 13 (25 mg, 0.088 mmol) in DCM (0.1 mL). The reaction mixture was allowed to warm to - 50 °C and stirred for 0.5 h, warmed to 0 °C, and stirred for 1.5 h. The reaction mixture was warmed to 5 °C and stirred for 2 h after which time saturated NaHC0 3 in water was added drop wise until reach pH 10.
  • ER-885906 A stirred solution of 13 (85.5 mg, 0.302 mmol) in thionyl chloride (2 mL) was warmed to 85 °C for 24 h, after which time the excess thionyl chloride was removed and the crude product was purified over a reverse-phase preparative HPLC column eluting with 0-50 % acetonitrile in water, provided ER-885906 (4.3 mg, 0.014 mmol, 4.7 % yield) after combining the desired collected fractions, concentration and drying in vacuo.
  • the completed reaction was poured over saturated aqueous NaHC0 3 (4 mL) with 10 % aqueous sodium thiosulfate (2 mL). The mixture was stirred for 30 min after which time the mixture was extracted three times with DCM (4 mL each). The combined organic layers were washed with brine (4 mL), dried over Na 2 S0 4 , filtered and concentrated.
  • the crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 10 - 100% EtOAc in heptane) to provide 5-((2i?, ii?)-2- formyl-6-methylmorpholino)quinoline-8-carbonitrile, 43 or ER-886250 (110 mg, 0.391 mmol, 55.4 % yield) as a yellow syrup after combining the desired fractions, concentration and drying in vacuo.
  • silica gel Biotage SP4, 25 g, eluting with 10 - 100% EtOAc in heptane
  • the crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 20 - 100% EtOAc in heptane.
  • the stereochemistry for the free alcohol functionality for both examples was arbitrarily assigned.
  • ER-895326 To a stirred solution ER-895200 (17.9 mg, 0.060 mmol) in THF
  • the crude product was purified over silica gel (Biotage, eluting with a gradient of 0 - 10 % EtOAc in heptane) to provide ER-895326 (20.3 mg, 0.054 mmol, 90.1 % yield) after collection of the desired fractions, concentration and drying in vacuo.
  • ER-895327 (6.4 mg, 0.017 mmol, 63 % yield) was prepared in a similar manner to ER-895326- starting with ER-895310 (7.9 mg, 0.027 mmol) and 2- bromopyrimidine (8 mg, 0.0.50 mmol).
  • a reverse-phase preparative HPLC column Water's X-Bridge CI 8 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.1 % formic acid
  • the completed reaction was poured over saturated aqueous NaHC0 3 (0.4 mL) with 10 % aqueous sodium thiosulfate (0.2 mL). The mixture was stirred for 30 min after which time the mixture was extracted three times with DCM (0.3 mL each). The combined organic layers were washed with brine (0.35 mL), dried over Na 2 S0 4 , filtered and concentrated.
  • the crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 10 - 80% EtOAc in heptane) to provide 45 or ER-886625 (7 mg, 0.023 mmol, 37.1 %> yield) as a yellow solid after combining the desired fractions, concentration and drying in vacuo.
  • ER-886626 (10.8 mg, 0.030 mmol, 90.9 % yield) was prepared in a similar manner to ER-886625 starting with the mixture of ER-886532 and ER-886533 (12 mg, 0.033 mmol) .
  • ER-886629 (6.6 mg, 0.017 mmol, 81 % yield) was prepared in a similar manner to ER-886625 starling with the mixture of ER-886567 and ER-886568 (8 mg, 0.021 mmol) .
  • ER-886912 and ER- 886913 fractions were separately concentrated to dry, dissolved in MeOH (3 mL) and eluted over a carbonate impregnated silica gel column (Biotage Isolute SPE, Si-C0 3 , lg), washed with MeOH (3 mL), concentrated and dried in vacuo to provide ER-886912 (1.4 mg, 0.003 mmol, 3.9 % yield) as the first eluted peak and ER-886913 (0.6 mg, 0.001 mmol, 1.5 % yield) as the second eluted.
  • the stereochemistry for the amine functionality for both examples was arbitrarily assigned.
  • reverse-phase preparative HPLC column Water's X-Bridge CI 8 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA
  • ER-885113 To a stirred solution of 2-(di-/er -butylphosphino)biphenyl (20 mg, 0.067 mmol) and tris(dibenzylideneacetone)dipalladium(0) (20 mg, 0.022 mmol) in toluene (0.8 mL) under an nitrogen atmosphere was added commercially available 5-bromo- 8-methoxyquinoline (201 mg, 0.844 mmol), sodium t-butoxide (122 mg, 1.27 mmol) and cis- 2,6-dimethylmorpholine (125 mg, 1.085 mmol) at rt followed by toluene (0.8 mL).
  • 5-bromo- 8-methoxyquinoline 201 mg, 0.844 mmol
  • sodium t-butoxide 122 mg, 1.27 mmol
  • cis- 2,6-dimethylmorpholine 125 mg, 1.085 mmol
  • the reaction mixture was warmed to reflux and stirred for 3 h, after which time the completed reaction was cooled to rt followed by addition of water (5 mL).
  • the resultant mixture was extracted two times with EtOAc(5 mL each) and the combined organic layers were washed with brine (2 mL), dried over Na 2 S0 4 , filtered and concentrated to dryness.
  • the crude product was purified over silica gel twice (Biotage SP4, 25+S eluting with 12-100%) EtOAc in heptane) to provide ER-885113 (49 nig, 0.180 mmol, 21.3 % yield) after collection of the desired fractions, concentration and drying in vacuo.
  • ER-887960 (13.7 mg, 0.049 mmol, 23.5 % yield) was prepared in a similar manner to ER-885113 starting with 5-bromo-8-chloro- 1 ,7-naphthyridine (51 mg, 0.210 mmol) and czs-2,6-dimethylmorpholine (31.4 mg, 0.273 mmol)
  • reaction mixture was micro waved at 140 °C and stiiTed for 3 h after which time the completed reaction was cooled to rt, concentrated and purified over silica gel (Biotage, eluting with 30 - 80 % EtOAc in heptane) to provide 5-((25, (5S)-2-(hydroxymethyl)-6- methylmorpholino)quinolinc-8-carbonitrile or ER-885477 (165.2 mg, 0.583 mmol, 89.2 % yield) after concentration of the desired combined fractions and drying under vacuo.
  • the mixture was diluted with DCM (10 mL), the layers separated after which time the organic layer was washed two times with water (5 mL each), dried over MgS0 4 , filtered and concentrated.
  • the crude product was purified over a reverse phase HPLC column (X-Bridge C18 19 x 100 mm column; eluting with a linear gradient of 10% - 90% acetonitrile in water with 0.1% fomiic acid) and concentrating the desired peak followed by high vacuum to dryness to provide ER-886133 (35.2 mg 0.123 mmol, 69.3 % yield).
  • the completed reaction mixture was azeotroped two times with toluene (60 mL each) and then purified by silica gel column chromatography (n-heptane/MTBE 1 : 1) to give 66 (1.382 g, 3.29 mmol, 92% yield) as yellow oil.
  • Crude product was purified by silica gel column chromatography ( «-heptane/MTBE 4: 1) to provide 67 (847mg, 2.52 mmol, 77% yield) as a colorless oil and its stereoisomer (8.3 mg, 0.25 mmol, 7.5% yield) as a colorless oil.
  • the resultant mixture was heated to 140 °C and stirred for 2 h after which time the completed reaction was cooled to rt and partitioned between EtOAc(40 mL) and water (20 mL). Aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with water (10 ml) and concentrated to give crude product as brownish solid/oil. The crude product was purified over silica gel (eluting with n-heptane/EtOAcl : l) to give a 4: 1 mixture of the desired intermediated (0.684 mg).
  • the crude intermediate mixture (0.684 mg) was suspended in acetonitrile (6.0 ml) followed by iodotrimethylsilane (0.377 mL, 2.65 mmol) followed by heating to 60 °C and stirring for 2 h.
  • the completed reaction was cooled to 40 °C followed by the addition of water (3.0 ml) and the reaction was cooled to rt with stirring for an additional 1 h. 28% aq.
  • ER-890094 A solution of (3-(bromomethyl)phenyl)boi nic acid (129.5 mg,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Description

Selectively Substituted Quinoline Compounds CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to United States provisional patent application no. 61/890,718, filed on October 14, 2013. That application is incorporated by reference herein.
BACKGROUND
[0002] Field of the Disclosure
[0003] Embodiments of the disclosure relate to selectively substituted quinoline compounds and pharmaceutical agents comprising one or more of those compounds as active ingredient(s). More particularly, embodiments of the disclosure relate to those compounds that act as an antagonist or inhibitor for Toll-like receptors (TLR) 7 and 8, and their use in a pharmaceutical composition effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
[0004] Description of Related Art
[0005] Systemic lupus erythematosus (SLE) and lupus nephritis are autoimmune diseases characterized by inflammation and tissue damage. For example, SLE may cause damage to the skin, liver, kidneys, joints, lungs, and central nervous system. SLE sufferers may experience general symptoms such as extreme fatigue, painful and swollen joints, unexplained fever, skin rash, and kidney dysfunction. Because organ involvement differs amongst patients, symptoms may vary. SLE is predominantly a disease of younger women, with peak onset between 15-40 years of age and an approximate 10-fold higher prevalence in women vs. men.
[0006] Current treatments for SLE typically involve immunomodulatory drugs such as belimumab, hydroxychloroquine, prednisone, and cyclophosphamide. All of these drugs may have dose-limiting side effects, and many patients still have poorly controlled disease. BRIEF SUMMARY OF THE DISCLOSURE
[0007] Embodiments of the disclosure provide compounds and methods of use for preventing or treating diseases or conditions characterized by Toll-like receptor 7 or 8 activation in patients. One embodiment features a compound of formula (I):
Figure imgf000003_0001
wherein at least one of Ri and R2 is -H, methyl, or ethyl, and the other is
-H; or the other is
Ci-C6 alkyl that is optionally substituted with:
-OH, methoxy, ethoxy, -OCH(CH3)2, -0(CH2)2CH3, phenyl, furanyl, - 0(CH2)2OH, phenoxy, methylthio, -F, -N(C¾)2, cyano, pyridinyloxy, fluorophenoxy, isochromanyl, phenol, benzylamino, -NHCH3, oxo-, amino, carboxyl, 7-member spiroaminyl, a three to six member cycloalkyl, saturated or unsaturated and optionally including one or more heteroatoms selected from O and N, and optionally substituted at one or more C or N atoms by methyl, cyano, fluoro, methylamino, or trifluoromethyl; or the other is C3-C7 cycloalkane, saturated or unsaturated, optionally bridged, optionally including one or more heteroatoms selected from O, S, and N, and optionally substituted at one or more C or N atoms by methyl, ethyl, pyridinyl, azetidinyl, acetamidyl, carboxamidyl, cyano, fluoro, methylamino, or trifluoromethyl; or
Ri and R2, together with the nitrogen atom to which they are attached, form an 8 to 11 member spirodiamine, an 8 member bicyclodiamine, a 7 member spiroxamine, a piperidinyl optionally substituted with ethyl, or a four to six member cycloalkyl, optionally substituted with at least one of carboxamidyl, aminomethyl, methyl, (ethylamino)methyl, (dimethylamino)methyl, dimethylamino, (methylamino)methyl, and amino; and wherein R3 is -H or methyl.
[0008] In a further embodiment the compound is a compound of Formula (I), having the stereochemistry set forth in one of Formula (la), (lb), (Ic), or (Id), having the same substituent options as set forth above for Formula (la):
Figure imgf000004_0001
[0009] A further embodiment provides a compound of Formula (Ie) (relative stereochemistry indicated):
Figure imgf000005_0001
[0010] In a further embodiment the compound is a compound of Formula (II):
Figure imgf000005_0002
wherein
R is -H or methyl;
R5 is Ci-Cs alkyl that is saturated, partially saturated, or unsaturated, and that is optionally substituted with:
-H, -CI, -F, -OH, -NH2, oxo-, -N(CH2CH3)2, phenyl, cyclohexyl, phenyltriazolyl, cyclohexyltriazolyl, pyridinyl, pyrrolidinyl,
moipholinyl optionally substituted with methyl or hydroxymethyl,
-0-, substituted with:
Ci-C6 alkyl, methylphenyl, methylcyclohexyl, pyridinyl, diazinyl, or phenyl optionally substituted with -F or methyl,
-NH-, substituted with:
C2-C alkyl that is linear, branched, or cyclic, saturated or unsaturated, and optionally substituted with oxo-, phenyl, methyl, or -OH,
pyridinyl optionally substituted with methyl, methoxy, phenyl, or amino, diazinyl optionally substituted with ethyl, benzoimidazolyl, methylphenyl, phenylpyrazolyl, naphthyridyl, phenyl optionally substituted with -F, methyl, ethyl, or ethoxy, imidazolidin l optionally substituted with methyl
or R5 is
Figure imgf000006_0001
, wherein n is 1-3, and wherein the cyclic amine is optionally substituted with
Ci-C3 alkyl optionally substituted with
-OH, -F, phenyl, -NH2, cyclohexyl, -N(CH3)2, -C(0)NH2, methylsulfonamidyl, benzenesulfonamidyl, methylbenzenesulfonamidyl, or
pyrrolidinyl optionally substituted with methyl or hydroxyl, or -NHC(0)R6, wherein R6 is
Ci-Cs alkyl, phenyl, pyridinyl, fluorophenyl, methylsulfonyl, fluorobenzenesulfonyl, dimethyl pyrazole sulfonyl, or
pyrazolyl optionally substituted with methyl;
piperidinyl optionally substituted with -C(0)CH3, -C(0)CH2CH3, methyl, oxo-,
C(0)Ph, -NH2, -NH-C(0)CH3,
Figure imgf000006_0002
piperazinyl optionally substituted with -C(0)OC(CH3)3, methyl, -C(0)CH3, -C(0)Ph,
-C(0)CH3, or methylsulfonyl; or
Figure imgf000006_0003
, where n is 1 or 2, and wherein the cyclic diamine is optionally substituted on at least one carbon atom with
methyl, oxo-, -N(CH3)2, amino, -CH2CH3, or
piperidinyl optionally substituted with methyl, -C(0)CH3, -C(0)CH(CH3)2, -C(0)Ph, or -C(0)OC(CH3)3, and
wherein R7 is -H, phenyl, -C(0)CH3, C C3 alkyl, -C(0)NH2, or -C(0)Ph; and R8 is methoxy or cyano. [0011] A further embodiment provides a compound of Formula (III):
Figure imgf000007_0001
wherein
Rn is H or methyl;
Rio is H or, when both R14 and R are H, is methyl- 1, 4 '-bipiperidinyl;
R9 is -H or is -CH2- substituted by 1,4 '-bipiperidinyl, oxo-, hydroxyl, methylpyridinyl, or piperidinyl optionally substituted with hydroxyl, -N(CH3)2, or piperidinyl.
[0012] In a further embodiment the compound is selected from \-{2R, ^i?)-4-(8- cyanoquinolin-5-yl)-N-((5i?^5)-4-fluoiOpyrrolidin-3-yl)-6-methylmorpholine-2-carboxamide hydrochloride, (2R, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l -methylpiperidin-4- yl)morpholine-2-carboxamide, 5-((25', (5i?)-2-([l,4'-bipiperidin]- -ylmethyl)-6- methylmoipholino)quinoline-8-carbonitrile, and 5-((2R, 7i?)-2-(hydroxymethyl)-7-methyl- l,4-oxazepan-4-yl)quinoline-8-carbonitrile.
[0013] In a further embodiment the compound or pharmaceutically effective salt thereof of the preceding paragraph has an IC50 less than or equal to 20 nM against human TLR7 receptors expressed in a HEK-293 cell line. In a further embodiment the compound or pharmaceutically effective salt thereof of the preceding paragraph of this disclosure has an IC50 less than or equal to 100 nM against human TLR7 receptors expressed in a HEK-293 cell line. In a further embodiment the IC50 against human TLR7 receptors expressed in a HEK-293 cell line is measured by (1) plating cells of the HEK-293 cell line stably expressing TLR7 in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum at a density of 2.22X105 cells/ml into a 384-well plate and incubating for 2 days at 37 °C, 5 % CO2; (2) adding the compound or pharmaceutically acceptable salt thereof and incubating the cells for 30 minutes; (3) adding CL097 (InvivoGen) at 3ug/ml and incubating the cells for approximately 20 hours; and (4) quantifying NF-kappaB dependent reporter activation by measuring luminescence. [0014] In further embodiments of the disclosure, compounds have an IC50 against human TLR7 receptors expressed in a HEK-293 cell line less than or equal to 200 nM, less than or equal to 180 nM, less than or equal to 160 nM, less than or equal to 140 nM, less than or equal to 120 nM, less than or equal to 100 nM, less than or equal to 80 nM, less than or equal to 60 nM, less than or equal to 40 nM, or less than or equal to 20 nM. In further embodiments of the disclosure, compounds have an IC50 against human TLR7 receptors expressed in a HEK-293 cell line from 10 nM to 30 nM, from 10 nM to 50 nM, from 10 nM to 100 nM, from 30 nM to 50 nM, from 30 nM to 100 nM, or from 50 nM to 100 nM. In further embodiments the IC50 against human TLR7 receptors expressed in a HEK-293 cell line is measured by (1) plating cells of the HEK-293 cell line stably expressing TLR7 in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum at a density of 2.22X105 cells/ml into a 384-well plate and incubating for 2 days at 37 °C, 5 % C02; (2) adding the compound or pharmaceutically acceptable salt thereof and incubating the cells for 30 minutes; (3) adding CL097 (InvivoGen) at 3ug/ml and incubating the cells for approximately 20 hours; and (4) quantifying NF-kappaB dependent reporter activation by measuring luminescence.
[0015] Further embodiments provide methods for treatment of lupus, including but not limited to treatment of systemic lupus erythematosus, cutaneous lupus, neuropsychiatric lupus, fetal heart block, and antiphospholipid syndrome, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
[0016] Further embodiments provide methods for antagonizing TLR7, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
[0017] Further embodiments provide methods for antagonizing TLR8, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
[0018] Further embodiments provide pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt of the disclosure and at least one pharmaceutically acceptable carrier.
[0019] Further embodiments provide methods for treatment of systemic lupus erythematosus or lupus, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure. [0020] Further embodiments provide methods for antagonizing TLR7, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
[0021] Further embodiments provide methods for antagonizing TLR8, including administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of the disclosure.
[0022] Further embodiments provide pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt of the disclosure and at least one pharmaceutically acceptable carrier.
[0023] The term "optionally substituted," as used herein, means that the subject structure may include, but is not required to include, one or more substituents independently selected from lower alkyl, methoxy-, -OH, -N¾, -CH2-NH-CH2, -OCH2CH2C¾, or - OCH(CH3)2. If the optionally substituted moiety is cyclic, then the optional substitution may be a methyl bridge between two atoms in the ring.
[0024] The symbol "C(O)" as used herein refers to a carbonyl group having the formula C=0.
[0025] Unless otherwise specified, "a" and "an" as used in this disclosure, including the claims, mean "one or more."
[0026] As used herein, "lower alkyl" refers to straight, or, in the case of three- and four-carbon groups, straight, branched, or cyclic saturated hydrocarbons having between one and four carbon atoms.
[0027] As used herein, the term "attached through a nitrogen" when referring to a heterocyclic moiety including nitrogen, means that a point of attachment of the moiety to another structure is through a nitrogen that is part of the heterocycle.
[0028] As used herein, the term "TLR7/8" means "TLR7 and TLR8" or "TLR7 or
TLR8" or "TLR7 and/or TLR8." The particular meaning can be understood by a person skilled in the art based upon the context in which "TLR7/8" appears.
[0029] Heterocyclic moieties recited herein include azetidinyl, pyrrolidinyl, piperidinyl, methylazetidinyl, pyrazolyl, piperazinyl, morpholinyl, thiazolyl, pyrrolopyrrolyl, imidazolidinyl, and isothiazolyl. Where a heterocyclic group is mentioned, unless otherwise indicated it will be understood that the heterocyclic atom(s) in the group may be at any position in the group. It will further be understood that imidazolyl, pyrazolyl, thiazolyl, and pyrrolyl may be unsaturated or partially unsaturated. An embodiment of the disclosure may include a pharmaceutical composition that includes one or more compounds of the disclosure with a pharmaceutically acceptable excipient. These pharmaceutical compositions may be used to treat or prevent a disease or condition characterized by TLR7/8 activation in a patient, typically a human patient, who has or is predisposed to have such a condition or disease. Examples of diseases or conditions characterized by TLR7/8 activation include systemic lupus erythematosus (SLE) and lupus nephritis.
[0030] As used herein, "effective amount" of a compound of an embodiment of the disclosure is effective amount of the above-identified compounds in an amount sufficient to treat or prevent SLE and lupus nephritis.
[0031] Embodiments presented herein may include asymmetric or chiral centers.
Embodiments include the various stereoisomers and mixtures thereof. Individual stereoisomers of compounds of embodiments of the disclosure may be prepared synthetically from commercially available starting materials that contain asymmetric or chiral centers, or by preparation of mixtures of enantiomeric compounds followed by resolution of those compounds. Suitable methods of resolution include attachment of a racemic mixture of enantiomers, designated (+/-), to a chiral auxiliary, separation of the resulting diastereomer by chromatography or recrystallization and separation of the optically pure product from the auxiliary; or direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
[0032J Embodiments of the disclosure also include a pharmaceutical composition including any compound of the disclosure as well as a pharmaceutically acceptable excipient. The pharmaceutical compositions can be used to treat or prevent SLE and lupus nephritis. Therefore, embodiments of the disclosure may also feature a method for treating or preventing SLE or lupus nephritis in a human patient having or predisposed to having lupus nephritis or SLE.
[0033] Embodiments of the disclosure include pharmaceutically acceptable salts of the compounds presented herein. The term "pharmaceutically acceptable salt" refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic response. Pharmaceutically acceptable salts are well laiown in the art. For example, S. M. Berge, et al, describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences 66: 1-19, 1977. Salts can be prepared in situ during final isolation and purification of a compound or separately by reacting a free base group with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, monomaleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, trifluoroacetate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
[0034] The term "pharmaceutically acceptable ester," as used herein, represents esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic, and alkanedioic acids, in which each alkyl or alkenyl group typically has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyates, acrylates, and ethylsuccinates.
[0035] In this application enantiomers are designated by the symbols "R " or "5"' or are drawn by conventional means with a bolded line defining a substituent above the plane of the page in three-dimensional space and a hashed or dashed line defining a substituent beneath the plane of the printed page in three-dimensional space. If no stereochemical designation is made, then the structure definition includes both stereochemical options. If a structure or chemical name includes "REL" or "rel" then that structure is understood to show relative stereochemistry.
BRIEF SUMMARY OF THE FIGURES
[0036] FIG. 1A and FIG. IB show short-term in vivo suppression of the TLR7 pathway in mouse by compounds ER-899742 and ER-899464. Figure Legend: Female BALB/c mice were dosed by oral gavage with Vehicle alone (0.5% aqueous methyl- cellulose) or compound formulated in Vehicle at 33mg/kg, lOOmg/kg or 300mg/kg. At 6, 13 or 24 hours following oral dosing, mice were injected subcutaneously with 15ug R848 to stimulate TLR7. Blood plasma was collected by cardiac puncture, and the IL-6 level at 1.5 hours after TLR7 stimulation was then assessed by standard ELISA procedure. (FIG. 1A). ER-899742 and ER-899464 were tested side by side in a single experiment. (FIG. IB) A repeat experiment was done with ER-899742 examining all three doses at all three timepoints.
[0037] FIG. 2A through FIG. 2C show results of testing ER-899742 in the
NZBxNZW strain (abbreviated hereafter as NZBWF1/J or NZB/W) lupus disease model. Figure Legend: Female NZBWF1/J mice were received at 5 weeks of age, baseline bleeds were performed, and mice were monitored for disease progression by following anti-dsDNA titers. At 27 weeks of age, mice were randomized into groups with equivalent median anti- dsDNA titers and treated at 29 weeks of age with Vehicle (Veh; 0.5% methyl-cellulose) alone or 33, 100, or 300mg/kg once-a-day orally (QD PO). At 46 weeks of age after 17 weeks of treatment mice were bled and tested for anti-dsDNA titers. All mice were sacrificed at 50 weeks of age (21 weeks of compound treatment). (FIG. 2 A) Just prior to termination at 50 weeks of age (following 21 weeks of treatment), urine was collected from individual mice, and the Urinary Albumin Creatinine Ratio (UACR, proteinuria) was determined for each animal as an indirect measure of kidney function. (FIG. 2B) Timecourse of mortality observed in this study for the highest and lowest dose groups. No mortality was seen with compound treatment. Further, no mortality was observed in the middle dose group (not shown). (FIG. 2C) Impact of treatment on anti-dsDNA titers after 17 weeks of dosing, at 46 weeks of age. No statistically significant effect was observed.
[0038] FIG. 3 A through FIG. 3E show results of testing compound ER-899742 in the
Pristane: DBA/1 strain lupus disease model. Figure Legend: Female DBA/1 mice at 9 weeks of age were given an intraperitoneal injection of 0.5ml pristane or PBS. At 9 weeks post- pristane animals were bled for auto-antibody titers. Once-a-day oral dosing with Vehicle (Veh; 0.5% methyl-cellulose) or 33 mg/kg, 100 mg/kg, or 300 mg/kg of ER-899742 was begun 10 weeks after pristane injection and continued for 13 weeks of treatment. Mice were euthanized after 13 weeks of compound treatment, and anti-dsDNA (FIG. 3 A), anti- Sm/nRNP (FIG. 3B), anti-histone (FIG. 3C) and anti-RiboP (FIG. 3D) titers were measured in blood plasma samples by ELISA (statistical significance of treatment versus vehicle determined by ANOVA with Dunnett's post-test). (FIG. 3E) The expression of IFN- regulated genes in whole blood was measured by a qPCR panel after 13 weeks of treatment with 300 mg/kg of ER-899742, and an IFN gene signature score was calculated (see Pharmacology Materials and Methods section for details regarding IFN score calculation). The table shows the full list of genes significantly upregulated by pristane treatment vs. PBS controls. When interferon scores were calculated, no significant difference was seen between treated and vehicle-treated animals. However six genes were significantly reduced by compound treatment vs. vehicle treatment (Student's t-test) and are marked in the table.
[0039] FIG. 4A through FIG. 4C show results of testing E -899464 in the NZB/W disease model in the same experiment as FIG. 2 A. Figure Legend: (FIG. 4 A) Just prior to termination at 50 weeks of age (following 21 weeks of treatment), urine was collected from individual mice, and the Urinary Albumin Creatinine Ratio (UACR, proteinuria) was determined for each animal as an indirect measure of kidney function. (FIG. 4B) Summary of mortality observed in this study for the highest and lowest dose groups. No mortality was seen in the middle dose group (not shown). (FIG. 5C) Impact of treatment on anti-dsDNA titers after 17 weeks of dosing, at 46 weeks of age. No statistically significant effect was observed.
[0040] FIG. 5A through FIG. 5D show results of testing ER-899464 in the Pristane disease model in the same experiment as that shown in FIG. 3A through FIG. 3E. Figure Legend: Mice were euthanized after 13 weeks of compound treatment, and anti-dsDNA (FIG. 5A), anti-Sm/nRNP (FIG. 5B), anti-histone (FIG. 5C), and anti-RiboP (FIG. 5D) titers were measured in blood plasma samples by ELISA (statistical significance of treatment versus vehicle determined by ANOVA with Dunnett's post-test). As was done for ER- 899742, interferon-driven gene expression was tested, but none of the disease up-regulated genes shown in FIG. 3B were affected by treatment with ER-899464.
[0041] FIG. 6 shows structures and corresponding chemical names according to various embodiments presented herein. "ER-Number" is a reference number assigned to each compound. Where available, activity against a HEK cell line stably expressing human TLR7, activity against a HEK cell line stably expressing human TLR9, 1H NMR data, and mass spectrometry data are also included.
[0042] FIG. 7A through FIG. 7G show the effect of dosing with ER-899742 in
Pristane-induced disease in DBA/1J mice. Figure Legend: Female DBA/1 mice at 9 weeks of age were given an intraperitoneal injection of 0.5ml pristane or PBS. At 10 weeks post- pristane animals were bled for auto-antibody titers. Once-a-day oral dosing with Vehicle (Veh; 0.5% methyl-cellulose) or 33 mg/kg, or 300 mg/kg of ER-899742 was begun 11 weeks after pristane injection and continued for 14 weeks of treatment. Mice were euthanized after 14 weeks of compound treatment, and anti-dsDNA (FIG. 7A), anti-RiboP (FIG. 7B), anti- Sm/nRNP (FIG. 7C), and anti-histone (FIG. 7D) titers were measured in blood plasma samples by ELISA (statistical significance of treatment versus vehicle determined by ANOVA with Dunnett's post-test). The same plasma was used to measure total IgG titers by ELISA at the end of dosing (FIG. 7E). Control of autoantibody against dsDNA and RiboP was seen in the presence of minimal changes in overall IgG level. Pristane-treated mice in this experiment developed arthritis, with swollen joints in the rear paws. Arthritis scores were assigned according to severity, each paw was scored on a scale of 0-4 based on signs of swelling and inflammation. Scores were summed for the two hind paws assessed on each animal, and graphed in FIG. 7F with statistical assessment as for ELISA titers above. Dose- dependent statistically significant suppression was observed. When interferon scores were calculated, no significant difference was seen between treated and vehicle-treated animals. However FIG. 7G demonstrates the downregulation of five out of 28 disease-related interferon-modulated genes upon treatment with ER-899742.
[0043] FIG. 8 contains the result of treating for a month with ER-899742 in Pristane- induced disease in DBA/1 J mice with advanced disease, after development of high levels of autoantibody. Figure Legend: DBA/1 J mice were injected i.p. with pristane at 10 weeks of age. Three months later anti-RiboP and anti-dsDNA titers were taken, and animals randomized into groups with matching mean titers. Groups were sacrificed after one, two or four weeks of oral dosing with ER-899742, and RiboP titers measured in serum. FIG. 8 demonstrates no statistically significant reversal of anti-RiboP or DNA titers after 28 days of dosing, although dosing was associated with lack of increase in titers.
[0044] FIG.. 9 is an ORTEP plot of the crystal structure of ER-899742 as a HC1 salt.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0045] I. TLRs and Lupus
[0046] In addition to their role as innate immune receptors capable of detecting exogenous ("non-self) pathogen-associated molecular patterns (PAMPs - i.e., bacterial LPS detection by TLR4), mammalian Toll-like receptors (TLRs) are also capable of recognizing endogenous stimuli (DAMPs) released following host tissue damage or stress. Kono, H. and K.L. Rock, How dying cells alert the immune system to danger. Nat Rev Immunol, 2008. 8(4): p. 279-89. In the last decade an appreciation for the link between TLR activation by endogenous ("self) danger-associated molecular patterns (DAMPs) and the etiology of autoimmune disorders has emerged. Specifically, TLR7 can be activated by single-stranded RNA (ssRNA) derived from both mammalian and viral sources, whereas TLR9 can be activated by DNA derived from mammalian, viral, and bacterial sources.
[0047] Lupus is characterized by auto-antibodies reactive against double-stranded
DNA (dsDNA) itself and associated proteins (histones) as well as against a broad array of RNA-associated proteins such as Ro, La, Smith (Sm), and Ul snR P. Kirou, K.A., et al., Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthiitis Rheum, 2005. 52(5): p. 1491-503. A second common hallmark of lupus, which was shown to correlate directly with disease severity, is dysregulated expression of type-1 interferons (IFNs), in particular IFNa, and the corresponding elevation of a large panel of IFNalpha- regulated genes in lupus patients' PBMC (the so called "type-1 IFN gene signature"). Kirou, K.A., et al., supra. A major source of IFN in the blood is a specialized immunocyte called a plasmacytoid dendritic cell (pDC), which constitutively expresses both TLR7 and TLR9.
[0048] A causal relationship between these two disease characteristics, autoantibodies and IFN levels, was postulated when a number of research groups collectively demonstrated that antibody complexes isolated from lupus patients but not from healthy donors are capable of driving IFN production by pDC in a TLR7/9- and RNA/DNA- dependent manner. Means, T.K., et al., Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest, 2005. 115(2): p. 407-17; Vollmer, J., et al., Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med, 2005. 202(1 1): p. 1575-85; Savarese, E., et al., Ul small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood, 2006. 107(8): p. 3229-34. Moreover, IFN stimulates increased TLR7/9 expression on B-cells, thereby enhancing TLR/BCR (B-cell receptor) activation of auto-reactive B-cells to differentiate to antibody- producing plasma cells. Banchereau, J. and V. Pascual, Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity, 2006. 25(3): p. 383-92; In this fashion, levels of auto-antibody complexes containing nucleic acid TLR7/9 ligands drive the pro-inflammatory cycle and lupus disease progression. We believe it is likely that pharmacological antagonism of TLR7/8 will offer therapeutic benefit to lupus patients by disrupting this pro-inflammatory cycle, decreasing IFN levels, and dampening the autoimmune disease process mediated by pDC and B-cells.
[0049] Several other lines of evidence suggest a role for TLR7 in human lupus etiology and support the notion that TLR receptors are valid targets for disease intervention. Specific polymorphisms in the 3' UTR of TLR7 have been identified and shown to correlate with both elevated TLR7 expression and enhanced IFN gene signature. Shen, N., et al., Sex- specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A, 2010. 107(36): p. 15838-43. Deng, Y. et al, MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLOS Genetics, 2013. el003336. In addition, lupus standard-of-care (SOC) anti-malarial drugs such as chloroquine disrupt endosomal TLR7/9 signaling and inhibit PBMC and/or pDC IFNalpha production induced by ssRNA- ribonucleoprotein complexes or lupus patient serum. Moreover, myeloid DC and monocytes produce IL-12p40, TNF alpha, and IL-6 following self-RNA/TLR8 signaling, suggesting the additional contribution of TLR8 -dependent pro -inflammatory cytokines to human lupus etiology in addition to TLR7-driven IFN by pDC. Vollmer, supra; Gorden, K.B., et al, Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol, 2005. 174(3): p. 1259-68.
[0050] Mouse model evidence also exists for the role of TLR in lupus. Published studies have collectively demonstrated that both single TLR7 or dual TLR7/9 gene deletion or dual TLR7/9 pharmacologic inhibition reduces disease severity in four distinct lupus models. Nickerson, K.M., et al., TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol, 2010. 184(4): p. 1840-8; Fairhurst, A.M., et al., Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur J Immunol, 2008. 38(7): p. 1971-8; Deane, J.A., et al., Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity, 2007. 27(5): p. 801-10; Savarese, E., et al., Requirement of Toll-like receptor 7 for pristane- induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum, 2008. 58(4): p. 1107-15. Highlighting the role of TLR7 as a critical determinant of autoimmunity, transgenic overexpression of TLR7 alone leads to spontaneous anti-RNA auto-reactivity and nephritis in the normally disease-resistant C57BL/6 strain. Deane, supra.
[0051] From a safety perspective, there are no reports that TLR7, 8, or 9-single or
7/8- and 7/9-dual gene deficient mice are immune-compromised to the extent that infection by opportunistic pathogens is observed. Likewise, SOC anti-malarials are thought to be largely safe and effective for long-term use in humans to control lupus disease flare at doses predicted to at least partially inhibit TLR7/9 signaling. Lafyatis, R., M. York, and A. Marshak-Rothstein, Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum, 2006. 54(10): p. 3068-70; Costedoat-Chalumeau, N., et al, Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum, 2006. 54(10): p. 3284-90. In fact, save for increased susceptibility to Gram-positive bacterial infections in childhood and to a lesser extent in adulthood, humans with highly compromised TLR and IL-1R signaling pathways (MyD88- or IRAK-4-deficiency) are nonetheless healthy and maintain sufficient host defense mechanisms. Casanova, J.L., L. Abel, and L. Quintana-Murci, Human TLRs and IL-IRs in Host Defense: Natural Insights from Evolutionary, Epidemiological, and Clinical Genetics. Annu Rev Immunol, 2010.
[0052] Based on this and other information, we believe that TLR7 in particular is a well-validated target in the context of mouse pre-clinical SLE models. Both genetic and functional human studies support the hypothesis that antagonism of the TLR7 and/or TLR8 pathways will afford therapeutic benefit to lupus patients. Moreover, both mouse TLR gene deletion studies and the long-term use of anti-malarials in humans suggest that pharmacological TLR7, 8 and/or 9 suppression can be undertaken without significantly compromising host defense.
[0053] A compound that suppresses TLR7, TLR8, or both TLR7 and TLR8 may therefore be expected to act as a therapeutic or prophylactic agent for SLE or lupus nephritis.
[0054] The present inventors have found compounds that suppress TLR 7 and/or 8 and are therefore expected to have a prophylactic or therapeutic effect on SLE or lupus nephritis. Compounds and methods of the disclosure are described herein.
[0055] II. Therapeutic Use
[0056] Dosage levels of active ingredients in the pharmaceutical compositions of the disclosure may be varied to obtain an amount of the active compound(s) that achieves the desired therapeutic response for a particular patient, composition, and mode of administration. The selected dosage level depends upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. Doses are determined for each particular case using standard methods in accordance with factors unique to the patient, including age, weight, general state of health, and other factors that can influence the efficacy of the compound(s) of the disclosure. In general, in the case of oral administration, the compound according to the present disclosure or a pharmaceutically acceptable salt thereof is administered at a dose of approximately 30 μg to 100 μg, a dose of 30 μg to 500 μg, a dose of 30 μg to 10 g, a dose of 100 μg to 5 g, or a dose of 100 μg to 1 g per adult per day. In the case of administration via injection, it is administered at a dose of approximately 30 μg to 1 g, a dose of 100 μg to 500 mg, or a dose of 100 μg to 300 mg per adult per day. In both cases, a dose is administered once or divided over several administrations. Dosage may be simulated, for example, using the Simcyp® program. [0057] It is not intended that the administration of a compound of the disclosure to a mammal, including humans, be limited to a particular mode of administration, dosage, or frequency of dosing. The present disclosure contemplates all modes of administration, including oral, intraperitoneal, intramuscular, intravenous, intraarticular, intralesional, subcutaneous, or any other route sufficient to provide a dose adequate to prevent or treat SLE or lupus nephritis. One or more compounds of the disclosure may be administered to a mammal in a single dose or multiple doses. When multiple doses are administered, the doses may be separated from one another by, for example, several hours, one day, one week, one month, or one year. It is to be understood that, for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of a pharmaceutical composition that includes a compound of the disclosure.
[0058] For clinical applications, a compound of the present disclosure may generally be administered intravenously, subcutaneously, intramuscularly, colonically, nasally, intraperitoneally, rectally, buccally, or orally. Compositions containing at least one compound of the disclosure that is suitable for use in human or veterinary medicine may be presented in forms permitting administration by a suitable route. These compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media, and various non-toxic organic solvents. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988, 1999, Marcel Dekker, New York. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs, or syrups, and the compositions may optionally contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, and stabilizers to obtain pharmaceutically acceptable preparations.
[0059] The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the product, the particular mode of administration, and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, and dicalcium phosphate and disintegrating agents such as starch, alginic acids, and certain complex silicates combined with lubricants (e.g., magnesium stearate, sodium lauryl sulfate, and talc) may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used, they may contain emulsifying agents that facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol, chloroform, or mixtures thereof may also be used.
[0060] For parenteral administration, emulsions, suspensions, or solutions of the compositions of the disclosure in vegetable oil (e.g., sesame oil, groundnut oil, or olive oil), aqueous-organic solutions (e.g., water and propylene glycol), injectable organic esters (e.g., ethyl oleate), or sterile aqueous solutions of the pharmaceutically acceptable salts are used. The solutions of the salts of the compositions of the disclosure are especially useful for administration by intramuscular or subcutaneous injection. Aqueous solutions that include solutions of the salts in pure distilled water may be used for intravenous administration with the proviso that (i) their pH is adjusted suitably, (ii) they are appropriately buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride, and (iii) they are sterilized by heating, irradiation, or microfiltration. Suitable compositions containing a compound of the disclosure may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid canier for use in a dry powder inhaler. Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the disclosure.
[0061] Dosage formulations of a compound of the disclosure to be used for therapeutic administration should be sterile. Sterility is readily accomplished by filtration through sterile membranes (e.g., 0.2 micron membranes) or by other conventional methods. Formulations typically are stored in lyophilized form or as an aqueous solution. The pH of the compositions of this disclosure in some embodiments, for example, may be between 3 and 11, may be between 5 and 9, or may be between 7 and 8, inclusive.
[0062] While one route of administration is by oral dosage administration, other methods of administration may be used. For example, compositions may be administered subcutaneously, intravenously, intramuscularly, colonically, rectally, nasally, or intraperitoneally in a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations, and topical formulations such as ointments, drops, and dermal patches. Compounds of embodiments of the disclosure may be incorporated into shaped articles such as implants, including but not limited to valves, stents, tubing, and prostheses, which may employ inert materials such as synthetic polymers or silicones, (e.g., Silastic® compositions, silicone rubber, or other commercially available polymers). Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy- propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide- polylysine substituted with palmitoyl residues. Furthermore, a compound of the disclosure may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross linked or amphipathic block copolymers of hydro gels.
[0063] A compound of the disclosure may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine, or phosphatidylcholines. A compound of the disclosure may also be delivered using antibodies, antibody fragments, growth factors, hormones, or other targeting moieties to which the compound molecules are coupled (e.g., see Remington: The Science and Practice of Pharmacy, vide supra), including in vivo conjugation to blood components of a compound of an embodiment of the disclosure.
[0064] III. Synthesis
[0065] General and specific synthesis routes are provided that we found useful for preparation of embodiments of the disclosure. Those skilled in the art may recognize that certain variations or modifications of these procedures could also lead to synthesis of compounds according to the disclosure. In some situations the phrase "such as" is used to enumerate various alternatives for more generic compounds or structures. It will be understood that "such as" should not be construed to be limiting, and that its meaning is in accord with "including, for example, but not limited to."
[0066] Certain conditions were common to specific examples presented below.
Microwave heating was done using a Biotage® Emrys Liberator or Initiator microwave reactor. Column chromatography was carried out using Biotage® SP4 flash chromatography system. Solvent removal was carried out using either a Biichii rotary evaporator or a Genevac® centrifugal evaporator. NMR spectra were recorded at 400 MHz on a Varian Unity® spectrometer using deuterated solvents. Chemical shifts are reported relative to residual protonated solvent. [0067] Thin layer chromatography was performed on Whatman® glass plates precoated with a 0.25 mm layer of silica gel using various ratios of one or more of the following solvents: EtOAc, heptane, dichloromethane or MeOH.
[0068] Analytical LC/MS was performed for many examples on a Waters Acquity™ system using an XBridge™ CI 8 1.7μηι 2.1 χ 50mm column. Solvents A and B are Water w/ 0.1% formic acid and Acetonitrile w/ 0.1% formic acid, respectively. 5 minute total method time with 5% B to 99% B over 4 minutes with a flow rate of 0.3 ml/min. Mass spectral data were acquired on a Waters SQD from 100-2000 amu in electrospray positive mode.
[0069] Alternatively, purity and mass confirmation were carried out on a Waters
Autopurification system using an XBridge™ C8 3.5μηι 4.6 χ 50mm column. Solvents A and B are water w/ 0.1% formic acid and acetonitrile w/ 0.1% formic acid, respectively. 6 minute total method time with 10% B to 95% B over 5 minutes with a flow rate of 2.5 ml/min. Mass spectral data were acquired on a Micromass ZQ™ from 130-1000 amu in electrospray positive mode.
[0070] Preparative reverse phase LC/MS was carried out for many examples on a
Waters Autopurification system using an XBridge™ C8 5μιη, 19 x 100mm column. Solvents A and B are water w/ 0.1% formic acid and Acetonitrile w/ 0.1% formic acid, respectively. 12 minute total method time with 30% B to 95% B over 10 minutes with a flow rate of 20 ml/min. Mass spectral data were acquired on a Micromass ZQ™ from 130-1000 amu in electrospray positive mode.
[0071] Preparative HPLC resolution of racemic compounds was earned out for many examples using one of the following chiral columns: Chiralpak® IA (5 cm x 50 cm or 2 cm x 25 cm), Chiralpak® AD (2 cm χ 25 cm) or Chiralcel® OD (2 cm x 25 cm). Enantiomer ratios of purified compounds were determined by HPLC analysis on a 0.45 cm x 25 cm column comprised of the same stationary phase (IA, AD or OD).
[0072] General methods and experimentals for preparing compounds of the present disclosure are set forth below. In certain cases, a particular compound is described by way of example. However, it will be appreciated that in each case a series of compounds of the present disclosure were prepared in accordance with the schemes and experimentals described below. For those compounds where NMR and/or mass spectrometry data are available, the data is presented in FIG. 6.
[0073] The following abbreviations are used herein:
Definitions: The following abbreviations have the indicated meanings:
AcOH: acetic acid anhyd: anl ydrous
aq.: aqueous
Bn: benzyl
Boc: tert-butoxycabonyl
CSA: Camphor sulfonic acid
d: day(s)
DAMP: Danger- Associated Molecular Pattern
DBU: l,8-Diazobicyclo[5.4.0]undec-7-ene
DCE: 1,2-dichloroethane
DCM: dichloromethane
DIPEA: N,N-diisopropylethylamine
DMA: N,N-Dimethylacetamide
DMAP: 4-Dimethylaminopyridine
DMF: N,N-dimethylformamide
DMSO: Dimethyl sulfoxide
dsDNA: double-stranded DNA
EDC: l-(3-dimethylaminopiOpyl)-3-ethylcarbodiimide hydrochloride ee: enantiomeric excess
EtOAc: ethyl acetate
EtOH: ethanol
h: hour(s)
HATU: N.N.N'.N'-Tetramethyl-O-CT-azabenzotriazol-l-yl) hexafluoropho sphate
HC1: hydrochloric acid
HCQ: hydroxychloroquine
hep: n-heptane
HEPES: 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid
HPLC: high performance liquid chromatography
IFN: interferon
IP A: isopropyl alcohol or isopropanol
K2C03: potassium carbonate
MeOH: methanol
MgS04: magnesium sulfate (anhydrous)
min: minute(s) MTBE: methyl teri-butyl ether
Na2C03: sodium carbonate
Na2S04: sodium sulfate (anhydrous)
NaBH4: sodium borohydride
NaCl: sodium chloride
NaH: 60% sodium hydride dispersed in oil
NaHC03 : sodium bicarbonate
NaOH: sodium hydroxide
NBS: N-bromosuccinimide
NH4CI: ammonium chloride
NH4CI: ammonium chloride
NH4OH: ammonium hydroxide
NMP: N-methylpyrrolidone
Ns: Nosyl or o-nitrobenzenesulfonyl
°C: degrees Celsius
PAMP: Pathogen- Associated Molecular Pattern
PBMC: peripheral blood mononuclear cell
PBS: phosphate buffered saline
pDC: plasmacytoid dendritic cell
PhNTf2 : N-phenyltrifluoromethanesulfonimide
qPCR: quantitative polymerase chain reaction
R848: resiquimod
rt: room temperature
sat: saturated
SNAP: BIOTAGE® brand flash chromatography cartridge
SOC: standard-of-care
ssRNA: single-stranded RNA
T3P: Propylphosphonic anhydride
tBuOK: potassium fe/ -butyloxide
TEA: triethylamine
TEMPO: 2,2,6,6-Tetramethylpiperidine 1-oxyl
Tf: trifluoromethanesulfonate
TFA: trifluoroacetic acid
THF: tetrahydrofuran TLDA: Taqman® Low Density Array
TLR: Toll-like receptor
TSA: p-toluenesulfonic acid
|0074] General Synthetic Methods :
[0075] Compounds were made according to the general synthetic methods shown in
Schemes 1 - 31:
[0076] Scheme 1
Figure imgf000024_0001
[0077] 1 *■ °
[0078] The preparation of several of the examples use key intermediate 3, which is can be prepared according to the route depicted in Scheme 1. The commercially available 5- bromoquinoline-8-carbaldehyde 1 (Frederieric de Montigny, Gilles Argouarch, Claude Lapinte, "New Route to Unsymmetrical 9,10-Disubstituted Ethynylanthracene Derivatives," Synthesis, 2006 , 293-298.) is treated with hydroxylamine hydrochloride to provide the oxime 2. 2 is subsequently converted to the corresponding nitrile 3 in the presence of catalytic amount of copper acetate to provide one of the key intermediates reported herein. Intermediate 3 is used for the generation of compounds reported herein by the displacement of the 5-position of 5-bromoquinoline-8-carbaldehyde with appropriate aromatic, heteroaromatic and saturated heterocyclic compounds such as piperidines, piperazines and morpholines using appropriate conditions described in detail below.
[0079] An alternative method for the generation of the key intermediate 3 is shown in
Scheme 2 wherein triethylamine for the first step of the synthesis is replaced with sodium acetate.
[0080] Scheme 2
Figure imgf000025_0001
[0081] 1 ί ύ
[0082J Several examples are produced by the general condensation process as depicted in Scheme 3, wherein bromoquinoline 3 is condensed with the appropriate nucleophile 4 to form 5 which may be either a key intermediate or a final compound described in more detailed below.
[0083J Scheme 3
Figure imgf000025_0002
[0085] A number of the examples represented by compound 15 were prepared from the advanced intermediate 14 as depicted in the general method shown in Scheme 4. An appropriately protected chiral epoxide 6 is condensed with allyl amine to provide the chiral aminoalcohol 7. After protection of the secondary amine with a nesylate the resultant intermediate 8 is intermolecularly cyclized to form the unsaturated pyran 9. Reduction of the enamine double bond to form 10 was followed by deprotection of the nesyl group to provide 9. Condensation of 11 with the bromide 3 (Scheme 1 or 2) with or without the use of a palladium catalyst provides 12, after which deprotection of 13 followed by activation of the resulting alcohol provides the key intermediate 14. Activated 14 can be easily transformed to a number of the examples provided below by the use of the appropriately substituted amine and condensation reagents to provide compounds of general structure 15. [0086] Scheme 4
Figure imgf000026_0001
[0088] An alternative method for the preparation of general structure 10 is depicted in
Scheme 5. Radical cyclization of the protected alcohol 8 can be obtain by treatment with N- bromosuccinimide to provide 16. Elimination of the bromo-group using base provides the enol 17, which is then reduced with a silane to provide intermediate 10.
[0089] Scheme 5
Figure imgf000026_0002
[0090] 8 16 17 10
[0091] An alternative method for the preparation of general structure 11 is depicted in
Scheme 6. Starting with the chiral epoxy starting material 6, one forms the alcohol 18 after protection of the secondary amine with a Boc-protecting group. Lactonation using water soluble DCC provides 19 which then can be subjected to alkylation using an alkyl lithium, such as methyl lithium to form a mixture of ketals, 20 and 21. The ketal mixture is subsequently reduced to form a diastereomeric mixture of morpholine compounds 22 (being the desired diastereomer isomer) and 23 which can be easily separated by silica gel column chromatography. The ratio of the methyl morpholine mixture was found to be from 4:1 to 9:1 in favor of structure 22. X-ray crystal stractures were obtained of subsequent, advanced compounds to confirm the absolute stereochemistry of compound 22. Compound 22 is easily converted to 11 by deprotection with acid such as TFA followed by neutralization with a base.
[0092] Scheme 6
Figure imgf000027_0001
- e:22 (desired; major) 22 11
[0093] a-Me: 23 (undesired; minor)
[0094] A third method for the preparation of key intermediate 11 is shown in Scheme
7. The commercially available protected epoxide 6 is condensed with aqueous ammonia to provide the amino alcohol 23 which in turn is condensed with the chiral chloropropinate 24 to form the enantiomerically pure amide 25. Ether formation using a strong base such as sodium hydride provides lactam 26, which can be converted to intermediate 11 by amide reduction to the cyclic amine.
[0095] Scheme 7
Figure imgf000028_0001
23 24
Figure imgf000028_0002
[0096] 25 26 11
[0097] An alternative method for the production of examples encompassed in the generic structure 5 in Scheme 3 and compound 12 in Scheme 4 is illustrated in Scheme 8. The starting materials 28 and 30, prepared from commercially available sources (27 & 29), can be easily condensed in the presence of an inorganic base to form 31. The phenolic protecting group is removed via reductive hydrolysis to form 32, the acetal protecting group is hydrolized with acid to form the aldehyde 33, and then formation of the bicyclic heterocycle 34 under catalytic acidic, condensation conditions. The phenolic hydroxyl group on 34 is then activated to form 35, which subsequently can be condensed with 11 to form 12 as shown in Scheme 4. Compound 11 can be replaced by other nucleophiles as shown in the examples below.
[0098] Scheme 8
Figure imgf000029_0001
[0099]
[0100] Two alternative methods for the preparation of compounds with general structure 15 use the processes depicted in Scheme 9 and 10. Intermediate 13 is activated by fomiing the triflate 36 followed by displacement with the appropriate amine in the presence of base such as potassium carbonate to form the desired target compound 15 as depicted in Scheme 9.
[0101] Scheme 9
Figure imgf000029_0002
[0103] Starting with the Boc-protected chiral morpholine 22 from Scheme 6, one familiar in the art is able to produce additional examples of compounds with general structure 15 by the conversion of the protected alcohol to the azide intermediate 37 as shown in Scheme 10. 37 is easily converted to the primary amine ER-884884 after reduction of the azide, deprotection of the Boc-group, and condensation with 3. ER-884884 likewise can be converted to additional analogs depicted by general structure 15 by either alkylation or acylation processes.
[0104] Scheme 10 [0105]
Figure imgf000030_0001
[0106] Preparation of alternative set of compound examples is by oxidation of the key intermediate 13 to form 38 followed by formation of the examples via amide coupling conditions to form 39 as shown in Scheme 11. The preparation of some of the examples using this general method will require one or two additional steps to provide the desired target compounds of general structure 40. Likewise various esters depicted by general structure 41 can be easily produced from 38 using various methods by those persons familiar with the art.
[0107] Scheme 11
Figure imgf000030_0002
[0109] Likewise, ether examples are prepared by two possible methods: (1) the displacement of activated group on an alkyl, alkenyl or aryl functional group using base and compound 11 from Scheme 4; or using the activated alcohol 14 or 36 with phenols or alkyl alcohols in the presences of an appropriate base. Both methods to provide examples with the general chemical structure 42 are shown in Scheme 12.
[0110] Scheme 12
Figure imgf000030_0003
[0111] 14 or 36 [0112] Key intermediate 13 may also be oxidized to form an aldehyde 43 followed by condensation with various alkyl and aryl coupling reagents to provide examples 44 or 46 as depicted in Scheme 13. The resultant products can then be transformed to additional examples by either oxidation of 44 to provide compounds of general structure 45 or reduction of 46 to provide compounds of general structure 47 where n = 2. Likewise persons familiar with the art may generate the additional examples from intermediate 44 by activation of the hydroxyl group such as forming the triflate followed by reduction using several possible reducing reagents to provide examples that contains one less methylene group or 47 where n = 1.
[0113] Scheme 13
Figure imgf000031_0001
[0114] 46
[0115] A final set of examples are prepared by the use of Scheme 14. Using the same synthetic methodology to prepare compound 13 in Scheme 4, one can prepare the desired seven-membered heterocycle 68 replacing allyl amine with l-amino-3-butente 62. 68 can then be activated and then condensed with various substituted amines to generate additional analogs in a similar manner as shown in several the schemes depicted above.
[0116] Scheme 14
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000032_0003
[0117] 67 68 or ER-889363
[0118] Preparation of Examples
[0119] Compound 3 - Scheme 1
[0120] To a suspension of 5-bromoquinoline-8-carbaldehyde 1 (1.00 g, 4.24 mmol) and hydroxylamine hydrochloride (1.177 g, 16.94 mmol) in acetonitrile (110 mL) was added TEA (2.362 mL, 16.94 mmol) followed by heating to reflux for 3 h to afford a yellow suspension. The completed reaction completion was cooled to rt, the precipitate was filtered, and the filter cake rinsed with acetonitrile (50 mL). The crude solid was purified over a short pad of silica gel (10 g) eluting with EtOAc (300 mL) providing the aldoxime 2 as a yellow solid.
[0121] Aldoxime 2 (l.OOlg, 4.0 mmol) and copper (II) acetate monohydrate (84.6 mg, 0.424 mmol) in anhydrous acetonitrile (180 mL) were stiffed at reflux for 12 h. The completed reaction was cooled to rt, filtered and the filter pad washed with H20 to afford a brown solid. The crade solid was purified over a short pad of silica gel (ca. 10 g) eluting with (DCM 100 mL) to provide 5-bi moquinoline-8-carbonitrile, 3 (0.783 g, 3.4 mmol, 79.3 % yield over 2 steps) as a white-beige solid after concentration and drying in vacuo the eluted product. See: Frederieric de Montigny, Gilles Argouarch, Claude Lapinte, Synthesis, 2006 , 293.
[0122] Compound 3- Scheme 2
[0123] To a stirred solution of sodium acetate trihydrate (31.6 g, 0.232 mol) in EtOH
(0.498 L) at 15 °C was added 5-bromoquinoline-8-carbaldehyde (49.84 g, 0.211 mol) followed by hydroxylamine hydrochloride (15.55 g, 0.223 mol). The resultant mixture was heated to 70 °C for 3 h after which time the reaction was cooled to 35 °C and then diluted with water (250 mL). The mixture was partially concentrated to approximately 250 mL after which time water (250 mL), 2-methoxy-2-methylpropane (120 mL), and heptane (120 mL) were added followed by re-concentrated the mixture to approximately 250 mL. The resultant slurry was diluted with water (250 mL) and cooled to 0 °C after which time 1 M NaOH in water (211mL) was added and the final mixture was stirred vigorously for lOmin. The suspension was filtered, rinsed with water (498 mL) and the filter cake dried at 30 °C for 18 h to afford aldoxime 2 (49.75 g, 0.198 mol, 93.9% yield) as tan powder.
[0124] To a stirred suspension of 2 (48.21 g, 0.192 mol) in acetonitrile (386 mL) at 15
°C was added copper (II) acetate (0.523 g, 2.9 mmol) followed by acetic acid (13.1 mL, 0.229 mol). The resultant mixture was heated to reflux for 21 h after which time the completed reaction was cooled to 50 °C. Water (0.39 L) was added and the mixture was partially concentrated followed by dilution with water (290 mL) and cooled to 5 °C. 1 M NaOH in water (230 mL) was added and vigorous stirring was continued for 10 min. The suspension was filtered, the filter cake rinsed with water (500 mL) and dried to afford compound 3 (42.80 g, 0.183 mol, 95.6 % yield) as dark gray powder.
[0125] Synthesis of ER-878952 - Scheme 3 & 15 (Method 1)
[0126] Scheme 15
Figure imgf000033_0001
[0128] 3 (200.2 mg, 0.86 mmol) in NMP (1 mL) and commercially available cis-2,6 dimethylmorpholine 69 (133.4 mg, 1.16 mmol - as a representative of compound 4 in Scheme 3) was micro waved at 150 °C for 1 h. The completed reaction was filtered and divided into several vials, diluted with NMP and purified by HPLC (CI 8 column, gradient 10/90-95/5 acetonitrile/water with 0.1 % TFA, 15 min run, t = 8.5 - 9 min) to yield ER-878952 (180 mg. 0.68 mmol, 79.1 % yield) after concentration and drying in vacuo the desired combined fractions.
[0129] ER-880369 (8.2 mg, 0.031 mmol, 48.4 % yield) was produced in a similar manner to ER-878952 using 3 (15 mg, 0.064 mmol) and 2-ethylmorpholine (22.2 mg, 0.191 mmol). The separation of the enantiomers was not performed. [0130] ER-885618 (385.2 mg, 1.032 mmol, 60.7 % yield) was produced in a similar manner to ER-878952 using 3 (400 mg, 1.716 mmol) and 11 (398.1 mg, 1.799 mmol) from Scheme 4.
[0131] Synthesis of compound ER-878952 (Method 2, Scheme 3 & 15)
[0132] To a stirred suspension of Compound 3 (12.00 g, 0.0515 mol) in NMP (30.0 mL) was added 69 (14.8 g, 0.129 mol) followed by heating at 120 °C for 4 h. The completed reaction was cooled to 50 °C, diluted with IP A (30 mL), heptane (60 mL) and then further cooled to 0 °C. After 30 min, the precipitates were collected by filtration, rinsed with pre- chilled (at 0 °C) IP A (18.0 mL)/heptane (36 mL) mixture and dried under N2/vacuum for 2 h to afford ER-878952 (11.00 g) as a yellow powdered. The filtrate was concentrated, partitioned between EtOAc (120 mL) and saturated aqueous NaHC03 (60 mL). The organic layer was separated, washed with water (60 mL) and passed through pre-conditioned (heptane-EtOAc 1 : 1) silica gel, eluted with EtOAc (120 mL) then concentrated. Brownish solid thus obtained was suspended in EtOAc (10 mL) heptane (10 mL) and heated to 70 °C and then allowed to cool down to 20 °C. Precipitates were collected by filtration, rinsed with a mixture of EtOAc (5.0 mL) and heptane (5.0 mL), then dried under N2/vacuum for 1 h, affording the additional ER-878952 (0.649 g) as yellow powder. Overall the process provided ER-878952 (11.64 g, 43.6 mmol, 89.6 % yield).
[0133] ER-879484 (Method 3, Scheme 3 and 16)
[0134] Scheme 16
Figure imgf000034_0001
[0135] To a stirred solution of 3 (15 mg, 64.4 mmol) and 4-benzyl-2-
(chloromethyl)morpholine, 70 (43.6 mg (0.193 mmol) in DMF (0.5 mL) was added TEA (0.27 uL, 0.194 mmol). The reaction mixture was microwaved at 160 °C for lh after which time the completed reaction was directly purified over a C-18 reverse phase preparative HPLC column (Water's X-Bridge CI 8 19 x 100 mm column; eluting with 0 - 40 % gradient of acetonitrile in water with 0.05 % TFA). The fractions containing the desired product were combined, concentrated and dried in vacuo to provide ER-879484 (4.2 mg, 0.015 mmol, 22.7 % yield). The enantiomers of ER-879484 (3.0 mg, 0.010 mmol) were separated using a chiral HPLC column to providing ER-879569 (1.0 mg, 0.004 mmol) and ER-879570 (1.0 mg, 0.004mmol) after concentration the desired fractions and drying in vacuo. The absolute stereochemistry is unknown, but arbitrarily assigned.
[0136] ER-879739 (12 mg, 0.047 mmol, 73.6 % yield) was produced in a similar manner to ER-879484 starting using 3 (15 mg, 0.064 mmol) and 2-methylmorpholine (19.5 mg, 0.195 mmol). Separation of the enantiomers was not performed.
[0137] ER-880191 (9.5 mg, 0.036 mmol, 23.7 % yield) was produced in a similar manner to ER-879484 starting using 3 (35 mg, 0.150 mmol) and (2S,6S)-2,6- dimethylmorpholine (741 mg, 6.434 mmol). The cw-isomer ER-878952 (15.2 mg, 0.057 mmol, 37.9 % yield) was also isolated. TEA was not used in this preparation.
[0138] Additional Examples derived from ER-878952:
[0139] ER-885160: ER-878952 (85.6 mg, 0.320 mmol) was dissolved in 1,2- ethanediol (1 mL) followed by the addition of potassium hydroxide (60 mg, 1.069 mmol). The reaction mixture was micro waved at 120 °C for 10 h after which time, it was filtered then directly injected onto a C-18 reverse-phase preparative HPLC for purification (Water's X- Bridge C18 19 x 100 mm column, eluting with 10-100 % acetonitrile in water with 0.05 % TFA). The desired fractions were concentrated to dry, dissolved in MeOH (3 mL) and eluted over a carbonate impregnated silica gel column (Biotage Isolute SPE, Si-C03, lg), washed with MeOH (3 mL), concentrated and dried in vacuo to provide ER-885160 (56.2 mg, 0.197 mmol, 61.6 % yield).
[0140] Preparation of compound ER-890963 as an example of Compound 15,
Scheme 4
[0141] Compound 7: A 22L reactor was charged with (2i?)-benzyl 2-epoxypropyl ether (0.7692 kg, 4.684 mol) T-internal 18-19C. Allylamine (3800 mL, 51 mol) was added at 18-19 °C and resultant mixture was heated to 50 °C. After 20 h, the mixture was concentrated, azeotroped with MTBE (4 L x 3) to give (i?)-l-(allylamino)-3- (benzyloxy)propan-2-ol, 7 (ca. 1037 g, 4.684 mol, 100 % yield assumed) as colorless oil.
[0142] Compound 8: To a stirred suspension of sodium bicarbonate (1180 g, 14.0 mol) in water (7.2 L) at 10-11 °C was added a solution of o-nitrobenzenesulfonyl chloride (1038 g, 4.684 mol) in DCM (3100 mL) followed by warming the resultant biphasic mixture to 20 °C. A solution of 7 (ca. 1037 g, 4.684 mol assumed) in DCM (4100 mL) was added over 3 h while maintaining-T-internal between 20-23 °C and vigorous stirring was continued overnight. The mixture was diluted with water (4100 mL) with stirring followed by separation of the layers. The aqueous layer was extracted with MTBE (4100 mL). The combined organic layers were diluted with ^-heptane (4100 mL), sequentially washed with 1.0 M HCl (4700 mL), saturated NaHC03 (2.0 kg), water (4100 mL), concentrated, and azeotroped with MTBE (5200 mL x 3) to dry to provide (i?)-N-allyl-N-(3-(benzyloxy)-2- hydroxypropyl)-2-nitrobenzenesulfonamide, 8 (1.855 kg, 4.56 mol, 97% yield) as brownish green oil after drying for 3 days in vacuo.
[0143J Compound 9: A stirred suspension of 8 (1.80 kg, 4.429 mol) in DMA (5.40
L) was heated to 40 °C to achieve complete dissolution, then cooled down to 25 °C after which time the mixture was added to a separate reactor was containing Cu(II) acetate (0.145 kg, 0.797 mol) followed by rinsing the original vessel with DMA (5.40 L). Palladium(II) chloride (0.063 kg, 0.354 mol) was added followed by was replacing internal atmosphere with oxygen (1 bar) and warming up 28-32 °C for 3 days. The completed reaction mixture was split into equal 2 portions to facilitate work-up. Each portion was separately poured into a mixture of 0.1 M HCl (23 L) and MTBE (9.0 L) while controlling T-internal < 25 °C. The layers were separated and the aqueous layer was extracted with MTBE (9.0 L & 5.4 L). All organic layers were combined, sequentially washed with 0.1 M HCl (5.5 L), 8 % NaHC03 (5.9 kg), 29 % NaCl (6.3 kg). Celite 545 (270 g) was added to the organic layer, stirred for 30 min, filtered, and filter cake were rinsed with MTBE (2.7 L). All filtrates were combined and concentrated. The reddish oil was re-dissolved in DCM (3.6 L) and treated with l,3,5-triazinane-2,4,6-trithione (79 g kg, 0.44 mol) at 25 °C for 1 h. The mixture was diluted with MTBE (18 L) and filtered through Celite 545 (270 g). The reactor and filter cake were rinsed with MTBE (3.6 L) and combined filtrate was concentrated to give (R)-2- ((benzyloxy)methyl)-6-methyl-4-((2-nitrophenyl)sulfonyl)-3 ,4-dihydro-2H- 1 ,4-oxazine, 9 (1748 g, 4.322 mol, 97.6 % yield) as yellow oil.
[0144] Compound 10: To a stirred suspension of 9 (1748 g, 4.322 mol) in DCM (3.5
L) was heated to 33-35 °C until a free-flowing suspension was obtained after which time the mixture was cooled to 18-20 °C. A separate reactor TFA (1.67 L, 21.6 mol) in DCM (2.62 L) was cooled to 5 °C with stilling after which time triethylsilane (1.04 L, 6.48 mol) was added maintaining the temperature at 5-6 °C followed by cooling to - 5 °C. The suspension of 9 in DCM was slowly added to the main reactor over 1.5 h while maintaining the temperature between -5 and -3 °C followed by stining for 4 h continuing at -5 to -3 °C. The completed reaction was diluted with pre-chilled ^-heptane (8.74 L at -10 °C) then poured into pre- chilled NaOH solution (NaOH: 890 g, 22.3 mol in water: 8.7 L at 5 °C) while controlling T- internal < 15 °C (over 1 h) followed by rinsing the reactor rinsed with MTBE (3.5 L). The mixture was diluted with MTBE (5.2 L) and the layers separated. The organic layer was sequentially washed with: water (8.7 L), 30 wt % NaCl (3.5 kg) in water, water (5.2 L), treated with Celite 545 (175 g) and filtered. The work-up vessel and filter cake were rinsed with MTBE (1.75 L) and the combined filtrates were concentrated under vacuum to approx. 3.5 L, azeotroped with ^-heptane (8.7 L) and concentrated to approx. 5 L. The tan precipitates were collected by filtration, rinsed with -heptane (3.5 L) and dried under N2/vacuum for 1 h. 1.65 kg of the resultant solid was combined with 353 g solid obtained from a separate batch and suspended in «-heptane/EtOAc 1 :1 (8.0 L). The mixture was heated to 61-63 °C to achieve complete dissolution, cooled down to 23-25 °C over 1 h, diluted with heptane (4 L) and further cooled down to 10-12 °C over 30 min. Stirring was continued at this temperature for 30 min. Light tan precipitates were collected by filtration, rinsed with ^-heptane/ EtOAc 6: 1 (2 L) and then ^-heptane (4 L) followed by drying under N2/vacuum overnight, and then vacuum oven dried at 35 °C for 2 d to give (2R, 6R)-2- ((benzyloxy)methyl)-6-methyl-4-((2-nitrophenyl)sulfonyl)morpholine, 10 (1616 g, 3.98 mol, 74% yield in 2 steps from 8) as a tan solid.
Figure imgf000037_0001
[0146] The minor product: (2^ (51S')-2-((benzyloxy)methyl)-6-methyl-4-((2- nitrophenyl)-sulfonyl)morpholine, 71 (diastereoisomer ) isolated by purification of 10 mother liquor.
[0147] Compound 11: To a stirred solution of 1.0 M of t-BuOK in THF (0.650 L,
0.650 mol). In THF (0.310 L) cooled to 5 °C was added benzenethiol (63.66 niL, 0.620 mol) while maintaining at < 10 °C. The mixture was stirred at 10 °C for 30min, then warmed up to 15 °C for 1 h after which time a solution of 10 (240.00 g, 590.5 mmol) in THF (0.60 L) was added while maintaining the temperature 15-20 °C followed by and stirring 2 h. The completed reaction was slowly quenched with mixture of 1.0 M HC1 (1.30 L) in n-heptane (3.60 L, previously cooled to 10 °C) while maintaining the reaction mixture at < 15 °C. Resultant mixture was vigorously stirred for 10 min followed by separation of the layers. The organic layer was extracted with water (0.24 L) with rinsing with ^-heptane (0.24 L). All aqueous layers were combined and washed with ^-heptane (3.60 L) followed by the addition of NaCl (240 g) with stilling. The aqueous mixture was rendered basic with 5.0 M of NaOH (165 mL) followed by extraction two times with DCM (3.60 L & 2.40 L each). The combined organic layers were washed with 20 wt % NaCl in water (1400 g), concentrated, azeotroped with MTBE (1400 mL), re-diluted with MTBE (960 mL) and filtered through a glass filter. The filtrate was concentrated to give (2i?, 6i?)-2-((benzyloxy)methyl)-6- methylmorpholine, 11 as brownish clear oil which was used for subsequent reaction without further purification.
[0148] Compound 12: To a stirred solution of 3 (137.6 g, 0.591 ttiol) in DMA (260 mL) was added DIPEA (308 mL, 1.77 mol) followed by a solution of 11 (130.67 g, 0.5905 mol) in DMA (260 ml) rinsing with DMA (130 mL). The reaction mixture was heated at 125-130 °C for 2h. The completed reaction mixture was cooled to 30 °C and diluted with EtOAc (1.96 L) and water (0.65 L) after which time it was poured into water (2.61 L) with vigorous stining. The resulting mixture was filtered through a pad of Celite 545 (260g) and the layers separated. The aqueous layer was extracted with EtOAc (1.31 L) followed by combining the organic layers washing two times with 5% NaCl (1.0 kg, each) and concentrated to give black solid. The solid was dissolved in DCM (1 L), diluted with n- heptane (520 mL) followed by the addition of silica gel (196 g) and MgS04 (130 g). The resultant slurry was stirred at 20 °C for 30 min, filtered and eluted with isopropyl acetate (2.09 L). The combined filtrate was concentrated and resultant brownish solid was suspended in a mixture of EtOAc (196 mL) and n-heptane (523 mL). The mixture was heated to 70 °C, followed by cooling to rt and stirred overnight. The precipitates were collected by filtration, washed with a mixture of EtOAc//¾-heptane 3 :8 (220 mL), and dried under vacuum to provide 5-((2R, ii?)-2-((benzyloxy)methyl)-6-methylmorpholino)quinoline- 8-carbonitrile, 12 (178.44 g, 0.478 mol, 80% yield) as tan powder.
[0149] Compound 13: To a stirred suspension of 12 (167.3 g, 0.45 mol) in acetonitrile
(500 mL) was added trimethylsilyl iodide (82.9 mL, 0.582 mol) at rt. The resultant mixture was heated at 70 °C for 2 h after which time it was cooled to rt, slowly quenched with water (167 g) and stirred at 25-30 °C for 1 h. The reaction mixture was cooled to 15 °C followed by the addition 28%o aqueous ammonium hydroxide (500 g) after which time the reaction was stirred at rt overnight. The mixture was partially concentrated and then diluted with water (0.5 L), MTBE (0.04 L) and ^-heptane (0.3 L) followed by cooling to 0-5 °C. Precipitates were collected by filtration and rinsed with pre-chilled water (500 ml), then «-heptane/MTBE 7: 1 (400 ml) followed by drying under vacuum (40 °C) overnight to 5-((2i?, <5R)-2- (hydroxymethyl)-6-methylmoi-pholino)quinoline-8-carbonitrile, 13 or ER-885493 (127.2g, 0.45 mol, 100%) yield) as tan powder.
[0150] Compound 14: To a stirred solution of 13 (24.8 g, 0.0875 mol) in DCM (200 mL) was added portion wise / toluenesulfonyl chloride (17.95 g, 94.17 mmol) followed by TEA (24.60 mL, 0.1765 mol) at rt. The reaction was stirred for 3 h after which time the completed reaction was quenched with water (200 mL). The separated organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated to a brownish tar. The crude product was purified over silica gel (SNAP 340 x 2 g, eluting with heptane/EtOAc = 5/1 to 3/1, TLC heptane/EtOAc = 3/1, rf= 0.6) to provide ((2i?, 5i?)-4-(8-cyanoquinolin-5- yl)-6-methylmoi holin-2-yl)methyl 4-methylbenzenesulfonate, 14 (34.98 g. 79.95 mmol, 84.9% yield) as a yellow powder after concentration of the desired fractions and drying in vacuo.
[0151] Compound 15 as Boc-protected ER-890963: To a solution of 14 (13.9 g,
31.77 mmol) and TEA (8.86 mL, 63.541 mmol) in DMA (89 mL) at rt was added dropwise commercially available (S)-tert-bvXy\ 2-ethylpiperazine-l -carboxylate (7.49 g, 34.95 mmol) over 5-min period. The reaction mixture was stirred at 1 10 °C for 12 h to completion after which time the reaction was cooled to rt. The reaction was concentrated to remove DMA followed by dilution with DCM (30 mL). The resultant organic solution was washed two times with water (30 mL each), brine (30 mL), and dried over MgS04. The crude was filtered, concentrated in vacuo, and purified over silica gel (SNAP 340 g eluting 10% to 30% EtOAc in heptene, TLC heptane/EtOAc = 3/1 , it = 0.6) gave 5-((2S, 6R)-2-(((S)-4-(3,3- dimethylbutanoyl)-3 -ethylpiperazin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile or Boc-protected ER-890963 (12.27 g, 24.15 mmol, 76% yield) as yellow powder after concentration of the combined desired fractions and drying in vacuo.
|0152| ER-890963 or Compound 15:
[0153] Boc-protected ER-890963 (23.55 g, 49.10 mmol) was dissolved with stirring in DCM (50 mL) followed by TFA (50 mL) at rt. The reaction was stirred for 4 h at rt after which time the completed reaction was concentrated in vacuo. The crude dark orange material dissolved with stirring in DCM (50mL) and neutralized with the addition of sat. aqueous NaHC03 at 20 °C until the solution became pH 5-6. The separated aqueous layer was extracted two times with DCM (50 mL each) after which time the combined organic layers were washed with brine (20 mL), dried over Na2S04, filtered, concentrated to dry. The crude residue was crystallized from DCM/ PrOH/heptane/Et20 = 1/1/1/1 to provide ER- 890963 (17.89 g, 47.14 mmol, 96% yield) as a yellow powder.
[0154] ER-886604 (7.8 mg, 0.021 mmol, 73 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-4- methylbenzene (0.030 mL, 0.290 mmol) using a microwave at 180 °C for 15 min. ER- 886604 was purified by reverse-phase HPLC (Water's X-Bridge C18 19 x l00 mm column, eluting with 10 % acetonitrile in water containing 0.05 % TFA). The product fractions were combined and concentrated to dry followed by dilution in MeOH (1 niL), passed through as basic silica gel plug (Biotage SiC03, 1 g, eluting with MeOH (ImL)), concentrated and dried in vacuo. Boc-deprotection was not required.
[0155] ER-886608 (8.2 mg, 0.019 mmol, 67 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5-Amino-l,2- dimethylbenzimidazole dihydrochloride (30 mg, 0.128 mmol) along with TEA (0.040 mL, 0.290 mmol).
[0156] ER-886609 (7.4 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5-amino-l- ethyl-2-methylbenzimidazole (30 mg, 0.171 mmol).
[0157] ER-886611 (9.2 mg, 0.027 mmol, 88 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1- aminocyclohexane (30 mg, 0.171 mmol).
[0158] ER-886787 (4.5 mg, 0.012 mmol, 43.9 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- aminopyrimidine (24.7 mg, 0.263 mmol).
[0159] ER-886788 (5.2 mg, 0.014 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- aminopyridine (24.4 mg, 0.263 mmol).
[0160] ER-886789 (4.5 mg, 0.012 mmol, 42 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-6- methylpyridine (28.1 mg, 0.263 mmol).
[0161] ER-886790 (4.6 mg, 0.012 mmol, 43 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-5- methylpyridine (28.1 mg, 0.263 mmol).
[0162] ER-886814 (4.2 mg, 0.012 mmol, 40.4 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and D-prolinol (26.2 mg, 0.263 mmol).
[0163] ER-886815 (4.0 mg, 0.011 mmol, 38.2 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2,2- dimetylpyrrolidine (14.2 mg, 0.145 mmol). [0164] ER-886816 (6.0 mg, 0.016 mmol, 60 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- isopropylpyiTolidine (29.4 mg, 0.263 mmol).
[0165] ER-886817 (4.2 mg, 0.012 mmol, 62 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-2- methylpyrrolidine (22.1 mg, 0.263 mmol).
[0166] ER-886818 (4.2 mg, 0.010 mmol, 35.2 % yield) was prepared by a similar method described for ER-890604 starting with 14 (12.5 mg, 0.029 mmol) and (S) 3- phenylpyrrolidine (38.2 mg, 0.263 mmol).
[0167] ER-886819 (5.2 mg, 0.015 mmol, 52 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-3- methylpyrrolidine (22.1 mg, 0.263 mmol).
[0168] ER-886820 (6.2 mg, 0.018 mmol, 62 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S)-3- hydroxypyrrolidine (22.6 mg, 0.263 mmol).
[0169] ER-886853 (6.2 mg, 0.017 mmol, 58 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-4- methylpyridine (28.1 mg, 0.263 mmol).
[0170] ER-886854 (2.9 mg, 0.007 mmol, 25 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3- phenylpyrrolidine hydrochloride (47.7 mg, 0.263 mmol).
[0171] ER-886855 (4.9 mg, 0.013 mmol, 44 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-5- methoxypyridine (32.2 mg, 0.263 mmol).
[0172] ER-886856 (7.8 mg, 0.022 mmol, 78 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and S -2- methylpyiTolidine (22.1 mg, 0.263 mmol).
[0173] ER-886857 (5.6 mg, 0.015 mmol, 54 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2,5- dimethylpyiTolidine (25.7 mg, 0.263 mmol).
[0174] ER-886858 (3.6 mg, 0.009 mmol, 32 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-4- methoxypyridine (32.2 mg, 0.263 mmol). [0175] ER-886859 (2 mg, 0.005 mmol, 20 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-6- methoxypyridine (32.2 mg, 0.263 mmol).
[0176] ER-886860 (2.5 mg, 0.006 mmol, 21 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5 -amino- 1 - phenylpyrazole (41.3 mg, 0.263 mmol).
[0177] ER-886866 (8.2 mg, 0.022 mmol, 78 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and L-prolinol (22.1 mg, 0.263 mmol).
[0178] ER-886867 (4.5 mg, 0.013 mmol, 45 % yield) was prepared by a similar method described for ER-886604 stalling with 14 (12.5 mg, 0.029 mmol) and (R)-3- hydroxypyrrolidine (22.6 mg, 0.263 mmol).
[0179] ER-886868 (6.5 mg, 0.019 mmol, 65 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S 3- methylpyiTolidine (22.1 mg, 0.263 mmol).
[0180] ER-886869 (5.3 mg, 0.015 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3,3- dimetylpyrrolidine (25.7 mg, 0.263 mmol).
[0181] ER-886948 (6.2 mg, 0.016 mmol, 56 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- methoxypyridine (32.2 mg, 0.263 mmol).
[0182] ER-886949 (4.8 mg, 0.013 mmol, 46 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-3- hydiOxypiperidine (26.2 mg, 0.263 mmol).
[0183] ER-886950 (5.0 mg, 0.013 mmol, 46 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R, S)-2,6- dimethylpiperidine (29.4 mg, 0.263 mmol).
[0184] ER-886951 (3.2 mg, 0.009 mmol, 31 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S)-3- hydroxypiperidine (26.2 mg, 0.263 mmol).
[0185] ER-886953 (5.8 mg, 0.016 mmol, 55 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- hydroxypiperidine (26.2 mg, 0.263 mmol). [0186] ER-886955 (7.5 mg, 0.020 mmol, 69 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2- hydroxymethylpiperidine (29.9 mg, 0.263 mmol).
[0187] ER-887137 (4.5 mg, 0.012 mmol, 42 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2,3 dimethylpiperazine (29.6 mg, 0.263 mmol).
[0188] ER-887138 (5.9 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3- aminopyridine (24.4 mg, 0.263 mmol).
[0189] ER-887139 (6.5 mg, 0.018 mmol, 63 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 3- aminopyridine (24.4 mg, 0.263 mmol).
[0190] ER-887141 (5.2 mg, 0.014 mmol, 50 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- methylpiperidine (25.7 mg, 0.263 mmol).
[0191] ER-887142 (4.5 mg, 0.012 mmol, 41 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4,4- diffuroropiperidine (31.4 mg, 0.263 mmol).
[0192] ER-887143 (4.7 mg, 0.011 mmol, 38 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- phenylpiperidine (41.8 mg, 0.263 mmol).
[0193] ER-887144 (6.2 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- fluroiOpiperidine (26.8 mg, 0.263 mmol).
[0194] ER-887145 (6.5 mg, 0.019 mmol, 65 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1- aminocyclopentane (22.1 mg, 0.263 mmol).
[0195] ER-887146 (7 mg, 0.018 mmol, 60 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-3- methylcyclohexane (29.4 mg, 0.263 mmol).
[0196] ER-887177 (5.3 mg, 0.014 mmol, 49 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- methylpyridine (20 mg, 0.145 mmol). [0197] ER-887253 (10.2 mg, 0.029 mmol, 60 % yield) was prepared by a similar method described for ER-886604 starting with 14 (20 mg, 0.046 mmol) and piperazine (40 mg, 0.460 mmol).
[0198] ER-887442 (6.2 mg, 0.016 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.2 mg, 0.028 mmol) and l-amino-4- methylcyclohexane (30 mg, 0.265 mmol).
[0199] ER-887443 (4.5 mg, 0.013 mmol, 47 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1-amino- cyclobutane (10 mg, 0.141 mmol).
[0200] ER-887444 (7.7 mg, 0.020 mmol, 70.7 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1 -amino- cycloheptane (20 mg, 0.177 mmol).
[0201] ER-887526 (6.2 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-4- hydroxycyclohexane (30 mg, 0.260 mmol).
[0202] ER-887528 (5.4 mg, 0.015 mmol, 51.2 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1 -amino-2- hydroxycyclopentane (30 mg, 0.297 mmol).
[0203] ER-887539 (5.3 mg, 0.014 mmol, 49 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-2- methylcyclohexane (30 mg, 0.265 mmol).
[0204] ER-887538 (6.5 mg, 0.014 mmol, 51.8 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-5- phenylpyridine (50 mg, 0.294 mmol).
[0205] ER-887540 (6.1 mg, 0.014 mmol, 49 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- phenylpyridine (50 mg, 0.294 mmol).
[0206] ER-887586 (6.2 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (S.R)-l- amino-2-hydroxypyrrolidine (10 mg, 0.099 mmol).
[0207] ER-887587 (7.5 mg, 0.019 mmol, 65 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-3- ethoxylpyridine (40 mg, 0.290 mmol). [0208] ER-887588 (5.6 mg, 0.013 mmol, 45 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4-amino-2- phenylpyridine (20 mg, 0.118 mmol).
[0209] ER-887589 (2.4 mg, 0.006 mmol, 19 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino~6- pheny .pyridine (20 mg, 0.118 mmol).
[0210] ER-887722 (3.5 mg, 0.009 mmol, 32 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 5- methylpiperazin-2-one (20 mg, 0.175 mmol).
[0211] ER-887723 (6.2 mg, 0.017 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1-JV- methylpiperazine (10 mg, 0.100 mmol).
[0212] ER-887724 (6.2 mg, 0.016 mmol, 55 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1-N- propylpiperazine (40 mg, 0.138 mmol).
[0213] ER-887725 (7.2 mg, 0.018 mmol, 64 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 4- (dimethylamino)-piperidine (20 mg, 0.156 mmol).
[0214] ER-887927 (10.2 mg, 0.024 mmol, 82.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1,4'- bipiperidine (20 mg, 0.119 mmol).
[0215] ER-887928 (3.2 mg, 0.009 mmol, 31 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (R)-Iert -butyl piperidin-3-ylcarbamate (30 mg, 0.150 mmol).
[0216] ER-888070 (4.5 mg, 0.012 mmol, 43 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and tert-butyl piperidin-4-ylcarbamate (30 mg, 0.150 mmol).
[0217] ER-888202 (6.2 mg, 0.018 mmol, 62 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and piperidine (0.034 niL, 0.348 mmol).
[0218] ER-888203 (7.2 mg, 0.020 mmol, 58 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and morpholine (0.030 niL, 0.350 mmol). [0219] ER-888204 (6.2 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and (2S, 6R)-2,6- dimethylmorpholine (0.070 mL, 0.580 mmol).
[0220] ER-888205 (4.6 mg, 0.012 mmol, 41 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and ((2R, 6R)-6- methylmorpholin-2-yl)melhanol or ER-885491 (40 mg, 0.305 mmol).
[0221] ER-885491: To a stirred suspension of 1 (890.2 mg, 4.023 mmol) in MeOH
(8 mL) was added 5 % palladium on carbon (270 mg) after which time the mixture was purged with H2 gas three times with vacuum evacuation between charges. The reaction was stirred under a H2 atm at 40 °C for 8 h. The incomplete reaction was degassed under vacuum with purging with N2 gas, followed by 5 % palladium on carbon (100 mg) and 2 drops cone. HCl after which time the reaction was placed under a H2 atm as described above for 4 h at 40 °C. The completed reaction was purged with N2 gas, followed by filtering over Celite 545, eluting with MeOH (5 mL), concentrating and drying in vacuo. The crude product ER- 885491 (378. 2 mg, 2.883 mmol, 71.7 % yield) was used in the previous step without further purification.
[0222] ER-888285 (8.6 mg, 0.020 mmol, 59 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and N-(2- pyridyl)piperazine (30 mg, 0.184 mmol).
[0223] ER-888286 (10.2 mg, 0.020 mmol, 71.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (14.6 mg, 0.033 mmol) and 7V-(4- pyridyl)piperazine (30 mg, 0.184 mmol).
[0224] ER-888288 (7.2 mg, 0.016 mmol, 52 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and N-(piperidin-4- yl)acetamide (20 mg, 0.141 mmol). The HCl salt is formed by procedures previously described.
[0225] ER-888289 (16.2 mg, 0.039 mmol, 21.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (80 mg, 0.183 mmol) and 1 ,8- naphthyridin-2-amine (100 mg, 0.689 mmol).
[0226] ER-888320 (5.8 mg, 0.015 mmol, 42 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and piperidine-4- carboxamide (20 mg, 0.156 mmol). [0227] ER-888321 (6.2 mg, 0.013 mmol, 37 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and N-(piperidin-4- yl)benzamide (40 mg, 0.196 mmol).
[0228] ER-888322 (10.5 mg, 0.027 mmol, 75.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and 1- isopropylpiperazine (20 mg, 0.156 mmol).
[0229] ER-888330 (4.2 mg, 0.011 mmol, 30 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol) and piperazine-1- carboxamide (20 mg, 0.155 mmol).
[0230] ER-888479 (7.6 mg, 0.018 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 4- cyclohexylpiperidine (30 mg, 0.179 mmol).
[0231] ER-888480 (8.3 mg, 0.020 mmol, 58 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 4-(pyrrolidin-l- yl)piperidine (30 mg, 0.194 mmol).
[0232] ER-888838 (6.2 mg, 0.015 mmol, 45 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 3,5- dimethylpyridine-2,6-diamine (20 mg, 0.146 mmol).
[0233] ER-888977 (1.2 mg, 0.003 mmol, 1 1 % yield) was prepared by a similar method described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and 1,3-dimethyl- lH-pyrazol-5-amine (28.8 mg, 0.259 mmol).
[0234] ER-889448 (8.2 mg, 0.022 mmol, 63 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 1- ethylpiperazine (0.020 mL, 0.136 mmol).
[0235] ER-889469 (6.5 mg, 0.018 mmol, 52 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and l-(azetidin-3- yl)pyrrolidine (20 mg, 0.158 mmol).
[0236] ER-889470 (7.2 mg, 0.017 mmol, 48 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and l-(azetidin-3- yl)piperidine (20 mg, 0.158 mmol).
[0237] ER-889557 (7.7 mg, 0.020 mmol, 58.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and pipcridin-4- ylmethanol (20 mg, 0.174 mmol). [0238] ER-889571 (3.2 mg, 0.008 mmol, 23 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and (R)-l,3'- bipyiTolidine (20 mg, 0.143 mmol).
[0239] ER-889572 (1.1 mg, 0.003 mmol, 7.7 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and (R)-\ - (pyrrolidin-3-yl)piperidine (20 mg, 0.130 mmol).
[0240] ER-889601 (6.7 mg, 0.018 mmol, 51 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and 1 -methyl- 1 ,4- diazepane (20 mg, 0.175 mmol).
[0241] ER-889602 (10.2 mg, 0.022 mmol, 65.3 % yield) was prepared by a similar method described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and phenyl(piperazin-l-yl)methanone (30 mg, 0.158 mmol).
[0242] ER-891084 (7.2 mg, 0.016 mmol, 47 % yield) was prepared by a similar method described for ER-886608 starting with 14 (15 mg, 0.034 mmol) and l-(piperidin-4- yl)azepane (30 mg, 0.165 mmol).
[0243] ER-890108 (15.2 mg, 0.036 mmol, 58.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (27 mg, 0.062 mmol) and l-(azetidin-3- yl)-4-methylpiperazine (90.2 mg, 0.581 mmol). Triethylamine (0.008 mL, 0.062 mmol) was also added to the reaction.
[0244] ER-890112 (296.5 mg, 0.683 mmol, 74.7 % yield) was prepared by a similar method described for ER-886604 starting with 14 (400.6 mg, 0.916 mmol) and 4,4'- bipiperidine (290 mg, 1.723 mmol).
[0245] ER-894472 (53.9 mg, 0.143 mmol, 25 % yield) and ER-894473 (51.2 mg,
0.135 mmol, 23.6 % yield) was prepared by a similar method described for ER-886604 starting with 14 (250 mg, 0.571 mmol) and 5-methylpiperazin-2-one (78.3 mg, 0.686 mmol). The stereochemistry of each diastereomeric methyl group is arbitrarily assigned.
[0246] ER-886507 (4.2 mg, 0.013 mmol, 51.9 % yield) was prepared by a similar method described for ER-886604 starting with 14 (10.6 mg, 0.024 mmol) and pyrrolidine (0.022 mL, 0.257 mmol) using toluene (1 mL) instead of DMA as solvent. Boc-deprotection was not required.
[0247] ER-886508 (3.3 mg, 0.010 mmol, 38.9 % yield) was prepared by a similar method described for ER-890507 starting with 14 (10.8 mg, 0.025 mmol) and N,N- diethylamine (0.027 mL, 0.262 mmol). [0248] ER-886509 (4.8 mg, 0.013 mmol, 44.9 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and benzylamine (0.028 mL, 0.263 mmol).
[0249] ER-88660 (6.6 mg, 0.018 mmol, 64.2 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and phenylamine (0.008 mL, 0.087 mmol).
[0250] ER-886602 (6.4 mg, 0.017 mmol, 60.1 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and l -amino-3- methylbenzene (0.028 mL, 0.263 mmol).
[0251] ER-887104 (2.1 mg, 0.005 mmol, 17.9 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and (S')-2- (trifluoiOmethyl)pyrrolidine (36.1 mg, 0.260 mmol).
[0252] ER-886603 (7.6 mg, 0.020 mmol, 71 % yield) was prepared by a similar method described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol) and l-amino-2- methylbenzene (0.030 mL, 0.290 mmol) using NMP(1 mL) instead of toluene as a solvent.
[0253] ER-886957 (4.7 mg, 0.013 mmol, 45 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2- methylpiperidine (25.7 mg, 0.263 mmol).
[0254] ER-886958 (6.2 mg, 0.016 mmol, 57 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2- ethylpiperidine (29.3 mg, 0.263 mmol).
[0255] ER-887139 (2.1 mg, 0.005 mmol, 18 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and (S)-2- trifluoromethypyrrolidine (36.1 mg, 0.263 mmol).
[0256] ER-887252 (2.6 mg, 0.006 mmol, 21 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2-amino-4- phenylpyridine (20 mg, 0.145 mmol).
[0257] ER-887258 (4.2 mg, 0.010 mmol, 34 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and N-phenyl piperazine (0.040 mL, 0.290 mmol) in toluene (0.5 mL).
[0258] ER-887259 (3.2 mg, 0.009 mmol, 30 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 2,6- dimethylpyridine (30 mg, 0.290 mmol). [0259] ER-887260 (3.3 mg, 0.009 mmol, 30.1 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and (S,S)-2,5- dimethylpiperazine (29.6 mg, 0.263 mmol).
[0260] ER-887261 (4.2 mg, 0.011 mmol, 39 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12 mg, 0.027 mmol) and N-acetyl piperazine (40 mg, 0.274 mmol).
[0261] ER-887262 (2.4 mg, 0.006 mmol, 22 % yield) was prepared by a similar method described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol) and 4-(R)- hydiOxy-2-(5 -hydroxymethylpyrrolidine (30.4 mg, 0.263 mmol).
[0262] ER-887268 (9.3 mg, 0.017 mmol, 10 % yield) was prepared by a similar method described for ER-886608 starting with 14 (50 mg, 0.114 mmol) and (R)-tert-b tyi 3- methylpiperazine-l-carboxylate (100 mg, 0.570 mmol) using toluene (1 mL). Boc- deprotection was required as described for Boc-protected ER-890963 above. ER-887268 was purified by reverse-phase HPLC (Water's X-Bridge C18 19 x 100 mm column, eluting with 10 - 40 % acetonitrile in water with 0.05% TFA) followed by neutralization as described for ER-886608.
[0263] ER-887269 (6.2 mg, 0.025 mmol, 21.4 % yield) was prepared by a similar method described for ER-887268 starting with 14 (51.8 mg, 0.118 mmol) and (R)-tert-butyl 2-methylpiperazine-l-carboxylate (100 mg, 0.570 mmol).
[0264] ER-887270 (12.2 mg, 0.033 mmol, 30 % yield) was prepared by a similar method described for ER-887268 starting with 14 (50 mg, 0.114 mmol) and S)-ter t-b tyl 2- methylpiperazine-l-carboxylate (200 mg, 1.14 mmol).
[0265] ER-887271 (2.3 mg, 0.006 mmol, 5.5 % yield) was prepared by a similar method described for ER-887268 starting with 14 (48.2 mg, 0.110 mmol) and (llR)-iert- butyl 2,5-dimethylpiperazine-l-carboxylate hydrochloride (100 mg, 0.399 mmol) and DIPEA (0.10 mL, 0.55 mmol).
[0266] ER-887272 (3.2 mg, 0.008 mmol, 7.1 % yield) was prepared by a similar method described for ER-887268 starting with 14 (52.7 mg, 0.120 mmol) and (S,R)-tert- butyl 2,5-dimethylpiperazine-l-carboxylate (100 mg, 0.467 mmol).
[0267] ER-890119 (256.2 mg, 0.630 mmol, 58.6 % yield) was prepared by a similar method described for ER-890963 starting with 14 (450 mg, 1.029 mmol) and /e/7-butyl 4- (azetidin-3-yl)piperazine-l-carboxylate (314.2 mg, 1.302 mmol). Triethylamine (0.172 mL, 1.23 mmol) was also added to the reaction. Dioxane (2 mL) was used instead of DMA. Deprotection of a Boc-group with TFA was required followed by neutralization of the final product as described previously.
[0268] ER-892253 (152.3 mg, 0.362 mmol, 4.0 % overall yield) was prepared by a similar method described for ER-890119 starting with 14 (4.0 g, 9.1 mmol) and /e/7-butyl (l -(azetidin-3-yl)piperidin-4-yl)carbamate (2.52 g, 9.9 mmol).
[0269] ER-888605 (7.6 mg, 0.017 mmol, 5.0 % yield) was prepared by a similar method described for ER-890119 starting with 14 (150 mg, 0.343 mmol) and [1,4'- bipiperidin]-2-one hydrochloride (82.5 mg, 0.377 mmol). Boc-group deprotection was not required.
[0270] ER-888605 (7.6 mg, 0.017 mmol, 5.0 % yield) was prepared by a similar method described for ER-890119 starting with 14 (150 mg, 0.343 mmol) and [1 ,4'- bipiperidin]-2-one hydrochloride (82.5 mg, 0.377 mmol). Boc-group deprotection was not required.
[0271] ER-890093 (15.2 mg, 0.035 mmol, 45.4 % yield) was prepared by a similar method described for ER-890119 starting with 14 (33.6 mg, 0.077 mmol) and 4-(piperidin- 4-yl)morpholine (52 mg, 0.305 mmol). Boc-group deprotection was not required.
[0272] ER-890104 (569 mg, 1.06 mmol, 42.6 % yield) was prepared by a similar method described for ER-890119 starting with 14 (1.08 g, 2.5 mmol) and tert-butyl 4- (piperidin-4-yl)piperazine-l-carboxylate (1.00 g, 3.7 mmol). Boc-group deprotection of ER- 890104 (21 mg, 0.039 mmol) was performed as described above to provide ER-890106 (12.4 mg, 0.029 mmol, 73.2 % yield).
[0273] ER-89010S (65 mg, 0.122 mmol, 1 1.3 % yield) was prepared by a similar method described for ER-890119 starting with 14 (1.08 g, 2.5 mmol) and tert-bntyl 4- (piperidin-4-yl)piperazine-l-carboxylate (1.00 g, 3.7 mmol). DIPEA (0.65 mL, 3.7 mmol) was also added to the reaction mixture. Boc-group deprotection of ER-890105 (60 mg, 0.112 mmol) was performed as described above to provide ER-890107 (11.3 mg, 0.026 mmol, 23.2 % yield).
[0274] ER-890311 (4.5 mg, 0.01 1 mmol, 31 % yield) was prepared by a similar method described for ER-886608 starting with 14 (15 mg, 0.034 mmol) and (S)-l- (pyrrolidin-3-yl)piperidine dihydrochloride (30 mg, 0.108 mmol) replacing DMA with acetonitrile (1 mL). Triethylamine (0.014 mL, 0.102 mmol) was also added to the reaction. The dihydrochloride salt of the product was produced according to processes described previously. [0275] ER-890342 (41.3 mg, 0.101 mmol, 1 1 % yield) was prepared by a similar method described for ER-890311 starting with 14 (150.2 mg, 0.916 mmol) and 4-(azetidin-3- yl)morpholine (221.6 mg, 1.030 mmol).
[0276] ER-890343 (25.2 mg, 0.062 mmol, 77.2 % yield yield) was prepared by a similar method described for ER-890311 starting with 14 (35.2 mg, 0.080 mmol) and 1- (azetidin-3-yl)-4-methylpiperazine (40.3 mg, 0.0201 mmol).
[0277] ER-890344 (21.4 mg, 0.059 mmol, 73.8 %) was prepared by a similar method described for ER-890311 starting with 14 (35.2 mg, 0.080 mmol) and (S)-tert-butyl 3- methylpiperazine-l-carboxylate (28.2 mg, 0.201 mmol). Deprotection of the Boc-group with TFA followed by neutralization was performed.
[0278] ER-890963 (685.2 mg, 1.806 mmol, 86 %) was prepared by a similar method described for ER-890344 starting with 14 (919 mg, 2.101 mmol) and (S)-ter t-b tyl 2- ethylpiperazine-l-carboxylate (500 mg, 2.333 mmol). The dihydrochloride salt of the product was produced according to processes described previously.
[0279] ER-891090 (54.2 mg, 0.133 mmol, 46.8 % yield) was prepared by a similar method described for ER-890311 starting with 14 (137.5 mg, 0.314 mmol) and (£)-1,3'- bipyiTolidine dihydrochloride (30 mg, 0.165 mmol). Boc-group deprotection was not required.
[0280] ER-895204 (35.2 mg, 0.084 mmol, 73.1 % yield) was prepared by a similar method described for ER-890311 starting with 14 (50 mg, 0.114 mmol) and N- ethylpiperidine-4-carboxamide (21.4 mg, 0.137 mmol). The hydrochloride salt of the product was produced according to processes described previously.
[0281] Preparation of ER-887612 as a modified example of Compound 15 from
Scheme 4:
[0282] A mixture of Compound 3 (201 mg, 0.862 mmol) and (i?)-2-hydroxymethyl morpholine hydrochloride (132, 0.856 mmol) in NMP(3 mL) was heated to 170 °C for 16 h. The completed reaction was cooled, filtered, eluted with MeOH (2 mL) then purified directly by HPLC using a C-18 column eluting with a 10 - 100 % acetonitrile in water containing 0.1 % TFA. The desired product was collected and concentrated to dry. The resulting product was dissolved in MeOH (2 mL) and passed over a basic silica plug (Biotage, lg, SiC03) eluting with MeOH (5 mL) to provide (i?)-5-(2-(hydiOxymethyl)morpholino)quinoline-8- carbonitrile or ER-886849 (108 mg, 0.401 mmol, 46.9 % yield).
[0283] To a stirred solution of ER-886849 (101 mg, 0.375 mmol) in DCM (2 mL) was added >-toluenesulfonyl chloride (78.5 mg, 0.412 mmol) followed by DIPEA (0.13 mL, 0.746 mmol) and DMAP (2.3 mg, 0.019 mmol). The reaction mixture was stirred at rt for 2 h after which time additional -toluenesulfonyl chloride (78.7 mg, 0.413 mmol) was added followed by stirring at rt for 4 h. Water (1.2 mL) and DCM (5.9 mL) were added to the completed reaction with stirring followed separation of the layers. The organic layer was washed with brine (1.2 mL), dried over MgS04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage SP4, Interchim 25g, eluting with 20 -100 % EtOAc in heptane gradient), the desired fractions collected, concentrated and dried in vacuo to provide (i?)-(4-(8-cyanoquinolin-5-yl)moi holin-2-yl)methyl 4-methylbenzenesulfonate (85 mg, 0.201 mmol, 53.6 % yield).
[0284] A solution of (i?)-(4-(8-cyanoquinolin-5-yl)morpholin-2-yl)methyl 4- methylbenzene- sulfonate (27 mg, 0.064 mmol) and 2-aminopyridine (90 mg, 0.956 mmol) in NMP (1 mL) was microwaved at 150 °C for 15 min. The cooled reaction was diluted with NMP (3 mL) and purified directly by HPLC using a C-18 column eluting with a 10 - 100 % acetonitrile in water containing 0.1 % TFA. The desired product was collected and concentrated to dry. The resulting product was dissolved in MeOH (2 mL) and passed over a basic silica plug (Biotage, lg, SiC03) eluting with MeOH (5 mL) to provide ER-887 12 (16 mg, 0.046 mmol, 71.9 % yield).
[0285] ER-885211 (4 mg, 0.016 mmol, 24.7 % yield) was prepared in a similar manner to ER-886849 starting with Compound 3 (15 mg, 0.064 mmol) and (R)-2- methylmoipholine (22 mg, 0.160 mmol). TEA (0.05 mL, 0.359 mmol) was added to the reaction.
[0286] Alternative Synthesis of Compound 10 - Scheme 5
[0287] Compound 16: To a stirred solution of compound 8 (2.869 g, 7.06 mmol) in acetonitrile (14.4 ml) cooled to 5-6 °C was added TFA (0.163 ml, 2.12 mmol) followed by NBS (1.385 g, 7.78 mmol). The reaction mixture was stirred for lh after which time 9% NaHC03 (6.6 g, 7.1 mmol) was added followed by sodium sulfite (Na2S03; 0.27 g, 2.1 mmol) and then stirred for 5 min . The mixture was diluted with water (5.7 ml) and toluene (29 ml), stirred for an additional 5 min followed by separation of the layers. The aqueous layer was extracted with toluene (14.4 ml) after which time the combined organic layers were washed with 20 % NaCl (7.20 ml), concentrated to approx. 5 ml, and then diluted with MTBE (29 ml). 2 M NaOH (7.1 ml) was added and resultant biphasic mixture was vigorously stirred for 10 min. The organic layer was separated and sequentially washed two times with 20 % NaCl (14 ml each), water (5.7 ml), concentrated to approx. 5 ml, and diluted with toluene (14.4 ml). The resultant solution containing (2R)-2- ((benzyloxy)methyl)-6-(bi momethyl)-4-((2-nitiOphenyl)-sulfonyl)moi-pholine, 16, was used directly in the next reaction.
[0288] Compound 17: To the stirred solution of 16 (ca. 3.43 g, 7.06 mmol from above) in toluene was added DBU (2.66 ml, 17.648 mmol) followed by heating at 100 °C for 4 h. The completed reaction was cooled to 15 °C followed by the addition of MTBE (60 ml) and 1 M HC1 (21.2 ml) with stilling. The layers were separated after which time the aqueous layer was extracted with MTBE (20 ml). The combined organic layers were washed with water (10 ml), 9 wt % NaHC03 in water (10 g, 10.713 mmol), 20 wt % NaCl (10 ml), concentrated to dry. The give crude yellow oil with salts was diluted with DCM (10 ml), filtered and concentrated to give crude (i?)-2-((benzyloxy)methyl)-6-methylene-4-((2- nitrophenyl)sulfonyl)morpholine, 17 (3.2 g) as orange-colored oil.
[0289] Compound 10: To a stirred solution triethylsilane (1.69 ml, 10.6 mmol) in
DCM (4 ml) at 0 °C was added TFA (2.72 ml, 35.3 mmol) followed by cooling to -15 °C. Crude 17 (ca. 2.86 g, 7.06 mmol) in DCM (4 ml) was added while maintaining the temperature at -5 °C followed by adding the rinsed residuals with DCM (4 ml). The resultant mixture was stirred at -10 to -5 °C for lh then warmed to 2-3 °C for an additional 1 h. The completed reaction was cooled to -10 °C, poured into pre-chilled (2 °C) 2 M NaOH (21.2 ml, 42.4 mmol) rinsing the reactor with DCM (2 ml). The final mixture was extracted with MTBE (50 ml) and the organic layer was washed with water (10 ml), 20 wt % NaCl (10 ml) and concentrated to give orange-colored oil. Crude product was purified over silica gel (n- heptane/MTBE 1 :2) to provide (2i?, (5i?)-2-((benzyloxy)methyl)-6-methyl-4-((2- nitrophenyl)sulfonyl)morpholine, 10 (1.437 g, 3.54 mmol, 50% yield in 3 steps from 8) as light yellow solid after combining and concentration of the desired fractions then drying in vacuo.
[0290] Alternative Synthesis of Compound 11 - Scheme 6
[0291] Compounds 18 & 19: To a stirred suspension of glycine (85.86 g, 1.144 mol) was in 1,4-dioxane (660 mL) was added 1.0 M aqueous NaOH (1144 mL, 1.114 mol) followed by heating to 80 °C after which time a solution of (2i?)-benzyl 2-epoxypropyl ether 6 (93.90 g, 0.5718 mol) in 1,4-dioxane (94 mL) was added slowly while maintaining T- inte nal between 77-82 °C over a 2-h period. The completed reaction mixture was cooled to 18 °C followed by the addition of di-tert-butyl dicarbonate (262.1 g, 1.201 mol) maintaining the temperature between 18 and 21°C. The mixture was stirred at rt overnight after which time the completed mixture was washed two times with heptane (2000 mL). The aqueous layer was acidified with 20 wt% citric acid (270 g) and extracted three times with EtOAc (2000 mL & 2 x 1000 mL). The combined organic layers were washed twice with 20 wt% NaCl (460 g each), concentrated, dissolved in EtOAc (560 mL), filtered, concentrated and diluted with DCM (280 mL) to give (i?)-2-((3-(benzyloxy)-2-hydiOxypropyl)(fer?- butoxycarbonyl)amino)acetic acid, 18 in a solution.
[0292] To a stilted solution of EDC (120.6 g, 0.6290 mol) and DMAP (2.10 g, 0.0172 mol) were suspended in DCM (380 mL) at 15 °C was added the above 18 solution over a 30- min period while maintaining the temperature below 20 °C. The reaction mixture was stirred at 18-20 °C for 3h after which time it was cooled to 10 °C and then quenched with of 20 wt % citric acid (820 g) with stirring. The layers were separated and the aqueous layer was extracted with MTBE (1.4 L). The combined organic layers were washed with saturated aqueous NaHC03 (480 g), 30 % NaCl (470 g) and concentrated. The crude product thus obtained was purified over silica gel (eluting with tt-heptane/EtOAc 4:1 to 3 :1) to provide (R)-tert-butyl 2-((benzyloxy)methyl)-6-oxomorpholine-4-carboxylate, 19 (96 g, 0.298 mol, 26.1 % yield in two steps) as clear yellow oil after combining the desired fractions, concentration and drying in vacuo.
[0293] Compounds 22 & 23: To a stirred solution of 19 (134.29 g, 0.418 mol) in THF
(1100 mL) cooled to -75 °C was added 1.5 M of MeLi-LiBr complex in diethyl ether (334 mL, 0.501 mol)) was dropwise over 1 h while maintaining the temperature at < -65 °C. The mixture was cooled to -75 °C and stirred for 1.5 h after which time the reaction was slowly quenched over a 10-min period with 20 wt % aqueous NH4C1 (270 g) while maintaining the temperature at < -55 °C. The mixture was warmed to 0 °C over lh, partitioned between water (270 g) and MTBE (1340 mL. The aqueous layer was extracted with MTBE (1100 mL) followed by combining the organic layers and washing them with 20 wt % NaCl (270 g) and concentrated to dry. The residue was dissolved in toluene (1100 mL), filtered, concentrated, azeotroped to dry with toluene (1100 mL), and then dissolved in DCM (1200 ml). The mixture was cooled to -72 °C and triethylsilane (0.200 L, 1.25 mol) was added followed by trimethylsilyl trifluoromethanesulfonate (151 mL, 0.836 mol) over 45-min period while maintaining the temperature at < -68 °C. TFA (129 mL, 1.67 mol) in DCM (336 mL, 5.24 mol) was added over 20-min period to the completed reaction while maintaining the temperature at < -65 °C. The mixture was warmed up to -10 °C followed by the addition of saturated aqueous NaHC03 (0.70 kg) with stilling. The layers were separated and the aqueous layer was extracted two times with DCM (940 mL each). The combined organic layers were washed with saturated aqueous NaHC03 (0.70 kg), concentrated, dissolved in acetonitrile (400 mL), treated with di-fert-butyl dicarbonate (91.2 g, 0.418 mol) at 20-25 °C, and stirred for lh. The completed reaction azeotroped to dry with toluene (800 ml) and purified over silica gel (eluted with «-heptane/EtOAc 9:1 to 4:1) to provide {2R, 6R)-tert- butyl 2-((benzyloxy)methyl)-6-methylmorpholine-4-carboxylate, 22 (61.90g, 0.193 mol, 46% yield from 19) as white solid after combining the desired fractions, concentration and drying in vacuo. The minor stereoisomer 2R,
Figure imgf000056_0001
2-((benzyloxy)methyl)-6- methylmorpholine-4-carboxylate, 23, was separable by silica gel column chromatography.
[0294] Compound 11: To a stirred solution of 22 (27 mg, 0.084 mol) in DCM (0.60 mL) was added TFA (0.30 mL, 0.0039 mol) at rt followed by stirring for 30 min. The completed reaction was concentrated, azeotroped twice to dryness with toluene (1.8 mL x 2) and dissolved in DCM (3.0 mL). The organic solution was washed with saturated aqueous NaHC03 (0.50 g), concentrated, and dried in vacuo to provide (2R, <5i?)-2- ((benzyloxy)methyl)-6-methylmoi"pholine, 11 (19 mg, 100 % yield) as colorless film.
[0295] 2nd Alternative Synthesis of Compound 11 - Scheme 7
[0296] Compound 23: A solution of (2i?)-benzyl 2-epoxypropyl ether, 6 (21.0 g,
0.128 mol) in EtOH (100 mL) was added slowly to a solution of 7.0 M ammonia in MeOH (100 mL) and 28% aq. ammonium hydroxide (210 mL) at rt. The reaction vessel was tightly capped and stirred at rt for 23 h. The completed reaction was concentrated in vacuo, and the crude product was azeotroped to dry twice with toluene (100 mL) to provide (i?)-l-amino-3- (benzyloxy)propan-2-ol, 23 (23 g) as waxy solid containing approximately 15% of dimer. The crude was used for next reaction without further purification.
Compound 25: To the solution of 23 (12.0 g, 49.7 mmol) in EtOH (15 mL) was added commercially available methyl
Figure imgf000056_0002
24 (6.69 g, 54.6 mol). The mixture was heated to 70 °C and stirred for 14 h after which time the completed reaction was concentrated in vacuo. The crude product was diluted with EtOAc (50 mL), washed with IN HC1 (20 mL), brine (20 mL), and then the organic phase was dried over anhydrous Na2S04; filtered and concentrated to dry. Purification over silica gel (SNAP lOg, heptane/EtOAc = 5/1 to 1/5, then EtOAc only, TLC hep/EtOAc = 1/3, rf= 0.45) provided the colorless syrup (5)-N-((i?)-3-(benzyloxy)-2-hydiOxypiOpyl)-2-chloiOpropanamide, 25 (9.86 g, 36.2 mmol, 73% yield) after the desired collected fractions were concentrated and dried in vacuo.
[0297] Compound 26: To the stirred suspension of 60 % sodium hydride (5.82 g,
0.0728 mol) in THF (440 mL) cooled to 0 °C was added 25 (9.89 g, 36.4 mmol) in THF (100 mL) dropwise over a 15 min period. The reaction mixture was stirred at 0 °C an additional 30 min after which time it was allowed to warm to rt for 1 h. The completed reaction completion cooled to 0 °C upon which time isopropyl alcohol (100 mL) was added slowly. The crude solution was neutralized with Dowex H+ followed by filtering off the resin, washing with isopropanol two times (20 mL each) and concentrating the filtrate to dry. The crude product was purified over silica gel (SNAP 100 g, hep/EtOAc = 1/1 to EtOAc only, TLC hep/EtOAc = 1/3, rf = 0.4) ) to provide (2i?, tfi?)-6-((benzyloxy)methyl)-2- methylmorpholin-3-one, 26 (6.42 g, 27.3 mmol, 75% yield) after the desired collected fractions were collected, concentrated and dried in vacuo.
[0298] Compound 11:
[0299] To a stirred solution of 26 (6.67 g, 28.3 mmol) in THF (20 mL) solution was added to 1 M of lithium tetrahydroaluminate in THF (40.0 mL) at rt drop wise. The reaction was stirred at rt for 2.5 h after which time the completed reaction was cooled to 0 °C followed by a slow dropwise addition of water (13 mL) , then 1 M of NaOH in water (0.8 mL). The quenched reaction was stirred at rt until a free flowing white precipitate formed. The precipitate was filtered over a Celite 545 pad and washed with EtOAc, DCM, and Et20 (10 mL each). The filtrate was concentrated and purified over silica gel (SNAP 100 g, DCM only to DCM/MeOH = 97/3, TLC CHCl3/MeOH=9/l, rf/ra,„ =0.5, r¾, =0.4). Obtained the cis/trans diastereomer mixture of 11 (4.42 g, 20.0 mmol, 70.6% yield) of which pure 11 (0.93 g, 4.2 mmol, 15 % yield) was obtained.
[0300] Alternative Preparation of Compound 12 - Scheme 8
[0301] Compound 28: To a suspension of sodium carbonate (31 g, 0.37 mol) in water
(50 ml) was added a solution of l-amino-3,3-diethoxypropane (10.00 mL, 61.81 mmol) in DCM (50 mL) followed by cooling to 0 °C. benzenesulfonyl chloride (7.65 mL, 60.0 mmol) was added at 0 °C with vigorous stirring followed by warming to 20 °C and continued stirring for 2 h after which time MTBE (150 mL) was added. Organic layer was separated, washed with 1.0 M of HC1 (50 mL), saturated NaHC03 (50 g), water (50 g), concentrated and azeotroped to dry two times with MTBE (150 mL x 2) to provide N-(3,3- diethoxypropyl)benzenesulfonamide, 28 (17.34 g, 60.34 mmol, 97% yield) as light yellow clear oil.
[0302] Compound 30: To a stirred solution of 2-fluoi -4-hydroxybenzonitrile, 29
(15.00 g, 0.1094 mol) in DMF (45.0 mL) cooled to 0 °C was added potassium carbonate (37.8 g, 0.274 mol) followed by stilling at 0-5 °C for 30 min. Benzyl bromide (13.7 mL, 0.115 mol) was added to the reaction mixture at < 5 °C, stirred at 5 °C for lh followed by warming to 20 °C and stirring for additional 2.5 h. The completed reaction was partitioned between water (180 ml) and MTBE (220 mL), the layers separated and the organic layer was washed with water (90 mL), concentrated and azeotroped to dry two times with EtOAc (150 mL each) to provide 4-(benzyloxy)-2-fluorobenzonitrile, 30 (24.64 g, 0.1084 mol, 99% yield) as white solid.
[0303] Compounds 32: To a stirred solution of 28 (13.28 g, 46.21 mmol) in NMP
(30.0 mL) was added 30 (10.00 g, 44.01 mmol) at rt followed by Cs2C03 (21.5 g, 66.0 mmol). Resultant mixture was heated at 110 °C for 16 h followed cooling to rt. The mixture was partitioned between water (120 g) and MTBE (120 mL) and the aqueous layer was extracted with MTBE (120 mL). The combined organic layers were washed with water (60 g) concentrated and azeotroped to dry two times with EtOAc (100 mL each) to give N-(5- (benzyloxy)-2-cyanophenyl)-iV-(3,3-diethoxypi pyl)benzenesulfonamide, 31, as a brownish oil. The crude product was subjected to hydrogenolysis with 10 wt % Pd-C(1.40 g) in EtOAc (100 mL) under a hydrogen gas atmosphere (balloon pressure) for 3 h, after which time the purged reaction mixture was filtered through a pad of Celite, rinsed with EtOAc (100 mL) and concentrated. The crude product thus obtained was purified over silica gel (eluting with ft-heptane/MTBE 2:3) to provide N-(2-cyano-5-hydroxyphenyl)-N-(3,3- diethoxypropyl)benzene-sulfonamide, 32 (16.38g, 40.50 mmol, 92% yield) as yellow viscous oil.
[0304] Compound 33 : To a stirred solution of 32 (5.45 g, 13.5 mmol) in THF (40 mL) cooled to 0 °C. was added water (5.4 mL) followed by TFA (11 mL, 0.14 mol). The resultant mixture was allowed to warm to 20 °C and stirred overnight. The completed reaction was azeotroped to dry two times with toluene (54 mL each) to provide 7Y-(2-cyano-5- hydiOxyphenyl)-N-(3-oxopropyl)benzenesulfonamide, 33 (4.55 g, 13.8 mmol, 100 %> yield, as viscous oil.
[0305] Compound 34: To a stirred suspension of 33 (1.64 g, 4.96 mmol) in a mixture of toluene (29.5 mL) and NMP (1.2 mL) heated at 70 °C was added D-(+)- 10- camphorsulfonic acid (1.15 g, 4.96 mmol) followed by heating at 100 °C for 14 h. The completed reaction was cooled to rt, diluted with EtOAc (60 mL), washed with water (6.3 mL), and concentrated to give dark brownish oil. Crude product was purified over silica gel (eluting with ^-heptane/EtOAc 1 : 1) to provide 5-hydroxy-l-(phenylsulfonyl)-l,2- dihydi quinoline-8-carbonitrile, 34 (685 mg, 2.19 mmol, 44%> yield) as yellow solid.
[0306] Compounds 35 and 12: To a stirred suspension of 34 (0.393 g, 1.26 mmol) in
DCM (3.0 ml) was added 2,6-lutidine (0.437 ml, 3.78 mmol) followed by cooling to 1-2 °C. A solution of trifluoromethanesulfonic anhydride (0.275 ml, 1.64 mmol) in DCM (1.0 ml) was added while maintaining the temperature below 4 °C. The reaction mixture was stirred at 2-3 °C for lh, poured into a pre-chilled (5 °C) mixture of MTBE (20 ml) and 1 M HC1 (6.3 ml). The resultant, separated organic layer was washed with 9 wt % NaHC03 (3 g), 20 wt % NaCl (5 g), dried over Na2S04 (2 g) for lh, filtered and concentrated to give crude 8-cyano-l- (phenylsulfonyl)-l,2-dihydroquinolin-5-yl trifluoromethane-sulfonate, 35 as a yellow oil. 35 was dissolved in NMP (2.5 ml) and DIPEA (1.75 ml, 10.1 mmol) followed by 11 (0.446 g, 2.02 mmol) and resultant mixture was heated at 125 °C overnight. The completed reaction was cooled to rt and partitioned between EtOAc (30 ml) and water (10 ml). The organic layer was washed with water (10 ml), concentrated and purified over a silica gel plug column (eluting with «-heptane/EtOAc 1 : 1) to provide 5-((2i?, 5i?)-2-((benzyloxy)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile, 12 (80.2 mg, 0.215 mmol, 17% yield) as brownish solid.
[0307] Synthesis of Compound 36 - Scheme 9: To a stirred suspension of 13 (10.97 g, 38.72 mmol) in DCM (44 mL) was added 2,6-lutidine (5.38 mL, 46.5 mmol) followed by cooling to 0 °C. A solution of trifluoiOmethanesulfonic anhydride (Tf20; 6.84 mL, 40.7 mmol) in DCM (22 mL) was added while maintaining the temperature at < 5 °C and stirring for lh. The completed reaction was quenched with saturated sodium bicarbonate (65 g) and the mixture was warmed up to 15 °C. The layers were separated and the aqueous layer was extracted with DCM (55 mL). The combined organic layers were washed with 20 wt % NaCl (33 g) and stirred over Florisil (11 g) for 1.5 h after which time the mixture was filtered, eluted with MTBE (55 mL) and concentrated. The tan solid was suspended in DCM (11 ml), diluted with ??-heptane (110 ml), filtered, rinsed with /7-heptane/DCM 10:1 (121 ml), and dried under vacuum to provide ((2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2- yl)methyl trifluoromethanesulfonate, 36 (15.20 g, 36.6 mmol, 94% yield) as light tan solid.
[0308] Synthesis of ER-887927 using Schemes 9 and 17:
[0309] Scheme 17
Figure imgf000059_0001
[0311 ] To a stirred suspension of 36 (1.002 g, 2.412 mmol) in acetonitrile (6.0 mL) was added potassium carbonate (1.33 g, 9.65 mmol) followed by commercially available 1,4'- bipiperidine, 72 (609 mg, 3.62 mmol). The reaction mixture was heated at reflux for 5 h after which time the completed reaction was cooled to rt, diluted with water (12 mL) and partially concentrated. N-Heptane (10 mL) and MTBE (10 mL) were added and the mixture was partially concentrated upon which time a brownish solid thus formed was collected by filtration, rinsed with: (1) water (15 mL) and (2) ^-heptane (15 mL), and dried under vacuum overnight. The dried solid was dissolved in ^-heptane (10 mL, 0.2 mol), diluted with acetonitrile (5.0 mL, 0.096 mol) then treated with Florisil (0.50 g) at rt for 10 min. The mixture was filtered, eluted with acetonitrile (10 mL) and concentrated to give tan solid, which was triturated with MTBE/«-heptane 1 :2 (15 ml), filtered, rinsed with MTBE/n- heptane 1 :3 (10 ml) and dried under N2/vacuum to give ER-887927 as light tan powder (1.001 g, 2.31 rnmol, 95% yield).
[0312] ER-893881 (15.2 mg, 0.037 rnmol, 51.6 % yield) was prepared by a similar method described for ER-887927 starting with 36 (30 mg, 0.072 rnmol) and (5)-1,3'- bipyrrolidine dihydrochloride (20.5 mg, 0.144 rnmol) using TEA (0.020 mL, 0.141 rnmol) instead of K2C03.
[0313] ER-894483 (30 mg, 0.079 rnmol, 32.8 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and (R)-3- methylpiperazin-2-one (54.9 mg, 0.481 rnmol).
[0314] ER-894484 (30 mg, 0.079 rnmol, 32.8 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and (S)-3- methylpiperazin-2-one (54.9 mg, 0.481 rnmol).
[0315] ER-894504 (30 mg, 0.076 rnmol, 31.5 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and (2S,5R)-2,5- dimethylpiperazine (54.9 mg, 0.481 rnmol).
[0316] ER-894505 (30 mg, 0.076 rnmol, 31.5 % yield) was prepared by a similar method described for ER-893881 starting with 36 (100 mg, 0.241 rnmol) and 2,3- dimethylpiperazine (54.9 mg, 0.481 mmol).
[0317] ER-894655 (140 mg, 0.309 mmol, 64.2 % yield) was prepared by a similar method described for ER-893881 starting with 36 (200 mg, 0.482 mmol) and tert-butyl 2,2- dimethylpiperazine-l-carboxylate (206 mg, 0.961 mmol). The Boc-protecting group was hydrolyzed using 4 N HCl dioxane followed by isolation of the desired product by azeotroping to dry with toluene and drying under vacuo.
[0318] ER-894151 (1.066 g, 3.16 mmol, 65.4 % yield) was prepared by a similar method described for ER-893881 starting with 36 (2.0 g, 4.81 mmol) and tert-biityl azetidin- 3-ylcarbamate (0.995 g, 5.78 mmol). The Boc-protected intermediate was deprotected using TFA (3 mL) in DCM (3 mL). The reaction was allowed to stir for 30 m, after which time the reaction was concentrated to dry with azeotroping three times with toluene (5 mL each). The residue was diluted with DCM (10 mL), washed two times with sat. NaHC03 (5 mL), water (5 mL), brine (5 mL), dried over MgS04, filtered, concentrated and dried in vacuo to provide the desired product.
[0319] ER-890250: To a cooled stirring solution of ER-887927 (50 mg, 0.1 15 mmol) in THF (1 mL) at - 78 °C was added 1.6 M methyl lithium-lithium bromide complex in ethyl ether (0.15 mL, 0.24 mmol) whereupon the pale yellow solution was changed to bright red/orange. The reaction mixture was stirred for 1.5 h at - 78 °C after which time it was quenched with aqueous ammonium hydroxide (2 mL) followed by slowly warming to rt. The reaction was extracted three times with DCM (5 mL) and the combined organic layers were dried over , filtered and concentrated to dry.
The crude intermediate was dissolved in acetone (1 mL) followed by a solution of eerie ammonium nitrate (300 mg, 0.547 mmol) in water (1.5 mL). The reaction mixture was stirred for 30 min after which time the reaction mixture was concentrated to a crude solid. The solid was suspended in acetone 5 mL, stirred for 5 min, filtered and the solid filter pad eluted three times with acetone (5 mL each). The combined filtrates were concentrated in then purified by reverse-phase HPLC (X-Bridge C18 19 x 100 mm column using a acetonitrile/water gradient containing 0.1 % formic acid). The desired fractions were combined, concentrated, dissolved in MeOH (2 mL), passed over a SiC03 column, eluted two times with MeOH, concentrated and dried in vacuo to provide ER-890250 (4.4 mg, 0.010 mmol, 8.5 % yield).
[0320] Synthesis of ER-884884 from Scheme 10:
[0321] Compound 37: To a stirred solution of 22 from Scheme 6 (1.003 g, 3.121 mmol) in EtOH (5 mL) was added 5 % Pd on carbon (100 mg) followed by charging the flask several times with hydrogen gas. The reaction was heated to 40 °C maintaining a hydrogen atmosphere (balloon pressure) and stirred overnight, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with EtOH (5 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo. The crude product, (3 R, 5 S)-ter t-butyl 3-(hydroxymethyl)- 5-methylpiperidine-l-carboxylate (0.720 g, 3.114 mmol, 99.8% yield) was used in the next step without further purification.
[0322] To a stirred solution of (3 R, 5 S)-ter -butyl 3-(hydroxymethyl)-5- methylpiperidine-l-carboxylate (0.783 g, 3.385 mmol) in DCM (5 mL) was added p- toluenesulfonyl chloride ( 0.968 g, 5.078 mmol) followed by DMAP (40 mg, 0.33 mmol) and DIPEA (1.18 mL, 6.77 mmol) at rt. The reaction mixture was stirred at rt for 3 h after which time water (5 mL) was added followed by stirring an additional 15 min. The resultant organic layer was washed with 0.1 N HC1 (5 mL), brine (3 mL), dried over MgS04, filtered and concentrated to dryness. The crude product was purified over silica gel (Biotage, eluting with 3: 1 heptanes: EtOAc) to provide (3 S, 5 R)-ter f-butyl 3-methyl-5- ((tosyloxy)methyl)piperidine-l-carboxylate (0.8602 g, 2.232 mmol, 65.9 % yield).
[0323] To a stirred solution of (3 S, 5 R)-rer t-b tyl 3-methyl-5-
((tosyloxy)methyl)piperidine-l-carboxylate (0.860 g, 2.232 mmol) in DMF (7 mL) at rt was added sodium azide (0.218 g, 3.347 mmol) after which time the reaction was warmed to 80 °C and stirred an additional 3 h. The completed reaction was cooled to rt, diluted with EtOAc (25 mL) and washed three times with water (5 mL each). The resultant organic layer was dried over anhydrous Na2S04, filtered, concentrated after which time the crude product was purified over silica gel (Biotage eluting with 0 to 15 % EtOAc in heptane gradient) to provide (2R, 6R)-tert-butyl 2-(azidomethyl)-6-methylmorpholine-4-carboxylate, 37 (0.545 g, 2.126 mmol, 95.3 % yield) as a colorless crystalline solid after concentration of the desired combined fractions and drying in vacuo.
[0324] ER-884884: To a stirred solution of 37 (0.545 g, 2.126 mmol) in MeOH (5 mL) was added 5 % palladium on activated carbon (250 mg) followed by charging the flask several times with hydrogen gas. The reaction was maintaining under a hydrogen atmosphere (balloon pressure) at rt and stirred for 12 h, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with EtOH (2 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo. The crude product, (2S, 6R)-tert-bu yl 2-(aminomethyl)-6- methylmorpholine-4-carboxylate (0.489 g, 2.10 mmol, 99.9% yield) was used in the next step without further purification.
[0325] To a stirred solution of (2S, 6R)-tert-buty\ 2-(aminomethyl)-6- methylmorpholine-4-carboxylate (50.2 mg, 0.218 mmol) in DCM (0.5 mL) was added TFA (0.25 mL, 3.4 mmol) at rt. The reaction mixture was stirred for 1 h after which time it was concentrated and azeotroped to dry two times with toluene (2 mL each) and dried in vacuo. The crude deprotected morpholine was dissolved with stirring in DMA (1 mL) followed by TEA (2 mL) and compound 3 (50 mg, 0.214 mmol). The reaction mixture was warmed to 140 °C and stirred for lh after which time the completed reaction was cooled to rt and directly injected onto a preparative reverse-phase HPLC column (after filtering) to provide ER-884884 (12.1 mg, 0.043 mmol, 19.7 % yield) after concentration of the desired combined fractions and drying under vacuo.
103261 Substituted Compound 15, Scheme 10 or ER-879713: To a stirred solution of ER-884884 (30.2 mg, 0.107 mmol) in DCM (0.5 mL) was added TEA (30 uL, 0.20 mmol) followed by 2,2-dimethylpropanoyl chloride (20 uL, 0.162 mmol). The reaction mixture was stirred at rt for 3 h after which time the completed reaction was concentrated, filtered, and purified directly via preparative reverse-phase HPLC (Water's X-Bridge C18 19xl00mm column; eluted with a gradient of acetonitrile in water containing 0.05 % TFA) to provide ER-879713 (20.5 mg, 0.056 mmol, 52.3 % yield) after concentration of the desired combined fractions and drying under vacuo.
[0327] ER-886432 (10.2 mg, 0.023 mmol, 52.7 % yield) was obtained using a similar process to ER-879713 starting with ER-884884 (50 mg, 0.177 mmol) and 1 - phenylcyclobutanecarbonyl chloride (8.5 mg, 0.044 mmol).
[0328] ER-886563 (3.6 mg, 0.023 mmol, 20.3 % yield) was obtained using a similar process to ER-879713 starting with ER-884884 (12.4 mg, 0.044 mmol) and benzeneacetyl chloride (0.007 mL, 0.053 mmol). .
[0329] ER-888137: To a stirred solution of ER-884884 (30.2 mg, 0.107 mmol) in
NMP(0.5 mL) was added 2-chloiO-5-fluoiOpyrimidine (140 mg, 1.056 mmol). The reaction mixture was micro waved at 150 °C for 5 min, after which time the cooled reaction was purified over a C-18 reverse-phase HPLC preparative column eluting with a 10 to 40 % acetonitrile in water gradient. The desired fractions were concentrated and dried under vacuo to provide ER-888137 (6.5 mg, 0.017 mmol, 9.7 % yield).
[0330] ER-888701 (12.2 mg, 0.031 mmol, 17.7% yield) was prepared in a similar manner to ER-888137 starting with ER-884884 (50 mg, 0.177 mmol) and 2-chloro-5- ethylpyrimidine (150 mg, 1.052 mmol).
[0331] ER-888896 (3.0 mg, 0.008 mmol, 23.1 % yield) was prepared in a similar manner to ER-888137 starting with ER-884884 (10.1 mg, 0.036 mmol) and 2- chloropyrazine (30 mg, 0.261 mmol).
[0332] Scheme 18: Alternative Route to Substituted Compound 15:
Figure imgf000064_0001
[0333] 75 [15 R = H, R2 = -C(0)R]
[0334] ER-879713 or Compound 76 using Scheme 18:
[0335] Compound 73: To a stirred solution of 37 (0.545 g, 2.126 mmol) in MeOH (5 mL) was added 5 % palladium on activated carbon (250 mg) followed by charging the flask several times with hydrogen gas. The reaction was maintaining under a hydrogen atmosphere (balloon pressure) at rt and stirred for 12 h, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with EtOH (2 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo. The crude product, (2S, 6R)-tert-buty\ 2-(aminomethyl)-6- methylmorpholine-4-carboxylate, 73 (0.489 g, 2.10 mmol, 99.9% yield) was used in the next step without further purification.
[0336] Compound 74: To a stirred solution of 73 (50.2 mg, 0.218 mmol) in DCM
(0.5 mL) ) was added TEA (36.5 uL, 0.268 mmol) followed by 2,2-dimethylpropanoyl chloride (29.5 uL, 0.235 mmol). The reaction mixture was stirred at rt for 1 h after which time the completed reaction was poured over water, extract three times with DCM (3 mL each) and the combined organic layers were dried over MgS04, filtered, concentrated, and dried under vacuo to provide crude (2R, 6S)-tert-buty\ 2-methyl-6- (pivalamidomethyl)morpholine-4-carboxylate, 74 (R = tBu).
[0337] ER-879713: To as stirred solution of crude 74 in DCM (5 mL) was added
TFA (0.25 mL, 3.4 mmol) followed by stirring at rt for 1 h. The completed reaction was concentrated and azeotroped two times with toluene and then dried in vacuo for 30 min, after which time the crude, advanced intermediate, 75, was dissolved in DMA (1 mL) followed by TEA (2 mL) and compound 3 (50 mg, 0.214 mmol). The reaction mixture was warmed to 140 °C and stirred for lh after which time the completed reaction was cooled to rt and directly injected onto a preparative reverse-phase HPLC column (after filtering) to provide an example of 76 or ER-879713 (9.3 mg, 0.025 mmol, 11.6 % yield, R = tBu) after concentration of the desired combined fractions and drying under vacuo.
[0338] ER-879689 (4.3 mg, 0.013 mmol, 6.0 % yield, R = Me) was obtain using a similar process to ER-879713 starting with 73 (50.2 mg, 0.218 mmol, R = Me) and 3 (50 mg, 0.215 mmol).
[0339] ER-886360 (14.3 mg, 0.035 mmol, 15.8% yield, R = CH(Me)Ph) was obtain using a similar process to ER-879713 starting with 73 (50.2 mg, 0.218 mmol, R = CH(Me)Ph) and 3 (50 mg, 0.215 mmol).
[0340] Additional examples of substituted Compound 15:
[0341] ER-888603: To stirred solution of 37 (58.1 mg, 0.227 mmol) and cyclohexylacetylene (0.026 mL, 0.200 mmol) in tert-butyl alcohol (0.08 mL) and water (0.07 mL) was added sodium bicarbonate (2.5 mg, 0.030 mmol) followed by copper(II) sulfate pentahydrate (2.5 mg, 0.010 mmol) and sodium ascorbate (7.8 mg, 0.039 mmol). The reaction mixture was stirred at rt for 14 h after which time DCM (5 mL) and saturated sodium bicarbonate (5 mL) was added and stirred an additional 10 min. The layers were separated and the aqueous layer was extracted two times with DCM (3 mL each). The combined organic layers were dried over anhydrous MgS04, filtered and concentrated to dry. The crude Boc-protected intermediate was dissolved with stirring in DCM (3 mL) followed by TFA (0.8 mL). The reaction was stirred at rt for 1 h after which time the completed reaction was concentrated and azeotroped to dryness using toluene (2 times @ 5 mL each). The crude product was purified via HPLC (Water's X-Bridge C18 19 x 100 mm column; eluted with a gradient of acetonitrile in water containing 0.05 % TFA) to provide (2R, <5i?)-2- ((4-cyclohexyl-lH-l,2,3-triazol-l-yl)methyl)-6-methylmorpholine (8.9 mg, 0.034 mmol, 16.8 % yield)
|0342| To a stirred solution of (2i?^i?)-2-((4-cyclohexyl-lH- 1,2,3 -triazol-1- yl)methyl)-6-methylmorpholine (8.9 mg, 0.034 mmol) in DMA (0.3 mL) and TEA (0.005 mL, 0.036 mmol) was added 3 (7.85 mg, 0.034 mmol). The mixture was microwaved at 150 °C for 30 min after which time the cooled reaction was directly injected onto a preparative, C-18 reverse phase HPLC column (Water's X-Bridge C18 19 x l00 mm column; eluting with a gradient of 10 - 40 % acetonitrile in water containing 0.05 % TFA). The desired collected fractions were concentrated and dried in vacuo to provide ER-888603 (3.3 mg, 0.008 mmol, 23.3 % yield or a 3.9 % overall yield). [0343] ER-888604 (5.2 mg, 0.013 mmol, 6.5 % overall yield) was prepared in a similar manner to ER-888603 starting with 37 (58.1 mg, 0.227 mmol), phenylacetylene (0.022 mL, 0.200 mmol) and 3 (7.85 mg, 0.034 mmol).
[0344] ER-889556: To a stirred suspension of ER-887268 (140.3 mg, 0.384 mmol) in water (1.5 mL) was added formaldehyde (1 mL) and formic acid (0.55 mL) after which time the reaction mixture was micro waved at 110 °C for 1.5 h. The completed reaction was cooled and directly injected onto a preparative, C-18 reverse phase HPLC column eluting with a gradient of 10 - 40 % acetonitrile in water containing 0.1 % TFA. The desired collected fractions were concentrated, dissolved in MeOH (5 mL), passed over a plug of SiC03 eluting with MeOH (10 mL), concentrated and dried in vacuo to provide ER-889556 (75 mg, 0.197 mmol, 51.5 % yield).
[0345] ER-890114 (75.9 mg, 0.170 mmol, 40.5 % yield) was prepared in a similar manner to ER-889556 starting with ER-890112 (182 mg, 0.420 mmol).
[0346] ER-890108 (72.1 mg, 0.171 mmol, 40.7 % yield) was prepared in a similar manner to ER-889556 starting with ER-890119 (170.6 mg, 0.420 mmol).
[0347] ER-890345 (43.5 mg, 0.115 mmol, 38 % yield) was prepared in a similar manner to ER-889556 starting with ER-890344 (110.2 mg, 0.302 mmol).
[0348] ER-890346 (52.6 mg, 0.139 mmol, 73.3 % yield) was prepared in a similar manner to ER-889556 starting with ER-887269 (69 mg, 0.189 mmol).
[0349] ER-890831 (85.2 mg, 0.225 mmol, 74.5 % yield) was prepared in a similar manner to ER-889556 starting with ER-887270 (110.2 mg, 0.302 mmol).
[0350] ER-890964 (506.2 mg, 1.286 mmol, 71.2 % yield) was prepared in a similar mamier to ER-889556 starting with ER-890963 (685.2 mg, 1.806 mmol).
[0351] ER-890186 (10.2 mg, 0.023 mmol, 20.7 % yield) was prepared in a similar manner to ER-889556 starting with ER-890107 (48 mg, 0.111 mmol).
[0352] ER-890223 (35 mg, 0.078 mmol, 42.9 % yield) was prepared in a similar mamier to ER-889556 starting with ER-890106 (100 mg, 0.182 mmol) as the TFA salt.
[0353] ER-894656 (31.7 mg, 0.068 mmol, 61.5 % yield) was prepared in a similar manner to ER-889556 starting with ER-894655 (50 mg, 0.1 1 1 mmol) as the dihydrochloride salt.
[0354] ER-889728: To a stirred solution of ER-888070 (12.5 mg, 0.034 mmol) in
DCM (0.5 mL) was added TEA (0.01 mL, 0.072 mmol) followed by nicotinoyl chloride (10 mg, 0.071 mmol). The reaction mixture was stirred at rt for 1 h after which time the reaction was diluted with DCM (5 mL), washed with water (2 mL), brine (2 mL), dried over MgS04, filtered and concentrated to dry. The crude product was purified over a preparative, C-18 reverse phase HPLC column eluting with a gradient of 10 - 25 % acetonitrile in water containing 0.1 % TFA. The desired collected fractions were concentrated, dissolved in MeOH (5 mL), passed over a plug of SiC03 eluting with MeOH (10 mL), concentrated and dried in vacuo to provide ER-889728 (7.2 mg, 0.015 mmol, 45 % yield).
[0355] ER-889729 (8.2 mg, 0.017 mmol, 51.3 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and isonicotinoyl chloride (10 mg, 0.071 mmol).
[0356] ER-889734 (8.6 mg, 0.018 mmol, 52.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and picolinoyl chloride (10 mg, 0.071 mmol).
[0357] ER-889744 (12 mg, 0.028 mmol, 80.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and hexanoyl chloride (9 mg, 0.067 mmol).
[0358] ER-889745 (8 mg, 0.018 mmol, 54 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and isobutyryl chloride (7 mg, 0.066 mmol).
[0359] ER-889746 (7.6 mg, 0.017 mmol, 50 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and 2,2- dimethylpropanoyl chloride (8 mg, 0.066 mmol).
[0360] ER-890113 (25.6 mg, 0.054 mmol, 66.7 % yield) was prepared in a similar manner to ER-889728 starting with ER-890112 (35.2 mg, 0.081 mmol) and acetic anhydride (0.093 mL, 0.984 mmol).
[0361] ER-890120 (20.3 mg, 0.045 mmol, 54.2 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (33.7 mg, 0.083 mmol) and acetic anhydride (0.012 mL, 0.127 mmol).
[0362] ER-890122 (35.2 mg, 0.069 mmol, 43.1 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (65.2 mg, 0.160 mmol) and benzoyl chloride (0.037 mL, 0.318 mmol).
[0363] ER-890142 (45.2 mg, 0.084 mmol, 53.1 % yield) was prepared in a similar manner to ER-889728 starting with ER-890112 (68.5 mg, 0.158 mmol) and benzoyl chloride (0.037 mL, 0.318 mmol). [0364] ER-890187 (9.4 mg, 0.020 mmol, 18.0 % yield) was prepared in a similar manner to ER-889728 starting with ER-890107 (48 mg, 0.11 1 mmol) and acetic anhydride (0.125 mL, 1.3 mmol).
[0365] ER-890188 (8.9 mg, 0.018 mmol, 16.0 % yield) was prepared in a similar manner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) and isobutyryl chloride (0.051 mL, 0.487 mmol).
[0366] ER-890189 (10 mg, 0.019 mmol, 16.7 % yield) was prepared in a similar manner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) and benzoyl chloride (0.056 mL, 0.482 mmol).
[0367] ER-890190 (6.5 mg, 0.014 mmol, 36.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (15.6 mg, 0.038 mmol) and isobutyryl chloride (0.006 mL, 0.058 mmol).
[0368] ER-890219 (32.0 mg, 0.067 mmol, 91.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-890106 (40.2 mg, 0.073 mmol) as the TFA salt, TEA (0.20 mL, 1.43 mmol) and acetic anhydride (0.10 mL, 1.06 mmol).
[0369] ER-890221 (28.2 mg, 0.056 mmol, 76.7 % yield) was prepared in a similar manner to ER-890219 starting with ER-890106 (40.2 mg, 0.073 mmol) as the TFA salt and isobutyryl chloride (0.080 mL, 0.764 mmol).
[0370] ER-890222 (30.1 mg, 0.056 mmol, 76.7 % yield) was prepared in a similar manner to ER-890219 starting with ER-890106 (40.5 mg, 0.074 mmol) as the TFA salt and benzoyl chloride (0.20 mL, 1.723 mmol).
[0371] ER-892254 (24.2 mg, 0.0.52 mmol, 67.5 % yield) was prepared in a similar manner to ER-889728 starting with ER-892253 (32.2 mg, 0.077 mmol) and acetic anhydride (0.015 mL, 0.151 mmol). Acetonitrile (0.5 mL) was added to the reaction mixture.
[0372] ER-892256 (25.2 mg, 0.052 mmol, 41.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-890119 (50.2 mg, 0.124 mmol) and methanesulfonyl chloride (0.011 mL, 0.142 mmol).
[0373] ER-893926 (124.2 mg, 0.255 mmol, 51.7 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (180.2 mg, 0.493 mmol) and 1,3-dimethyl- iH-pyrazole-4-carbonyl chloride (93.8 mg, 0.592 mmol).
[0374] ER-893927 (45.2 mg, 0.0.83 mmol, 57.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-892253 (60.5 mg, 0.144 mmol) and 1 ,3-dimcthyl- yH-pyrazole-4-carbonyl chloride (27.4 mg, 0.173 mmol). [0375] ER-893948 (65.3 mg, 0.147 mmol, 29.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (180.2 mg, 0.493 mmol) and methanesulfonyl chloride (68 mg, 0.593 mmol).
[0376] ER-894149 (67.2 mg, 0.133 mmol, 80.6 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (60.2 mg, 0.165 mmol) and benzenesulfonyl chloride (0.023 mL, 0.180 mmol).
[0377] ER-894150 (58.2 mg, 0.11 1 mmol, 69.9 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (58.2 mg, 0.159 mmol) and 4- fluorobenze esulfonyl chloride (0.025 mL, 0.188 mmol).
[0378] ER-894152 (36.2 mg, 0.095 mmol, 63.6 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.6 mg, 0.150 mmol) and acetic anhydride (0.014 mL, 0.135 mmol).
[0379] ER-894153 (5.4 mg, 0.012 mmol, 7.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (52.2 mg, 0.155 mmol) and 4- fluorobenzenzoyl chloride (25 mg, 0.158 mmol).
[0380] ER-894154 (38.5 mg, 0.093 mmol, 62.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.4 mg, 0.149 mmol) and methanesulfonyl chloride (0.012 mL, 0.146 mmol).
[0381] ER-894155 (42.1 mg, 0.085 mmol, 57.1 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.3 mg, 0.149 mmol) and 4- fluorobenzenesulfonyl chloride (29 mg, 0.149 mmol).
[0382] ER-894159 (20.4 mg, 0.041 mmol, 27.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.5 mg, 0.150 mmol) and 1,3-dimethyl- iH-pyrazole-4-sulfonyl chloride (29 mg, 0.149 mmol).
[0383] ER-894160 (47.2 mg, 0.0.90 mmol, 65.8 % yield) was prepared in a similar manner to ER-889728 starting with ER-888070 (50.1 mg, 0.137 mmol) and 1,3-dimethyl- 7H-pyrazole-4-sulfonyl chloride (27 mg, 0.139 mmol).
[0384] ER-894206 (1 1.3 mg, 0.029 mmol, 19 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (50.6 mg, 0.150 mmol) and isobutyryl chloride (16. mg, 0.150 mmol).
[0385] ER-894594 (215 mg, 0.487 mmol, 46.4 % yield) was prepared in a similar manner to ER-889728 starting with ER-894151 (354 mg, 1.049 mmol) and benzoic anhydride (407 mg, 1.81 mmol). Acetonitrile (2 mL) was used instead of DCM. [0386] Preparation of ER-890252: To a stirred solution of 36 (2.0 g, 4.8 mmol) from Scheme 9 in acetonitrile (15 mL) was added (R)-tert-butyl pyrrolidin-2-ylcarbamate (1.10 g, 5.9 mmol) followed by TEA (1.6 mL, 1 1.5 mmol). The reaction was stirred at 70 °C for 3h after which time the completed reaction was concentrated to a crude syrup, diluted with DCM (20 mL), washed with water (5 mL), dried over , filtered and concentrated to dryness. The crude product was purified over silica gel (Biotage SP4, 40+M, eluting with a gradient of 5% MeOH in 1 : 1 EtOAc:DCM to 10% MeOH in 1 : 1 EtOAc:DCM over a 10 column volume cycle. The product containing fractions were combined, concentrated and dried under vacuo to provide fe/ -butyl ((i?)-l-(((21S') (ii?)-4-(8-cyanoquinolin-5-yl)-6- methylmoipholin-2-yl)methyl)pyrrolidin-3-yl)carbamate (1.35 g, 3.0 mmol, 62 % yield).
[0387] To a stirred solution of tert-butyl ((J?)-l-(((25, ^)-4-(8-cyanoquinolin-5-yl)-6- methylmorpholin-2-yl)methyl)-pyiTolidin-3-yl)carbamate (1.35 g, 3.0 mmol) in DCM (10 mL) was added TFA (8.1 mL). The reaction was stirred at rt after which time it was concentrated and azeotroped to dryness tliree times with toluene (10 mL each) and then dried under vacuo to provide crude 5-((25', (5i?)-2-(((i?)-3-aminopynOlidin-l-yl)methyl)-6- methylmoi holino)quinoline-8-carbonitrile (1.39 g, 3.0 mmol, 100% yield) as the TFA salt.
[0388] ER-890252 (120.3 mg, 0.306 mmol, 71.2 % yield) was prepared in a similar manner to ER-890222 starting with 5-((2S, 6R)-2-(((R)-3 -aminopyrrolidin- 1 -yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and acetic anhydride (0.80 mL, 8.46 mmol).
[0389] ER-890253 (146.5 mg, 0.348 mmol, 80.8% yield) was prepared in a similar manner to ER-890122 starting with 5 -((2$ 6Λ)-2-(((Λ)-3 -aminopyrrolidin- 1 -yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and isobutyryl chloride (0.50 mL, 4.77 mmol).
[0390] ER-894544 (103.6 mg, 0.227 mmol, 52.9 % yield) was prepared in a similar manner to ER-890122 starting with 5-((2S, 6.fl)-2-(((/ -3 -aminopyrrolidin- 1 -yl)methyl)-6- methylmoipholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and benzoyl chloride (0.50 mL, 4.31 mmol).
[0391] ER-894546 (96.7 mg, 0.214 mmol, 49.8 % yield) was prepared in a similar manner to ER-890222 starting with 5-((2»S,, ^)-2-(((5)-3-aminopynOlidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and acetic anhydride (0.80 mL, 8.46 mmol). 5-((25', (5i?)-2-(((lS -3-aminopyiTolidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile was prepared in a similar manner to 5-((25', (5i?)- 2-(((i?)-3-aminopyrrolidin-l-yl)methyl)-6-methylmoipholino)quinoline-8-carbonitrile using (<S)-tert-butyl pyiTolidin-2-ylcarbamate as the starting material in the first step described above for the preparation of ER-890252.
[0392] ER-894547 (120.8 mg, 0.287 mmol, 66.7 % yield) was prepared in a similar manner to ER-894546 starting with 5-((25,, <5i?)-2-(((5 -3-aminopyiTolidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and isobutyric anhydride (0.70 mL, 4.22 mmol).
[0393] ER-894548 (1 10.4 mg, 0.242 mmol, 56.4 % yield) was prepared in a similar manner to ER-894546 starting with 5-((2lS,, (ii?)-2-(((1S)-3-aminopyiTolidin-l-yl)methyl)-6- methylmorpholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA salt and benzoic anhydride (0.50 g, 2.21 mmol).
[0394] ER-894545 (32 mg, 0.084 mmol, 19.6 % yield) was prepared in a similar manner to ER-889556 starting with 5-((25,, 5i?)-2-(((i?)-3-aminopyrrolidin-l-yl)methyl)-6- methylmoipholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA.
[0395] ER-894549 (103.8 mg, 0.274 mmol, 63.6 % yield) was prepared in a similar manner to ER-889556 starting with 5-((2S, 6 ?)-2-(((lS')-3-aminopynOlidin- 1 -yl)methyl)-6- methylmoipholino)-quinoline-8-carbonitrile (200 mg, 0.430 mmol) as the TFA.
[0396] Preparation of 886355 using modifications to Scheme 7 and Scheme 4: To a stirred solution of (R)- 1 -amino-3-(bcnzyloxy)propan-2-ol, Compound 22 in Scheme 7 (8.0 g, 44.1 mmol) in DMF (60 mL) was added (S)-2-chlorobutanoic acid (5.0 g, 40.8 mmol) followed by TEA (10.5 g. 103.8 mmol), DMAP (0.4 g, 3.3 mmol) and finally EDC (9.52 g, 49.7 mmol). The reaction mixture was stirred at rt for 5 d after which time the completed reaction was concentrated to a crude syrup. Purification over silica gel (Biotage, eluting with a gradient of 20 - 100 % EtOAc in heptanes) followed by collection of the desired fractions, concentration and drying in vacuo provided (5 -N-((i?)-3-(benzyloxy)-2-hydiOxypropyl)-2- chlorobutanamide (683.5 mg, 2.392 mmol, 5.9 % yield).
[0397] To stirred suspension of sodium hydride (203.1 mg, 5.1 mmol as a 60% oil dispersion) in THF (18 mL) cooled to 0 °C was added dropwise (S)-N-((i?)-3-(benzyloxy)-2- hydroxypropyl)-2-chlorobutanamide (362.8 mg, 1.270 mmol) in THF (3.8 mL) over a 5-min period after which the reaction was stirred at 0 °C for 30 min followed by stirring at rt for 5 h. The completed reaction was quenched with the slow addition of IP A (1 mL) followed by adding Dowex 50, H+ form, until a neutral to acidic pH was observed. The final suspension was filtered and the solid was rinsed two times with EtOAc. The combined filtrated were concentrated and the resultant crude product was purified over silica gel (Biotage, eluting with 1 : 1 EtOAc: heptane). The desired fractions were combined, concentrated and dried in vacuo to provide (2i?, ii?)-6-((benzyloxy)methyl)-2-ethylmorpholin-3-one (314 mg, 1.260 mmol, 99.2 % yield).
[0398] To a stirred solution of (2i?, i?)-6-((berizyloxy)rnethyl)-2-ethylrnorpholin-3- one (362.2 mg, 1.453 mmol) in THF (2 mL) was added 1 M lithium tetrahydroaluminate in THF (2 mL, 2 mmol) dropwise at rt over a 2-min period. The reaction was stilted at rt for 2.5 h after which time it was cooled to 0 °C followed by a dropwise addition of water (0.6 mL) and then 1 M sodium hydroxide in water (.04 mL). The quenched reaction was warmed to rt, stirred until a granular solid was formed and filtered over a Celite 545 pad rinsing with EtOAc (5 mL), DCM (5 mL) and ethyl ether (5 mL). The filtrate was concentrated and the resultant crude product was purified over silica gel (Biotage, eluting with a gradient of 5 - 10 % MeOH in DCM) followed by combining the desired fractions, concentration and drying in vacuo to provide (2R, (5i?)-2-((benzyloxy)methyl)-6-ethylmoi-pholine (50.2 mg, 0.213 mmol, 14.6 % yield).
[0399] To a stirred solution of (2i?, (ii?)-2-((benzyloxy)methyl)-6-ethylmoi-pholine
(12.4 mg, 0.053 mmol) and Compound 3 (10.2 mg, 0.044 mmol) in DMA (2 mL) was added DIPEA (0.015 mL, 0.086 mmol) followed by microwaving at 150 °C for 7 h. The cooled completed reaction was directly injected onto a C-18 reverse phase HPLC (Water's X-Bridge C18, 19 x 100 mm column, eluting with a linear gradient of 10% - 90% acetonitrile in water with 0.1% formic acid) and concentrating the desired peak followed by high vacuum to dryness to provide ER-88635S (6.2 mg 0.016 mmol, 36.4 % yield).
[0400] Preparation of ER-887199: To a stirred solution of (2R, 6R)-2-
((benzyloxy)methyl)-6-ethylmorpholine (552.2 mg, 2.347 mmol) in MeOH (10 mL) was cycled over 10 % Pd(OH)2 column with ¾ gas at 1 atmosphere over 16 h using a H-Qube hydrogenation instrument. The completed reaction solution was concentrated and dried in vacuo to provide crude product, ((2R,(ii?)-6-ethylmorpholin-2-yl)methanol (320 mg, 2.204 mmol, 93.9 % yield) that was used in the next step without further purification.
[0401] ((2i?, 6i¾-6-ethyln^holin-2-yl)methanol (145.2 mg, 1.00 mmol) and
Compound 3 (266.4 mg, 1.143 mmol) in 1 -methyl pyrro 1 idin-2-one (2 mL) was micro waved at 180 °C for 15 minutes after which time it was cooled to room temperature and directly injected onto a C-18 reverse phase HPLC (Water's X-Bridge CI 8, 19 x 100 mm column, eluting with a linear gradient of 10% - 90% acetonitrile in water with 0.1% formic acid) and concentrating the desired peak followed by high vacuum to dryness to provide ER-887199 (92.3 mg 0.313 mmol, 31.3 % yield).
[0402] Preparation of example ER-899742 using Scheme 11 and 19 [0403] Scheme 19
Figure imgf000073_0001
ER-899742-HCI ER-899745-HCI
[0405] ER-895194 or 38: To a stirred solution of 13 (231.0 g, 815.3 mmol) in DCM
(3.93 L) at 0 - 5 °C was added iodobenzene diacetate (525 g, 1630.6 mmol) while maintaining the temperature at < 5 °C. TEMPO (25.4 g, 162.8 mmol) was added followed by water (151 mL) after which time the resulting reaction mixture was warmed to 10 °C, stirred for 30 minutes and then allowed to warm to rt and stirred for 15 h. The completed reaction was cooled to < 15 °C and quenched by the slow addition of 1.34 L of a 10 % (w/v) solution of sodium thiosulfate in water while maintaining the reaction temperature < 15 °C followed by additional stirring at rt for 45 min. The pH of the quenched reaction was adjusted to pH 9 by the slow addition of 1M sodium hydroxide in water while maintaining the temperature at < 25 °C. The stining layers were separated and the organic layer was washed with water (560 mL). 1-Butanol (2.31 L) was added to the combined aqueous layers after which time the mixture was cooled to 10 - 15 °C followed by the slow addition of 5 M sulfuric acid (231 mL) maintaining the temperature at < 25 °C to obtain an approximate pH 5. The resultant layers were separated and the aqueous layer was extracted 3 times with 1-butanol (2.31 L) while maintaining the pH of the aqueous layer approximately pH 5 between extractions. The combined aqueous layers were concentrated while warming to 50 - 55 °C after which time the resultant yellow solid-slurry was concentrated via azeotroping three times with / -heptane (693 mL each) to a volume of 1.5 L followed by the addition of DCM (2.31 L). The yellow solid suspension was stirred at rt for 1 h followed by filtration, washing the filter pad two times with DCM (462 mL). The collected yellow cake was dried under vacuum) overnight at 40 °C followed by suspending in toluene (1.16 L) and concentrated to complete dryness at 45 °C in vacuo to provide 38 or ER-895194 (187 g, 629 mmol, 77% yield) as a yellow solid.
[0406] To a stirred solution of 38 (300 mg, 1.01 mmol) in DCM (2 mL) was added the mixture of ( 3S, 4R)-tert- ty\ 3-amino-4-fluoiOpyrrolidine-l-carboxylate and (3R,4S)-tert- butyl 3-amino-4-fluoiOpyrrolidine-l-carboxylate, 77 (205.3 mg, 1.005 mmol mmol), HBTU (247 mg, 1.211 mmol) and DIEA (0.70 mL, 4.04 mmol) followed by stilling at rt for 16 h. The was found complete and concentrated to dryness followed by dissolving in EtOAc (20 mL), washed 1 time with water (10 mL), 2 N citric acid in water (10 mL), saturated NaHC03 (10 mL), and brine (10 mL). The combined aqueous layers were extracted 3 times with EtOAc (10 mL ea.) after which time the combined organic fractions were dried over MgS04, filtered and concentrated to dry. The crude product was purified over a 25 g Biotage silica gel column eluting with 0-10% MeOH in DCM (200 mL total) to provide the diastereomeric mixture of 78 and 79.
[0407] 78 and 79 were separated using Chiral Technologies' 5 uM Chiralpak I A column of appropriate size eluting with a Heptane:EtOH:MeOH:DEA (70:15: 15:0.1) solvent system. Obtained after concentration and bringing to a dry solid via house vacuum: 72 (95 mg, 0.196 mmol, 19.5 % yield) as the first eluted fraction; and 73 (75 mg, 0.155 mmol, 15.4% yield) as the second eluted fraction.
[0408] 78 (95 mg, 0.196 mmol) was dissolved with stirring in dioxane (17 uL) followed by a dropwise addition of 4 N HQ in dioxane (0.49 mL 1.97 mmol, 10 equivalents) over a 3 -minute period at rt. The reaction was stirred for an additional 4 h after which time the completed reaction was concentrated and azeotroped 3 times using toluene (10 mL each) to dryness and then high vacuumed dried to obtain ER-899742-HC1 (69 mg, 0.164 mmol, 84%) yield) as the HC1 salt that did not require further purification.
[0409] Indirect determination of the absolute stereochemistry of ER-899742
[0410] Scheme 20
Figure imgf000075_0001
Figure imgf000075_0002
[041 11 An indirect method was used to determine the absolute stereochemistry of
ER-899742 using the confirmed chiral starting material that described by Tsuzuki, et. al., in Tetrahedron Asymmetry 2001, 12, 29891 to provide the chiral compound 81 in Scheme 20.
[0412] To a stirred solution of (3S, 4S)-tert -butyl 3-(benzylamino)-4- hydroxypyrrolidine-l-carboxylate, 80 (3.091 g, 10.57 mmol) and imidazole (3.60 g, 52.9 mmol) in DCM (185 ml) was added triethylamine (4.42 ml, 31.7 mmol). The resultant mixture was cooled to 1-2 °C, and then a solution of thionyl chloride (1.16 ml, 15.9 mmol) in DCM (46 ml) was added dropwise over 30-min period. The mixture was stirred at 1-2 °C for 6 h, warm up to rt and stirred overnight after which time the reaction was quenched with water (46 ml). The organic layer was separated, concentrated to give crude product as white solid/foam, which was subjected to silica gel column chromatography (w-heptane/EtOAc 2: 1) to give (3S, 6S)-tert-buty\ 3-benzyltetrahydiOpyrrolo[3,4-d][l,2,3]oxathiazole-5(5H)- carboxylate 2-oxide (2.10 g, 6.21 mmol, 58.7 % yield) as white solid.
[0413] To stirred solution of (3S, 6S)-tert-butyl 3-benzyltetrahydropyrrolo[3,4- d][l,2,3]oxathiazole-5(3H)-carboxylate 2-oxide (2.10 g, 6.21 mmol) in 1,2-dichloroethane (10 ml) diluted with acetonitrile (10 ml) and water (10 ml) cooled down to 2-3 °C was added ruthenium(III) chloride hydrate (14 mg) followed by sodium periodate (1.39 g, 6.50 mmol). The resultant mixture was stirred at 2-3 °C for 1 h, warmed up to 17-18 °C over lh, and stirred at this temperature for 16 h. 20 wt% Na2S04 (5 g) was added followed by EtOAc (30 ml) after which time the resultant mixture was stirred vigorously for 10 min and filtered through a pad of Celite (2 g). Organic layer was separated, washed with 20 wt% sodium sulfite (5 g), 20 wt% NaCl (5 g) and concentrated to give light purple/gray oil. The crude oil was passed over silica gel plug (10 g) eluting with EtOAc (120 ml) and concentrated to dryness to provide (3S, 6S)-tert-butyl 3-benzyltetrahydropyrrolo[3,4-d][l,2,3]oxathiazole- 5(3H)-carboxylate 2,2-dioxide (1.54 g, 4.35 mmol, 70.0 % yield) as white solid.
[0414] (3S,
Figure imgf000076_0001
3-benzyltetrahydi pyrrolo[3,4-d][l,2,3]oxathiazole-5(3H)- carboxylate 2,2-dioxide (20 mg, 0.056 mmol) was dissolved in TBAF (1 M solution in THF, 1.0 ml) and heated at reflux overnight, after which time the reaction was cooled to room temperature and acidified with HC1 (1 M solution, 2 ml). After 2h, the mixture was neutralized with NaHC03 (9% aqueous solution, 2.5 g) and extracted with EtOAc (10 ml). Organic layer was separated, concentrated and combined with two additional batches using 100 mg (0.282 mmol ea.) of starting oxathiazole for each batch. The combined crude products were purified over silica gel column chromatography (o-heptane/EtOAc 1 : 1) to provide (3S,4S)-tert-butyl 3-(benzylamino)-4-fluoi pynOlidine-l-carboxylate, 82 (29 mg, 0.099 mmol, 15.9 % yield) as a light brown oil and being less polar via TLC (silica gel), and (3S, 4R)-tert-butyl 3-(benzylamino)-4-fluoiOpyrrolidine-l-carboxylate, 81 (20 mg, 0.068 mmol, 11.0 % yield) as a light brown oil and being more polar via TLC (silica gel).
[0415] (3S, 4 R)-ter t-buty\ 3-(benzylamino)-4-fluoiOpyrrolidine-l-carboxylate, 81 (16 mg, 0.054 mmol) was subjected to hydrogeno lysis with 10 wt% Pd-C (10 mg) in ethanol (3 ml). The completed reaction mixture was filtered, concentrated and azeotroped with CDC13 to provide (3S,4R)-tert-buty\ 3-amino-4-fluoropyrrolidine-l-carboxylate, 83 (8.3 mg, 0.041 mmol, 75.9 % yield).
[0416] To a stirred solution of (3S, 4 R)-ter t-butyl 3-amino-4-fluoi pyrrolidine-l- carboxylate and 38 or ER-89S194 (15 mg, 0.050 mmol) in DMF (0.2 ml) was added propylphosphonic anhydride ( 0.2 g of a 50% solution in EtOAc) at 40 °C for 2 h. The reaction mixture was passed over a silica gel plug (3 g, eluting with heptane-EtOAc 1 :3), and then further purified by preparative TLC (w-heptane/EtOAc 1 :4) to give corresponding amide, 78, as yellow/green oil (11.2 mg, 0.023 mmol, 56% yield in 2 steps). The 7H-NMR & HPLC matched with Compound 78 as described earlier thus the absolute stereochemistry of ER- 899742 was confirmed indirectly. [0417] Absolute stereochemistry of ER-899742 was also confirmed by X-Ray diffraction. Crystallization process: 5.3 mg of ER-899742-01 (lot. MC2-1130-120-1) was dissolved in 0.5mL IP A and 0.3mL H20. The vial containing the solution was capped and stored at room temperature for a day. The next day the cap was opened and IPA was evaporated slowly for a day at room temperature. The next day the cap was closed and the vial was stored at room temperature for 2 weeks, after which colorless needle crystals of ER- 899742-01 appeared from which a single crystal was selected for X-ray analysis. X-ray diffraction analysis: Equipment: R-AXIS RAPID II (RIGAKU); X-ray source: CuKa (1 = 1.54187A); Temperature: 297 K; Measurement: oscillation method along the ω axis; Crystal size: 0.1 x 0.1 x 0.4 mm. The crystal structure was solved with a final i?-factor of 0.0606 and a Flack parameter of -0.01. The structure of ER-899742-01 was determined as (2R, 6i?)-4-(8- cyanoquinolin-5-yl)-/V-[(3S', 4i?)-4-fluoiOpyn lidin-3-yl]-6-methylmoi"pholine-2- carboxamide hydrochloride. See FIG. 8 for ORTEP drawing.
[0418] (3S,4S)-tert-buty\ 3-(benzylamino)-4-iluoropyrrolidinc-l -carboxylate, 82 (24 mg, 0.082 mmol) was subjected to hydrogenolysis with 10 wt% Pd-C (10 mg) in ethanol (3 ml). The reaction mixture was filtered, concentrated and azeotroped dry with CHC13 to provide (3S,4S)-tert-butyl 3-amino-4-fluoropyrrolidine-l-carboxylate (16.6 mg, 0.081 mmol, 99.2% yield) that was used in the next step without purification.
[0419] To a stirred solution of (3S,4S)-tert-butyl 3-amino-4-fluoropyrrolidine-l- carboxylatc (12.5 mg, 0.061 mmol) and 38, or ER-895194 (18 mg, 0.061 mmol) in DMF (0.2 ml) was treated with propylphosphonic anhydride (50% solution in EtOAc; 0.2 g, ) at 40 °C for 2 h. The reaction mixture was passed over silica gel plug (3 g, eluting with heptane- EtOAc 1 :3), and then further purified by preparative TLC (ft-heptane/EtOAc 1 :4) to provide (3S, 4S)-tert-buty\ 3-((2R, i5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholine-2-carboxamido)- 4-fluoiOpyrrolidine-l-carboxylate, 85 (14.2 mg, 0.029 mmol, 47% yield in 2 steps) as yellow/green oil.
[0420] ER-899745-HCL (62.3 mg, 0.148 mmol, 96% yield) was obtained using the same equivalents of reagents as for ER-899742-HC1, starting with compound 79 (75 mg, 0.155 mmol).
ER-894550 (5.3 mg, 0.016 mmol, 18.4 % yield) was prepared in a similar manner to ER- 899742 starting with 38 (25.9 mg, 0.087 mmol) and ethyl amine hydrochloride (206 mg, .962 mmol). DMF (0.5 mL) was used instead of DCM. The ER-894550 was purified by reverse- phase HPLC (X-Bridge C18 19 x 100 mm column; eluting with a gradient of increasing acetonitrile in water containing 0.1 % formic acid) followed by combining the desired fractions, concentration and drying in vacuo. The product fractions were combined and concentrated to dry followed by dilution in MeOH (1 mL), passed through as basic silica gel plug (Biotage SiC03, 1 g, eluting with MeOH (ImL)), concentrated and dried in vacuo.
[0421] ER-895473 (103 mg, 0.261 mmol, 27.1 % yield) was prepared in a similar manner to ER-899742 starting with 38 (286 mg, 0.962 mmol) and (S)-tert-butyl 2- ethylpiperazine-l-carboxylate (206 mg, .962 mmol). DMF (3 mL) was used instead of DCM for the amide forming reaction and 2.0 M HC1 in ethyl ether (1.3 mL, 2.6 mmol) was used in the Boc-deprotection process using acetonitrile (1 mL) as a solvent. ER-895473 was purified by reverse-phase HPLC (X-Bridge CI 8 19 x 100 mm column; eluting with a gradient of increasing acetonitrile in water containing 0.1 % fomiic acid). The product fractions were combined and concentrated to dry followed by dilution in MeOH (1 mL), passed through as basic silica gel plug (Biotage S1CO3, 1 g, eluting with MeOH (ImL)), concentrated and dried in vacuo.
[0422] ER-895474 (6.3 mg, 0.015 mmol, 19.6 % yield) was prepared in a similar manner to ER-899742 starting with 38 (22.5 mg, 0.076 mmol) and (3,4- difluorophenyl)methanamine (10.83 mg, .076 mmol). Boc-deprotection was not required.
[0423] ER-895475 (16.2 mg, 0.044 mmol, 71.5 % yield) was prepared in a similar to
ER-895473 starting with 38 (18.3 mg, 0.062 mmol) and (/ )-/er/-butyl pyrrolidin-3- ylcarbamate (1 1.46 mg, .062 mmol).
[0424] ER-895476 (14.0 mg, 0.042 mmol, 28.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (43.0 mg, 0.145 mmol) and azetidine hydrochloride (13.53 mg, .145 mmol).
[0425] ER-895477 (26.1 mg, 0.058 mmol, 32.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (54.0 mg, 0.182 mmol) and l,4'-bipiperidine (30.6 mg, .182 mmol).
[0426] ER-895478 (15.9 mg, 0.047 mmol, 29.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (48.4 mg, 0.163 mmol) and cyclopropanamine (11.42 μΐ, .163 mmol).
[0427] ER-895479 (14.9 mg, 0.042 mmol, 23.7 % yield) was prepared in a similar manner to ER-895473 starting with 38 (53.2 mg, 0.179 mmol) and ferf-butyl azetidin-3- ylcarbamate (30.8 mg, .179 mmol).
[0428] ER-897922 (15.1 mg, 0.041 mmol, 48.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and l -aminobutan-2-ol (13.0 mg, 0.146 mmol). [0429] ER-897923 (13.9 mg, 0.038 mmol, 44.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-ethoxyethanamine (13.0 mg, 0.146 mmol).
[0430] ER-897924 (17.0 mg, 0.046 mmol, 54.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-2-aminobutan-l-ol (14.0 mg, 0.157 mmol).
[0431] ER-897925 (4.5 mg, 0.012 mmol, 14.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-aminopropane- 1 ,3-diol (14.0 mg, 0.154 mmol).
[0432] ER-897926 (7.6 mg, 0.021 mmol, 24.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 3-aminopropane-l,2-diol (15.0 mg, 0.165 mmol).
[0433] ER-897927 (15.0 mg, 0.039 mmol, 46.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-(tetrahydrofuran-2- yl)methanamine (15.0 mg, 0.148 mmol).
[0434] ER-897928 (14.9 mg, 0.039 mmol, 46.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (tetrahydrofuran-2- yl)methanamine (16.0 mg, 0.158 mmol).
[0435] ER-897929 (10.3 mg, 0.027 mmol, 32.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-propoxyethanamine (16.0 mg, 0.155 mmol).
[0436] ER-897930 (12.8 mg, 0.033 mmol, 39.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-2-aminopentan-l-ol (16.0 mg, 0.155 mmol).
[0437] ER-897931 (11.1 mg, 0.029 mmol, 34.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-isopropoxyethanamine (15.0 mg, 0.145 mmol).
[0438] ER-897932 (10.0 mg, 0.026 mmol, 31.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 1 -methoxybutan-2-amine (0.0160 g, 0.155 mmol).
[0439] ER-897933 (9.0 mg, 0.021 mmol, 24.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-amino-l-(2- fluorophenyl)ethanol (23.0 mg, 0.148 mmol). [0440] ER-897934 (13.3 mg, 0.035 mmol, 41.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (5f)-2-amino-3-methylbutan- l-ol (15.0 mg, 0.145 mmol).
[0441] ER-897935 (15.7 mg, 0.041 mmol, 48.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2,2-dimethoxyethanamine (15.0 mg, 0.143 mmol).
[0442] ER-897936 (10.4 mg, 0.027 mmol, 32.2 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-(2-aminoethoxy)ethanol (16.0 mg, 0.152 mmol).
[0443] ER-897937 (12.1 mg, 0.031 mmol, 36.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (lS S)-2- aminocyclohexanol (23.0 mg, 0.200 mmol).
[0444] ER-897938 (8.5 mg, 0.022 mmol, 25.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-aminocyclohexanol (17.0 mg, 0.148 mmol).
[0445] ER-897939 (10.1 mg, 0.025 mmol, 30.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-aminohexan-l-ol (18.3 mg, 0.156 mmol).
[0446] ER-897940 (10.3 mg, 0.026 mmol, 30.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (<S 2-amino-3,3- dimethylbutan-l-ol (19.0 mg, 0.162 mmol).
[0447] ER-897941 (14.0 mg, 0.035 mmol, 42.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (,S> 2-aminohexan- 1 -ol (19.0 mg, 0.162 mmol).
[0448] ER-897942 (9.9 mg, 0.025 mmol, 29.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (2£35 2-amino-3- methylpentan-l-ol (18.0 mg, 0.154 mmol).
[0449] ER-897943 (11.1 mg, 0.028 mmol, 33.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (>S)-2-amino-4- methylpentan-l-ol (18.0 mg, 0.154 mmol).
[0450] ER-897944 (10.9 mg, 0.027 mmol, 32.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (i?)-2-amino-4- methylpentan-l-ol (18.0 mg, 0.154 mmol). [0451] ER-897945 (13.2 mg, 0.032 mmol, 38.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (4-methylmorpholin-2- yl)methanamine (20.0 mg, 0.154 mmol).
[0452] ER-897946 (16.1 mg, 0.035 mmol, 42.0 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (,S 2-amino-4- (methylthio)butan-l-ol (20.0 mg, 0.148 mmol).
[0453] ER-897947 (12.0 mg, 0.029 mmol, 34.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-phenoxyethanamine (21.0 mg, 0.153 mmol).
[0454] ER-897948 (12.0 mg, 0.028 mmol, 33.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (S)-2-amino-3- phenylpropan-l-ol (24.0 mg, 0.159 mmol).
[0455] ER-897949 (11.7 mg, 0.027 mmol, 32.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-phenoxypropan-l -amine (29.0 mg, 0.192 mmol).
[0456] ER-897950 (11.7 mg, 0.027 mmol, 32.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and l-amino-3-phenylpropan-2- ol (23.0 mg, 0.152 mmol).
[0457] ER-897952 (14.0 mg, 0.032 mmol, 38.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-(pyridin-3-yloxy)propan- 1-amine (24.0 mg, 0.158 mmol).
[0458] ER-897955 (8.2 mg, 0.019 mmol, 22.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-(4- fluorophenoxy)ethanamine (23.0 mg, 0.148 mmol).
[0459] ER-897956 (11.2 mg, 0.026 mmol, 26 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 2-amino-l-(3- fluorophenyl)ethanol (24.0 mg, 0.155 mmol).
[0460] ER-897957 (9.8 mg, 0.022 mmol, 26.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (S)-2-amino-3- cyclohexylpropan-l-ol (30.0 mg, 0.191 mmol).
[0461] ER-897958 (13.6 mg, 0.031 mmol, 36.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and isochroman-1- ylmethanamine (24.0 mg, 0.147 mmol). [0462] ER-897960 (13.0 mg, 0.029 mmol, 34.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and l-amino-3-phenoxypropan- 2-ol (25.0 mg, 0.150 mmol).
[0463] ER-897961 (9.7 mg, 0.022 mmol, 25.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and 4-((lS, 2R)-2-anam.o-l- hydroxypropyl)phenol (32.0 mg, 0.191 mmol).
[0464] ER-897962 (17.8 mg, 0.040 mmol, 47.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and (AS;25 2-amino-l- phenylpropane-l,3-diol (26.0 mg, 0.155 mmol).
[0465] ER-897963 (3.1 mg, 0.007 mmol, 8.4 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl 4-(3-amino-2- hydi xypropyl)piperazine-l-carboxylate (40.0 mg, 0.154 mmol).
[0466] ER-897964 (12.7 mg, 0.036 mmol, 21.5 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl 3-aminoazetidine- 1-carboxylate (27.0 mg, 0.157 mmol).
[0467] ER-897965 (0.4 mg, 0.001 mmol, 1.3 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (S)-tert-butyl 3- aminopyrrolidine-l-carboxylate (29.0 mg, 0.156 mmol).
[0468] ER-897966 (0.4 mg, 0.001 mmol, 1.3 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (R)-tert-buty\ 3- aminopyiTolidine-l-carboxylate (29.0 mg, 0.156 mmol).
[0469] ER-897967 (0.3 mg, 0.001 mmol, 0.9 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (.S /er/-butyl 3- aminopiperidine-l-carboxylate (30.0 mg, 0.150 mmol).
[0470] ER-897968 (0.4 mg, 0.001 mmol, 1.3 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (R)-tert-buty\ 3- aminopiperidine-l-carboxylate (30.0 mg, 0.150 mmol).
[0471] ER-897969 (0.2 mg, 0.001 mmol, 0.6 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and (S)-tert-buty\ 2- (aminomethyl)pyrrolidine-l-carboxylate (30.0 mg, 0.150 mmol).
[0472] ER-897970 (3.4 mg, 0.008 mmol, 9.4 % yield) was prepared in a similar manner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl (2- aminoethyl)(benzyl)carbamate (38.0 mg, 0.152 mmol). [0473] ER-898560 (11.2 mg, 0.030 mmol, 30.9 % yield) was prepared in a similar manner to ER-895473 starting with 38 (28.8 mg, 0.097 mmol) and pyridin-2-amine (9.12 mg, .097 mmol).
[0474] ER-898561 (12.8 mg, 0.033 mmol, 44.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (22.1 mg, 0.074 mmol) and 6-methylpyridin-2-amine (8.04 mg, .074 mmol).
[0475] ER-898562 (7.4 mg, 0.020 mmol, 18.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (31.2 mg, 0.105 mmol) and 5-methylisoxazol-3-amine (10.30 mg, .105 mmol).
[0476] ER-898563 (6.5 mg, 0.017 mmol, 16.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30.7 mg, 0.103 mmol) and 2,2,2-trifhioroethanamine hydrochloride (13.99 mg, .103 mmol).
[0477] ER-898564 (1.4 mg, 0.004 mmol, 3.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and 2,2-difluoroethanamine (8.18 mg, .101 mmol).
[0478] ER-898565 (3.0 mg, 0.008 mmol, 7.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30.2 mg, 0.102 mmol) and 3,3,3-trifluoropropan-l - amine (1 1.49 mg, .102 mmol).
[0479] ER-898566 (14.6 mg, 0.037 mmol, 20.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (53.7 mg, 0.181 mmol) and N2,N2,2- trimethylpropane-l ,2-diamine (20.99 mg, .181 mmol).
[0480] ER-898914 (31.6 mg, 0.092 mmol, 28.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (95.2 mg, 0.320 mmol) and 2-fluoroethanamine hydrochloride (31.9 mg, .32 mmol).
[0481] ER-898915 (19.1 mg, 0.054 mmol, 19.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (82.3 mg, 0.277 mmol) and 3-fluorapropan- 1 -amine hydrochloride (31.4 mg, .277 mmol).
[0482] ER-898916 (14.6 mg, 0.037 mmol, 21.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (51.4 mg, 0.173 mmol) and (R)- 1 , 1 , 1 -trifluoropropan- 2-amine (20 mg, .177 mmol).
[0483] ER-898917 (27.6 mg, 0.066 mmol, 20.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (95.7 mg, 0.322 mmol) and (R)- 1 ,1 ,1 -trifluoro-3- methylbutan-2-amine (45.4 mg, .322 mmol). [0484] ER-898918 (15.0 mg, 0.038 mmol, 19.3 % yield) was prepared in a similar manner to ER-895474 starting with 38 (59.2 mg, 0.199 mmol) and 1,3-dimethyl-iH-pyrazol- 5-amine (22.13 mg, .199 mmol).
[0485] ER-898919 (13.1 mg, 0.035 mmol, 10.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (98.1 mg, 0.33 mmol) and l-methyl-iH-pyrazol-5- amine (32.0 mg, .33 mmol).
[0486] ER-898920 (20.1 mg, 0.060 mmol, 21.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (83.3 mg, 0.280 mmol) and 2-aminoacetonitrile hydrochloride (25.9 mg, .28 mmol).
[0487] ER-898921 (11.4 mg, 0.032 mmol, 12.8 % yield) was prepared in a similar manner to ER-895474 starting with 38 (73.1 mg, 0.246 mmol) and cyclopropanecarbonitrile hydrochloride (25.5 mg, .246 mmol).
[0488] ER-898922 (25.4 mg, 0.067 mmol, 33.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (59.0 mg, 0.198 mmol) and l,2,4-thiadiazol-5-amine (20.07 mg, .198 mmol).
[0489] ER-898923 (12.6 mg, 0.032 mmol, 16.5 % yield) was prepared in a similar manner to ER-895474 starting with 38 (57.6 mg, 0.194 mmol) and 3 -methyl- 1,2,4-thiadiazol- 5-amine (22.31 mg, .194 mmol).
[0490] ER-899017-HC1 (328 mg, 0.769 mmol, 65.3 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (350 mg, 1.177 mmol) and /ert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate (250 mg, 1.177 mmol).
[0491] ER-899019-HC1 (26 mg, 0.059 mmol, 58.2 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and ferf-butyl 4- (aminomethyl)-4-fluoropiperidine-l-carboxylate (23.4 mg, .101 mmol).
[0492] ER-899020-HC1 (25 mg, 0.062 mmol, 61.4 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) fert-butyl 3- (aminomethyl)azetidine-l-carboxylate (18.8 mg, .101 mmol).
[0493] ER-899023-HC1 (25.5 mg, 0.060 mmol, 59.4 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and /<?/ -butyl 1,6- diazaspiro[3.4]octane-6-carboxylate (21.4 mg, .101 mmol).
[0494] ER-899024-HC1 (30.1 mg, 0.068 mmol, 67.5 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and /e/v-butyl 1,7- diazaspiro[4.4]nonane-l-carboxylate (22.8 mg, .101 mmol)., [0495] ER-899025-HC1 (32.1 mg, 0.077 mmol, 76 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and 4-amino-l -methyl- ///- pyrazole-3-carboxamide (14.1 mg, .101 mmol). Boc-deprotection was not required.
[0496] ER-899031-HC1 (30.1 mg, 0.079 mmol, 78 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (3-methyloxetan-3- yl)methanamine (10.2 mg, .101 mmol). Boc-deprotection was not required.
[0497] ER-899032-HC1 (28.7 mg, 0.079 mmol, 78 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and 2-oxo-6- azasprio[3.3]helptane (10.0 mg, .101 mmol). Boc-deprotection was not required.
[0498] ER-899033-HC1 (32.8 mg, 0.093 mmol, 92 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and oxetane-3-amine (7.4 mg, .101 mmol). Boc-deprotection was not required.
[0499] ER-899034-HC1 (26.4 mg, 0.067 mmol, 66.2 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and oxetane-3,3- diyldimethanamine dihydrochloride (19.1 mg, .101 mmol). Boc-deprotection was not required.
[0500] ER-899035-HC1 (25.9 mg, 0.071 mmol, 70.1 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and oxetan-2- ylmethanamine (8.8 mg, .101 mmol). Boc-deprotection was not required.
[0501] ER-899036-HC1 (33.1 mg, 0.082 mmol, 82 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl piperazine-1- carboxylate (18.8 mg, .101 mmol).
[0502] ER-899191-HC1 (30.7 mg, 0.081 mmol, 80 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and azetidine-3- carboxamide (10.1 mg, .101 mmol). Boc-deprotection was not required.
[0503] ER-899192-HC1 (34.4 mg, 0.078 mmol, 77 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 2,7- diazaspiro[4.4]nonane-2-carboxylate (22.8 mg, .101 mmol).
[0504] ER-899193-HC1 (38.1 mg, 0.081 mmol, 80 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 3,9- diazaspiro[5.5]undecane-3-carboxylate (25.7 mg, .101 mmol).
[0505] ER-899196-HC1 (23.7 mg, 0.057 mmol, 56.4 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and 4- aminonicotinamide (13.84 mg, .101 mmol). Boc-deprotection was not required. [0506] ER-899282-HC1 (29.6 mg, 0.079 mmol, 79 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and pyridin-4-amine (9.5 mg, .101 mmol). Boc-deprotection was not required.
[0507] ER-899283-HC1 (31.1 mg, 0.083 mmol, 83 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and pyridin-3 -amine (9.5 mg, .101 mmol). Boc-deprotection was not required.
[0508] ER-899285-HC1 (28.5 mg, 0.059 mmol, 58.6 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-buXyl 4-(4- amino-lH-pyrazol-l-yl)piperidine-l-carboxylate (26.9 mg, .101 mmol).
[0509] ER-899286-HC1 (31.7 mg, 0.070 mmol, 69.2 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and te/7-butyl 3-(4- amino-lH-pyrazol-l-yl)azetidine-l-carboxylate (24.0 mg, .101 mmol).
[0510] ER-899287 (29.7 mg, 0.079 mmol, 78 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (iH-pyrazol-5- yl)methanamine (9.80 mg, .101 mmol).
[0511] ER-899288 (20.7 mg, 0.057 mmol, 56.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and iH-pyrazol-4-amine (8.38 mg, .101 mmol).
[0512] ER-899289 (35.5 mg, 0.078 mmol, 77 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (3-(trifluoromethyl)pyridin- 2-yl)methanamine (17.77 mg, .101 mmol).
[0513] ER-899290 (15.0 mg, 0.034 mmol, 33.9 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and l-(pyridin-2-yl)ethanamine (12.33 mg, .101 mmol).
[0514] ER-899291 (26.1 mg, 0.067 mmol, 66.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and pyridin-2-ylmethanamine (10.91 mg, .101 mmol).
[0515] ER-899292 (31.0 mg, 0.077.2 mmol, 76.4 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (6-methylpyridin-2- yl)methanamine (12.3 mg, .101 mmol).
[0516] ER-899293 (32.0 mg, 0.079 mmol, 77.7 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (l-methylpiperidin-2- yl)methanamine (12.9 mg, .101 mmol). [0517] ER-899294 (32.2 mg, 0.080 mmol, 79 % yield) was prepared in a similar manner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and (3-methylpyridin-2- yl)methanamine (12.3 mg, .101 mmol).
[0518] ER-899334 (51.3 mg, 0.140 mmol, 11.7 % yield) was prepared in a similar manner to ER-895473 starting with 38 (357.2 mg, 1.201 mmol) and (R)-tert-buly\ 2- (aminomethyl)pyrrolidine-l-carboxylate (224 mg, 1.201 mmol).
[0519] ER-899414-HCI (31.1 mg, 0.075 mmol, 74.1 % yield) was prepared in a similar mamier to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (7?)-to7-butyl 2-(aminomethyl)pyiTolidine-l-carboxylate (20.2 mg, .101 mmol).
[0520] ER-899415-HC1 (30.5 mg, 0.071 mmol, 70.3 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (S)-tert-butyl 2-(aminomethyl)piperidine-l-carboxylate (21.6 mg, .101 mmol).
[0521] ER-899416-HC1 (24.2 mg, 0.055 mmol, 54.3 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 3- amino-8-azabicyclo[3.2.1]octane-8-carboxylate (22.84 mg, .101 mmol).
[0522] ER-899417-HC1 (32.8 mg, 0.076 mmol, 76 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 4- aminoazepane-l-carboxylate (21.62 mg, .101 mmol).
[0523] ER-899418-HCI (29.6 mg, 0.072 mmol, 70.9 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and (lR,5S,6S)-tert- butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate (20.0 mg, .101 mmol).
[0524] ER-899476-HC1 (31.0 mg, 0.068 mmol, 67.4 % yield) or the diastereomeric mixture of ER-899742 and ER-899745 was prepared in a similar manner to ER-899742-I 1C1 starting with 38 (30 mg, 0.101 mmol) and a 1 : 1 mixture of (3R,4S)-tert-butyl 3-amino-4- fluoropyrrolidine-l-carboxylate and ' (3 S,4R)-ter t-butyl 3-amino-4-fluoi pyrrolidine-l- carboxylate (20.6 mg, .101 mmol).
[0525] ER-899477-HCI (25.5 mg, 0.059 mmol, 58.2 % yield) as a diaslcreomer mixture was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and a 1 :1 mixture of (3 R,4S)-ter t-butyl 3-amino-4-fluoiOpiperidine-l-carboxylate and (3S, 4 R)-ter t-butyl 3-amino-4-fluoiOpiperidine-l-carboxylate (22.02 mg, .101 mmol).
[0526] ER-899479-IIC1 (30.5 mg, 0.071 mmol, 70.6 % yield) was prepared in a similar manner to ER-899742-HC1 starting with 38 (30 mg, 0.101 mmol) and tert-butyl 6- amino-2-azaspiro[3.3]heptane-2-carboxylate (21.42 mg, .101 mmol). [0527] ER-897383 (14.2 mg, 0.017 mmol, 14.1 % yield) was prepared in a similar manner to ER-895474 starting with 38 (35.2 mg, 0.1 18 mmol) and 2-aminoethanol (10.9 mg, 0.178 mmol). DMF (1 mL) was used instead of DMAC.
[0528] ER-897385 (14.2 mg, 0.017 mmol, 14.1 % yield) was prepared in a similar manner to ER-897383 starting with 38 (35 mg, 0.118 mmol) and 2-methoxyethanamine (13.7 mg, 0.178 mmol).
[0529] ER-897445 (87 mg, 0.245 mmol, 72.9 % overall yield) was prepared in a similar manner to ER-897383 starting with 38 (100 mg, 0.336 mmol) and (R)-2-((tert- butyldiphenylsilyl)oxy)propan-l -amine (158 mg, 0.505 mmol) followed by the removal of the tert-butyldiphenylsilyl-protecting group using 1 M TBAF in THF (0.43 mL, 0.43 mmol) in DCM (1.1 mL) stilling for 1 h at rt. The desired product was purified over silica gel (eluted with 80 - 100 % EtOAc in heptane).
[0530] ER-897446 (67 mg, 0.189 mmol, 75 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (75 mg, 0.252 mmol) and (S)-\-((tert- butyldiphenylsilyl)oxy)propan-2-amme (103 mg, 0.329 mmol).
[0531] ER-897447 (78 mg, 0.220 mmol, 65.5 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (100 mg, 0.336 mmol) and (R)- l -((ter(- butyldiphenylsilyl)oxy)propan-2-amine (158 mg, 0.505 mmol).
[0532] ER-897827 (48.2 mg, 0.131 mmol, 64.9 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (S)-\ -((tert- butyldiphenylsilyl)oxy)butan-2-amine (90 mg, 0.303 mmol).
[0533] ER-897828 (49.4 mg, 0.129 mmol, 64 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (S)-l-((tert- butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (103 mg, 0.303 mmol).
[0534] ER-897829 (65.2 mg, 0.157 mmol, 77.7 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (S)-2-((tert- butyldiphenylsilyl)oxy)-l -phenyl ethanamine (1 14 mg, 0.303 mmol).
[0535] ER-897830 (60.2 mg, 0.145 mmol, 71.8 % overall yield) was prepared in a similar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and (R)-2-((tert- butyldiphenylsilyl)oxy)-l-phenylethanamine (114 mg, 0.303 mmol).
[0536] ER-899722 (79 mg, 0.215 mmol, 25.6 % yield) was prepared in a similar manner to ER-895474 starting with 38 (250 mg, 0.841 mmol) and 2-methylpropane-l ,2- diamine (0.09 mL, 0.841 mmol). DCM (2 mL) was used instead of DMAC. [0537] ER-899295 (27.5 mg, 0.0.71 mmol, 70.4 % yield) was prepared in a similar manner to ER-899722 starting with 38 (30 mg, 0.101 mmol) and 3-amino-/H-pyrazole-4- carbonitrile (10.9 mg, 0.101 mmol) .
[0538] ER-898946: 38 (50 mg, 0.168 mmol), HATU (128 mg, 0.336 mmol) and
DIEA (0.176 ml, 1.009 mmol) was dissolved in DCM:DMF (5 mL : 2 mL) followed by tert- butyl 4-aminopiperidine-l-carboxylate (67.4 mg, 0.336 mmol). The resulting reaction mixture was stirred at rt for 16 h after which time additional HATU (128 mg, 0.336 mmol), and by tert-bvAy\ 4-aminopiperidine-l -carboxylate (67.4 mg, 0.336 mmol) was added followed by stirring for an additional 3 h.. The completed reaction was concentrated to dry and the crude product was purified by chromatography (25 g Silica gel) eluting with 10% acetonitrile in DCM to give pure Boc protected product. The Boc-protected product was dissolved in DCM(4 ml)/TFA (0.5 ml) and stirred at rt for 3 h after which time the solvent was removed under reduced pressure, the residue was dissolved in MeOH (10 mL) and 0.3 g of MP-carbonate was added (pH>7). The resulting suspension was stirred at rt for 30 min after which time the polymer beads were filtered, washed with MeOH (10 mL) and the solvent was concentrated and high vacuum to dry to give ER-898946 (12 mg, 0.027 mmol, 16.0 % yield).
[0539] ER-898694-2 HC1 (67 mg, 0.155 mmol, 46.1 % yield) was prepared in a similar manner to ER-898946 starting with 38 (100 mg, 0.336 mmol) and (S)-fert-butyl 2- (aminomethyl)moipholine-4-carboxylate (95 mg, .437 mmol) followed by the addition of 3N HC1 in dioxane (31 uL) to provide the dihydrochloride salt after concentration and high vacuum to dryness.
[0540] Alternative method for the preparation of ER-899742 & ER-899745: To a stirred solution 38 (2.91 g, 9.79 mmol and TEA (1.706 ml, 12.24 mmol) in DCM (50.0 ml) was added 77 (2.000 g, 9.792 mmol) and HOBT (2.65 g, 19.59 mmol). The reaction mixture was cooled to 0°C followed by the portion wise addition of EDC (3.75 g, 19.59 mmol) after which time mixture was warmed to 40 °C and stirred for 3 hours. DCM (50 mL) was added, the layers separated after which time the organic layer was washed with sat. ammonium chloride (20 mL), sat. NaHC03 (20 mL), brine (20 mL), dried over Na2S04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage SP4, eluting with 10%) MeOH:DCM). The diastereomers were separated as described above to obtain 78 (1.65 g, 3.41 mmol, 34.8 % yield) and 79 (1.49 g, 3.08 mmol, 31.5 % yield).
[0541] 78 (470 mg, 0.97 mmol) was dissolved in a stilling solution of DCM (5.0 mL) followed by the addition of TFA (2.5 mL, 32.45 mmol) after which time the reaction was warmed to 49 °C and stirred for 2 h. The completed reaction was azeotroped to dryness three times with toluene (2 niL each) and then dried in vacuo to provide ER-899742-TFA (543 mg, 0.97 mmol, 100 % yield-the product contained 1.5 molecules of TFA to one molecule of ER- 899742 via mass spectrum) as an orange solid.
[0542] ER-899742 free base can be obtained by dissolving the TFA salt in MeOH and adding Amberlite IRA 400 hydroxide form and stimng for 10 min or once a neutral pH is obtained. The resultant suspension is filtered, washed with MeOH two times with MeOH of equal volumes, and concentration of the combined filtrates to paste. The paste is azeotroped two times with toluene to provide ER-899742 in the free base form in quantitative yield. The HC1 salt form can be then be generated as described above.
[0543] ER-899742 -I lCl salt may be obtained directly from 78 by treatment with 5.5
N HCL in isopropanol to provide desired product in quantitative yield after stimng for 2 h at if followed by azeotroping to dry 3 times with toluene and high vacuum drying as 1.5 molecules of HC1 to one molecule of ER-899742 demonstrated by mass spectra analyses.
[0544] ER-899464 - HC1: To a stirred solution of 38 (50 g, 168.2 mmol) in DMF
(250 mL) was added TEA (29.3 mL, 210.2 mmol) followed by 4-amino-l-methylpiperidine (28.8 g, 252.3 mmol) and HOBT (45.4 g, 336.4 mmol). The reaction mixture was cooled to 0 °C followed by a portion wise addition of EDC (64.5 g, 336.4 mmol). The reaction mixture was warmed to 40 °C and stirred for an additional 6 h. The completed reaction was slowly poured into a flask containing water (1.5 L) with stirring after which time DCM (1.5 L) was added, stirred an additional 10 min. The two layers were separated and the aqueous layer was extracted three times with DCM (600 mL each). The combined organic layers were concentrated to a DMF solution followed by concentration at 50 °C under vacuum. The resultant yellow sluny was diluted with ethyl ether (1 L) and stirred for 15 min, after which time the solid was collected by filtration followed by rinsing the filter pad with ethyl ether (0.5 L) and dried in vacuo to provide ER-899464 (44.9 g, 114 mmol, 67.9% yield). The HC1 salt is obtained by dissolving ER-899464 (22.8 g, 57.9 mmol) in 10 volumes of isopropanol and 1 volume of water followed by the addition of 1 equivalent of 5.5 N HC1 in isopropanol to provide a white precipitate. The solid is filtered and washed with isopropanol (2 vol) followed by drying in a vacuo to provide ER-899464.HC1 (20.3 g, 47.2 mmol, 81.5%).
[0545] ER-899477 (78 mg, 0.196 mmol, 58.3% yield) was prepared in a similar manner to ER-899464 starting with 38 (100 mg, 0.336 mmol) and (3S,4R)-tert-butyl 3- amino-4-fluoiOpiperidine-l-carboxylate (220 mg, 1.009 mmol). [0546] ER-897968 (475 mg, 1.252 mmol, 37.2 % yield) was prepared in a similar manner to ER-899464 starting with 38 (1.00 g, 3.364 mmol) and (R)-teH-butyl 3- aminopiperidine-l-carboxylate (2.021 g, 10.091 mmol).
[0547] ER-899018 (370 mg, 0.975 mmol, 58.0 % yield) was prepared in a similar manner to ER-899464 starting with 38 (500 mg, 1.682 mmol) and te -butyl (azetidin-3- ylmethyl)(methyl)carbamate (500 mg, 2.497 mmol).
[0548] ER-899819 (62 mg, 0.158 mmol, 31.3 % yield) was prepared in a similar manner to ER-899464 starting with 38 (150 mg, 0.505 mmol) and tert-butyl 3- aminoazepane-l-carboxylate (324 mg, 1.514 mmol).
[0549] ER-899416-HC1 (53 mg, 0.120 mmol, 35.7 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and (!R S S)- tert-bntyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (76 mg, .336 mmol).
[0550] ER-899417-HC1 (56 mg, 0.130 mmol, 38.7 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and tert-butyl 4- aminoazepane-l-carboxylate (144 mg, .673 mmol).
[0551] ER-899285-HC1 (52 mg, 0.108 mmol, 32.1 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and /e/7-butyl 4- (4-amino-iH-pyrazol-l-yl)piperidine-l-carboxylate (179 mg, .673 mmol)
[0552] ER-899021-HC1 (62 mg, 0.140 mmol, 41.7 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and tert-butyl 2,6- diazaspiro[3.5]nonane-6-carboxylate (152 mg, .673 mmol).
[0553] ER-899619-HC1 (36 mg, 0.084 mmol, % yield) was in a similar manner to
ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and (5 -tert-butyl 3- (methylamino)piperidine-l-carboxylate (216 mg, 1.009 mmol).
[0554] ER-899616-HC1 (21 mg, 0.049 mmol, % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (100 mg, 0.336 mmol) and (fl)-tert-butyl 3- (methylamino)piperidine-l -carboxylate (216 mg, 1.009 mmol).
[0555] ER-898566-HC1 (272 mg, 0.630 mmol, 37.5 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (500 mg, 1.682 mmol) and N2,N2,2- trimethylpropane-l,2-diamine (586 mg, 5.045 mmol).
[0556] ER-899618-HC1 (4.8 mg, 0.011 mmol, 3.2 % yield) was prepared in a similar manner to ER-899464-HC1 starting with 38 (500 mg, 1.682 mmol) and 4-aminopicolinamide (138 mg, 1.009 mmol). [0557] ER-899477 (78 mg, 0.196 mmol, 58.3 % yield as a diastereomeric mixture) was prepared in a similar manner to ER-899464 starting with 38 (100 mg, 0.336 mmol) and a racemic mixture of (3S,4R)-tert- vXy\ 3-amino-4-fluoropiperidine-l-carboxylate and (3R,4S)- fert-butyl 3-amino-4-fluoropiperidine-l-carboxylate (220 mg, 1.009 mmol).
[0558] ER-895415 as an example for Compound 41 in Scheme 11: To a stirred solution of 38 (1.10 g, 3.70 mmol) in DCM ( 5 mL) at 0 °C was added oxalyl chloride (1.0 mL, 11.42 mmol) dropwise over 2 min. The reaction mixture was allowed to warm to rt and stir for 1 h after which time the reaction was concentrated and dried in vacuo. The dried syrup was cooled to 0 °C followed by the slow addition of MeOH (5 mL) with stirring. The completed reaction was concentrated to dry, diluted with DCM (10 mL), washed with saturated sodium sulfite (3 mL), brine (3 mL) and then dried over Na2S04, filtered and concentrated to dry. The crude product was purified over silica gel (eluting w a 0 - 50 % EtOAc in heptane gradient) to provide ER-895415 (894 mg, 2.81 mmol, 76 % yield) after combining the desired fractions, concentrating and drying in vacuo.
[0559] Preparation of example ER-899332 following Scheme 21:
[0560] Scheme 21
Figure imgf000092_0001
[0561] ER-899472 ER-899332
[0562] The solution of ER-899472-HC1 (49.8 mg, .119 mmol) and paraformaldehyde
(8.90 mg, .297 mmol) in DCM (0.5 mL) was stirred at room for 1 hr. Sodium triacetoxyborohydride (62.8 mg, .297 mmol) was added and resulting solution was stirred at rt for 2 days. After the solvents were removed, the crude was chromatographied on silica
(15% MeOH in DCM) to give ER-899332 (8.16 mg, 0.021 mmol, 18.3 % yield).
[0563] ER-899457 (50 mg, 0.117 mmol, 97 % yield) was prepared in a similar manner to ER-899332 starting with ER-89933 (50 mg, 0.122 mmol) .
[0564] ER-899836: A stirred solution of ER-899477 (76 mg, .191 mmol) in solution of 37 % formaldehyde in water (0.5 g, 16.652 mmol) and formic acid (0.5 ml, 13.036 mmol) was warmed to 80 °C for 3 h after which time the completed reaction is cooled to rt. The mixture was azeotroped to dryness four times with toluene (2 mL each) and the resultant residue was dissolved in MeOH (5 mL) followed by the addition of Amberlite IRA400 hydroxide form (2 g) and stirred for 10 min. Additional Amberlite IRA400 is added with stilling until a neutral pH is obtained after which time the suspension was filtered, concentrated, and azeotroped two times with toluene (2 mL each). The crude material was then purified over silica gel (Biotage SNAP Ultra, 25g, eluting with a 1- 40% MeOH in DCM) to provide ER-899836 (55 mg, 0.134 mmol, 69.9 % yield) after combining the desired fractions, concentrating and drying in vacuo.
[0565] ER-899836 (50 mg, 0.124 mmol) was dissolved in acctonitrilc (1 mL) followed by the addition of 2 M HC1 in diethyl ether (0.062 ml, 0.124 mmol) and stirred at rt for 30 min. The resultant orange solution was concentrated to dryness and placed under high vacuum overnight to provide ER-899836-HC1 in quantitative yield.
[0566] ER-899688-HC1 (381 mg, 0.886 mmol, 88.4 % yield) was prepared in a similar manner to ER-899836-HC1 starting with ER-897968 (600 mg, 1.58 mmol) .
[0567] ER-899820-HC1 (45 mg, 0.110 mmol, 69.9 % yield) was prepared in a similar manner to ER-899836-HC1 starting with ER-899819 (62 mg, 0.158 mmol) .
[0568] ER-899337 (35.6 mg, 0.087 mmol, 24. % yield) was similarly prepared in a similar manner to ER-899836 starting with ER-897968 (142 mg, 0.361 mmol) as a free base.
[0569] ER-899835 (29 mg, 0.071 mmol, 81. % yield) was similarly prepared in a similar manner to ER-899836 starting with ER-899718 (34 mg, 0.086 mmol) as a free base.
[0570] ER-899837 (35.6 mg, 0.087 mmol, 24.2 % yield) was similarly prepared in a similar manner to ER-899836 starting with ER-899417 (142 mg, 0.361 mmol) as a free base.
[0571] ER-898707-formate (17 mg, 0.0.36 mmol, 78. % yield) was prepared in a similar manner to ER-899836 starting with ER-898694 (20 mg, 0.046 mmol) maintaining as the formate salt instead of conversion to the HC1 salt as above.
[0572] Other examples depicted by general structure 39 or 40 in Scheme 11
ER-895472: To a cooled solution of 38 (22.7 mg, .076 mmol) and TEA (12.8 μΐ, .092 mmol) in THF at - 15 °C was added ethyl chloroformate (8.1 μΐ, .084 mmol). After stirring 1.5 hr, ammonium hydroxide (6.0 μΐ, .153 mmol) was added after which time stilling continued for an additional 2 hr at -10 °C. The reaction was allowed to warm to rt and stirred an additional 2 h. The completed reaction was quenched by addition of sat. NaHC03 (5 mL) followed by the extraction of the aqueous phase 3 times with EtOAc (5 mL each). The combined organic layers were dried over anhydrous Na2S04, filtered and concentrated to give a pale yellow oil. The crude product was purified using reverse phase HPLC C-18 (Water's X-B ridge CI 8 19 x 100 mm column; gradient using acetonitrile/water containing 0.1 % formic acid) to provide ER-895472 (6.2 mg, 0.021 mmol, 27.5% yield).
[0573] ER-899122: To a cooled solution of 38 (80 mg, .24 mmol) and 4- methylmorpholine (32 μΐ, .288 mmol) in THF (4 mL) at 0 °C was added isopropyl chloroformate (38 μΐ, .084 mmol). After stilling 30 min, Tetrahydro-pyran-4-ylamine (29.1 mg, .288 mmol) was added after which time stirring continued for an additional 2 hr at -10 °C. The reaction was allowed to warm to rt and stirred an additional 16 h. The completed reaction was quenched by addition of sat. NaHC03 (5 mL) followed by the extraction of the aqueous phase 3 times with EtOAc (5 mL each). The combined organic layers were dried over anhydrous Na2S04, filtered and concentrated to give a pale yellow oil. The crude product was purified over silica gel (25 g) eluting with a linear gradient of 80 - 100% EtOAc in heptane to provide ER-899122 (40 mg, 0.100 mmol, 41.7 % yield) after concentration of the desired fractions to dry and placing the product under high vacuum.
[0574J ER-899121 (40 mg, 0.104 mmol, 43.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 3-aminomethyl-oxctane (25.06 mg, .288 mmol).
[0575] ER-899123 (40 mg, 0.109 mmol, 45.5 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 3-aminotetrahydrofuran (25.06 mg, .288 mmol).
[0576] ER-899140 (20 mg, 0.051 mmol, 21.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and tert-butyl (2- aminoethyl)(methyl)carbamate (50.1 mg, .288 mmol) after removal of the Boc group using TFA and neutralizing with MP-carbonate as described.
[0577] ER-899151 (15 mg, 0.035 mmol, 14.6 % yield) and ER-899152 (15 mg,
0.035 mmol, 14.6 % yield) were prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 3-Amino-l,l,l-trifluoiO-2-propanol (37.1 mg, .288 mmol) as a mixture of stereoisomers. The two products were separated using the chromatography method described for ER-899122. The stereocenters were arbitrarily assigned and have not been definitively determined.
[0578] ER-899153 (32 mg, 0.083 mmol, 34.4 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and glycine methyl ester hydrochloride (36.1 mg, .288 mmol). [0579] ER-899154 (16 mg, 0.041 mmol, 17.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and dimethylethylenediamine (31.6 μΐ, .288 mmol).
[0580] ER-899159 (14 mg, 0.033 mmol, 13.8 % yield) and ER-899160 (13 mg,
0.031 mmol, 12.8 % yield) were prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 4-amino-l,l,l-trifiuoiObutan-2-ol hydrochloride (51.6 mg, .288 mmol) as a mixture of stereoisomers. The two products were separated using the chromatography method described for ER-899122. The stereocenters were arbitrarily assigned and have not been definitively determined.
[0581] ER-899161 (13 mg, 0.031 mmol, 12.9 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and 4,4,4-tri ITuorobutanc- 1 ,3- diamine dihydrochloride (61.9 mg, .288 mmol) as a diastereomeric mixture.
[0582] ER-899152 (9 mg, 0.024 mmol, 37.0 % yield) was prepared by dissolving
ER-899153 (24 mg, 0.65 mmol) in MeOH (2 mL) and water (0.5 n L) followed by the addition of lithium hydroxide (3.12 mg, 13.0 mmol). The reaction was stirred for 16 h at rt after which time the completed reaction was acidified with 3 N HCl to pH 3 followed by extraction 3 times with EtOAc (10 mL each), combining the organic layers, drying over anhydrous Na2S0 , filtering and concentrating to dryness. The crude product was purified over a C-18 reverse phase HPLC column eluting with a linear gradient of 10% - 90% acetonitrile in water with 0.1 % formic acid and concentrating the desired peak followed by high vacuum to dryness.
[0583] ER-899278 (20 mg, 0.051 mmol, 33.8 % yield) was prepared in a similar manner to ER-899140 starting with 38 (50 mg, 0.15 mmol) and (R)-te/7-butyl 2- (aminomethyl)moipholine-4-carboxylate (48.6 mg, .225 mmol).
[0584] ER-899366 (70 mg, 0.171 mmol, 42.4 % yield) was prepared in a similar manner to ER-899140 starting with 38 (120 mg, 0.404 mmol) and (2S, 6R)-tert-b tyl 2-
(aminomethyl)-6-methylmoipholine-4-carboxylate (112 mg, .484 mmol).
[0585] ER-899367 (40 mg, 0.102mmol, 38 % yield) was prepared in a similar manner to ER-899140 starting with 38 (80 mg, 0.269 mmol) and tert-butyl hexahydropyiTolo[3,4-c]pyrrole-2(7H)-carboxylate (68.5 mg, .373 mmol).
[0586] ER-899459 (30 mg, 0.074 mmol, 31.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (70 mg, 0.235 mmol) and N, N-di mcthy lpipcridin-4- amine (36.2 mg, .283 mmol). [0587] ER-899464 (20 mg, 0.051 mmol, 18.9 % yield) was prepared in a similar manner to ER-899122 starting with 38 (80 mg, 0.269 mmol) and l-methylpiperidin-4-amine (36.9 mg, .323 mmol).
[0588] ER-899588 (40 mg, 0.105 mmol, 44.8 % yield) was prepared in a similar manner to ER-899140 starting with 38 (70 mg, 0.235 mmol) and tert-butyl piperidin-4- ylcarbamate (56.6 mg, .283 mmol).
[0589] ER-899608 (40 mg, 0.102 mmol, 37.8 % yield) was prepared in a similar manner to ER-899140 starting with 38 (70 mg, 0.235 mmol) and /e/7-butyl (4- methylpiperidin-4-yl)carbamate (63.4 mg, .296 mmol).
[0590] ER-899680 (40 mg, 0.098 mmol, 19.2 % yield) was prepared in a similar manner to ER-899122 starting with 38 (100 mg, 0.336 mmol) and l-ethylpiperidin-3 -amine (43.1 mg, .336 mmol).
[0591] ER-899431 (53 mg, 0.103 mmol, 51.3 % yield) was prepared in a similar mamier to ER-899122 starting with 38 (99 mg, 0.333 mmol) and methylamine (2M in THF) (1.50 mL, 3.00 mmol).
[0592] ER-899626 (29 mg, 0.071 mmol, 35.3 % yield) was prepared in a similar manner to ER-899122 starting with 38 (60 mg, 0.202 mmol) and 4-amino-l -ethyl piperidine (25.9 mg, .202 mmol).
[0593] ER-899718 (32 mg, 0.081 mmol, 40.1 % yield) was prepared in a similar manner to ER-899140 starting with 38 (60 mg, 0.202 mmol) and /e/7-butyl 4-amino-4- methylpiperidine-l-carboxylate (47.6 mg, .222 mmol).
[0594] Additional Examples: Modification of general structure 39, Scheme 11:
[0595] Scheme 22
Figure imgf000096_0001
[0597] ER-899333-HC1: To a stirred solution of 38 (58.2 mg, .196 mmol) and
HBTU (89 mg, .235 mmol) in DCM (1.94 mL) was added DIEA (137 μΐ, .783 mmol) followed by (3 R,4S)-ter t-butyl 3-amino-4-fluoropiperidine-l-carboxylate (42.7 mg, .196 mmol). The reaction was stirred overnight after which time the completed reaction was concentrated and diluted with EtOAc (10 mL). The organic solution was washed with 2N aqueous citric acid, saturated NaHC03, dried over anhydrous Na2S04, filtered and concentrated to dryness. The crude product was purified over silica gel (50 g, eluting with a 40 -100% EtO Ac in heptane, 20 column volumes) to provide 86 (58.5 mg, , 0.118 mmol, 56.2 % yield) as a pale yellow solid.
[0598] To a stirred solution of 86 (58.8 mg, .118 mmol) and methyl iodide (7.39 \iL,
.118 mmol) in DMF (1 mL) cooled to 0 °C was added NaH (5.20 mg, .13 mmol, oil dispersion). The reaction was warmed to rt and stirred for 3.5 h. The completed reaction was cooled with ice/water bath and quenched by the slow addition of saturated ammonium chloride (5 mL) followed by water (5 mL) and extraction two times with EtO Ac (10 mL each). The combined organic phases were dried over anhydrous Na2S04, filtered and concentrated to dryness. The crude product was purified over silica gel (25 g, eluting with a 40 - 100% gradient of EtO Ac in heptane, 20 column volumes) to provide 87 (42.9 mg, 0.084 mmol, 71.0 %) as a pale yellow solid.
[0599] To a stirred solution of 87 (42.9 mg, .084 mmol) in EtOAc (1 mL) was added
4.0 N HC1 in 1,4-Dioxane (0.419 mL, 1.677 mmol) followed by stirring at rt for 1 hr, after which time the completed reaction was concentrated and dried in vacuo to provide ER- 89933-HCL (23.4 mg, 0.054 mmol, 62.3%).
0600] Scheme 23
Figure imgf000097_0001
[0602] ER-8999335: To a stirred solution 38 (357.2 mg, 1.201 mmol) and HBTU
(547 mg, 1.442 mmol) in DCM (10 mL) was added DIEA (0.84 mL, 4.806 mmol) and tert- butyl(azetidin-3-ylmethyl)carbamate (224 mg, 1.201 mmol). The reaction mixture was stirred for 3 h after which time the completed reaction concentrated, dissolved in EtO Ac (25 mL) and washed with 2N aqueous citric acid (20 mL), saturated NaHC03 (20 mL), and dried over anhydrous Na2S04, filtered and concentrated to dry. The crude product was purified over silica gel (40 g, eluting with a 50-100%) EtO Ac/heptane, 20 column volumes) to provide 88 (181.6 mg, 0.390 mmol, 32.5 % yield) of pale yellow solid.
[0603] To a stirred solution 88 (52.6 mg, .113 mmol) and ethyl iodide (10.50 μΤ, .13 mmol) in DMF (1.0 mL, 12.915 mmol) at 0 °C was added 60% sodium hydride (5.87 mg, .147 mmol) after which time the reaction was allowed to warm to rt and stirred for 6 h. The completed reaction was cooled to 0 °C and quenched by the slow addition of saturated NH4C1 (5 mL) followed by dilution with water (5 mL) and extraction two times with EtOAc (10 mL each). The combined organic phases were dried over anhydrous Na2S04, filtered and concentrated to dryness. The crude product was purified over silica gel (25 g, eluting with 70 -100% EtOAc in heptane, 20 column volumes) to provide the Boc-protected intermediate which was used in the next step. The Boc was removed by dissolving the intermediate in EtOAc (1 mL) and adding TFA (0.5 mL) followed by stirring for 1 h. The completed reaction was concentrated to dry, dissolved in DCM (10 mL), washed 2 times with saturated NaHC03, dried over anhydrous Na2S04, filtered, concentrated, and high vacuum to dry to provide ER-899335 (4.1 mg, 0.010, mmol, 9.3 %) as a pale yellow solid.
[0604] Scheme 24
Figure imgf000098_0001
[0605]
[0606] ER-899336: To a stirred solution of ER-899334 (35.4 mg, .097 mmol) and iodomethane (0.013 mL, .213 mmol) in DMF (1 mL) at 0 °C was added 60% sodium hydride (9.69 mg, .242 mmol) after which time the reaction was warmed to rt and stirred overnight. The completed reaction was cooled to 0 °C and quenched by the slow addition of saturated NH4C1 (5 mL) followed by dilution with water (5 mL) and extraction two times with EtOAc (10 mL each). The combined organic phases were dried over anhydrous Na2S04, filtered and concentrated to dryness. The crude product was purified over silica gel (25 g, eluting with 70 -100% EtOAc in heptane, 20 column volumes) to provide ER-89933 (5.2 mg, 0.013 mmol, 13.6 % yield) after collection of the desired material, concentration and high vacuo..
Figure imgf000098_0002
[0609] ER-899481: To a stirred solution of ER-898946 (60 mg, .158 mmol) in acetonitrile (10 niL) was added K2C03 (87 mg, .632 mmol) and 2-bromoacetamide (43.6 mg, .316 mmol). The reaction mixture was warmed to 60 °C and stirred for 16 h, after which time the completed reaction was filtered. The resultant solution was concentrated and the crude product was purified over a C-18 HPLC column (eluting with 10% to 50% acetonitrile in water with 0.1% formic acid) to provide ER-899481 (43 mg, 0.099 mmol, 62.3 % yield) after collection of the desired material, concentration and high vacuo.
[0610] ER-885612 as an example of Compound 42, Scheme 12: To a cooled, stirred solution of 13 (25 mg, 0.088 mmol) in DMF (0.5 mL) at 0 °C was added NaH (3.5 mg, 0.088 mmol, 60% oil dispersion) followed by methyl iodide (16.5 uL, 0.265 mmol). The reaction was stirred an additional 20 min after which time water (1 mL) was slowly added. The quenched reaction was extracted two times with DCM (2 mL each), dried over MgS04, filtered and concentrated to dry. Purification over a reverse-phase preparative HPLC column (X-Bridge C18 19 x 100 mm column; eluting with 0-50% acetonitrile in water containing 0.05 % TFA) provided ER-885612 (16.9 mg, 0.057 mmol, 64.6% yield) after combining the desired collected fractions, concentration and drying in vacuo.
[0611] ER-885807 (15.2 mg, 0.049 mmol, 55.7 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and iodoethane (20.6 mg, .132 mmol).
[0612] ER-885808 (8.2 mg, 0.025 mmol, 28.6 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and isopropyl iodide (22.5 mg, .132 mmol).
[0613] ER-885892 (3.1 mg, 0.009 mmol, 10.4 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and 1 -iodo-2-methylpropane (15.2 uL, .132 mmol).
[0614] ER-885929 (17.5 mg, 0.048 mmol, 54.6 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and 1 -iodohcxanc (37.4 mg, .176 mmol).
[0615] ER-885930 (7.9 mg, 0.021 mmol, 23.7 % yield) was prepared in a similar manner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and cyclohexylmethyl bromide (31.3 mg, .177 mmol).
[0616] ER-895324 (35.2 mg, 0.098 mmol, 54.7 % yield) was prepared in a similar manner to ER-885612 starting with 13 (50.6 mg, 0.179 mmol) and 2-bromopyridine (20.4 uL, .214 mmol). THF (1 mL) was used instead of DMF. [0617] ER-895325 (54.2 mg, 0.150 mmol, 83.8 % yield) was prepared in a similar manner to ER-893324 starting with 13 (50.6 mg, 0.179 mmol) and 2-bromopyrimidine (57 mg, .359 mmol).
[0618] ER-894552 (5 mg, 0.014 mmol, 19.2 % yield) was prepared in a similar manner to ER-893324 starting with 13 (20.4 mg, 0.072 mmol) and 2-chloropyrazine (8.3 mg, .0.072 mmol).
[0619] ER-886137: In a dry microwave reaction vessel was added cesium carbonate
(172.5 mg, 0.529 mmol), copper (I) iodide (33.6 mg, 0.176 mmol), l,l'-binaphthyl-2,2'- diamine (50.2 mg, 0.177 mmol, 2-iodo-l,3-dimethylbenzene (123 mg, 0.53 mmol) in DMSO (0.3 mL) followed by 13 (50 mg, 0.177 mmol). The reaction mixture was micro waved at 110 °C for 12 h after which time the mixture was directly injected on a reverse-phase preparative HPLC column (Water's X-Bridge C18 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA) for purification eluting with, providing a crude product. The crude product was purified over silica gel (Biotage eluting with a gradient from 25 % EtOAc in heptane to 100 % EtOAc) to provide ER-886137 (12.1 mg, 0.031 mmol, 17.6% yield) after combining the desired collected fractions, concentration and drying in vacuo.
[0620] ER-886514: To a stirred suspension of 14 (10.5 mg, 0.024 mmol) and potassium carbonate (30 mg, 0.217 mmol) in toluene (1 mL) was added phenol (24.4 mg, 0.259 mmol). The reaction mixture was microwaved at 150 °C for 5 h after which time the crude mixture was filtered and directly injected on a reverse-phase preparative HPLC column (Water's X-Bridge C18 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA) to provide ER-886514 (4.5 mg, 0.013 mmol, 54.1 % yield) after combining the desired collected fractions, concentration and drying in vacuo.
[0621] ER-886515 (3.2 mg, 0.009 mmol, 37.6 % yield) was prepared in a similar manner to ER-886514 starting with 14 (10.6 mg, 0.024 mmol) and 3-methylphenol (28.1 mg, 0.260 mmol).
[0622] ER-886516 (4.7 mg, 0.013 mmol, 52.4 % yield) was prepared in a similar manner to ER-886514 starting with 14 (10.6 mg, 0.024 mmol) and 4-methylphenol (28.1 mg, 0.260 mmol).
[0623] ER-886605 (7.9 mg, 0.020 mmol, 85.1 % yield) was prepared in a similar manner to ER-886514 starting with 14 (10.3 mg, 0.024 mmol) and 3,4-diflurorphenol (20 mg, 0.154 mmol). 1-Methylpyrrolidinone (1 mL) was used instead of toluene in this preparation. [0624] ER-886606 (7.2 mg, 0.019 mmol, 81.2 % yield) was prepared in a similar manner to ER-886605 starting with 14 (10.3 mg, 0.024 mmol) and 3-flurorphenol (13.2 mg, 0.118 mmol).
[0625] ER-886624 (5.1 mg, 0.014 mmol, 59 % yield) was prepared in a similar manner to ER-886605 starting with 14 (10 mg, 0.023 mmol) and 2-flurorphenol (10 mg, 0.089 mmol).
[0626] ER-886786 (8.2 mg, 0.022 mmol, 76.9 % yield) was prepared in a similar manner to ER-886605 starting with 14 (12.5 mg, 0.029 mmol) and 2-methylphenol (28.1 mg, 0.260 mmol).
[0627] Other Examples using Compound 13 or ER-885493 as a starting material:
[0628] ER-885621: To a stirred solution of bis(2-methoxyethyl)aminosulfur trifluoride (24.4 uL, 0.132 mmol) in DCM (0.1 mL) cooled to - 78 °C under a N2 atmosphere was added 13 (25 mg, 0.088 mmol) in DCM (0.1 mL). The reaction mixture was allowed to warm to - 50 °C and stirred for 0.5 h, warmed to 0 °C, and stirred for 1.5 h. The reaction mixture was warmed to 5 °C and stirred for 2 h after which time saturated NaHC03 in water was added drop wise until reach pH 10. The layers were separated and the organic layer was washed two times with water (1 mL), dried over MgS04, filtered and concentrated to dry. Purification over a reverse-phase preparative HPLC column eluting with 0-50% acetonitrile in water, provided ER-885621 (12.5 mg, 0.044 mmol, 49.8 % yield) after combining the desired collected fractions, concentration and drying in vacuo.
[0629] ER-885906: A stirred solution of 13 (85.5 mg, 0.302 mmol) in thionyl chloride (2 mL) was warmed to 85 °C for 24 h, after which time the excess thionyl chloride was removed and the crude product was purified over a reverse-phase preparative HPLC column eluting with 0-50 % acetonitrile in water, provided ER-885906 (4.3 mg, 0.014 mmol, 4.7 % yield) after combining the desired collected fractions, concentration and drying in vacuo.
[0630] Preparation of ER-886431 & ER-886480 as examples of Compound 44,
Scheme 13
[0631] Compound 43 or ER-886250: To a stirred solution of 13 (200 mg, 0.706 mmol) in DCM (5 mL) and pyridine (0.114 mL, 1.4 mmol) at 0 °C under a nitrogen atmosphere was added Dess-Martin periodinane (359 mg, 0.846 mmol) after which time the reaction was warmed to rt and stirred for 1 h. The reaction was found to be incomplete thus additional Dess-Martin periodinane (359 mg, 0.846 mmol) and pyridine (0.114 mL, 1.4 mmol) were added followed by stilling for an additional 30 min. The completed reaction was poured over saturated aqueous NaHC03 (4 mL) with 10 % aqueous sodium thiosulfate (2 mL). The mixture was stirred for 30 min after which time the mixture was extracted three times with DCM (4 mL each). The combined organic layers were washed with brine (4 mL), dried over Na2S04, filtered and concentrated. The crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 10 - 100% EtOAc in heptane) to provide 5-((2i?, ii?)-2- formyl-6-methylmorpholino)quinoline-8-carbonitrile, 43 or ER-886250 (110 mg, 0.391 mmol, 55.4 % yield) as a yellow syrup after combining the desired fractions, concentration and drying in vacuo.
[0632] To stirred solution of 43 (25 mg, 0.089 mmol) in THF (0.5 mL) at 0 °C under a nitrogen atmosphere was added 1 M vinyl magnesium bromide (0.098 mL, 0.098 mmol) in THF dropwise over a 2- min period. The reaction was stirred at 0 °C for 2 h after which time saturated ammonium chloride (0.5 mL) was added slowly followed by water (0.25 mL). The quenched reaction was warmed to rt, stirred for an additional 10 min, and extracted two times with EtOAc (2 mL each). The combined organic layers were washed with brine (1 mL), dried over Na2S04, filtered and concentrated. The crude product was purified on preparative TLC plates (Merck Silica Gel 60 F254, 2 20 x 20 cm plates, eluting with EtOAc) to provide ER-886431 (3 mg, 0.010 mmol, 11.2 % yield, Rf = 0.75, EtOAc) and ER-886480 (3 mg, 0.0.10 mmol, 11.2 % yield, Rf = 0.80. EtOAc) as a yellow syrup after the desired fractions were eluted separately from the silica gel, concentration and drying in vacuo. The stereochemistry for the free alcohol functionality for both examples was arbitrarily assigned.
[0633] ER-886530 (11 mg, 0.032 mmol, 36.4 % yield, Rf = 0.80, EtOAc) and ER-
886531 (3 mg, 0.0.10 mmol, 11.2 % yield, Rf = 0.75, EtOAc) were prepared in a similar manner to ER-886431 and ER-886480 starting with 43 (25 mg, 0.089 mmol) and 2 M butylniagnesium chloride in THF (0.131 mL, 0.262 mmol). The crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 20 - 100% EtOAc in heptane. The stereochemistry for the free alcohol functionality for both examples was arbitrarily assigned.
[0634] ER-886532 (4 mg, 0.011 mmol, 6.3 % yield, Rf = 0.80, EtOAc) and ER-
886533 (4 mg, 0.011 mmol, 6.3 % yield, Rf = 0.75, EtOAc) were prepared in a similar manner to ER-886530 and ER-886531 starting with 43 (49 mg, 0.174 mmol) and 1.3 M cyclohexylmagnesium chloride in THF (0.20 mL, 0.260 mmol). The stereochemistry for the free alcohol functionality for both examples was arbitrarily assigned.
[0635] ER-886567 (3.6 mg, 0.009 mmol, 5.3 % yield, Rf = 0.80, EtOAc) and ER-
886568 (8.6 mg, 0.022 mmol, 12.8 % yield, Rf = 0.75, EtOAc) were prepared in a similar manner to ER-886530 and ER-886531 starting with 43 (49 mg, 0.174 mmol) and 1 M phenethylmagnesium chloride in THF (0.26 mL, 0.260 mmol). The stereochemistry for the free alcohol functionality for both examples was arbitrarily assigned.
[0636] ER-886520 (26 mg, 0.084 mmol, 49.1 % yield, Rf = 0.80, EtOAc) was prepared in a similar manner to ER-88653G and ER-886531 starting with 43 (48 mg, 0.171 mmol) and 2 M ethylmagnesium chloride in THF (0.128 mL, 0.256 mmol). The diastereomeric mixture was used for additional studies.
[0637] ER-886564 and ER-886S65 via Scheme 26
[0638] Scheme 26
Figure imgf000103_0001
[0640] To a stirred solution of 22 (2.51 g, 7.8 mmol) in EtOH (40 mL) was added 10
% palladium on activated carbon in 50 % water (1.66 g) followed by charging the flask several times with hydrogen gas. The reaction was maintaining under a hydrogen atmosphere (balloon pressure) at 40 °C and stirred for 16 h, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with EtOH (85 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo. The crude product, (2R, 6R)-ter t-butyl 2-(hydroxymethyl)- 6-methylmoipholine-4-carboxylate, 89 (1.56 g, 6.7 mmol, 86.5% yield) was used in the next step without further purification.
[0641] To a stirred solution of 89 (1.501 g, 6.5 mmol) in DCM (30 mL) and pyridine
(1.05 mL, 13.0 mmol) at 0 °C under a nitrogen atmosphere was added Dess-Martin periodinane (3.3 g, 7.8 mmol) after which time the reaction was warmed to rt and stirred for 1 h. The reaction was found to be incomplete thus additional Dess-Martin periodinane (1.4 g, 3.3 mmol) and pyridine (0.52 mL, 6.4 mmol) were added followed by stirring for an additional 2 h. The completed reaction was poured over saturated aqueous NaHC03 (37 mL) with 10 % aqueous sodium thiosulfate (18 mL). The mixture was stirred for 30 min after which time the mixture was extracted three times with DCM (40 mL each). The combined organic layers were washed with brine (37 mL), dried over Na2S04, filtered and concentrated. The crude product was purified over silica gel (Biotage 40+S, 40 g, eluting with 10 - 100% EtOAc in heptane) to provide (2R, 6R)-tert- u y\ 2-formyl-6-methylmorpholine-4- carboxylate, 90 (1.285 g, 5.6 mmol, 86.2 % yield) as a colorless syrup after combining the desired fractions, concentration and drying in vacuo.
[0642] To stirred solution of 90 (208 mg, 0.907 mmol) in THF (5 mL) at 0 °C under a nitrogen atmosphere was added 1 M benzylmagnesium bromide (2.3 mL, 2.3 mmol) in THF drop wise over a 2- min period. The reaction was stirred at 0 °C for 2.5 h after which time saturated ammonium chloride (4.8 mL) was added slowly followed by water (2.5 mL). The quenched reaction was warmed to rt, stirred for an additional 10 min, and extracted two times with EtOAc (20 mL each). The combined organic layers were washed with brine (9.5 mL), dried over Na2S04, filtered and concentrated. The crude product over silica gel (Biotage SP4, 25 g, eluting with 25 - 100% EtOAc in heptane) to provide (2R,
Figure imgf000104_0001
2-((i?j(S)-l-hydroxy-2-phenylethyl)-6-methylmorpholine-4-carboxylate, 91 (172 mg, 0.539 mmol, 59.4 %> yield, R = -CH2C6H5) as a colorless oil after the desired fractions were combined, concentration and drying in vacuo.
[0643] To a stirred solution of 91 (172 mg, 0.539 mmol) in DCM (1.2 mL) was added
TFA (1.2 mL). The reaction was stirred for 30 min at rt after which time the completed reaction was diluted with toluene (4.6 mL), concentrated and azeotroped to dry two times with toluene (4.6 mL each) to dryness to provide l-((2i-, di?)-6-methylmorpholin-2-yl)-2- phenylethanol, 92 (179 mg, 0.534 mmol, 99.0 % yield, R = -CH2C6H5) as the TFA salt without further purification.
[0644] Crude 92 (179 mg, 0.534 mmol), was dissolved in N-methylpyrrolidone (3 mL) followed by 3 (187 mg, 0.802 mmol) and DIPEA (0.2 mL, 1.1 mmol). The mixture was micro waved at 170 °C for 5 h after which time the cooled mixture was directly injected onto a C-18 reverse-phase preparative HPLC column eluting with 10-60% acetonitrile in water with 0.1 % TFA. The two eluted fractions were separately concentrated to dry, azeotroped two times with MeOH (5 mL each). Each isomer was dissolved in MeOH (2 mL) and passed over a basic plug of silica gel (silica gel-C02) eluting two times with MeOH (2 mL each) followed by concentration and drying in vacuo to provide separately 93 or ER-886564 (19 mg, 0.051 mmol, 9.5 % yield, first fraction, R = -CH2C6H5) and 94 or ER-886565 (23 mg, 0.062 mmol, 11.5 % yield, second fraction, R = -CH2C6H5). The stereochemistry of the alcohol position was arbitrarily assigned. [0645] E -895200 (22.2 mg, 0.075 mmol, 32.1 % yield, first fraction) and ER-
895310 (15.2 mg, 0.051 mmol, 21.8 % yield, second fraction) were prepared in a similar fashion to ER-886564 and ER-886564 starting with 3 (54.6 mg, 0.234 mmol) and 1- ((2i?, (5i?)-6-methylmoi-pholin-2-yl)ethanol (68.2 mg, 0.470 mmol). The stereochemistry of the alcohol position was arbitrarily assigned.
[0646] ER-895326: To a stirred solution ER-895200 (17.9 mg, 0.060 mmol) in THF
(0.3 mL) was added sodium hydride (4.8 mg, 0.120 mmol, 60% oil dispersion) followed by 2-bi mopyrimidine (19 mg, 0.120 mmol). The reaction was warmed to 60 °C and stirred for 30 min after which time it was cooled to rt and slowly quenched with a dropwise addition of water (0.5 mL). The mixture was extracted three times with DCM (3 mL each) and the combined organic layers were washed with brine (3 mL), dried over Na2S04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage, eluting with a gradient of 0 - 10 % EtOAc in heptane) to provide ER-895326 (20.3 mg, 0.054 mmol, 90.1 % yield) after collection of the desired fractions, concentration and drying in vacuo.
[0647] ER-895327 (6.4 mg, 0.017 mmol, 63 % yield) was prepared in a similar manner to ER-895326- starting with ER-895310 (7.9 mg, 0.027 mmol) and 2- bromopyrimidine (8 mg, 0.0.50 mmol).
[0648] ER-895412: To a stirred solution of 1.6 M o-butyl lithium in THF (1.36 mL,
2.18 mmol) at - 40 °C was added dropwise 2-bromopyridine (0.21 mL, 2.20 mmol) in diethylether (2 mL) followed by stirring for 30 min at - 40 °C. 90 (500 mg, 2.18 mmol) in THF (2 mL) was added dropwise over a 3 -min period after which time the reaction mixture was stirred at - 40 °C for 2 h and then at 0 °C for 1 h. The completed reaction was slowly quenched with saturated ammonium chloride in water (2 mL) followed warming to rt, separation of the layers and extracting the aqueous layer two times with EtOAc ( 2 mL each). The combined organic layers were washed with brine (2 mL), dried over Na2S04, filtered and concentrated to dry. The crude product was purified first by passing over a silica gel (Biotage, eluting with 30 % EtOAc in heptane followed by crystallization from 3:1 DCM:MeOH to provide after filtering and drying in vacuo (2R, 6R)-tert-buty\ 2-((5)- hydroxy(pyridin-2-yl)methyl)-6-methylmoipholine-4-carboxylate (150 mg, 0.486 mmol, 22.3 % yield)
[0649] To a stirred solution of (2R, 6R)-tert-buty\ 2-((5)-hydroxy(pyridin-2- yl)methyl)-6-methylmorpholine-4-carboxylate (150 mg, 0.486 mmol) in DCM (5 mL) was added TFA (1 mL) followed by stilling at rt for 1 h. The completed reaction was concentrated and azeotroped to dry three times with toluene (5 mL each) followed by diluting with DCM (10 ml) washing two times with saturated NaHC03 in water (2 mL), brine (2 mL), drying over MgS04, filtering and concentration and drying in vacuo to provide crude (S)- {{2R, 5i?)-6-methylmoi holin-2-yl)(pyridin-2-yl)methanol (97.8 mg, 0.469, 96.4 % yield).
[0650] To a stirred solution of (5)-((2i?, (5i?)-6-methylmorpholin-2-yl)(pyridin-2- yl)methanol (97.8 mg, 0.469 mmol) and Compound 3 (54.6 mg, 0.234 mmol) in DMAC (1 mL) was added TEA (0.132 mL, 0.947 mmol). The reaction was microwaved at 105 °C for 3 h after which time the cooled reaction was directly purified over a reverse-phase preparative HPLC column (Water's X-Bridge CI 8 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.1 % formic acid) to provided ER-895296 (15.2 mg, 0.042 mmol, 18.0 % yield, R = 2-pyridyl) after combining the desired collected fractions, concentration and drying in vacuo.
[0651] Preparation of ER-886625 as an example of Compound 45, Scheme 13
[0652] To a stirred solution of ER-886520 (19 mg, 0.061 mmol) in DCM (0.5 mL) and pyridine (0.010 mL, 0124 mmol) at 0 °C under a nitrogen atmosphere was added Dess- Martin periodinane (31.1 mg, 0.073 mmol) after which time the reaction was warmed to rt and stirred for 1 h. The reaction was found to be incomplete thus additional Dess-Martin periodinane (31.1 mg, 0.073 mmol)and pyridine (0.010 mL, 0124 mmol) were added followed by stirring for an additional 30 min. The completed reaction was poured over saturated aqueous NaHC03 (0.4 mL) with 10 % aqueous sodium thiosulfate (0.2 mL). The mixture was stirred for 30 min after which time the mixture was extracted three times with DCM (0.3 mL each). The combined organic layers were washed with brine (0.35 mL), dried over Na2S04, filtered and concentrated. The crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 10 - 80% EtOAc in heptane) to provide 45 or ER-886625 (7 mg, 0.023 mmol, 37.1 %> yield) as a yellow solid after combining the desired fractions, concentration and drying in vacuo.
[0653] ER-886626 (10.8 mg, 0.030 mmol, 90.9 % yield) was prepared in a similar manner to ER-886625 starting with the mixture of ER-886532 and ER-886533 (12 mg, 0.033 mmol) .
[0654] ER-886629 (6.6 mg, 0.017 mmol, 81 % yield) was prepared in a similar manner to ER-886625 starling with the mixture of ER-886567 and ER-886568 (8 mg, 0.021 mmol) .
[0655] Preparation of ER-886912 and ER-886913:
[0656] To a stirred solution of ER-886568 (124 mg, 0.32 mmol) in DCM (1.3 mL) at rt was added methanesulfonyl chloride (37 uL, 0.478 mmol) followed by DMAP (7.8 mg, 0.064 mmol) and DIPEA (0.17 mL, 0.959 mmol). The reaction was stirred at rt for 2 h after which time water (1 mL) and DCM (5 mL) were added followed by stirring an additional 5 min and separation of the layers. The organic layer was washed with brine (1 mL), dried over Na2S04, filtered and concentrated. The crude product was purified over silica gel (Biotage SP4, 25 g, eluting with 20 - 100% EtOAc in heptane) to provide (R)-l -((2R, 6R)-4- (8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)-3-phenylpropylmethane-sulfonate (136 mg, 0.292 mmol, 93.5 % yield) as a yellow solid after combining the desired fractions, concentration and drying in vacuo.
[0657] A solution of (i?)-l-((2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2- yl)-3-phenylpropyl methanesulfonate (38 mg, 0.082 mmol) in NMP (2 mL) and pyrrolidine (0.10 mL, 1.21 mmol) was microwaved at 150 °C for 15 min followed by cooling, filtering and direct injection onto a C-18 HPLC (Water's X-Bridge C18 19 x 100 mm column; gradient using 0-50 % acetonitrile in water containing 0.05 % TFA). ER-886912 and ER- 886913 fractions were separately concentrated to dry, dissolved in MeOH (3 mL) and eluted over a carbonate impregnated silica gel column (Biotage Isolute SPE, Si-C03, lg), washed with MeOH (3 mL), concentrated and dried in vacuo to provide ER-886912 (1.4 mg, 0.003 mmol, 3.9 % yield) as the first eluted peak and ER-886913 (0.6 mg, 0.001 mmol, 1.5 % yield) as the second eluted. The stereochemistry for the amine functionality for both examples was arbitrarily assigned.
[0658] Preparation of ER-886131: A modification of Scheme 7 via Scheme 27:
[0659] Scheme 27
Figure imgf000107_0001
[0661] A stirred solution of commercially available (5f)-2-propyloxirane, 95 (3.0 g,
34.8 mmol, R = ethyl) in ammonium hydroxide (100 mL) was sealed and stilted for 24 h followed azeotroping to dryness three times with toluene (100 mL each). The crude, colorless product (S)-l-aminopentan-2-ol, 96 (R = ethyl), was used in the next reaction without purification.
[0662] To a stirred solution of crude 96 (0.987 mg, 9.57 mmol) in EtOH (20 mL) was added (S)-methyl 2-chloropropanoate, 97 (1.568 g, 11.5 mmol, R' = methyl) followed by warming to 70 °C and stirring for 24 h. The complete reaction was cooled to rt, concentrated to dry and the residue dissolved in EtOAc (20 mL). The organic solution was washed three times with 1 N aqueous HCL (5 mL each), brine (5 mL), dried over MgS04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage, eluted with a gradient of 20 - 100 % EtOAc in heptanes) to provide (S)-2-chloro-N-((S)-2- hydiOxypentyl)propanamide, 98 (0.356 g, 1.839 mmol, 19.2 % yield, R = ethyl; R' = methyl).
[0663] To a stirred solution of 98 (0.356 g, 1.839 mmol) in THF (22 mL) at 0 °C was added sodium hydride (294.2 mg, 7.277 mmol, 60 % oil dispersion). The reaction was stirred at 0 °C for 30 min hen warmed to rt and stirred for an additional 5 h. The completed reaction was slowly quenched with IPA (1 mL) followed by adding Dowex 50, H+ form until a neutral pH is demonstrated. The suspension was filtered and washed two times with IPA (5 mL each). The filtrate was concentrated followed by purification over silica gel (Biotage 25 g, eluting with EtOAc). Obtained a mixture of (25,, (55)-2-methyl-6-propylmoi holin-3-one and (2i2, 55)-2-me l-6-propylmorpholin-3-ones 99 (168.2 mg, 1.07 mmol, 58.2 % yield, R = ethyl; R' = methyl) in a 2: 1, cis to trans, ratio after collection of the desired fractions, concentration and drying in vacuo.
[0664] To a stirred solution of 99 (168.2 mg, 1.07 mmol) in THF (0.8 mL) at rt was added 1 M lithium tetrhydroaluminate (1 mL, 1 mmol) drop wise over a 2-minute period. The reaction was stirred for an additional 2.5 h after which time the completed reaction was cooled to 0 °C followed by the addition of water (0.43 mL) andl M sodium hydroxide in water (0.03 mL) and then stirring for 30 min. The resultant precipitate was filtered over Celite 454 and eluted with EtOAc (2 mL), DCM (2 mL), and diethyl ether (2 mL). The combined filtrates were concentrated and dried in vacuo to provide crude (2R,S;6S)-2- methyl-6-propylmorpholine, 100 (R = ethyl; R' = methyl) that will be used directly in the next reaction.
[0665] Crude 100 was dissolved in NMP (5 mL) followed by 3 (150 mg, 0.636 mmol) and DIPEA (0.2 mL, 1.1 mmol). The mixture was microwaved at 145 °C for 7 h after which time the cooled mixture was directly injected onto a C-18 reverse-phase preparative HPLC column eluting with 10-60% acetonitrile in water with 0.1 % TFA. The two eluted fractions were separately concentrated to dry, azeotroped two times with MeOH (5 mL each). Each isomer was dissolved in MeOH (2 mL) and passed over a basic plug of silica gel (silica gel-C02) eluting two times with MeOH (2 mL each) followed by concentration and drying in vacuo to provide separately E -886131, 101 (64.2 mg, 0.217 mmol, 34.2 % yield, cis-isomer, R = ethyl; R' = methyl), and ER-886132, 102 (25.2 mg, 0.85 mmol, 13.4 % yield, trans-isomer, R = ethyl; R' = methyl).
[0666] ER-886212 (315.2 mg, 0.975 mmol, 8.5 % overall yield) was prepared in a similar manner to ER-886131 starting with commercially available (S)- 1 -aminoheptan-2-ol, 90 (3.08 g, 23.5 mmol, R = n-butyl) and (S)-methyl 2-chloropropanoate, 97 (1.568 g, 11.5 mmol, R' = methyl).
[0667] Alternative examples of 101 using Scheme 28:
[0668] Scheme 28
Figure imgf000109_0001
[0670] Preparation of ER-886211:
[0671] To a stirred solution of 2-ethyloxirane, 103 (621 mg, 8.61 mmol, R = ethyl) in
DCM (60 mL) was added benzylamine (996 mg, 9.30 mmol) followed by scandium triflate (341 mg, 0.693 mmol) under a nitrogen atmosphere. The reaction mixture was stirred at rt for 20 h after which time the completed reaction was quenched with saturated NaHC03 (20 mL), extracted three times with DCM (10 mL each), and the combined organic layers was dried over MgS04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage 25g, eluting with a 10: 10:0.1 ratio of heptanes:EtOAc:TEA) to provide l,r-(benzylazanediyl)bis(butan-2-ol), 104 (658 mg, 2.628 mmol, 30.4 % yield, R = ethyl) after concentration of the combined desired fractions and drying in vacuo.
[0672] To a stirred solution of 104 (584 mg, 2.323 mmol) in water (0.3 mL) was slowly added concentrated sulfuric acid (2 mL) over a 5 -minute period after which time the reaction was heated at 150 °C for 2 h. The completed reaction was cooled to rt and slowly poured over saturated NaHC03 (20 mL) with stirring. The mixture was extracted two times with DCM (10 mL each) and the combined organic layers was washed with water (5 mL), brine (5 mL), dried over MgS04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage 25g, eluting with a 2:1 ratio of heptanes :EtO Ac) to provide (¾5i?)-l-benzyl-3,5-diethylpiperidine, 105 (234.2 mg, 1.003 mmol, 43.2 % yield, R = ethyl) and (3i?,5i?)-l-benzyl-3,5-diethylpiperidine, 106 (190.2 mg, 0.815 mmol, 35.1 % yield, R = ethyl) after separately concentration of the combined desired fractions and drying in vacuo.
[0673] To a stirred solution 105 (107.1 mg, 0.462 mmol) in MeOH (5 mL) was added
5 % palladium on activated carbon (250 mg) followed by charging the flask several times with hydrogen gas. The reaction was maintaining under a hydrogen atmosphere (balloon pressure) at rt and stirred for 12 h, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with MeOH (2 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo. The crude product, (35l,5i?)-3,5-diethylpiperidine, 107 (0.066 g, 0.462 mmol, 99.9% yield, R = ethyl) was used in the next step without further purification.
[0674] To a stirred solution 107 (0.066 g, 0.462 mmol, R = ethyl) in NMP (2 mL) was added DIPEA (0.13 mL, 0.728 mmol) and 3 (86.3 mg, 0.370 mmol). The reaction mixture was micro waved at 150 °C for 1 h after which time it was directly purified over a reverse-phase preparative HPLC column (Water's X-Bridge CI 8 19 x 100 mm column; gradient using 0-50% acetonitrile in water containing 0.05 % TFA) to provide an analog of 101 or ER-886211 (45.2 mg, 0.153 mmol, 41.4 % yield, R = ethyl) after combining the desired collected fractions, concentration and drying in vacuo.
[0675] Other Examples:
[0676] ER-885113: To a stirred solution of 2-(di-/er -butylphosphino)biphenyl (20 mg, 0.067 mmol) and tris(dibenzylideneacetone)dipalladium(0) (20 mg, 0.022 mmol) in toluene (0.8 mL) under an nitrogen atmosphere was added commercially available 5-bromo- 8-methoxyquinoline (201 mg, 0.844 mmol), sodium t-butoxide (122 mg, 1.27 mmol) and cis- 2,6-dimethylmorpholine (125 mg, 1.085 mmol) at rt followed by toluene (0.8 mL). The reaction mixture was warmed to reflux and stirred for 3 h, after which time the completed reaction was cooled to rt followed by addition of water (5 mL). The resultant mixture was extracted two times with EtOAc(5 mL each) and the combined organic layers were washed with brine (2 mL), dried over Na2S04, filtered and concentrated to dryness. The crude product was purified over silica gel twice (Biotage SP4, 25+S eluting with 12-100%) EtOAc in heptane) to provide ER-885113 (49 nig, 0.180 mmol, 21.3 % yield) after collection of the desired fractions, concentration and drying in vacuo.
[0677] ER-887960 (13.7 mg, 0.049 mmol, 23.5 % yield) was prepared in a similar manner to ER-885113 starting with 5-bromo-8-chloro- 1 ,7-naphthyridine (51 mg, 0.210 mmol) and czs-2,6-dimethylmorpholine (31.4 mg, 0.273 mmol)
[0678] ER-886133 and ER-886134: A solution of (S)-2-((benzyloxy)methyl)oxirane
(65 g, 0.396 mol) and 28% NH4OH in water was stirred at rt for 14 h. after which time the completed reaction was concentrated and azeotroped two times with toluene (150 mL each) to obtained (S)-l-amino-3-(benzyloxy)propan-2-ol (70.6 g, 0.390 mol, 98 % yield) as a crude white solid.
[0679] To a stirred solution of crude (S)-l-ammo-3-(benzyloxy)propan-2-ol (54.4 g,
0.300 mol) in ethanol (400 mL) was added methyl (i?)-(+)-2-chloropropionate (40.44 g, 0.330 mol) dropwise over a 30-min period. The reaction was heated to 75 °C and stiiTed for 16 h after which time the completed reaction was concentrated to dryness. The crude mixture was diluted with EtOAc (200 mL), washed with aq. 1 N HC1 (100 mL), brine (100 mL), dried over Na2S04, filtered and concentrated to dry. The crude product was purified over silica gel (Biotage, eluting with a linear gradient of 30 - 80 % EtOAc in heptane) to provide (R)-N- ((i?)-l -(benzyloxy)propan-2-yl)-2-chloiOpiOpanamide (65.7 g, 0.239 mol, 79.7 % yield) after combining the desired fractions, concentration and drying in vacuo.
[0680] To a cooled stiiTed solution of (i?)-N-((i?)-l -(benzyloxy)propan-2-yl)-2- chloropropanamide (8.8 g, 0.032 mol) in THF (440 mL) at 0 °C was added portion wise NaH (5.181 g, 0.130 mol, as a 60% oil dispersion) over a 10-min period. The reaction mixture was stiiTed at 0 °C then allowed to warm slowly to rt and stiiTed an additional 6 h. The completed reaction was slowly quenched with IP A (20 mL) followed by Dowex 50, H+ resin (30 g) followed by stirring until an acidic pH was registered. The quenched suspension was filtered, washed with EtOAc (50 mL) and concentrated to dryness. The crude product was purified over silica gel (200 g, eluting with a 30 - 50 % gradient of EtOAc in heptane) to provide (25,, lS)-6-((benzyloxy)methyl)-2-methylmoi*pholin-3-one (6.12 g, 0.026 mol, 81.3 % yield) after combining the desired fractions, concentration and drying in vacuo.
[06811 To a stiiTed solution of (25,, 55 -6-((benzyloxy)methyl)-2-methylmoi-pholin-3- one (6.12 g, 0.026 mol) in THF (20 mL) under a nitrogen atmosphere at rt was added 1 M tetrahydroaluminate in THF (30 mL, 0.030 mol) dropwise over a 15-min period. The reaction mixture was stiiTed for 2.5 h after which time it was cooled to 0 °C followed by the slow addition of water (13 mL) and then 1 N aq. NaOH (0.9 mL). The quenched reaction was stirred until the precipitate became granular after which time Celite 545 (10 g) was added followed by filtering over a Celite pad and rinsing three times with DCM (30 mL) and ethyl ether (30 mL). The combined filtrates were concentrated and purified over silica gel (Biotage, eluting with a gradient of 0 - 5 % MeOH in DCM) to provide (2S, 6S)-2- ((benzyloxy)methyl)-6-methylmoipholine (2.7 g, 0.012 mol, 46.2 % yield) after combining the desired fractions, concentration and drying in vacuo.
[0682] To a stiiTed solution of (2iS', 6.S,)-2-((benzyloxy)mcthyl)-6-mcthylmorpholine
(2.7 g, 0.012 mol) in DCM (50 mL) was added di-feri-but ldicaarbonate (6.807 g, 0.031 mol) followed by TEA (4.35 mL, 0.031 mol) and DMAP (100 mg, 0.82 mmol). The reaction was stiiTed at rt for 3 h after which time the completed reaction was washed with 0.1 N HCl (50 mL) and brine (50 mL). The organic phase was concentrated followed by purification over silica gel (Biotage, eluting with a 10 - 20 % gradient of EtOAc in heptane) to provide to provide (2S, 6S)-tert-butyl 2-((benzyloxy)methyl)-6-methylmorpholine-4-carboxylate (3.68 g, 1 1.4 mmol, 95.4 % yield) after combining the desired fractions, concentration and drying in vacuo.
[0683] To a stirred solution of (2S, 6S)-tert -butyl 2-((benzyloxy)methyl)-6- methylmorpholine-4-carboxylate (3.102 g, 9.7 mmol) in ethanol (15 mL) was added 5 % Pd on carbon (300 mg) followed by evacuation and charging of the reaction vessel three times with hydrogen gas. The reaction was heated to 40 °C maintaining under a hydrogen atmosphere (balloon pressure) and stiiTed overnight, after which time the reaction was purged with nitrogen gas several times while evacuating the system with house vacuum between purges. The completed reaction was filtered over Celite 545, the filter pad washed two times with ethanol (10 mL each), followed by concentration of the combined filtrates were concentrated and dried in vacuo. The crude product, (2S, 6S)-tert-butyl 2-(hydroxymethyl)- 6-methylmorpholine-4-carboxylate (2.15 g, 9.3 mmol, 95.8% yield) was used in the next step without further purification.
[0684] To a stiiTed solution of (2S, 6 S)-ter t-buty\ 2-(hydroxymethyl)-6- methylmoipholine-4-carboxylate (200 mg, 0.865 mmol) in DCM (5 mL) was added TFA (0.5 mL, 6.7 mmol) at rt. The reaction mixture was stirred for 1 h after which time it was concentrated and azeotroped to dry two times with toluene (5 mL each) and dried in vacuo. The crude deprotected morpholine was dissolved with stirring in DMAC (1 mL) followed by DIPEA (0.23 mL, 1.3 mmol) and compound 3 (152.4 mg, 0.654 mmol). The reaction mixture was micro waved at 140 °C and stiiTed for 3 h after which time the completed reaction was cooled to rt, concentrated and purified over silica gel (Biotage, eluting with 30 - 80 % EtOAc in heptane) to provide 5-((25, (5S)-2-(hydroxymethyl)-6- methylmorpholino)quinolinc-8-carbonitrile or ER-885477 (165.2 mg, 0.583 mmol, 89.2 % yield) after concentration of the desired combined fractions and drying under vacuo.
[0685] To a cooled, stirred solution of bis(2-methoxyethyl)aminosulfur trifluoride
(Deoxo-Fluor®) (0.044 mL, 0.239 mmol) in DCM (2 mL) under a nitrogen atmosphere at - 78 °C was added dropwise ER-885477 (50.4 mg, 0.178 mmol) in DCM (2 mL) over a 3-min period. The reaction mixture was warmed to - 50 °C and stirred for 30 min after which time it was warmed to 0 °C and stirred for 1.5 h. The completed reaction was slowly quenched with a dropwise addition of saturated NaHC03 until a basic pH was observed (~ 5 mL). The mixture was diluted with DCM (10 mL), the layers separated after which time the organic layer was washed two times with water (5 mL each), dried over MgS04, filtered and concentrated. The crude product was purified over a reverse phase HPLC column (X-Bridge C18 19 x 100 mm column; eluting with a linear gradient of 10% - 90% acetonitrile in water with 0.1% fomiic acid) and concentrating the desired peak followed by high vacuum to dryness to provide ER-886133 (35.2 mg 0.123 mmol, 69.3 % yield).
[0686] To ER-885477 (25.2 mg, 0.089 mmol) was added thionyl chloride (2 mL) followed by warming to 85 °C and stirring for 24 h. The completed reaction was concentrated to dry with azeotroping two times with toluene (5 mL each). The crude product was purified over a reverse phase HPLC column (X-Bridge C18 19 x 100 mm column; eluting with a linear gradient of 10% - 90% acetonitrile in water with 0.1% formic acid) and concentrating the desired peak followed by high vacuum to dryness to provide ER-886134 (2.1 mg 0.007 mmol, 7.8 % yield).
[0687] Preparation of ER-889363 using Scheme 14: To a stirred suspension of 3- butenylamine hydrochloride, 62 (5.45 g, 50.6 mmol) was in DCM (33 mL) was added NaHC03 (110 g) followed by o-nitrobenzenesulfonyl chloride (13.5 g, 60.8 mmol). Resultant mixture was vigorously stirred at rt for 2 h after which time phenylhydrazme hydrochloride (2.9 g, 20 mmol) was added and stining was continued for additional lh. The completed reaction mixture was extracted with MTBE (70 mL) and then sequentially washed with 20 % aq. citric acid (35 mL), water (35 mL) and concentrated. Resultant purple solid (13.32g) was dissolved in NMP (70 mL) and potassium carbonate (21 g, 0.15 mol) was added followed by (ft)-glycidol-benzyl ether, 6 (9.98 g, 60.8 mmol). The mixture was heated to 50 °C and stirred for 22 h after which time it was diluted with water (300 mL) and extracted two times with MTBE (200 mL each). All organic layers were combined and concentrated to give orange-colored oil, which was subjected to silica gel column chromatography (n- heptane/MTBE 1 : 1) to give 64, (7.90g, 18.8 mmol, 37% yield in 2 steps) as orange colored oil.
[0688] To a stirred solution of 64 (7.90 g, 18.8 mmol) in DMAC ( 94.8 mL) was added copper (II) acetate (0.853 g, 4.70 mmol) followed by PdCl2 (0.416 g, 2.35 mmol) at rt. Resultant mixture was stirred under 02 (balloon) at rt for 16 h after which time additional PdCl2 (0.200 g, 1.13 mmol) was added and the mixture was heated to 40 °C and stirred for 6h. The completed reaction was quenched with pyridine (4.5 mL, 56 mmol), stirred for 5min followed by diluting with MTBE (400 mL). The mixture was washed with water (250 mL) and the organic layer was separated, concentrated. The crude yellow oil was purified by silica gel column chromatography (n-heptane/MTBE 1 :1) to give 65 (0.740 g, 1.77 mmol, 9.4% yield, 31% yield based on recovered substrate).
[0689] To a cooled, stirred solution of 65 (1.480 g, 3.54 mmol) in DCM (14.8 mL) at to 0 °C was added triethylsilane (2.96 mL, 18.6 mmol) followed by TFA (4.44 mL, 57.6 mmol). The reaction mixture was stirred at 0 °C for 1 h after which time the mixture was warmed to rt and stirred for an additional 1 h. The completed reaction mixture was azeotroped two times with toluene (60 mL each) and then purified by silica gel column chromatography (n-heptane/MTBE 1 : 1) to give 66 (1.382 g, 3.29 mmol, 92% yield) as yellow oil.
[0690] To a stirred solution of 66 (1.382 g, 3.29 mmol) in DMF (8.3 mL, 0.11 mol) was added potassium carbonate (1.45 g, 10.5 mmol) followed by benzenethiol (0.360 mL, 3.50 mmol). The resultant mixture was heated at 40 °C for 2 h after which time the completed reaction was diluted with water (12 mL). Di-ter^-butyl dicarbonate (0.897 g, 4.11 mmol) was added followed by stirring at rt for 1 h. The completed reaction was diluted with water (29 mL) and extracted two times with MTBE (40 mL each) and the combined organic layers were concentrated to give yellow oil. Crude product was purified by silica gel column chromatography («-heptane/MTBE 4: 1) to provide 67 (847mg, 2.52 mmol, 77% yield) as a colorless oil and its stereoisomer (8.3 mg, 0.25 mmol, 7.5% yield) as a colorless oil.
[0691] To a stirred solution of 67 (0.847 g, 2.52 mmol) in DCM (4.2 mL) was added
TFA (4.2 mL, 0.055 mol) at rt and stirred for 30 min. The completed reaction mixture was concentrated, azeotroped with toluene (20 mL) and partitioned between saturated NaHC03 (8.5 mL) and DCM (20 mL). Organic layer was separated, dried over MgS04 (2.0 g), filtered, and concentrated to dry. The crude intermediate was dissolved in NMP (2.12 mL) followed by DIPEA (0.66 mL, 3.8 mmol) and then 3 (0.706 g, 3.03 mmol). The resultant mixture was heated to 140 °C and stirred for 2 h after which time the completed reaction was cooled to rt and partitioned between EtOAc(40 mL) and water (20 mL). Aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with water (10 ml) and concentrated to give crude product as brownish solid/oil. The crude product was purified over silica gel (eluting with n-heptane/EtOAcl : l) to give a 4: 1 mixture of the desired intermediated (0.684 mg).
The crude intermediate mixture (0.684 mg) was suspended in acetonitrile (6.0 ml) followed by iodotrimethylsilane (0.377 mL, 2.65 mmol) followed by heating to 60 °C and stirring for 2 h. The completed reaction was cooled to 40 °C followed by the addition of water (3.0 ml) and the reaction was cooled to rt with stirring for an additional 1 h. 28% aq. ammonium hydroxide (1.0 mL) was added and the resultant mixture was extracted two times with EtOAc(20 mL each) after which time the combined organic layers were concentrated followed by purification over silica gel (eluting with EtOAc 100%) to give 68 or ER-889363 (404 mg, 1.36 mmol, 53% yield) as yellow solid.
[0692] To a stirred solution of ER-889363 (355 mg, 1.194 mmol) in DCM (4 mL) was added p-toluenesulfonyl chloride (350 mg, 1.836 mmol) followed by DIPEA (0.32 mL, 1.837 mmol) and DMAP (10 mg, 0.082 mmol). The reaction mixture was stirred at rt for 16 h after which time the completed reaction was washed with water (2 mL) and brine (2 mL) followed by drying over Na2S04, filtering and concentrating to dryness. The crude product was purified over silica gel (Biotage, SP4, 25+M eluting with 10 - 60 % EtOAc in heptane over 20 column volumes. The desired fractions were combined, concentrated and dried in vacuo to provide ((2R, 7i?)-4-(8-cyanoquinolin-5-yl)-7-methyl-l ,4-oxazepan-2-yl)methyl 4- methylbenzenesulfonate (476.6 mg, 1.056 mmol, 88.4 % yield)
[0693] ((2i?, 7i?)-4-(8-cyanoquinolin-5-yl)-7-methyl-l,4-oxazepan-2-yl)methyl-4- methyl-benzenesulfonate (19.4 mg, 0.043 mmol) and l,4'-bipiperidine (30 mg, 0.178 mmol) were dissolved in DMAC (0.5 mL) and then microwaved at 150 °C for 10 min. The cooled reaction was diluted with acetonitrile (0.5 mL), filtered and purified by reverse-phase HPLC (Xbridge CI 8 column, eluting with a gradient of 10 - 40 % acetonitrile in water containing 0.1 % formic acid). The combined desired fractions were concentrated, diluted with MeOH (1 mL) and passed over a basic SiC03 column eluting with MeOH (2 mL) followed by concentrations and drying in vacuo to provide ER-889822 (11 mg, 0.025 mmol, 57.2 % yield).
[0694] Other Examples:
[0695] ER-890094: A solution of (3-(bromomethyl)phenyl)boi nic acid (129.5 mg,
0.603 mmol) and 1 ,4'-bipiperidine (190 mg, 1.129 mmol) in DMAC (1 mL) was microwaved at 150 °C for 10 min after which time the reaction was cooled and concentrated to dryness to be used in the next step as crude (3-([l,4,-bipiperidin]-l,-ylmethyl)phenyl)boronic acid.
[0696] A stirred solution containing 3 (44.5 mg, 0.191 mmol), crude (3-([1,4'- bipiperidin]- -ylmethyl)phenyl)boronic acid (86.5 mg, 0.286 mmol), palladium(II) acetate (6 mg, 0.027 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (12 mg, 0.029 mmol) and 1 M sodium carbonate in water (0.029 ml, 0.029 mmol) in EtOH (0.6 mL) and toluene (0.6 mL) was heated to 70 °C for 16 h. The completed reaction was cooled, diluted with DCM (10 mL), washed with water (3 mL), dried over Na2S04, filtered and concentrated to dryness. The crude product was diluted with 1 : 1 DMSO:acetonitrile (2 mL) and directly purified by HPLC (Xbridge CI 8, eluting with a 10 - 40 % acetonitrile in water containing 0.1 % formic acid). The desired product was collected and concentrated to dry. The resulting product was dissolved in MeOH (2 mL) and passed over a basic silica plug (Biotage, lg, SiC03) eluting with MeOH (5 mL) to provide after concentration and drying in vacuo ER-890094 (5 mg, 0.012 mmol, 6.3 % yield).
[0697] ER-890244 (63.2 mg, 0.153 mmol, 27.3 % overall yield) was prepared in a similar manner to ER-890094 starting with (4-(bi momethyl)phenyl)boronic acid (134.2 mg, 0.625 mmol) and 1,4 -bipiperidine (125 mg, 0.564 mmol).
[0698] ER-888200: A stirred solution containing 3 (251 mg, 1.077 mmol), (3-formyl-
5-methylphenyl)boronic acid (350 mg, 2.135 mmol), bis(triphenylphosphine)palladium(II) chloride (150 mg, 0.214 mmol), lithium chloride (91 mg, 2.147 mmol), sodium carbonate (230 mg, 2.17 mmol) and 10 % sodium carbonate in water (2.3 ml) in DMF (11 mL) was heated to 90 °C for 3 h. The cooled reaction was diluted with EtOAc (48 mL) and water (12 mL) with stining followed by filtering through Celite 545 (1.2g) eluting with EtOAc (10 ml). The separated aqueous layer was extracted two times with EtOAc (12 mL each) and the combined organic layers was washed with water (24 mL) and brine (24 mL) followed by drying over Na2S04, filtering and concentrating to dry. The crude product was purified over silica gel (Biotage SP4, Interchim 25 g, eluting with 20 - 100% EtOAc in heptane) after which time the desired product fractions were combined, concentrated and dried in vacuo to provide ER-888200 (163 mg, 0.599 mmol, 55.6 % yield).
[0699] ER-888201 : To a stirred solution of ER-888200 (21mg, 0.077 mmol) in
MeOH (2.1 mL) cooled to 0 °C was added sodium tetrahydroborate (3.2 mg, 0.085 mmol). The reaction mixture was stirred for 1 h after which time water (2.1 mL) was added, the mixture concentrated to half volume, followed by extraction with EtOAc (19 mL). The organic layer was washed with brine (3.9 ml), dried over Na2S04, filtered and concentrated to dry to provide ER-888201 (17.4 mg, 0.63 mmol, 82.4 % yield).
|0700] ER-888644: To a stirred solution of ER-888201 (91 mg, 0.332 mmol) in
DCM (1.8 mL) was added ^-toluenesulfonyl chloride (101 mg, 0.530 mmol) followed by DMAP (2 mg, 0.016 mmol) and DIPEA (1.8 mL, 1.03 mmol). The reaction mixture was stirred at rt for 3 h after which time additional j toluenesulfonyl chloride (101 mg, 0.530 mmol) was added followed by stilling for 2 h. The completed reaction was diluted with stining with water (1 mL) and DCM (5.2 mL). The layers were separated and the organic layer was washed with brine (1 mL), dried over Na2S04, filtered and concentrated to dry. The crude product was purified over silica gel ( Biotage SP4, Interchim 25 g, eluting with 20 - 100% EtOAc in heptane) after which time the desired product fractions were combined, concentrated and dried in vacuo to provide ER-888644 (63 mg, 0.212 mmol, 65 % yield).
[0701] ER-888645: A solution of ER-888644 (20 mg, 0.068 mmol) and 4- hydroxypiperidine (70 mg, 0.692 mmol) in N-mefhylpyrrolidone (2 mL) was microwaved at 150 °C for 15 min. The cooled reaction was diluted with NMP (4 mL) and directly purified by HPLC using a C-18 column (Xbridge CI 8, eluting with a 10 - 40 % acetonitrile in water containing 0.1 % TFA). The desired product was collected and concentrated to dry. The resulting product was dissolved in MeOH (2 mL) and passed over a basic silica plug (Biotage, lg, SiC03) eluting with MeOH (5 mL) to provide after concentration and drying in vacuo ER-888645 (19.9 mg, 0.056 mmol, 81.5 % yield).
[0702] ER-88864 (17.9 mg, 0.047 mmol, 68.1 % yield) was prepared in a similar manner to ER-888645 starting with ER-888644 (20 mg, 0.068 mmol) and 4- dimethylaminopiperidine (87.6 mg, 0.683 mmol).
[0703] ER-888647 (15.3 mg, 0.043 mmol, 62.8 % yield) was prepared in a similar manner to ER-888645 starting with ER-888644 (20 mg, 0.068 mmol) and 1- methylpiperazine (68.4 mg, 0.683 mmol).
[0704] ER-889504 (46 mg, 0.108 mmol, 62 % yield) was prepared in a similar manner to ER-888645 starting with ER-888644 (51 mg, 0.174 mmol) and l ,4'-bipiperidine (102 mg, 0.606 mmol).
[0705] General Screening Assay and Pharmacology Strategy.
[0706] To identify potent and selective TL 7/8 compounds, analogs were initially screened across a cell-based panel of human TLR4, TLR7, and TLR9 reporter lines (see Pharmacology Materials and Methods for more details). A subset of compounds that were potent and selective for TLR7 were also tested for TLR8 activity (see Table 3 below) and for TLR7/8 potency in the primary human PBMC assay (see Pharmacology Materials and Methods for more details). Certain compounds were advanced into the short-term in vivo (STIV) assay to determine dose-dependent activity and duration-of-action against mouse TLR7 (see Pharmacology Materials and Methods for more details). Select compounds were then evaluated for impact in one or more of the following mouse lupus disease models: BXSB-Yaa, NZBxNZW, and Pristane DBA/1.
[0707] Many compounds reported as embodiments herein demonstrate nanomolar potency against both human and mouse TLR7 and human TLR8 when these receptors, expressed on either cell lines or primary cells, are stimulated by synthetic, small molecule (CL097, R848) or nucleic-acid (RNA) ligands. Conversely, most compounds reported as embodiments herein are inactive against the TLR9 pathway.
[0708] Current lupus SOC drags include anti-malarials such as chloroquine and hydroxychloroquine (HCQ) which have been shown to inhibit TLR7/9 activation in vitro. This may at least partially explain their effectiveness in controlling lupus flare. Embodiments of the disclosure, however, have been shown to offer significantly more potent inhibition. For example, compound ER-899742 (shown and discussed above) was found to be approximately 1000-fold more potent against the RNA-Ig TLR7/8 stimulus versus HCQ ( IC50 = 0.0009 uM, HCQ IC50 ~1.5uM). This suggests that ER-899742 would offer much more effective TLR7/8 pathway inhibition versus current lupus treatments. This is demonstrated by results shown in Table 1 below.
[0709] TABLE 1. Potency and selectivity of compound ER-899742 as compared to hydroxychloroquine (Plaquenil).
Figure imgf000118_0001
[0710] The comparative potency of ER-899742 versus hydroxychloroquine was further explored using cloned TLR7 and 8 in the HEK 293 cell line as described below in In Vitro Pharmacology. Effects on mouse TLR7 were also compared. Cells were stimulated overnight with TLR7/8 agonist CL097 at pre-determined ED7o-80: 3 ug/ml for HEK-hTLR7, 1.5 ug/ml for HEK-mTLR7 and 12 ug/ml for HEK-hTLR8, before reading luminescence intensity. Three tests were performed and IC50 value was determined using Graphpad Prism 6 nonlinear regression curve fit. Individual test results and their average are shown in Table 2. The data show that in this assay, ER-899742 had an average IC50 of 0.024 uM in the HEK TLR7 cell line, and an average IC50 of 0.0024 uM in the HEK/TLR8 cell line.
[0711] TABLE 2. ER-899742 effects on TLR7 and TLR8 response compared to hydroxychloroquine.
Figure imgf000119_0001
[0713] TABLE 3. Potency of select compounds against human TLR8 in the HEK-293 assay format (see Materials and Methods for more details).
Figure imgf000119_0002
ER-885493 0.1007 ER-887143 0.1480
ER-885612 0.0550 ER-887144 0.0480
ER-885618 0.0050 ER-887145 0.1050
ER-885621 0.0250 ER-887199 0.0770
ER-885892 0.0370 ER-887253 0.0020
ER-885906 0.0200 ER-887258 0.1750
ER-885930 0.1470 ER-887259 0.0005
ER-886355 0.0660 ER-887261 0.0770
ER-886431 0.0310 ER-887269 0.0032
ER-886507 0.1820 ER-887271 0.0016
ER-886508 0.1860 ER-887272 0.0029
ER-886509 0.1190 ER-887443 0.1380
ER-886514 0.0050 ER-887444 0.1930
ER-886530 0.0050 ER-887526 0.1220
ER-886532 0.0300 ER-887528 0.1350
ER-886533 0.0140 ER-887538 0.0850
ER-886565 0.0290 ER-887539 0.0005
ER-886567 0.0050 ER-887540 0.0030
ER-886568 0.0050 ER-887586 0.1265
ER-886624 0.0860 ER-887587 0.0018
ER-886625 0.0100 ER-887588 0.0005
ER-886626 0.0050 ER-887722 0.0210
ER-886629 0.0050 ER-887723 0.0090
ER-886814 0.0600 ER-887724 0.0060
ER-886816 0.1070 ER-887725 0.0010
ER-886818 0.0810 ER-887927 0.0005
ER-886820 0.0780 ER-887928 0.0110
ER-886854 0.0460 ER-890963 0.0028
ER-886857 0.0720 ER-894594 0.1160
[0714] Short-term in vivo (STIV) assay: To assess compound potency in vivo against mouse TLR7, a short-term in vivo (STIV) assay was utilized. Briefly, mice were orally dosed with compounds and at various time points afterwards were injected subcutaneously with agonist R848 to stimulate TLR7. The plasma IL-6 level following R848 stimulation was then measured by ELISA to assess compound potency and duration-of- action. Importantly, cytokine production following in vitro or in vivo stimulation with R848 was shown to be completely TLR7-dependent utilizing TLR7-deficient mice. Therefore, the activity of compounds in the STIV assay can be confidently attributed to their modulation of the TLR7 pathway. A single oral dose of ER-899742 at 300 mg/kg fully suppresses the R848/TLR7/IL-6 pathway in vivo for at least 24 hours (see FIG. 1A and FIG. IB). A summary of STIV assay potency for a panel of compounds appears in Table 4 below.
[0715] TABLE 4. Short-term in vivo (STIV) assay data summary for select compounds.
Figure imgf000121_0001
X - M ce not to erate t s ose.
Figure imgf000122_0001
Figure imgf000123_0001
X = M ice did not tolerate this dose
Figure imgf000124_0001
[0716] Mouse lupus disease models. Two distinct lupus disease models (NZB/W and Pristane) were chosen for compound POC evaluation because (1) the NZB/W strain develops spontaneous disease with polygenic etiology, demonstrating many hallmarks of human lupus such as DNA-associated autoreactivity, proteinuria, and immune-complex mediated nephritis, and (2) positive TLR7 and/or TLR9 target validation results have been reported for both disease models.
[0717] Key findings for ER-899742 in the SLE disease models are as follows (see
FIG. 2A-FIG. 2C, FIG.3A-3E, and FIG. 7A-7G, and Table 7):
1) ER-899742 at several doses between 33 and 300 mg/kg afforded pronounced survival benefit in the NZB/W model, corresponding to significantly reduced proteinuria and histological signs of glomerulonephritis.
2) ER-899742 suppressed various auto-antibody specificities in the Pristane model, with particularly robust impact on RNA-related reactivity such as anti-RiboP titers. Decreased expression of some IFN-modulated genes in whole blood resulted from treatment with ER-899742 in this model. Control of arthritis by ER-899742 in this model was also observed.
[0718] Key findings for ER-899464 in the SLE disease models are as follows (see
FIGs. 4-5):
1) ER-899464 at several doses between 33 and 300 mg/kg afforded significant survival benefit in the NZB/W model, accompanied by significantly reduced proteinuria. 2) ER-899464 suppressed various auto-antibody specificities in the Pristane model, with particularly robust impact on RNA-related reactivity such as anti-RiboP titers.
[0719] PHARMACOLOGY MATERIALS & METHODS:
[0720] In vitro pharmacology:
[0721] HEK-293 cells (ATCC) were engineered to stably express a NF-kappaB transcription factor inducible E-selectin (ELAM-1) luciferase reporter derived from the plasmid pGL3 (Promega) containing base pairs -2241 bp to -254bp from the promoter of the human E-selectin gene (Accession No. NM_000450). These cells were then subsequently engineered to stably and individually express human TLR4, TLR7 or TLR9 full-length ORF cDNAs. Human TLR4 cDNA (Accession No. NM_138554) was cloned into pcDNA 3.0 expression vector (Invitrogen). TLR4 transfected cells were also engineered to express human MD-2 co-receptor [MD-2 cDNA (Accession No. NM_015364) was cloned into the pEF-BOS vector] and were supplemented with lOnM soluble CD14 (R&D Systems) in the media to optimize LPS responsiveness. Human TLR9 cDNA (Accession No. NM_017442) was cloned into the pBluescript II KS vector (Agilent). Human TLR7 cDNA (Accession No. NM_016562) was obtained from OriGene. HEK-293 cells stably expressing human TLR8 (Accession No. NM_138636) or mouse TLR7 (Accession No. NM_133211) were purchased from InyivoGen and were then stably transfected with pNiFty2(NF-kappaB)-luciferase reporter plasmid (InvivoGen). Each cell type was plated in Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) at a density of 2.22X105 cells/ml into a 384-well plate and incubated for 2 days at 37 °C, 5 % C02. Varying concentrations of antagonist compounds were then added. Cells were then incubated for another 30 minutes before adding the appropriate TLR agonist as follows (final concentrations indicated): lipopolysaccharide (LPS; Sigma) at lOng/ml for TLR4, CL097 (InvivoGen) at 3 ug/ml for human TLR7 and TLR8 and mouse TLR7, and CpG-2006-2A [sequence: TCGTCGTTAAGTCGTTAAGTCGTT (SEQ ID NO: 1) with phosphorothioate backbone, synthesized by Sigma- Aldrich] at 0.6uM for TLR9. The cells were then incubated overnight, and NF-kappaB dependent luciferase reporter activation was quantified by measuring luminescence with SteadyGlo® (Promega) or Steadylite™ (Perkin Elmer) reagent as per the manufacturer's suggested protocol.
[0722] Human PBMC cell-based assay. Human peripheral blood mononuclear cells
(PBMC) were isolated from freshly-drawn heparinized (10 USP units/ml, Hospira, Lakeforest, IL) healthy donor whole blood by density gradient (Histopaque® 1077, Sigma, Inc., St. Louis, MO). Briefly, 25 ml blood was diluted with 15 ml PBS (without Ca2+, Mg2+) in a 50 ml conical tube, and 12 ml Histopaque was underlaid using a spinal needle. Tubes were centrifuged for 45 minutes at 1200 rpm (350xg), and PBMC were collected from the buffy coat. Cells were then washed twice in PBS, and red blood cells were lysed by suspension in 5 ml ammonium chloride solution (IX Red Blood Cell Lysis Buffer, eBioscience) for 5 minutes at room temperature. After a final wash in PBS, PBMC were resuspended at a final concentration of 2X106/ml in RPMI-1640 media with L-glutamine (Invitrogen) and supplemented with 25mM HEPES (Mediatech, Inc, Manassas VA), 10% fetal bovine serum (HyClone, Logan, UT), and Penicillin-Streptomycin-Glutamine (Mediatech) and plated at 100 ul/well (2X105 cells/well) in tissue culture treated 96-well plates (Falcon).
Antagonist compounds solubilized and serial diluted in 100 % DMSO were added in triplicate to cells to yield a final concentration of 0.1 % DMSO (v/v). Hydroxychloroquine (Acros Organics) solubilized and serial diluted in PBS was added in triplicate to cells. PBMC were incubated with antagonist compounds or HCQ for 30 minutes at 37 °C, 5 % C02 before adding various TLR agonist reagents in 100 ul complete media per well as follows (final concentrations indicated): R848 (Resiquimod; GLSynthesis, Worcester, MA) at luM for TLR7 and TLR8, LPS (Sigma) at 10 ng/ml for TLR4, and CpG-2216 (InvivoGen) at 5ug/ml for TLR9. To prepare a TLR7/8 agonist that mimics RNA-containing auto-antibody immune complexes in lupus patients, a 26-mer RNA with a sequence derived from human Ul snRNA stem loop IV [(sequence: GGGGGACUGCGU-UCGCGCUUUCCC (SEQ ID NO: 2) with phosphorothioate backbone] was synthesized (Dharmacon, Inc., Lafayette, CO), which has been shown previously to be a potent TLR7 and TLR8 agonist. This RNA molecule was diluted to 2.5 μΜ in serum-free RPMI, and mouse anti-human single stranded DNA monoclonal antibody (MAB3034, Millipore, Inc., Billerica, MA), which also cross-reacts with RNA, was added at a 1 :25 dilution or at lug/ml. The resulting "RNA-Ig" stimulus was incubated at room temperature for 15-30 minutes before adding to cells. PBMC were incubated with the various TLR agonists for 20 hours at 37 °C, 5 % C02. Cell culture supernatants were collected, and levels of various human cytokines were assessed as indicated by standard ELISA procedure according to the manufacturer's recommended protocol (BD Biosciences, Inc., San Diego, CA). Results are shown in Table 5. In a subsequent assay (Table 6) the ability of ER-899742 to block stimulation of normal PBMC by various TLR7/8 ligands, but not DNA-mediated activation of TLR9, was examined. In this assay cells were plated at 1X105 cells/well in 100 ul in 96-well plates.
[0723] Table 5 - PBMC Assay Data Summary for Selected Compounds
Figure imgf000127_0001
ER-887442 0.047 ER-888644 0.019
ER-887443 0.032 ER-888645 0.047
ER-887526 0.050 ER-888646 0.003
ER-887528 0.056 ER-888647 0.012
ER-887538 0.048 ER-888701 0.018
ER-887539 0.000 ER-888896 0.050
ER-887540 0.001 ER-888977 0.217
ER-887586 0.098 ER-889469 0.013
ER-887587 0.001 ER-889470 0.012
ER-887588 0.001 ER-889504 0.002
ER-887589 0.036 ER-889556 0.010
ER-887612 0.053 ER-889557 0.085
ER-887722 0.065 ER-889571 1.000
ER-887723 0.007 ER-889728 0.021
ER-887724 0.006 ER-889744 0.008
ER-887725 0.002 ER-889745 0.046
ER-887927 0.000 ER-889745 0.046
ER-887960 0.041 ER-889746 0.073
ER-888070 0.003 ER-889822 0.025
ER-888200 0.016 ER-890093 0.022
ER-888201 0.004 ER-890108 0.009
ER-888202 0.008 ER-890113 0.022
ER-888203 0.105 ER-890119 0.008
ER-888204 0.022 ER-890120 0.005
ER-888205 0.040 ER-890121 0.011
ER-888285 0.014 ER-890186 0.001
ER-888286 0.223 ER-890187 0.079
ER-888288 0.015 ER-890188 0.087
ER-888288 0.015 ER-890189 0.114
ER-888289 0.011 ER-890250 0.116
ER-888321 0.022 ER-890252 0.042
ER-888322 0.018 ER-890253 0.064
ER-888330 0.154 ER-890342 0.121
ER-888479 0.091 ER-890344 0.002
ER-888480 0.001 ER-895472 0.161
ER-890345 0.001 ER-895477 0.013
ER-890346 0.006 ER-897385 0.142
ER-890831 0.001 ER-897445 0.104
ER-890963 0.002 ER-897446 0.053
ER-890964 0.001 ER-897447 0.100
ER-892253 0.066 ER-897827 0.039
ER-893881 0.009 ER-897828 0.021 ER-893926 0.008 ER-897922 0.064
ER-893948 0.150 ER-897938 0.016
ER-894149 0.031 ER-897940 0.021
ER-894150 0.004 ER-897945 0.002
ER-894152 0.175 ER-897964 0.020
ER-894154 0.143 ER-897965 0.010
ER-894155 0.042 ER-897967 0.013
ER-894159 0.042 ER-897968 0.001
ER-894160 0.011 ER-897969 0.007
ER-894483 0.209 ER-7982 0.009
ER-894484 0.174 ER-899285 0.007
ER-894504 0.005 ER-899287 0.120
ER-894545 0.005 ER-899293 0.013
ER-894546 0.069 ER-899295 0.032
ER-894547 0.012 ER-899332 0.014
ER-894548 0.028 ER-899337 0.002
ER-894549 0.014 ER-899366 0.001
ER-894550 0.097 ER-899367 0.012
ER-894551 0.003 ER-899414 0.025
ER-894552 0.017 ER-899415 0.013
ER-894594 0.087 ER-899416 0.431
ER-894655 0.005 ER-899417 0.001
ER-894656 0.007 ER-899418 0.005
ER-895200 0.026 ER-899431 0.347
ER-895204 0.023 ER-899457 0.003
ER-895310 0.034 ER-899459 0.016
ER-895324 0.001 ER-899464 0.001
ER-895325 0.026 ER-899476 0.003
ER-895326 0.002 ER-899477 0.006
ER-895327 0.026 ER-899479 0.002
ER-898563 0.122 ER-899481 0.008
ER-898565 0.198 ER-899588 0.007
ER-898566 0.011 ER-899688 0.011
ER-898694 0.002 . ER-899742 0.001
ER-898707 0.002 ER-899745 0.004
ER-898914 0.168 ER-899134 0.010
ER-898919 0.055 ER-899140 0.011
ER-898921 0.302 ER-899152 0.036
ER-898922 > 1.00 ER-899154 0.014
ER-898923 0.631 ER-899160 0.252
ER-898946 0.002 ER-899161 0.125
ER-899017 0.004 ER-899193 0.009 ER-899018 0.009 ER-899278 0.001
ER-899019 0.014 ER-899282 0.034
ER-899020 0.035 ER-899616 0.054
ER-899021 0.005 ER-899619 0.033
ER-899121 0.142 ER-899626 0.001
ER-899122 0.080
[0724] TABLE 6. IL-6 and IFN-a blockade by ER-899742 in human PBMC across multiple ligands compared to hydroxychloroquine
Figure imgf000130_0001
1 NA, data not presented because values below detection limit, or replicates showed high variability
[0725] Mouse spleen cell-based assay. Spleens were harvested from female BALB/c mice (Jackson Labs, Bar Harbor, ME) euthanized by C02. A single cell suspension was obtained by passing spleens through a 40 μηι nylon cell strainer. Cells were washed twice with 50 ml PBS (Mediatech, Inc., Manassas, VA) and red blood cells were lysed in 5 ml RBC Lysis buffer (eBioscience, Inc., San Diego, CA) for 5 minutes at room temperature. Cells were washed twice more in PBS and finally resuspended in supplemented RPMI-1640 at 2.5X106 cells/ml. Cells were plated at 100 μΐ/well (2.5X105 cells/well) in 96-well tissue culture treated plates (Falcon). Serial dilutions of compounds solubilized in 100 % DMSO were added in triplicate to cells to yield a final concentration of 0.1 % DMSO. Cells were incubated with compound for 30 minutes at 37 °C, 5 % C02 before adding 100 μΐ/well of 740 nM R848 (Resiquimod; GLSynthesis, Worcester, MA) in complete media for a final concentration of 370nM R848. Cells were incubated for 20 hours at 37 °C, 5 % C02. Culture supernatants were collected, and levels of IL-6 were assessed by standard ELISA procedure according to the manufacturer's recommended protocol (BD Biosciences, Inc., San Diego, CA). Data is presented below in Table 7.
Table 7 - Mouse Splenocyte Results
Figure imgf000131_0001
[0726] In vivo pharmacology:
[0727] Short-term in vivo (ST1V) assay. Six to eight week old female BALB/c mice
(Jackson Labs, Bar Harbor, ME) were dosed by oral gavage in 200 ul volume with antagonist compounds formulated in 0.5 % aqueous methyl-cellulose (Sigma, St. Louis, MO). At various time points afterwards, mice were injected subcutaneously (s.c.) in 100 ul volume with 15 ug R848 (Resiquimod; GLSynthesis, Worcester, MA) to stimulate TLR7. Blood plasma was collected by cardiac puncture, and levels of IL-6 at 1.5 hours after TLR7 stimulation were then assessed by standard ELISA procedure according to the manufacturer's recommended protocol (R&D Systems). [0728] Mouse lupus disease model strains. Female NZBWF1/J mice were purchased from Jackson Labs (Bar Harbor, ME), both of which manifest with spontaneous lupus disease. Female DBA/1 mice were purchased from Harlan Laboratories (Indianapolis, IN) and at the indicated ages given an intraperitoneal injection of 0.5 ml pristane (2,6,10,14- Tetramethylpentadecane; Sigma, St. Louis, MO) to chemically induce lupus disease or of 0.5ml PBS to generate age-matched, non-diseased control mice.
[0729] Further testing of an embodiment is shown in FIG. 2A through FIG. 2C, which demonstrates testing of ER-899742 in the NZBxNZW strain (abreviated hereafter as NZBWF1/J or NZB/W) lupus disease model. Female NZBWF1/J mice were received at 5 weeks of age, baseline bleeds were performed, and mice were monitored for disease progression by following anti-dsDNA titers. At 27 weeks of age, mice were randomized into groups with equivalent median anti-dsDNA titers and treated at 29 weeks of age with Vehicle (Veh; 0.5 % methyl-cellulose) alone or 33, 100, or 300mg/kg once-a-day orally (QD PO). At 46 weeks of age after 17 weeks of treatment, mice were bled and tested for anti-dsDNA titers. All mice were sacrificed at 50 weeks of age (21 weeks of compound treatment). Fig. 2(A) shows that just prior to termination at 50 weeks of age (following 21 weeks of treatment), urine was collected from individual mice, and the Urinary Albumin Creatinine Ratio (UACR, proteinuria) was determined for each animal as an indirect measure of kidney function. Fig. 2(B) shows a timecourse of mortality observed in this study for the highest and lowest dose groups. No mortality was seen with compound treatment. Further, no mortality was observed in the middle dose group (not shown). Fig. 2(C) shows impact of treatment on anti- dsDNA titers after 17 weeks of dosing, at 46 weeks of age. No statistically significant effect was observed.
[0730] At the end of the experiment kidneys were collected from the animals tested in
FIG. 2A through 2C, fixed in 10 % formalin for 24 hours, embedded in paraffin, and H&E stained sections were generated for histopathology assessment in a blinded fashion (Grade 0/1 +: WNL to minimal; Grade 2: Mild; Grade 3: Moderate to Marked; Grade 4: Severe). Results are shown in Table 8.
[0731] Table 8.
Figure imgf000132_0001
0 0 11 15 9
2+ 1 5 1 7
3+ 4 1 1 0
4+ 14 1 0 2
% combined incidence of 74% 11% 6% 11%
Grade 3 and 4
[0732] Assessment of auto-antibody titers by ELISA. Anti-dsDNA, -Sm/nRNP, -
RiboP, and -Histone titers were evaluated by standard ELISA approach. Briefly, 96-well EIA/RIA ELISA plates (Corning) were coated with 100 ul of diluted antigen in PBS for 90 minutes at room temperature as follows (final concentrations indicated): 10 U/ml Sm/nRNP complex (Immuno vision), 10 ug/ml calf thymus dsDNA (Sigma), 5 U/ml RiboP (Immunovision), and 5 ug/ml Histone (Immuno vision). Plates were washed with PBS/0.05 % Tween20 (washing buffer) and blocked overnight with PBS/1 % BSA (blocking buffer) at 4 °C. Plates were washed, mouse plasma samples diluted in blocking buffer (ranging from 1 :25 - 1 : 10,000 depending on the model and the antigen) were added to wells in 100 ul volume per well, and plates were incubated for 90 minutes at room temperature. Plates were then washed, 100 ul anti-mouse-IgG-HRPO (Southern Biotech) diluted 1 :50,000 in PBS/1 %BSA/0.05 %oTween was added to each well, and plates were incubated for 90 minutes at room temperature. Plates were washed, and 100 ul of a 1 :1 mix of substrate components from the OptEIA TMB substrate kit (BD Biosciences) was added to the wells. Plates were incubated at room temperature, and after sufficient color development the reaction was stopped by adding 100 ul of 0.18M sulfuric acid solution. Plates were read by spectrophotometry at 450 nm.
[0733] Assessment of proteinuria. Urine was collected manually from individual mice or by housing 1-2 mice per metabolic cage for 18 hours, and the Urinary Albumin Creatinine Ratio (UACR) was determined for each animal as an indirect measure of kidney function (UACR calculated as the ratio of mg of albumin/ g of creatinine per dL of urine). Albumin levels in the urine samples were determined using a custom sandwich ELISA protocol using an anti-mouse albumin antibody set (Bethyl Labs), which included a coating antibody and a secondary antibody tagged with an HRP conjugate for detection. Creatinine levels were determined using a commercial creatinine assay kit (Cayman).
[0734] Histological assessment of nephritis. Kidneys were collected from individual mice, fixed in 10 % formalin for 24 hours, embedded in paraffin, and H&E stained sections were generated for histopathology assessment in a blinded fashion. Features of Nephritis Disease Scores are as follows: Grade 0 - normal limits; Grade 1 - ribbon-like capillary wall thickening; Grade 2 - hypercellularity, segmentation, crescent formation; Grade 3 - see Grade 2, increased severity and extent (% glomeruli affected) of glomerular lesions; Grade 4 - sclerosis; severe glomerular disease (non-functional organ).
[0735] Assessment of interferon gene expression in whole blood. The expression of IFN-regulated genes in whole blood was measured by qPCR. Briefly, mice were euthanized, blood was collected via the vena cava, and 100 ul was preserved in tubes containing RNAlater (Ambion, Austin TX). Total RNA was isolated using the Mouse RiboPure Blood RNA Isolation Kit (Ambion). RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Waltham MA). First strand cDNA was synthesized from 100 ng total RNA using Superscript® VILO™ Master Mix (Life Technologies, Grand Island, NY). After reverse transcription, cDNA was diluted with nuclease-free water and mixed with TaqMan® Fast Advanced Master Mix (Applied Biosystems). The mixture was then applied to a custom TaqMan® Low Density Array (TLDA) manufactured by Applied Biosystems, and qPCR was performed on the ABI 7900HT Fast Real-time PCR System (Applied Biosystems). Raw data was collected using RQ Manager 1.2.1 (Applied Biosystems) and analyzed using GeneData Analyst 2.2 software (GeneData).
[0736] The TLDA panel contained as many as 45 target genes chosen from Table 9 below, and 3 housekeeping genes for normalization. The housekeeping gene Hprtl was chosen for normalization based on coefficient-of-variation. Relative quantities were determined for the target genes and used to calculate a fold change for each diseased mouse relative to the non-diseased control group receiving intraperitoneal PBS injection only. A standard Student's t-test was performed to determine which target genes were significantly increased between the non-diseased group (PBS treated) and the vehicle-treated diseased group (pristane treated), thereby representing the disease-regulated gene set. For FIG. 7G a false discovery rate (FDR) correction was done using the p. adjust command in package "base" with default option. Holm, S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics, 1979. 6(2): p. 65-70. An "IFN score" was subsequently calculated for each mouse as the median fold change of all disease-regulated genes identified in the t-test.
Table 9 Gene symbol Taqman I I) Gene name
18S Hs99999901 si Eukaryotic 18S rRNA
Bst2 Mm01609165_gl bone maiTow stromal cell antigen 2
complement component 1, q
Clqa Mm00432142 ml subcomponent, alpha polypeptide
C3 Mm00437858 ml complement component 3
C3arl Mm02620006 si complement component 3 a receptor 1
Ccl2 Mm00441243 gl chemokine (C-C motif) ligand 2
Ccl5 Mm01302427 ml chemokine (C-C motif) ligand 5
Ccr2 Mm00438270 ml chemokine (C-C motif) receptor 2
Cd274 Mm00452054 ml CD274 antigen
Cd300e Mm00468131 ml CD300e antigen
Cd38 Mm01220906 ml CD 38 antigen
Cd40 Mm00441891 ml CD40 antigen
cyclin-dependent kinase inhibitor 2C
Cdkn2c Mm00483243 ml (pi 8, inhibits CDK4)
cytidine monophosphate (UMP-CMP)
Cmpk2 Mm00469582 ml kinase 2
CxcllO Mm00445235 ml chemokine (C-X-C motif) ligand 10
Cxcll l Mm00444662 ml chemokine (C-X-C motif) ligand 11
DEAD (Asp-Glu-Ala-Asp) box
Ddx60 Mm00460708 ml polypeptide 60
Elane Mm00469310 ml elastase, neutrophil expressed
Epstil Mm00712734 ml epithelial stromal interaction 1 (breast)
Fcgrl Mm00438874 ml Fc receptor, IgG, high affinity I
Fprl Mm00442803 si formyl peptide receptor 1
glyceraldehyde-3-phosphate
Gapdh Mm99999915_gl dehydrogenase
Herc6 Mm01341950 ml hect domain and RLD 6
hypoxanthine guanine phosphoribosyl
Hprt Mm00446968 ml transferase
Ifi202b Mm00839397 ml interferon activated gene 202B
Ifi204 Mm00492602 ml interferon activated gene 204
interferon, alpha-inducible protein 27
Ifi2712a Mm01329883 gH like 2A
Ifi35 Mm00510329 ml interferon-induced protein 35
Ifi44 Mm00505670 ml interferon-induced protein 44
interferon induced with helicase C
Ifihl Mm00459183 ml domain 1
interferon-induced protein with
Ifitl Mm00515153 ml tetratricopeptide repeats 1
interferon-induced protein with
Ifit2 Mm00492606 ml tetratricopeptide repeats 2
interferon-induced protein with
Ifit3 Mm01704846 si tetratricopeptide repeats 3
I13ra Mm00434273 ml interleukin 3 receptor, alpha chain
116 Mm00446190 ml interleukin 6
I16ra Mm00439653 ml interleukin 6 receptor, alpha
Irf5 Mm00496477 ml interferon regulatory factor 5
Figure imgf000136_0001
Xafl Mm01248390 ml XIAP associated factor 1

Claims

We claim:
1. A compound of formula (I):
Figure imgf000137_0001
wherein at least one of i and R2 is -H, methyl, or ethyl, and the other is
-H; or the other is
Ci-C6 alkyl that is optionally substituted with:
-OH, methoxy, ethoxy, -OCH(CH3)2, -0(CH2)2CH3, phenyl, furanyl, - 0(CH2)2OH, phenoxy, methylthio, -F, -N(CH3)2, cyano, pyridinyloxy, fluorophenoxy, isochromanyl, phenol, benzylamino, -NHCH3, oxo-, amino, carboxyl, 7-member spiroaminyl, a three to six member cycloalkyl, saturated or unsaturated and optionally including one or more heteroatoms selected from O and N, and optionally substituted at one or more C or N atoms by methyl, cyano, fluoro, methylamino, or trifluoromethyl; or the other is C3-C7 cycloalkane, saturated or unsaturated, optionally bridged, optionally including one or more heteroatoms selected from O, S, and N, and optionally substituted at one or more C or N atoms by methyl, ethyl, pyridinyl, azetidinyl, acetamidyl, carboxamidyl, cyano, fluoro, methylamino, or trifluoromethyl; or
Ri and R2, together with the nitrogen atom to which they are attached, form an 8 to 11 member spirodiamine, an 8 member bicyclodiamine, a 7 member spiroxamine, a piperidinyl optionally substituted with ethyl, or a four to six member cycloalkyl, optionally substituted with at least one of carboxamidyl, aminomethyl, methyl, (ethylamino)methyl, (dimethylamino)methyl, dimethylamino, (methylamino)methyl, and amino; and wherein R3 is -H or methyl.
2. The compound of formula 1, wherein said compound has a stereochemical configuration selected from one of those shown in the group consisting of Formula (la), Formula (lb), Formula (lc), and Formula (Id):
Figure imgf000138_0001
Figure imgf000139_0001
3. The compound of claim 1 , wherein said compound is selected from the group consisting of:
5-((2i?, (ii?)-2-formyl-6-methylmorpholino)quinoline-8-carbonitrile;
(2R, di?)-4-(8-cyanoquinolin-5-yl)-N-ethyl-6-methylmoipholine-2-carboxamide; (2R, (5i?)-4-(8-cyanoquinolin-5-yl)-N-isopi pyl-6-methylmoipholine-2-carboxamide; 5-((2i?; (5i?)-2-formyl-6-methylmoipholino)quinoline-8-carbonitrile;
(2R, 6K)-methyl 4-(8-cyanoquinolin-5-yl)-6-methylmoipholine-2-carboxylate;
(<ii?)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;
5-((2R, 6R)-2-((S)-3 -ethylpiperazine- 1 -carbonyl)-6-methylmorpholino)quinoline-8- carbonitrile;
(2i?) i?)-4-(8-cyanoquinolin-5-yl)-N-(3,4-difluoiObenzyl)-6-methylmorpholine-2- carboxamide;
5-((2R, ( i?)-2-((5)-3-aminopyiTolidine- 1 -carbonyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2i?, ^)-2-(azetidine-l-carbonyl)-6-methylmoi holino)quinoline-8-carbonitrile; 5-((2R, 6R)-2- [\ ,4'-bipiperidine]- 1 '-carbonyl)-6-methylmoipholino)quinoline-8- carbonitrile;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-iV-cyclopiOpyl-6-methylmorpholine-2- carboxamide;
5-((2R, 6R)-2-{ -aminoazetidine- 1 -carbonyl)-6-methylmorpholino)quinoline-8- carbonitrile;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-N-(2-hydi xyethyl)-6-methylmoi holine-2- carboxamide; (2i?, ^)-4-(8-cyanoqumolin-5-yl)-N-(2-methoxyethyl)-6-methylmoipholine-2- carboxamide;
(2i?,di?)-4-(8-cyanoquinolin-5-yl)-N-((i?)-2-hydiOxypiOpyl)-6-methylmorpholine-2- carboxamide;
(2i?,di?)-4-(8-cyaiioquinolin-5-yl)-N-((5 -l-hydiOxypiOpan-2-yl)-6- methylmoipholine-2-carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-N-((i?)-l-hydiOxypiOpan-2-yl)-6- methylmoipholine-2-carboxamide;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-iV-((tS - 1 -hydiOxybutan-2-yl)-6-methylmoipholine- 2-carboxamide;
(2i?, ii?)-4-(8-cyanoquinolin-5-yl)-N-((1S -l-hydiOxy-3-methylbutan-2-yl)-6- methylmoipholine-2-carboxamide;
(2R, 5i?)-4-(8-cyanoquinolin-5-yl)-N-((1S -2-hydroxy- 1 -phenylethyl)-6- methylmoipholine-2-carboxamide;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-N-((i?)-2-hydroxy- 1 -phenylethyl)-6- methylmoi holine-2-carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-N-(2-hydiOxybutyl)-6-methylmorpholine-2- carboxamide;
(2i?, ^i?)-4-(8-cyanoquinolin-5-yl)-N-(2-ethoxyetliyl)-6-methylmoiplioline-2- carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-N-((i?)-l-hydi xybutan-2-yl)-6-methylmoipholine- 2-carboxamide;
(2i?) ii?)-4-(8-cyanoquinolin-5-yl)-N-(l,3-dihydiOxypi pan-2-yl)-6- methylmoipholine-2-carboxamide;
(2i?, (5ii)-4-(8-cyanoquinolin-5-yl)-iV-(2,3-dihydi xypiOpyl)-6-methylmoipholine-2- carboxamide;
(2i?)^i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-iV-(((i?)-tetrahydi furan-2- yl)methyl)morpholine-2-carboxamide;
(2i?, (5^)-4-(8-cyanoquinolin-5-yl)-6-methyl-iV-((tetrahydi furan-2- yl)methyl)morpholine-2-carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-iV-(2-piOpoxyethyl)moipholine-2- carboxamide;
2R, (5i?)-4-(8-cyanoquinolin-5-yl)-N-((i?)- 1 -hydroxypentan-2-yl)-6- methylmoipholine-2-carboxamide; ( ?) ( ?)-4-(8-cyanoquinolin-5-yl)-N-(2-iso lΌ o yethyl)-6-methylmo holine-2- carboxamide;
(2i?, 6i¾-4-(8-cyanoquinolin-5-yl)-N-(l-m
carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-N-(2-(2-fluoiOplienyl)-2-hydiOxyethyl)-6- methylmoipholine-2-carboxamide;
(2R, 5i?)-4-(8-cyanoquinolin-5-yl)-N-((i?)- 1 -hydroxy-3 -methylbutan-2-yl)-6- metliylmorpholine-2-carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-N-(2,2-dimethoxyethyl)-6-methylmoipholine- carboxamide;
(2i?, <5i?)-4-(8-cyanoquinolin-5-yl)-N-(2-(2-hydi xyetlioxy)ethyl)-6- methylmoipholine-2-carboxamide;
(2R, ^)-4-(8-cyanoquinolin-5-yl)-N-((i,S') 21S)-2-hydroxycyclohexyl)-6- methylmorpholine-2-carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-N-(2-hydiOxycyclohexyl)-6-methylmoipholine-2- carboxamide;
(2R, ii?)-4-(8-cyanoquinolin-5-yl)-N-(l-liydiOxyhexan-2-yl)-6-methylmorpholine-2- carboxamide;
(2R, i?)-4-(8-cyanoquinolin-5-yl)-N-((5)- 1 -hydroxy-3 ,3 -dimethylbutan-2-yl)-6- methylmoipholine-2-carboxamide;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-N-((iS)- 1 -hydroxyhexan-2-yl)-6-methylmorpholine- 2-carboxamide;
(2R, 6i?)-4-(8-cyanoqumolin-5-yl)-N-((2£ 35)- 1 -hydroxy-3-methylpentan-2-yl)-6- methylmorpholine-2-carboxamide;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-iV-((<S)- 1 -hydroxy-4-methylpentan-2-yl)-6- methylmoipholine-2-carboxamide;
(2R, <5i?)-4-(8-cyanoquinolin-5-yl)-N-((i?)- 1 -hydroxy-4-methylpentan-2-yl)-6- methylmorpholine-2- carboxamide ;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((4-methylmorpholin-2- yl)methyl)moipholine-2-carboxamide;
(2i?, 6i¾-4-(8-cyanoqumolm-5-yl)-N^
methylmorpholine-2-carboxamide;
(2i?) ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-phenoxyethyl)moipholine-2- carboxamide; (2i?, i?)-4-(8-cyanoquinolin-5-yl)-iV-((5 -l-hydiOxy-3-phenylpiOpan-2-yl)-6- methylmorpholine-2-carboxamide;
(2i?, ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-phenoxypiOpyl)moi holine-2- carboxamide;
(2i?) 5i?)-4-(8-cyanoquinolin-5-yl)-iV-(2-hydiOxy-3-phenylpiOpyl)-6- methylmorpholine-2-carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-(pyridin-3- yloxy)piOpyl)morpholine-2-carboxamide;
(2i?, 6i?)-4-(8-cyanoquinolin-5-yl)-N-(2-(4-fluoiO^
2-carboxamide;
(2i?) ^)-4-(8-cyanoquinolin-5-yl)-N-(2-(3-fluoi phenyl)-2-hydiOxyethyl)-6- methylmoi holine-2-carboxamide;
(2i?, ( i?)-4-(8-cyanoqumolin-5-yl)-N-(fS^-l-cyclohexyl-3-hydiOxypiOpan-2-yl)-6- methylmorpholine-2-carboxamide;
(2R, (ii?)-4-(8-cyanoquinolin-5-yl)-N-(isochiOman- 1 -ylmethyl)-6-methylmorpholine-2- carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-iV-(2-hydiOxy-3-phenoxypiOpyl)-6- methylmorpholine-2 - carboxamide ;
2R, i?)-4-(8-cyanoquinolin-5-yl)-N-((i5, 2R)- 1 -hydroxy- 1 -(4-hydroxyphenyl)propan- 2-yl)-6-methylmorpholine-2-carboxamide;
(2i?, (ii?)-4-(8-cyanoquinolin-5-yl)-iV-((7S -l,3-dihydiOxy-l-phenylpiOpan-2-yl)-6- methylmorpholine-2-carboxamide;
(2i?, ii?)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxy-3-(piperazin-l-yl)piOpyl)-6- methylmoi holine-2-carboxamide;
(2i?, 5i?)-N-(azetidin-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmoi holine-2- carboxamide;
(2i?, diT)-4-(8-cyanoquinolm-5-yi)-6-mem^
carboxamide;
(2i?, <5i?)-4-(8-cyanoqumolm-5-yl)-6-n^
carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((5^-piperidin-3-yl)morpholine-2- carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((i?)-piperidin-3-yl)moipholine-2- carboxamide; (2i?, 6i?)-4-(8-cyanoquinolin-5-y
2-carboxamide;
(2R, (ii?)-N-(2-(benzylamino)ethyl)-4-(8-cyanoquinolin-5-yl)-6-methylmoi oline-2- carboxamide;
(2i?) i-)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(pyridin-2-yl)moi holine-2- carboxamide;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(6-methylpyridin-2-yl)morpholine-2- carboxamide;
(2R, 5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(5-methylisoxazol-3-yl)moi holine-2- carboxamide;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2,2,2-tiifluoi ethyl)moi holine-2- carboxamide;
(2i?, ^)-4-(8-cyanoquinolin-5-yl)-N-(2,2-difluoi ethyl)-6-methylmoi holine- carboxamide;
(2i?, 6i?)-4-(8-cyanoquinolin-5-yl)-6-me
carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-N-(2-(dimethylamino)-2-methylpi pyl)-6- methylmorpholine-2-carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-6-naethyl-N-((5)-morpholin-2- ylmethyl)moi holine-2-carboxamide hydrochloride;
(2i?, <5i?)-4-(8-cyanoquinolin-5~yl)-6-met^^
yl)methyl)moi*pholine-2-carboxamide acetic acetate;
(2i?, (ii?)-4-(8-cyanoquinolin-5-yl)-N-(2-fluoi ethyl)-6-methylmorpholine-2- carboxamide;
(2i?, (ii?)-4-(8-cyanoquinolin-5-yl)-N-(3-fluoiOpiOpyl)-6-methylmoipholine-2- carboxamide;
(2R, ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((iS)-l , 1 , 1 -trifluoi propan-2- yl)morpholine-2-carboxamide;
(2R, i<!)-4-(8-cyanoquinolin-5-yl)-6-methyl- V-((i?)- 1 ,1 ,1 -trifluoropropan-2- yl)morpholine-2-carboxamide;
(27?, 5i?)-4-(8-cyanoquinolm-5-yl)-N-(l,3-dimethyl-lH-pyrazol-5-yl)-6- methylmoipholine-2-carboxamide;
(2i?, ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l-methyl-lH-pyrazol-5- yl)morpholine-2-carboxamide; (2i?)5i?)-N-(cyanomethyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2- carboxamide;
(2R, 6R)-N-(l -cyanocyclopropyl)-4-(8-cyanoquinolin-5-yl)-6-methylmoi holine-2- carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l,2,4-thiadiazol-5-yl)morpholm^ carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(3-methyl-l,2,4-thiadiazol-5- yl)morpholine-2-carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-( iperidin-4-yl)morpholine-2- carboxamide;
5-((2i?, di?)-2-methyl-6-(2,6-diazaspiiO[3^]octane-2-carbonyl)morpholino)quinoline- 8-carbonitrile hydrochloride;
5-((2i?, (5i?)-2-methyl-6-(3-((methylamino)methyl)azetidine-l- carbonyl)morpholino)quinoline-8-carbonitrile hydrochloride;
(2i?)6 ?)-4-(8-cyanoquinolin-5-yl)-N-((4-fluoiOpiperidin-4-yl)methyl)-6- methylmoipholine-2-carboxamide hydrochloride;
(2i?, 6¾-N-(azetidii 3-yhTieth^
carboxamide hydrochloride;
5-((2i?, 5i?)-2-methyl-6-(2,6-diazaspiro[3.5]nonane-2-carbonyl)morpholino)quinoline- 8-carbonitrile hydrochloride;
5-((2i?, (5i?)-2-methyl-6-(l,6-diazaspiiO[3^]octane-l-carbonyl)moi holino)qumolme- 8-carbonitrile hydrochloride;
5-((2i?, (5i?)-2-methyl-6-(l,7-diazaspiro[4^]nonane-7-carbonyl)moipholino)quinoline- 8-carbonitrile hydrochloride;
(2R, 6R)-N-(3 -carbamoyl- 1 -methyl-iH-pyrazol-4-yl)-4-(8-cyanoquinolin-5-yl)-6- methylmoipholine-2-carboxamide;
(2i?, <5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-iV-(oxetan-3-ylmethyl)moi holine-2- carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(tetrahydiO-2H-pyran-4-yl)morpholine- 2-carboxamide;
(2i?; (ii?)-4-(8-cyanoqumolin-5-yl)-6-methyl-N-(tetrahydrofuran-3-yl)moipholine- carboxamide;
(2i?, <5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-7y-((3-methyloxetan-3- yl)methyl)morpholine-2-carboxamide; 5-((2i?, (5i?)-2-methyl-6-(2-oxa-6-azaspiiO[3.3]heptane-6- carbonyl)moi liolino)quinoline-8-carbonitrile;
(2i-) di?)-4-(8-cyanoquinoHn-5-yl)-6-methyl-N-(oxetan-3-yl)morpholine-2- carboxamide;
(2i?, 6'i?)-N-((3-(aminomethyl)oxetan-3-yl)methyl)-4-(8-cyanoquinolin-5-yl)-6- methylmorpholine-2-carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-niethyl-N-(oxetan-2-ylmethyl)moi holine-2- carboxamide;
5-((2i?, <5i?)-2-methyl-6-(piperazin^^
hydrochloride;
(2i?, ^)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-(methylamino)ethyl)moi holine- carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N 5^-3,3,3-trifluoiO-2- hydroxypiOpyl)morpholine-2-carboxamide;
(2^ ^)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(f ? -3,3,3-trifluoiO-2- hydiOxypiOpyl)morpholine-2-carboxamide;
methyl 2-((2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholine-2- carboxamido)acetate;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-N-(2-(dimethylamino)ethyl)-6-methyhTioipholine- 2-carboxamide;
(2i?, ^)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S^-4,4,4-trifluoro-3- hydroxybutyl)morpholine-2-carboxamide;
(2i?) i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((7? -4,4,4-trifluoi -3- hydroxybutyl)morpholine-2-carboxamide;
(2i?, 5i?)-N-(3-amino-4,4,4-trifluoiObutyl)-4-(8-cyanoquinolin-5-yl)-6- methylmorpholine-2-carboxamide;
2-((2i?i (5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamido)acetic acid; l-((2i?) i?)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carbonyl)azetidine-3- carboxamide;
5-((2i?) i?)-2-methyl-6-(2,7-diazaspiro[4^]nonane-2-carbonyl)moi holino)quinoline- 8-carbonitrile hydrochloride;
5-((2i?, (ii?)-2-methyl-6-(3,9-diazaspiiO[5.5]undecane-3- carbonyl)moipholino)quinoline-8-carbonitrile hydrochloride; (2i?, d7?)-N-(3-carbamoylpyridin-4-yl)^^
2-carboxamide;
(2i?, 6i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(( ?j-moi holin-2- ylmethyl)morpholine-2-carboxamide;
(2i?, ^)-4-(8-cyanoquinolin-5-yl)-6-methyl-iV-(pyridm-4-yl)morpholine-2- carboxamide;
(2i?; (ii?)-4-(8-cyanoqumolm-5-yl)-6-methyl-N-(pyridm-3-yl)moi holine-2- carboxamide;
(2i?, i?)-4-(8-cyanoquinolii 5-yl)-6-methyl-N-(l-(piperidin-4-yl)-iH-pyrazol-4- yl)morpholine-2-carboxamide hydrochloride;
(2i?, i?)-N-(l-(azetidin-3-yl)-7H-pyrazol-4-yl)-4-(8-cyanoquinolin-5-yl)-6- methylmorpholine-2-carboxamide hydrochloride;
(2i?)ii?)-N-((lH-pyrazol-5-yl)methyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin^ 2-carboxamide;
(2i?, (5i?)-N-((lH-pyrazol-4-yl)methyl)-4-(8-cyanoquinolin-5-yl)-6-rnethylmoi holme- 2-carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((3-(triiluoromethyl)pyridin-2- yl)methyl)morpholine-2-carboxamide;
(2i?) (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l-(pyridin-2-yl)ethyl)moi holine-2- carboxamide;
(2i?) ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(^yridin-2-ylmethyl)morpholine-2- carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((6-methylpyridm-2- yl)methyl)morpholine-2-carboxamide;
(2i?, ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((l-methylpiperidin-2- yl)methyl)moipholine-2-carboxamide;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((3-methylpyridin-2- yl)methyl)morpholine-2-carboxamide;
(2i?, (5i?)-N-(4-cyano-7H-pyrazol-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmoi holine^ 2-carboxamide;
(2R, 5i?)-4-(8-cyanoquinolin-5-yl)-N-((J5', ^)-4-fluoro-l -methylpyrrolidin-3-yl)-6- methylmoipholine-2-carboxamide;
(2^) ^)-4-(8-cyanoquinolin-5-yl)-N (J5,^i?)-4-fluoiOpiperidin-3-yl)-N,6- dimethylmorpholine-2-carboxamide hydrochloride; 5-((2i?, <ii?)-2-(3-(ammomethyl)azetid^
8-carbonitrile;
5-((2i?, (ii?)-2-(3-((ethylamino)methyl)azetidine-l-carbonyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (5i?)-2-(3-((dimethylamino)methyl)azetidine-l-carbonyl)-6- methylmoipholino)quinoline-8-carbonitrile;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l-methylazepan-4-yl)moipholine-2- carboxamide;
(2R, 5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(((2i?, (ii?)-6-methylmorpholin-2- yl)methyl)moipholine-2-carboxamide;
5-((2i?, (5i?)-2-metb.yl-6-(octahydiOpyi olo[3,4-c]pyiTole-2- carbonyl)moipholino)quinoline-8-carbonitrile;
(2i?, (ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(f ^-pynOlidin-2- ylmethyl)morpholine-2-carboxamide hydrochloride;
(2i?, 6i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-^^
2-carboxamide hydrochloride;
(2i?) ^)-N-((ii?,3i?)55)-8-azabicyclo[3.2.1]octan-3-yl)-4-(8-cyanoquinolin-5-yl)-6- methylmoipholine-2-carboxamide hydrochloride;
(2i?, (5i?)-N-(azepan-4-yl)-4-(8-cyanoqumolm-5-yl)-6-methylmoipholine-2- carboxamide hydrochloride;
(2R, 6R)-N-((1R, 5S, 6S)-3-azabicyclo[3.1.0]hexan-6-yl)-4-(8-cyanoquinolin-5-yl)-6- methylmorpholiiie-2-carboxamide hydrochloride;
(2R, 0i?)-4-(8-cyanoquinolin-5-yl)-N-6-dimethylmorpholine-2-carboxamide;
(2i?, ^-4-(8-cyanoquinolin-5-yl)-N-^
6-methylmorpholine-2-carboxamide;
5-((2R, (5i?)-2-(4-(dimethylamino)piperidine- 1 -carbonyl)-6- methylmorpholino)quinoline-8-carbonitrile;
(2i?, (ii?)-4-(8-cyanoquinolin-5-yl)-6-n ethyl-N-(l-methylpiperidin-4-yl)moipholine-2- carboxamide;
(2i?, i?)-4-(8-cyanoquinolin-5-yl)-N-((35,,^)-4-fluoiOpyrrolidin-3-yl)-6- methylmorpholine-2-carboxamide hydrochloride;
(2i?) ^)-4-(8-cyanoquinolin-5-yl)-N-((35')^)-4-fluoiOpiperidin-3-yl)-6- methylmorpholine-2-carboxamide hydrochloride; (2i?, ii?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-azaspiiO[3.3]heptan-6- yl)morpholine-2-carboxamide hydrochloride;
(2i?, ( i?)-N-(l-(2-amino-2-oxoethyl)piperidin-4-yl)-4-(8-cyanoquinolin-5-yl)-6- metliylmorpholine-2-carboxamide;
5-((2i?, (5i?)-2-(4-aminopiperidine-l-carbonyl)-6-methylmoipholino)quinoline-8- carboniti'ile;
5-((2i?J (5i?)-2-(4-amino-4-methylpiperidine-l-carbonyl)-6- methylmoi holino)quinoline-8-carbonitrile;
(2R, (5i?)-4-(8-cyanoquinolin-5-yl)-N,6-dim
carboxamide hydrochloride;
(2i?, (5i?)-N-(2-carbamoylpyridin-4-yl)-4-(8-cyanoquinolm-5-yl)-6-methylmoipholme- 2-carboxamide hydrochloride;
(2R, <5i^)-4-(8-cyanoquinolin-5-yl)-N-6-dim
carboxamide hydrochloride;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-N-(l-ethylpiperidin-4-yl)-6-methylmoipholine-2- carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-N-(l-ethylpiperidin-3-yl)-6-methylmoipholine-2- carboxamide;
(2i?, 5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((2^-l-methylpiperidin-3- yl)morpholine-2-carboxamide hydrochloride;
(2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(4-methylpiperidin-4-yl)moipholine-2- carboxamide;
(2i?, i?)-N-(2-amino-2-methylpropyl)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholine- 2-carboxamide;
rcl-(2^ ^)-4-(8-cyanoquinolin-5-yl)-N-((5i?^5)-4-fluoropyrrolidin-3-yl)-6- methylmorpholine-2-carboxamide hydrochloride;
rel-(2i?) ^)-4-(8-cyanoquinolin-5-yl)-N-((35, )¥i?)-4-fluoiOpyi olidin-3-yl)-6- methylmoipholine-2-carboxamide hydrochloride;
(2i?, (ii?)-N-(azepan-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholme-2- carboxamide hydrochloride;
(2 ?, 5 ?)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(l-methylazepan-3-yl)rno holine-2- carboxamide hydrochloride;
(2i?, <5i?)-4-(8-cyanoquinolin-5-yl)-iV-(l,4-dimethylpiperidin-4-yl)-6- methylmorpholine-2-carboxamide; and (2R, <5i?)-4-(8-cyanoqumolm-5-yl)-N-(4-fluoiO- 1 -methylpiperidin-3 -yl)-6- metliylmoipholine-2-carboxamide hydrochloride.
4. The compound of claim 3, wherein said compound is selected from the group consisting of rel-(2i?; <5i?)-4-(8-cyanoquinolin-5-yl)-N-((3i?, iS)-4-fluoiOpyiTolidin-3-yl)-6- methylmorpholine-2-carboxamide hydrochloride and (2i?, (5i?)-4-(8-cyanoquinolin-5-yl)-6- methyl-N-(l-methylpiperidin-4-yl)moipholine-2-carboxamide.
5. A compound of Formula (Ie), with relative stereochemistry indicated:
Figure imgf000149_0001
6. A compound of Formula (II):
Figure imgf000149_0002
wherein
R is -H or methyl;
R5 is C1-C5 alkyl that is saturated, partially saturated, or unsaturated, and that is optionally substituted with:
-H, -CI, -F, -OH, -NH2, oxo-, -N(CH2CH3)2, phenyl, cyclohexyl, phenyltriazolyl, cyclohexyltriazolyl, pyridinyl, pyrrolidinyl,
morpholinyl optionally substituted with methyl or hydroxymethyl,
-0-, substituted with: Ci-C6 alkyl, methylphenyl, methylcyclohexyl, pyridinyl, diazinyl, or phenyl optionally substituted with -F or methyl,
-NH-, substituted with:
C2-C alkyl that is linear, branched, or cyclic, saturated or unsaturated, and optionally substituted with oxo-, phenyl, methyl, or -OH,
pyridinyl optionally substituted with methyl, methoxy, phenyl, or amino, diazinyl optionally substituted with ethyl,
benzoimidazolyl, methylphenyl, phenylpyrazolyl, naphthyridyl, phenyl optionally substituted with -F, methyl, ethyl, or ethoxy, imidazolidinyl optionally substituted with methyl
Figure imgf000150_0001
or R5 is . , wherein n is 1-3, and wherein the cyclic amine is optionally substituted with
Ci-C3 alkyl optionally substituted with
-OH, -F, phenyl, -NH2, cyclohexyl, -N(CH3)2, -C(0)NH2, methylsulfonamidyl, benzenesulfonamidyl, methylbenzenesulfonamidyl, or
pyrrolidinyl optionally substituted with methyl or hydroxyl, or -NHC(0)R6, wherein R6 is
C1-C5 alkyl, phenyl, pyridinyl, fluorophenyl, methylsulfonyl, fluorobenzenesulfonyl, dimethyl pyrazole sulfonyl, or
pyrazolyl optionally substituted with methyl;
piperidinyl optionally -C(0)CH2CH3, methyl, oxo-,
C(0)Ph, -NH2, -NH-C(0)CH3,
Figure imgf000150_0002
piperazinyl optionally substituted with -C(0)OC(CH3)3, methyl, -C(0)CH3, -C(0)Ph, C(0)CH(CH3)2, -C(0)CH3, or methylsulfonyl; or R5 is
Figure imgf000151_0001
, where n is 1 or 2, and wherein the cyclic diamine is optionally substituted on at least one carbon atom with
methyl, oxo-, -N(CH3)2, amino, -CH2CH3, or
piperidinyl optionally substituted with methyl, -C(0)CH3, -C(0)CH(CH3)2, -C(0)Ph, or -C(0)OC(CH3)3, and
wherein R7 is -H, phenyl, -C(0)CH3, d-C3 alkyl, -C(0)NH2, or -C(0)Ph; and R8 is methoxy or cyano.
7. The compound of claim 3, wherein said compound is selected from the group consisting of:
5-((2i?, (55 -2,6-dimethylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (55 -2,6-dimethylmoi holino)quinoline-8-carbonitrile dihydrochloride;
5-((2i?, 5')-2,6-dimethylmorpholino)quinoline-8-carbonitrile methanesulfonate;
5-((2i?, (55)-2,6-dimethylmorpholino)quinoline-8-carbonitrile bis(2,2,2- trifluoroacetate);
5-((2i?, ^5)-2,6-dimethylmorpholino)quinoline-8-carbonitrile bis(sulfonate);
5-((2i?, (55)-2,6-dimethylmoipholino)quinoline-8-carbonitrile sulfonate;
5-((2S, (5i?)-2,6-dimethylmoipholino)quinoline-8-carbonitrile 2,3-dihydroxysuccinate; 5-((25', ^-2,6-dimethylmoipholino)quinoline-8-carbonitrile dimethanesulfonate; 5-(2-(chloromethyl)morpholino)quinoline-8-carbonitrile;
(¾)-5-(2-(chloromethyl)moipholino)quinoline-8-carbonitrile;
N-( (^2S, ^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)methyl)acetamide; N-( (^25', 6^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholm-2-yl)methyl)pivalam 5 -(2-methylmoipholino)quinoline- 8 -carbonitrile;
5-(( 5 ^-2,6-dimethylmoipholino)quinoline-8-carbonitrile;
5-(2-ethylmorpholino)quinoline-8-carbonitrile;
5-((2£, 6i^-2-(aminomethyl)-6^
5-(2-(hydiOxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile;
(2R, (55 -4-(8-methoxyquinolin-5-yl)-2,6-dimethylmorpholine;
5-((2i?, (i(S)-2,6-dimethylmoipholino)quinoline-8-carboxamide; ( ^-5-(2-methylmoi holino)quinoline-8-carbonitrile;
5-((2i?,(5i?)-2-(hydiOxymetliyl)-6-methylmoipholino)quinolme-8-carbonitrile;
5-((2i?,(ii?)-2-(methoxymethyl)-6-methylmoi holino)quinoline-8-carbomtrile; 5-((2i?)^)-2-((benzyloxy)methyl)-6-methylmoi holino)quinoline-8-carbonitrile; 5-((2i?)6^i?)-2-(fluoiOmethyl)-6-methylmoipholino)quinoline-8-carbonitrile;
5-((2i?,(ii?)-2-(ethoxymethyl)-6-methylmoipholino)quinoline-8-carbonitrile;
5-((2i?,(5i?)-2-(isopi poxymethyl)-6-methylmorpholino)quinoline-8-carbonitrik 5-((2i?,^i?)-2-(isobutoxymethyl)-6-methylmoipholino)quinoline-8-carbonitrile; 5-((2i?,(5i?)-2-(chloi methyl)-6-methylmoipholino)quinoline-8-carbonitrile;
5-((2i?)<5i?)-2-((hexyloxy)methyl)-6-methylmoipholino)quinoline-8-carbonitrile; 5-((2ii)ii?)-2-((cycloliexylmethoxy)methyl)-6-methylmoipholino)quinoline-8- carbonitrile;
5-((2i?,(55 -2-methyl-6-piOpylmoipholino)quinoline-8-carbonitrile;
5-(( 5',^-2-(fluoi methyl)-6-methylmoipholino)quinoline-8-carbonitri^
5-((^2¾55^-2-(chloromethyl)-6-methylmorpholino)quinoline-8-carbonitrile;
5-((2i?,(ii?)-2-((2,6-din ethylphenoxy)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2i?,i!S)-2,6-diethylmoipholino)quinoline-8-carbonitrile;
5-((2i?,6^5 -2-methyl-6-pentylmorpholino)quinoline-8-carbonitrile;
5-((2i?,(ii?)-2-formyl-6-methylmoipholino)quinoline-8-carbonitrile;
5-((2i?, i?)-2-((benzyloxy)methyl)-6-ethylmoipholino)quinoline-8-carbonitrile; N-( (^25,,5i^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)meth^
phenylpropanamide;
5-((2i?,(5i?)-2-(l-hydiOxyallyl)-6-methylmoipholino)quinoline-8-carbonitrile;
5-((2i?,67?)-2-((3^-l-hydiOxyallyl)-6-^
N-( (25',(5i^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)met^^
phenylcyclobutanecarboxamide;
5- 2R, 6R)-2-((R)- 1 -hydiOxyallyl)-6-methylmorpholino)quinoline-8-carbonitrile;
5 -((2R, <5<S)-2-methyl-6-(pyrrolidin- 1 -ylmethyl)morpholino)quinoline-8-carbonitrile;
5-((25')^-2-((diethylamino)methyl)-6-methylmoipholino)quinoline-8-carbo
5-((25',ii^-2-((benzylamino)methyl)-6-metliylmoipholino)qumolme-8-carb
5-((2i?,(ii?)-2-methyl-6-(phenoxymethyl)moipholino)quinoline-8-carbonitrile;
5-((2i?,(5i?)-2-methyl-6-((m-tolyloxy)m
5-((2i?,<5i?)-2-methyl-6-((p-tolyloxy)m 5-((2i?, <5i?)-2-(l -hydiOxypropyl)-6-m
5-{{2R, 6R)-2-((R)- 1 -hydiOxypentyl)-6-methylmorpholino)quinoline-8-carbonitrile; 5-((2R, 6R)-2-{(S)- 1 -hydi xypentyl)-6-methylmorpholino)quinoline-8-carbonitrile; 5-((2i?, 6i?)-2-((7^-cyclohexyl(hydroxy)m
carbonitrile;
5-((2i?J ii?)-2-((5^-cyclohexyl(hydiOxy)methyl)-6-methylmoi holino)quinoline-8^ carbonitrile;
N-ll^S, (5i^-4-(8-cyanoquin^
phenylacetamide;
5-((2R, 6R)-2- (R)- 1 -hydi xy-2-phenylethyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2i?) 5i?)-2-((¾^-l-hydiOxy-2-phenylethyl)-6-methylmoipholino)quinolm^ carbonitrile;
5-((2i?, (5ii)-2-(( ^)-1 iydroxy-3-phenylpiOpyl)-6-methylmoi holino)quinoline-8- carbonitrile;
5-((2i?, ^)-2-((^-l-hydiOxy-3-phenylpropyl)-6-methylmoipholino)quinoline-8- carbonitrile;
5-((2i?) 55 -2-methyl-6-((phenylamino)methyl)morpholino)quinoline-8-caA
5-((2i?; (55 -2-methyl-6-((m-tolylamino)methyl)moi holino)quinoline-8-carbonitri
5-((2i?; <i£)-2-methyl-6-((o-tolylamino)methy^
5-((2i?, ^-2-methyl-6-((p-tolylamino)methyl)moi holino)quinoline-8-carbonitrile; 5-((2i?, (¾)-2-((3,4-difluoiOphenoxy)methyl)-6-methylmorpholino)quin^ carbonitrile;
5-((2i?, i?)-2-((3-fluoi phenoxy)methyl)-6-methylmoi holino)quinoline-8- carbonitrile;
5-((2^ 5i? -2-(((l,2-dimethyl-7H-benzo[d]imidazol-5-yl)amino)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-((25, (5^-2-(((l-ethyl-2-methyl-iH-benzo[d]imidazol-5-yl)amino)methyl)-6- methylmoi holino)quinoline-8-carbonitrile;
5-((2¾ <5i^-2-((cyclohexylamino)m
carbonitrile;
5-((2i?, ^)-2-((2-fluorophenoxy)methyl)-6-methylmoipholino)quinoline-8- carbonitrile;
5-((2i?, (5i?)-2-methyl-6-propionylmoipholino)quinoline-8-carbonitrile 5-((2i?, i?)-2-(cyclohexanecarbonyl)-6-methylmoi holino)quinoline-8-carbonitrile; 5-((2i?, ^)-2-methyl-6-(3-phenylpiOpanoyl)morpholino)quinoline-8-carbonitri 5-((2i?, 6 ?)-2-methyl-6-((o-tolyloxy)m
Figure imgf000154_0001
carbonitrile;
5-((2i?, 6^5)-2-methyl-6-((pyiidin-2-ylamino)methyl)moipholino)quinoline-8- carbonitrile;
5-((2i?, (5.S -2-methyl-6-(((6-methylpyridin-2-yl)amino)methyl)moipholino)qui 8-carbonitrile;
5-((2i?, d5)-2-methyl-6-(((5-methylpyiidin-2-yl)amino)methyl)moi holino)qui 8-carbonitrile;
5-( 25, ) ^ -2-(((2? -2-(hydroxymethyl)pyiTolidin-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2R, dJ?)-2-((2,2-dimethylpyrrolidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2S, (5i?)-2-((2-isopiOpylpyiTolidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2i?, 6S)-2-metihyl-6-(((S^
carbonitrile;
5-((2R, (55 -2-methyl-6-(((¾)-3 -phenylpyrrolidin- 1 -yl)methyl)morpholino)quinoline-8- carbonitrile;
5-((2i?, (5S -2-methyl-6-(((2^-3-me
carbonitrile;
5-((2£, 6 ^-2-(((^-3-l^
8-carbonitrile;
5-((2i?, (55 -2-methyl-6-(((4-methylpyridin-2-yl)amino)methyl)moipholino)qui 8-carbonitrile;
5-((2i?, 6iS)-2-methyl-6-((3-phenylpyrroM
carbonitrile;
5-((21S, (5i?y)-2-(((6-methoxypyridin-3-yl)amino)methyl)-6- methylmoi'pholino)quinoline-8-carbonitrile;
5-((2R, (55 -2-methyl-6-(((¾)-2-methylpyiTolidin- 1 -yl)methyl)moi holino)quinoline-8- carbonitrile; 5-((2S, <5i? -2-((2,5-dimethylpyiTolidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2tS', (5i? -2-(((4-methoxypyridin-2-yl)amino)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
Figure imgf000155_0001
methylmorpholino)quinoline-8-carbonitrile;
5-((2R, d5)-2-methyl-6-(((l -phenyl-iH-pyrazol-5- yl)amino)methyl)morpholino)quinoline-8-cai-bonitrile;
5-((2S, 5i? -2-(((S 2-(hydroxymethyl)pyrrolidin- 1 -yl)methyl)-6- methylmorpholino)quinoline- 8 -carbonitrile ;
5-((25, ) 5i?^-2-((( ?j-3-hydiOxypyiiOlidin-l-yl)methyl)-6-methylm
8-carbonitrile;
5-((2i?, (55 -2-methyl-6-(((¾^-3-methylpynOlidin-l-yl)methyl)mo
carbonitrile;
5-((2S, 6R)-2-{{ ,3 -dimethylpyrrolidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2R, 6R)-2-met yl-6-((R)-3 -phenyl- 1 -(pyrrolidin- 1 - yl)propyl)moi holino)quinoline-8-carbonitrile;
5-((2i?) ^)-2-methyl-6-(f¾)-3-phenyl-l-(pyrrolidin-l- yl)propyl)moipholino)quinoline-8-carbonitrile;
5-((2S, 6R)-2-(((3 -methoxypyridin-2-yl)amino)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
Figure imgf000155_0002
8-carbonitrile;
5-((2S, 6R)-2-{{(2R, tfS)-2,6-dimethylpiperidin-l -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2S, 6^-2-(((S^-3-hydroxypiperidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2S, 6i? -2-((4-hydroxypiperidm^
carbonitrile;
5-((2S, (5i? -2-((2-(hydiOxymethyl)piperidin- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (55 -2-methyl-6-((2-methylpiperidin-l-yl)methyl)moi holino)quinoli carbonitrile; 5-((2S, 6i? -2-((2-ethylpiperidin- 1 -yl)methyl)-6-methylmoipholino)quinoline-8- carbonitrile;
5-((2S, 6i^-2-((2,3-dimethylp^
carbonitrile;
5-((2i?, 5 -2-methyl-6-((pyridin-3-ylamino)methyl)morpholino)quinoline-8- carbonitrile;
Figure imgf000156_0001
carbonitrile;
5-((2R, 6^S)-2-methyl-6-(((S -2-(trifluoiOmethyl)pynOlidin- 1 - yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2R, (5<S)-2-methyl-6-((4-methylpiperidin- 1 -yl)methyl)morpholino)quinoline-8- carbonitrile;
5-((2S, tfiy-2-((4,4-difluorop^
carbonitrile;
5-((2R, (55 -2-methyl-6-((4-phenylpiperidin- 1 -yl)metliyl)moipholino)quinoline-8- carbonitrile;
5-((2S, (5i?)-2-((4-fluoiOpiperidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-(f25,, ii?j-2-((cyclopen1ylamino)methyl)-6-methylmoipholino)quinoline-8- carbonitrile;
5-((2i?, (55 -2-methyl-6-(((3-methylcyclohexyl)amino)methyl)moipholino) carbonitrile;
5-((2i?) 5 -2-methyl-6-(((3-methylpyiidin-2-yl)amino)methyl)morpholino)quinoline- 8-carbonitrile;
5-((2i?, ^)-2-ethyl-6-(hydiOxymethyl)moipholino)quinoline-8-carbonitrile;
5-((2i?, (55 -2-methyl-6-(((4-phenylpyridin-2-yl)amino)methyl)moipholino)qui 8 -carbonitrile;
5-((2R, (55)-2-methyl-6-(piperazin- 1 -ylmethyl)morpholino)quinoline-8-carbonitrile;
5-((2i?, (55)-2-methyl-6-((4-phenylpiperazin-l-yl)methyl)moipholino)quinoline-8- carbonitrile;
Figure imgf000156_0002
8-carbonitrile;
5-((2S, <ii?j-2-((2,5-dimethylpiperazin- 1 -yl)methyl)-6-methylmoipholino)quinoline-8- carbonitrile; 5-((2S, di?)-2-((4-acetylpiperazin- 1 -yl)methyl)-6-methylmoipholino)quinoline-8- carbonitrile;
5-( 2£ 6.K 2-(((2S,4R)-4½droxy^
methylmoipholino)quinoline-8-carbonitrile;
5-((2R, 5S)-2-methyl-6-((f2? )-2-methylpiperazin- 1 -yl)methyl)morpholino)quinoline-8- carbonitrile;
5-((2i?, 5 -2-methyl-6-(((¾)-3-methylpiperazin-l-yl)methyl)moi hol^
carbonitrile;
5-((2R, 6S)-2-methyl-6-(((S^-3 -methylpiperazin- 1 -yl)methyl)morpholino)quinoline-8- carbonitrile;
5-((25') ^ -2-(((2R,5R)-2,5-dimethylpiperazin-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2S, ^ 2-(((2R,5S)-2,5-dimethylpiperazin-l -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (55)-2-methyl-6-(((4-methylcyclohexyl)amino)methyl)moipholino)quinoline-8- carbonitrile;
5-((25,, i^-2-((cyclobutylamino)methyl)-6-methylmoipholino)q
carbonitrile;
5-((2&, <5i?J-2-((cycloheptylamm^
carbonitrile;
5-(( S, i? -2-(((4-hydiOxycyclohexyl)amino)me1hyl)-6-methylm
8-carbonitrile;
5-((^2,¾ (5i^-2-(((2-hydiOxycyclopentyl)amino)methyl)-6-methylmoipholino)qm 8-carbonitrile;
5-((2i?, 5)-2-methyl-6-(((2-methylcyclohexyl)amino)methyl)moipholino)quinolin^ carbonitrile;
5-((2R, 6S)-2-methyl-6-(((5 -phenylpyridin-2-yl)amino)methyl)morpholino)quinoline- 8-carbonitrile;
5-((2i?, lS -2-methyl-6-(((3-phenylpyridin-2-yl)amino)methyl)moipholino)quinoline- 8-carbonitrile;
5-(f25') 5i? -2-((((l S,3R)-3-hydiOxycyclopentyl)amino)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-((21S, ) (5i^-2-(((3-ethoxypyridin-2-yl)amino)methyl)-6-methylmorpholino)qum^ 8-carbonitrile; 5-((2i?) 55 -2-methyl-6-(((2-p enylpyridin-4-yl)amino)methyl)moipholino)quinoline- 8-carbonitrile;
5-((2 ?, 6^5 -2-methyl-6-(((6-phenyl ylidin-2-yl)amino)methyl)mo l olino)quinoline- 8-carbonitrile;
(^-5-(2-((pyi din-2-ylamino)methyl)moipholino)quinoline-8-carbonitrile;
5-((2i?, (55 -2-methyl-6-((2-methyl-5-oxopiperazin-l-yl)methyl)moipholino)qm 8-carbonitrile;
5-((2R, )S -2-methyl-6-((4-methylpiperazin- 1 -yl)methyl)morpholino)quinoline-8- carbonitrile;
5-((2R, < S)-2-methyl-6-((4-propylpiperazin- 1 -yl)methyl)morpholino)quinoline-8- carbonitrile;
5-((2S, <5i^-2-((4-(dimethylamino)piperidin- 1 -yl)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-(( S,, ^-2-([l,4'-bipiperidin]- -ylmethyl)-6-methylmoipholino)
carbonitrile;
Figure imgf000158_0001
carbonitrile dihydrochloride;
5-((2S, 6R)-2-(((R)-3-ai nopipend A-y\)methyfy
carbonitrile;
(2R, 6^S -4-(8-chloro-l,7-naphtb.yridin-5-yl)-2,6-dimethylmoipholine;
5-((2S, 6^)-2-((4-aminopiperidin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((^5', 5i^-2-(((5-fluoiOpyrimidin-2-yl)amino)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2R, (55)-2-methyl-6-(piperidin- 1 -ylmethyl)morpholino)quinoline-8-carbonitrile; 5-((2i?, 6S)-2-methyl-6-(moipholino
5-((2S, 6R)-2-(((2S, (ii? -2,6-dimethylmoipholino)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-((25, ) 5i? -2-(((2i?) ^)-2-(hydroxymethyl)-6-methylmorpholino)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-((2R, (55 -2-methyl-6-((4-(pyridin-2-yl)piperazin- 1 -yl)methyl)morpholino)quinoline- 8-carbonitrile;
5-((2R, <55f)-2-methyl-6-((4-(pyridin-4-yl)piperazin- 1 -yl)methyl)moipholino)quinoline- 8 -carbonitrile; N-(l-(((2$ 6i? -4-(8-cyanoquinolm^
yl)acetamide;
N-(^l-((^251, (5i^-4-(8-cyanoquinolin-5-yl)-6-methylmoi holin-2-yl)met^^
yl)acetamide hydrochloride;
5-((2S, 6^-2-(((l,8-naphthyridin^
8-carbonitrile;
1 -(((2S, <5i? -4-(8-cyanoquinolin-5 -yl)-6-methylmorpholin-2-yl)methyl)piperidine-4- carboxamide;
N-( -(((^S, <5i? -(8-cyanoquinoH^
yl)benzamide;
5-((2S, 6R) -2-((4-isopropylpiperazin- 1 -yl)methyl)-6-methylmoi holino)quinoline-8- carbonitrile;
4- (( 25, i? -4-(8-cyanoquinolin-5-yl)-6-methylmoi holin-2-yl)methyl)piperaz carboxamide;
5- ((^25') (5i^-2-((4-cyclohexylpipendin-l-yl)methyl)-6-methylmorpholino)qu^ carbonitrile;
5- {2R, <55)-2-methyl-6-((4-(pyiTolidin- 1 -yl)piperidin- 1 - yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2R, di?)-2-((4-cyclohexyl-;H- 1 ,2,3-triazol- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2R, i?)-2-methyl-6-((4-phenyl-iH-l ,2,3-triazol- 1- yl)methyl)moi holino)quinoline-8-carbonitrile;
5-{ 2R, ( .S)-2-methyl-6-((2-oxo-[l ,4'-bipiperidin]-l '-yl)methyl)morpholino)quinoline- 8-carbonitrile;
5-((¾ (5i? -2-(((5-ethylpyrimidin^
8-carbonitrile;
5-(( 1¾ 6^-2-(((6-amino-3,5-dimethylpyridin-2-yl)amino)methyl)-6- methylmoi holino)quinoline-8-carbonitrile;
5-((2i?, (55)-2-methyl-6-((pyrazin-2-ylamino)methyl)moi holino)quinoline-8- carbonitrile;
5-(( 5', ii?j-2-(((l,3-dimethyl-77J-pyrazol-5-yl)amino)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2R, 7i?)-2-(hydroxymethyl)-7-methyl- 1 ,4-oxazepan-4-yl)quinoline-8-carbonitrile; 5-((2S, (5i? -2-((4-ethylpiperazm- 1 -yl)methyl)-6-methylmoi-pholino)quinoline-8- carbonitrile;
Figure imgf000160_0001
yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2i?, 5)-2-methyl-6-((3-(piperidin-l-yl)azetidin-l- yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2S, ^ 2-((^ -2,4-dimethylpiperazin- 1 -yl)methyl)-6- methylmoipholino)quinoline- 8 -carbonitrile ;
5-((2S, (5i?)-2-((4-(hydiOxymethyl)piperidin- 1 -yl)methyl)-6- methylmorpholino)quinoline- 8 -carbonitrile ;
5-((2¾ (5i?)-2-((7? - [ 1 ,3 '-bipy^
carbonitrile;
5-((2i?, ^-2-methyl-6-((f7? -3-( iperidin-l-yl)pyriOlidin-l- yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2i?, (5S)-2-methyl-6-((4-methyl-l,4-diazep
carbonitrile;
5-((2S, 5i^-2-((4-benzoylpiperazin- 1 -yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile;
N-( 1 -(((2S, 6i^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)methyl)piperidm^ yl)nicotinamide;
N-(l-(((25', (5iy-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)methyl)pi^ yl)isonicotinamide;
N-(l-(((^25') ^-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)pi^ yl)picolinamide;
N-(l-((( 5,, ^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)methyl)piperi yl)hexanamide;
N-(l-(((^21S', ^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)methyl)^ yl)isobutyramide;
N-(l-((( 5', ^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)meth^
yl)isobutyramide hydrochloride;
N-(l-((( (S', (5i^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)methyl)pipeiM^ yl)pivalamide;
5-((2S, 7i?)-2-([l,4'-bipiperidin]- -ylmethyl)-7-methyl-l,4-oxazepan-4-yl)quinoline-8- carbonitrile; 5 -{{2R, 55 -2-methyl-6-((4-moi holinopiperidin- 1 -yl)methyl)moi holino)quinoline-8- carbonitrile;
tert-butyl 4-(\-(((2S, (5i?/)-4-(8-cyanoquinolin-5-yl)-6-methylmoi-pholin-2- yl)methyl)piperidin-4-yl)piperazine- 1 -carboxylate;
tert-bu yl 4-(4-((( S, i?^-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2- yl)methyl)piperazin- 1 -yl)piperidine- 1 -carboxylate;
5-((2R, (55 -2-methyl-6-((4-(piperazin- 1 -yl)piperidin- 1 - yl)methyl)moi holino)quinoline-8-carbonitrile;
5-((2R, (55)-2-metb.yl-6-((4-(piperidin-4-yl)piperazin- 1 - yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2R, jS)-2-methyl-6-((3-(4-methylpiperazin-l -yl)azetidin- 1 - yl)methyl)morpholino)quinoline-8-carbonitrile;
5 -((2S, 6R) -2-( [4,4'-bipiperidin] - 1 -ylmethyl)-6-methylmorpholino)quinoline-8- carbonitrile;
5-((2S, ^ -2-((r-acetyl-[4,4'-bipiperidin]-l -yl)methyl)-6- methylmoi holino)quinoline-8-carbonitrile;
5-((2R, i(S)-2-methyl-6-((r-methyl-[4,4'-bipiperidin]- 1 - yl)methyl)moi*pliolino)quinoline-8-carbonitrile;
5-((2R, (5(S -2-methyl-6-((3 -(piperazin- 1 -yl)azetidin- 1 - yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2S, ( i? -2-((3-(4-acetylpiperazin- 1 -yl)azetidin-l -yl)methyl)-6- methylmoi holino)quinoline-8-carbonitrile;
5-(f25, ) ^;-2-((r-isobutyryl-[4,4'-bipiperidin]-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2S, (ii?)-2-((3-(4-benzoylpiperazin- 1 -yl)azetidin- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((21S') ^ 2-((r-benzoyl-[4,4'-bipiperidin]-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (5¾-2-methyl-6-((4-(l-methylpiperidin-4-yl)piperazm-l- yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2S, 6R)-2-((4-(l -acetylpiperidin-4-yl)piperazin- 1 -yl)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-((2S, 6R)-2- {4-{\ -isobutyrylpiperidin-4-yl)piperazin- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile; 5-(( i¾ i?J-2-((4-(l-benzoylpiperidin-4-yl)piperazin-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2S, <5i^-2-((3-(4-isobutyiylpiperazin- 1 -yl)azetidin- 1 -yl)methyl)-6- methylmoi-pholino)quinoline-8-carbonitrile;
5-((2S, <5i^-2-((4-(4-acetylpiperazin- 1 -yl)piperidin- 1 -yl)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-((2S, ii?)-2-((4-(4-isobutyrylpiperazin- 1 -yl)piperidin-l -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((25, (5i? -2-((4-(4-benzoylpiperazin-l-yl)piperidin-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2R, 6S)-2-methyl-6-((4-(4-methylpiperazin- 1 -yl)piperidin- 1 - yl)methyl)moipholino)quinoline- 8 -carbonitrile ;
5-((2R, (55)-2-methyl-6-((4-(4-methylpiperazin- 1 -yl)piperidin- 1 - yl)methyl)moipholino)quinoline-8-carbonitrile trihydrochloride;
5-(( 5, d ?j-2-([l,4'-bipiperidin]-l,-ylmethyl)-6-methylmorpholino)-2- methylquinoline-8-carbonitrile;
N-((R)- 1 -d(2S, (ii? -4-(8-cyanoqumolin-5-yl)-6-methylmorpholin-2- yl)methyl)pyiTolidin-3-yl)acetamide;
N-((R)- 1 -(((2S, (5i?)-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2- yl)methyl)pyrrolidin-3-yl)isobutyramide;
5-((2R, dS)-2-methyl-6-((^ 3 -(piperidin- 1 -yl)pyrrolidin- 1 - yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2R, 6S)-2-methyl-6-(((S)-3 -(piperidin- 1 -yl)pyrrolidin- 1 - yl)methyl)morpholino)quinoline-8-carbonitrile dihydrochloride;
5-((2i?, (5lS -2-methyl-6-((3-moipholinoazetidm-l-yl)methyl)moipliolino)qm carbonitrile;
5-((2R, d5)-2-methyl-6-((3 -((¾)-2-methylpyrrolidin- 1 -yl)azetidin- 1 - yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2R, (55 -2-methyl-6-(((¾)-2-methylpiperazin- 1 -yl)methyl)moipholino)quinoline-8- carbonitrile;
5-(^ ^ -2-(((S -2,4-dimethylpiperazin-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((25', 5i? -2-(((¾ -3,4-dimethylpiperazm-l-yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile; 5-((25, ) ^ -2-(((S -3,4-dimethylpiperazin-l-yl)methyl)-6- methylmoipholino)quinoline-8-carbonitrile;
5-(( £, 6i^-2-(((¾^-3-ethylpipe
carbonitrile;
5-((2S, <5i^-2-(((S^-3-ethylpiperazm^
carbonitrile dihydrochloride;
5-((2S, 6R)-2-(((S)-3 -ethyl-4-methylpiperazin- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2S, i? -2-((4-(azepan-l-yl)piperidin-l-yl)methyl)-6-me1iiylm
8-carbonitrile;
5-((2S, 6R)-2-((S)-[l '-bipynolid ]A'-ylme†h^
carbonitrile;
5-(( lS', ii?^-2-((3-(4-aminopiperidin-l-yl)azetidin-l-yl)metliyl)-6- methylmoipholino)quinoline-8-carbonitrile;
N-(l -(1 -{{(2S, 6 ?)-4-(8-cyanoquinolin-5-yl)-6-methylm
3-yl)piperidin-4-yl)acetamide;
5-((2R, (55 -2-methyl-6-((3 -(4-(methylsulfonyl)piperazin- 1 -yl)azetidin- 1 - yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2S, ^ -2-((3-(f¾)-3-hydiOxypyrrolidin-l -yl)azetidin- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
N-( 1 -(((2S, <5i^-4-(8-cyanoquinolin-5-yl)-6-methylm
yl)-l ,3 -dimethyl-7H-pyrazole-4-carboxamide;
N-(l-(l-(((2S, 6i?^-4-(8-cyanoquinolm^
3-yl)piperidin-4-yl)-l,3-dimethyl-iH-pyrazole-4-carboxamide;
N-( 1 -(((2S, ^)-4-(8-cyanoquinolin-5-yl)-6-methylmoi holin-2-yl)methyl)piperidin-4- yl)methanesulfonamide ;
N-(l-(((2>¾ 6^-4-(8-cyanoquinolm^
yl)benzenesulfonamide;
N-(l-((( ¾ 6^-4-(8-cyanoquinolm^
yl)-4-fluorobenzenesulfonamide;
5-((2S, 6i?^-2-((3-amu oazetidin-l-yl)meft^
carbonitrile;
N-(l-(((25 ^-4-(8-cyanoquinolin-5-yl)-6-methylmoi holin-2-yl)m
yl)acetamide;
Figure imgf000164_0001
yl)-4-fluorobenzamide;
N-(l-(( S, 6i^-4-(8-cyanoquinolin-5-yl)^^
yl)methanesulfonamide;
N-(l-(((^21S,, 5i^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)m
yl)-4-fluorobenzenesulfonamide;
N-(l-(((^2S, d^-4-(8-cyanoquinolin-5-yl)-6-methylmorp olin-2
yl)- 1 ,3 -dimethyl-iH-pyrazole-4-sulfonamide;
Figure imgf000164_0002
yl)- 1 ,3 -dimethyl-iH-pyrazole-4-sulfonamide;
N-(l-(((^25 ^-4-(8-cyanoquinolin-5-yl)-6-methylmoipholin-2-yl)meth^
yl)isobutyramide;
5-((2i?, (i5 -2-methyl-6-(( ¾)-2-methyl-5-oxopiperazm-l- yl)methyl)morpholino)quinoline-8-carbonitrile;
5-((2R, (51S)-2-methyl-6-((( ?)-2-methyl-5-oxopiperazin-l - yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2i?, ^-2-methyl-6-(((¾)-2-methyl-3-oxopiperazin-l- yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2R, 6S 2-methyl-6-(((Sj-2-methyl-3 -oxopiperazin- 1 - yl)methyl)moipholino)quinoline-8-carbonitrile;
5-((2i?, (55)-2-methyl-6-((2,4,5-trim
8-carbonitrile;
5-((2R, <5S)-2-methyl-6-((2,3 ,4-trimethylpiperazin- 1 -yl)methyl)moipholino)quinoline- 8-carbonitrile;
N-((7? -l-(( 25', ^ -4-(8-cyanoquinolin-5-yl)-6-methylmorpholm-2
yl)methyl)pyrrolidin-3-yl)benzamide;
5-((2S, 6R)-2-(((R)-3 -(dimethylamino)pyrrolidin- 1 -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
N-((S^-l-((( »S: 5i? -4-(8-cyanoquinolin-5-yl)-6-metliylmoipholin-2- yl)methyl)pyrrolidin-3-yl)acetamide;
N-((S)- 1 -{{(2S, (5i? -4-(8-cyanoquinolin-5-yl)-6-methylmoipliolm-2- yl)methyl)pyrrolidin-3-yl)isobutyramide;
N-((S)- 1 -{{(2S, di? -4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2- yl)methyl)pyrrolidin- 3 -yl)benzamide ; 5-((2¾ 5i? -2-(((S^-3-(dimethylamino)pyiTolidin-l -yl)methyl)-6- methylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (5i?)-2-methyl-6-((pyrazin-2-yloxy)methyl)moipholino)quinoline-8- carbonitrile;
N-(l -((( ¾ (5iy-4-(8-cyanoquinoK^
yl)benzamide;
5-(( S, 6i?)-2-((3,3-dimethylpi^^
carbonitrile dihydrochloride;
5-((2i?, d5)-2-methyl-6-((3,3,4- meth^
8 -carbonitrile dihydro chloride ;
5-((2R, 6R)-2-((R)- 1 -hydroxyethyl)-6-methylmoi holino)quinoline-8-carbonitrile; l-(((^1S, ) 5i^-4-(8-cyanoquinolin-5-yl)-6-methylmoi holin-2-yl)meth^
ethylpiperidine-4-carboxamide;
l-(((2S, d ^-4-(8-cyanoqu olin-5-yl)^^
ethylpiperidine-4-carboxamide hydrochloride;
5-((2R, 6R)-2-((S)- 1 -hydroxyethyl)-6-methylmorpholino)quinoline-8-carbonitrile;
5-((2i?, (5i?)-2-methyl-6-((pyridin-2-yloxy)methyl)morpholino)quinoline-8- carbonitrile;
5-((2i?, (5i?)-2-methyl-6-((pyiimidin-2-yloxy)methyl)moipholmo)quinoline-8- carbonitrile;
5-((2i?, <5i?)-2-methyl-6-((^^
carbonitrile;
5-((2i?, <5i?)-2-methyl-6-((3^-l-(pyri^^
carbonitrile; and
5-((2i?) ^)-2-((^-hydiOxy(pyridin-2-yl)methyl)-6-methylmorpholino)quinoline-8- carbonitrile.
8. The compound of claim 6, wherein said compound is selected from the group consisting of 5-((25 5i?)-2-([l,4'-bipipei in]- -ylmethyl)-6-methylmorpholino)quinoline-8- carbonitrile and 5-((2R, 7i?)-2-(hydroxymemyl)-7-methyl-l ,4-oxazepan-4-yl)quinoline-8- carbonitrile.
9. A compound of Formula (III):
Figure imgf000166_0001
wherein
Rn is H or methyl;
Rio is H or, when both Rn and R9 are H, is methyl- 1, 4 '-bipiperidinyl;
R9 is -H or is -C¾- substituted by 1,4 '-bipiperidinyl, oxo-, hydroxyl, methylpyridinyl, or piperidinyl optionally substituted with hydroxyl, -N(CH3)2, or piperidinyl.
10. The compound of claim 9, wherein said compound is selected from the group consisting of:
5-(3-([l,4'-bipiperidin]- -ylmethyl)phenyl)quinoline-8-carbonitrile;
5-(4-([l,4'-bipiperidin]- -ylmethyl)phenyl)quinoline-8-carbonitrile;
5-(3-formyl-5-methylphenyl)quinoline-8-carbonitrile;
5 -(3 -(hydroxymethyl) - 5 -methylphenyl)quinoline- 8 -carbonitrile ;
5-(3-(chloiOmethyl)-5-methylphenyl)quinoline-8-carbonitrile;
5-(3-((4-hydroxypiperidin-l-yl)methyl)-5-methylphenyl)quinoline-8-carbonitrile; 5-(3-((4-(dimethylamino)piperidin-l-yl)methyl)-5-methylphenyl)quinoline-8- carbonitrile;
5-(3-methyl-5-((4-methylpiperazin-l-yl)methyl)phenyl)quinoline-8-carbonitrile; and 5-(3-([l,4'-bipiperidin]- -ylmethyl)-5-methylphenyl)quinoline-8-carbonitrile.
11. A method for treatment of systemic lupus erythematosus or lupus, comprising administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of any one of claims 1-10.
12. The method of claim 11, wherein said compound is administered as a pharmaceutically acceptable salt.
13. A method for antagonizing TLR7, comprising administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of any one of claims 1- 10.
14. A method for antagonizing TLR8, comprising administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of any one of claims 1- 10.
15. A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt of any one of claims 1-10 and at least one pharmaceutically acceptable earner.
16. The pharmaceutical composition of claim 15, wherein said compound or pharmaceutically effective salt thereof has an IC50 less than or equal to 100 nM against human TLR7 receptors in a HEK-293 cell line.
17. The pharmaceutical composition of claim 15, wherein said compound or phamiaceutically effective salt thereof has an IC50 less than or equal to 20 nM against human TLR7 receptors expressed in a HEK-293 cell line.
18. The pharmaceutical composition of claim 15, wherein said compound or pharmaceutically effective salt thereof has an IC50 less than or equal to 5 nM against human TLR7 receptors expressed in a HEK-293 cell line.
19. The pharmaceutical composition of one of claims 16-18, wherein the IC50 against human TLR7 receptors expressed in a HEK-293 cell line is measured by (1) plating cells of the HEK-293 cell line stably expressing TLR7 in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at a density of 2.22X105 cells/ml into a 384-well plate and incubating for 2 days at 37°C, 5% C02; (2) adding the compound or pharmaceutically acceptable salt thereof and incubating the cells for 30 minutes; (3) adding CL097 (InvivoGen) at 3ug/ml and incubating the cells for approximately 20 hours; and (4) quantifying NF-kappaB dependent reporter activation by measuring luminescence.
20. A method for treatment of a systematic lupus erythematosus, cutaneous lupus, neuropsychiatric lupus, or lupus, comprising administering a pharmaceutically effective amount of a compound or pharmaceutically acceptable salt of any one of claims 1-10.
21. The method of claim 20, wherein said compound is administered as a
pharmaceutically acceptable salt.
PCT/US2014/060418 2013-10-14 2014-10-14 Selectively substituted quinoline compounds WO2015057659A1 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
CN201910424442.1A CN110105346B (en) 2013-10-14 2014-10-14 Optionally substituted quinoline compounds
DK14790937.8T DK3057964T3 (en) 2013-10-14 2014-10-14 SELECTIVELY SUBSTITUTED QUINOL COMPOUNDS
EP19194302.6A EP3626717A1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
KR1020187002263A KR102103256B1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
MX2016004632A MX364657B (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds.
PL14790937T PL3057964T3 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
NZ720129A NZ720129B2 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
EP21193428.6A EP3995495A1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
CA2927510A CA2927510C (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
KR1020167012593A KR101823488B1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
LTEP14790937.8T LT3057964T (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
MDA20160052A MD4635C1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
MYPI2016000624A MY192489A (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
CN201480066535.7A CN106414432B (en) 2013-10-14 2014-10-14 The quinoline compound selectively replaced
RU2016118619A RU2679622C2 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
SI201431479T SI3057964T1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
MA39034A MA39034B1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
EP14790937.8A EP3057964B1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
UAA201605195A UA120039C2 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
ES14790937T ES2773303T3 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
BR112016008359-8A BR112016008359B1 (en) 2013-10-14 2014-10-14 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS, A PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS AND USES THEREOF TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, CUTANEOUS LUPUS, NEUROPSICHIATRIC LUPUS OR LUPUS
SG11201602818TA SG11201602818TA (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
RS20200164A RS59911B1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
JP2016523329A JP6223563B2 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
AU2014334554A AU2014334554B2 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds
ZA2016/01882A ZA201601882B (en) 2013-10-14 2016-03-17 Selectively substituted quinoline compounds
PH12016500642A PH12016500642A1 (en) 2013-10-14 2016-04-07 Selective substituted quinoline compounds
IL245131A IL245131B (en) 2013-10-14 2016-04-14 Selectively substituted quinoline compounds
HK16111184.5A HK1223092A1 (en) 2013-10-14 2016-09-23 Selectively substituted quinoline compounds
IL26297018A IL262970B (en) 2013-10-14 2018-11-13 Selectively substituted quinoline compounds
AU2018264036A AU2018264036B2 (en) 2013-10-14 2018-11-14 Selectively substituted quinoline compounds
HRP20200147TT HRP20200147T1 (en) 2013-10-14 2020-01-30 Selectively substituted quinoline compounds
CY20201100129T CY1122776T1 (en) 2013-10-14 2020-02-12 OPTIONALLY SUBSTITUTED QUINOLINE COMPOUNDS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890718P 2013-10-14 2013-10-14
US61/890,718 2013-10-14

Publications (1)

Publication Number Publication Date
WO2015057659A1 true WO2015057659A1 (en) 2015-04-23

Family

ID=51842881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/060418 WO2015057659A1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds

Country Status (35)

Country Link
US (5) US9428495B2 (en)
EP (3) EP3057964B1 (en)
JP (3) JP6223563B2 (en)
KR (2) KR102103256B1 (en)
CN (2) CN110105346B (en)
AR (1) AR098014A1 (en)
AU (2) AU2014334554B2 (en)
BR (1) BR112016008359B1 (en)
CA (1) CA2927510C (en)
CL (1) CL2016000662A1 (en)
CY (1) CY1122776T1 (en)
DK (1) DK3057964T3 (en)
ES (1) ES2773303T3 (en)
HK (1) HK1223092A1 (en)
HR (1) HRP20200147T1 (en)
HU (1) HUE048706T2 (en)
IL (2) IL245131B (en)
JO (1) JO3554B1 (en)
LT (1) LT3057964T (en)
MA (1) MA39034B1 (en)
MD (1) MD4635C1 (en)
MX (2) MX364657B (en)
MY (1) MY192489A (en)
PE (1) PE20160608A1 (en)
PH (1) PH12016500642A1 (en)
PL (1) PL3057964T3 (en)
PT (1) PT3057964T (en)
RS (1) RS59911B1 (en)
RU (1) RU2679622C2 (en)
SG (3) SG11201602818TA (en)
SI (1) SI3057964T1 (en)
TW (2) TWI702218B (en)
UA (1) UA120039C2 (en)
WO (1) WO2015057659A1 (en)
ZA (4) ZA201601882B (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
WO2017106607A1 (en) * 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
CN108101860A (en) * 2018-02-08 2018-06-01 苏州敬业医药化工有限公司 The preparation method of cis -2,6- thebaines
US10087174B2 (en) 2013-10-14 2018-10-02 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
WO2019018354A1 (en) * 2017-07-18 2019-01-24 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
CN109563075A (en) * 2016-08-08 2019-04-02 默克专利股份公司 TLR7/8 antagonist and application thereof
KR20190045301A (en) * 2016-09-09 2019-05-02 브리스톨-마이어스 스큅 컴퍼니 Pyridyl substituted indole compounds
WO2019125849A1 (en) * 2017-12-19 2019-06-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020048595A1 (en) * 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel cyclic amidine compounds for the treatment of autoimmune disease
WO2020052738A1 (en) * 2018-09-11 2020-03-19 F. Hoffmann-La Roche Ag Pyrazolopyridine amine compounds for the treatment of autoimmune disease
WO2020064792A1 (en) * 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021099406A1 (en) * 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11220502B2 (en) 2018-02-12 2022-01-11 Hoffmann-La Roche, Inc. Sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
RU2783748C2 (en) * 2015-12-17 2022-11-16 Мерк Патент Гмбх Polycyclic antagonists of tlr7/8 and their use in treatment of immune disorders
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2794571T3 (en) * 2011-12-22 2017-02-06 Merck Patent Gmbh NEW HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
DK3510033T3 (en) * 2016-09-09 2022-02-28 Novartis Ag COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
ES2921020T3 (en) 2017-08-04 2022-08-16 Bristol Myers Squibb Co [1,2,4]triazolo[4,3-a]pyridinyl-substituted indole compounds
CN110997656B (en) 2017-08-04 2023-04-14 百时美施贵宝公司 Substituted indole compounds useful as TLR7/8/9 inhibitors
CN117659025A (en) * 2017-10-30 2024-03-08 科罗拉多州立大学董事会法人团体 TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof
KR20200086709A (en) 2017-11-14 2020-07-17 브리스톨-마이어스 스큅 컴퍼니 Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
HUE064473T2 (en) 2017-12-18 2024-03-28 Bristol Myers Squibb Co 4-azaindole compounds
JP7304352B2 (en) 2017-12-19 2023-07-06 ブリストル－マイヤーズ スクイブ カンパニー 6-azaindole compound
ES2922174T3 (en) 2017-12-19 2022-09-09 Bristol Myers Squibb Co Amide Substituted Indole Compounds Useful as TLR Inhibitors
CN111491930B (en) 2017-12-19 2023-09-26 百时美施贵宝公司 Substituted Indole Compounds Useful as TLR Inhibitors
US11299501B2 (en) 2017-12-20 2022-04-12 Bristol-Myers Squibb Company Diazaindole compounds
EA202091479A1 (en) 2017-12-20 2020-11-24 Бристол-Маерс Сквибб Компани ARYL- AND HETEROARYL-SUBSTITUTED INDOL COMPOUNDS
EA202091480A1 (en) 2017-12-20 2020-11-06 Бристол-Маерс Сквибб Компани AMINOINDOL COMPOUNDS SUITABLE AS TLR INHIBITORS
CN112119072A (en) 2018-03-20 2020-12-22 普莱希科公司 Compounds and methods for IDO and TDO modulation, and indications thereof
US20210371432A1 (en) * 2018-06-05 2021-12-02 Hoffmann-La Roche Inc. Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline Compounds for the Treatment of Autoimmune Disease
WO2019235553A1 (en) * 2018-06-07 2019-12-12 第一三共株式会社 Azetidine derivative, and prodrug thereof
US20210269451A1 (en) * 2018-06-13 2021-09-02 Hoffmann-La Roche Inc. Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
CA3103987C (en) * 2018-07-06 2023-08-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN112654620B (en) * 2018-09-06 2023-08-04 豪夫迈·罗氏有限公司 Novel pyrazolopyridine compounds for the treatment of autoimmune diseases
US20210253575A1 (en) * 2018-09-07 2021-08-19 Hoffmann-La Roche Inc. Pyrrolidine amine compounds for the treatment of autoimmune disease
EP3623369B1 (en) 2018-09-12 2023-10-25 F. Hoffmann-La Roche AG Novel morpholinyl amine compounds for the treatment of autoimmune disease
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
WO2020094749A1 (en) 2018-11-09 2020-05-14 F. Hoffmann-La Roche Ag 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
JP2022546863A (en) 2019-09-10 2022-11-09 エフ．ホフマン－ラ ロシュ アーゲー Novel quinoline compounds for the treatment of autoimmune diseases
CA3155290A1 (en) * 2019-09-23 2021-04-01 Accutar Biotechnology Inc. Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
EP4061816A1 (en) * 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
CN114667286A (en) * 2019-11-19 2022-06-24 豪夫迈·罗氏有限公司 Triazatricycles for the treatment of autoimmune diseases
WO2021112251A1 (en) * 2019-12-06 2021-06-10 第一三共株式会社 Azetidine sulfonamide compound
KR20240019340A (en) * 2021-06-11 2024-02-14 뉴로내슨트, 아이엔씨. Methods and compositions for lipid preparations of lipophilic small molecule therapy of heterocyclic type

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO156828C (en) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd ANALOGY PROCEDURE FOR THE PREPARATION OF ANTIBACTERYLY EFFECTIVE BENZOHETEROCYCLIC COMPOUNDS.
JPS5890511A (en) 1981-11-25 1983-05-30 Otsuka Pharmaceut Co Ltd Antibacterial agent
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
JPS6354363A (en) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd Quinoline derivative
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JPH08295690A (en) 1995-04-26 1996-11-12 Tokuyama Corp Chromene compound
PL329922A1 (en) * 1996-05-20 1999-04-26 Darwin Discovery Ltd Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
US6297283B1 (en) 1996-10-11 2001-10-02 Kowa Co., Ltd. Diamide compounds and compositions containing the same
DE19643048A1 (en) 1996-10-18 1998-04-23 Daimler Benz Ag Compounds and their use as well as processes for the production of liquid crystalline polymers therefrom
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2267484C2 (en) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Derivatives of diarylic acid and pharmaceutical composition based on thereof
DE60027420T2 (en) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS
DE19936437A1 (en) 1999-08-03 2001-02-08 Aventis Cropscience Gmbh Combinations of herbicides and safeners
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
CN1420881A (en) 2000-03-17 2003-05-28 布里斯托尔-迈尔斯斯奎布药品公司 Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha
JP2003528072A (en) 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
WO2002018335A1 (en) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Cyclic amine derivatives
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ES2302106T3 (en) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. PROCEDURE FOR PREPARATION OF BENCIMIDAZOL-2-IL QUINOLINE DERIVATIVES.
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
RU2003130752A (en) 2001-03-19 2005-03-10 Ниппон Синяку Ко., Лтд. (Jp) ANTIPROSIONAL AGENTS
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
DE10222166A1 (en) 2002-05-20 2003-12-11 Fraunhofer Ges Forschung New chiral compounds, used in liquid crystal functional layer for electrooptical display or for producing color or polarization filter layer, have at least 2 chiral groups, each with 1,3-dioxolane ring with at least 2 chirality centers
DE10229070A1 (en) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenyl derivatives 5
WO2004024693A1 (en) 2002-08-13 2004-03-25 Shionogi & Co., Ltd. Heterocyclic compound having hiv integrase inhibitory activity
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7041693B2 (en) 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
WO2004032846A2 (en) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
GB2396154B (en) 2002-10-15 2007-02-28 Merck Patent Gmbh 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices
KR20050109505A (en) 2003-02-22 2005-11-21 메르크 파텐트 게엠베하 Cyanopyridone derivatives as liquid crystals
US8013156B2 (en) 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
AU2004225965A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
JP2006526669A (en) 2003-04-01 2006-11-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Polymerizable chiral compounds
ZA200510028B (en) * 2003-06-20 2007-03-28 Coley Pharm Gmbh Small molicule toll-like receptor (TLR) antagonists
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
US7211671B2 (en) 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
JP2005132834A (en) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd Quinoline derivative
CN1291977C (en) * 2003-10-20 2006-12-27 复旦大学 Polysubstituted quinazine derivative funcional material, and preparing method and thereof
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050209247A1 (en) 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
KR101104100B1 (en) 2003-11-19 2012-01-12 제이엔씨 석유 화학 주식회사 Photopolymerizable liquid crystal composition, its polymer or polymer composition, and optical compensation element
BRPI0506881A (en) 2004-02-04 2007-06-26 Neurosearch As diazabicyclically arila derivative, pharmaceutical composition, use of a diazabicyclically arila derivative, and, method of treatment, prevention or alleviation of a disease or disorder or condition of a living animal body
US20070185178A1 (en) 2004-02-18 2007-08-09 Aatrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
RU2377988C2 (en) 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Modulation of inflammatory and metastatic processes
WO2005087217A1 (en) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
JPWO2005108370A1 (en) 2004-04-16 2008-03-21 味の素株式会社 Benzene compounds
CN101248069A (en) 2004-05-17 2008-08-20 阿卡蒂亚药品公司 Androgen receptor modulators and method of treating disease using the same
US20070004679A1 (en) 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
DE102004039789A1 (en) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006068594A1 (en) 2004-12-21 2006-06-29 Astrazeneca Ab HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7312181B2 (en) 2005-04-08 2007-12-25 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
AU2006266445B2 (en) 2005-06-30 2011-10-27 Bionumerik Pharmaceuticals, Inc. Monoimine ligand platinum analogs
JP2007045752A (en) 2005-08-10 2007-02-22 Takeda Chem Ind Ltd Five-membered aromatic heterocyclic derivative, its manufacturing method and use
JP2007131765A (en) 2005-11-11 2007-05-31 Fujifilm Corp Liquid crystalline composition
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
MX2009000310A (en) 2006-07-14 2009-01-26 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors.
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1900731A1 (en) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
CA2680761A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
DE102007015169A1 (en) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
ES2470341T3 (en) 2007-04-05 2014-06-23 Amgen, Inc Aurora kinase modulators and method of use
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
EP2170058B1 (en) 2007-06-20 2013-07-03 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
EP2170059B1 (en) 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
JP5057056B2 (en) 2007-08-03 2012-10-24 Ｊｓｒ株式会社 Liquid crystal aligning agent, method for producing liquid crystal aligning film, polyamic acid, polyimide and diamine compound
CN101910164A (en) 2007-10-29 2010-12-08 先灵公司 Diamido thiazole derivatives as protein kinase inhibitors
JP2009108152A (en) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd Polymerizable compound and optical film
CN101440062B (en) 2007-11-23 2011-09-28 齐齐哈尔大学 Synthesis of N-acyl-8-amino quinoline derivatives and use thereof as fluorescent molecular probe
JP2009149754A (en) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd Polymerizable compound and optical film produced by polymerizing the polymerizable compound
JP2011514898A (en) 2008-03-07 2011-05-12 エフ．ホフマン−ラ ロシュ アーゲー 2-Aminoquinoline derivative
JP5219583B2 (en) 2008-03-31 2013-06-26 住友化学株式会社 Composition, optical film and method for producing the same, optical member and display device
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009137081A2 (en) 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
WO2009139438A1 (en) 2008-05-15 2009-11-19 田辺三菱製薬株式会社 Process for production of optically active carboxylic acid
WO2009152025A1 (en) 2008-06-11 2009-12-17 Merck & Co., Inc. Imidazole derivatives useful as inhibitors of faah
EP2299824B1 (en) 2008-06-11 2013-06-19 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of faah
BRPI0915205A2 (en) 2008-06-11 2017-03-21 Dana Farber Cancer Inst Inc compounds and compositions useful for treating malaria
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
CA2728118C (en) 2008-06-16 2018-01-16 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
CN102171196B (en) 2008-08-04 2015-03-25 默沙东公司 Azole derivatives as inhibitors of fatty acid amide hydrolase
AR073010A1 (en) 2008-08-12 2010-10-06 Takeda Pharmaceutical AMIDA COMPOUND WITH GPR52 AGONIST ACTIVITY
JP5443720B2 (en) 2008-09-05 2014-03-19 住友化学株式会社 Composition, optical film and method for producing the same, optical member, and display device
JP2010066630A (en) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd Method for manufacturing optical film, and optical film
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR073920A1 (en) 2008-10-23 2010-12-09 Boehringer Ingelheim Int UREA DERIVATIVES OF SUBSTITUTED NORTROPANS, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE 11BETA-HYDROXIESTEROID DISHYDROGENASE DISEASE AND PROCESS FOR PREPARATION.
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
AU2009322342A1 (en) 2008-12-05 2011-06-30 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
MX2011006332A (en) 2008-12-23 2011-06-27 Abbott Lab Anti-viral compounds.
CN101759683B (en) 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 Preparation method of hydrindene amide compound, medical composition comprising hydrindene amide compound and application thereof as protein kinase inhibitor
EP2398771B1 (en) 2009-02-18 2015-07-29 Boehringer Ingelheim International GmbH Heterocyclic compounds which modulate the cb2 receptor
TWI482769B (en) 2009-03-16 2015-05-01 Sumitomo Chemical Co Compound, optical film and method for making an optical film
JP5899607B2 (en) 2009-03-16 2016-04-06 住友化学株式会社 Compound, optical film and method for producing optical film
JP2011008205A (en) 2009-05-27 2011-01-13 Fujifilm Corp Composition for producing biaxial optical anisotropic film
JP2011006360A (en) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd Compound, optical film and method for producing optical film
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
KR20120055608A (en) 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 Novel bicyclic urea compounds
JP2011042606A (en) 2009-08-20 2011-03-03 Sumitomo Chemical Co Ltd Compound, optical film and process for producing optical film
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
JP2013503163A (en) 2009-08-31 2013-01-31 持田製薬株式会社 Morpholinone compounds as factor IXa inhibitors
NZ626650A (en) 2009-09-09 2015-12-24 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
KR20120078715A (en) 2009-09-10 2012-07-10 노파르티스 아게 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
KR101746250B1 (en) 2009-12-01 2017-06-12 스미또모 가가꾸 가부시키가이샤 Process for preparation of cycloalkanedicarboxylic acid monoesters
AU2010330862B2 (en) 2009-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc Compounds and methods
RU2012136624A (en) 2010-01-28 2014-03-10 Мерк Шарп Энд Домэ Корп. PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER INDICATIONS
KR20130029368A (en) 2010-02-11 2013-03-22 벤더르빌트 유니버시티 Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
KR20120130777A (en) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
JP5871897B2 (en) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridyltriazole
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2593102B1 (en) 2010-04-22 2017-06-07 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
EP2560636A4 (en) 2010-04-23 2013-11-27 Kineta Inc Anti-viral compounds
AU2011242688B2 (en) 2010-04-23 2015-01-22 Kineta, Inc. Anti-viral compounds
US20120142701A1 (en) 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
JP5652011B2 (en) 2010-06-10 2015-01-14 住友化学株式会社 Optical film
US20130116231A1 (en) 2010-07-12 2013-05-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2609092B1 (en) 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US9006187B2 (en) 2010-09-10 2015-04-14 Green Cross Corporation Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP2014505041A (en) 2010-12-23 2014-02-27 ソルヴェイ（ソシエテ アノニム） Preparation of fac isomer of tris homoleptic metal complex
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
JP6088443B2 (en) 2011-03-14 2017-03-01 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Morpholine-spirocyclic piperidine amides as modulators of ion channels
CN102675289B (en) 2011-03-18 2014-11-05 浙江大德药业集团有限公司 Novel N-phenyl benzamide derivative serving as protein kinase inhibitor
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
TW201311149A (en) 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha Pesticide
ES2698847T3 (en) 2011-07-07 2019-02-06 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
JP2014527981A (en) 2011-09-23 2014-10-23 アドヴィナス・セラピューティックス・リミテッド Amide compound, composition and use thereof
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
RU2671496C2 (en) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. 5-piperidin-8-cyanochinoline derivatives
PE20160608A1 (en) * 2013-10-14 2016-07-08 Eisai Randd Man Co Ltd SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Pharmaceutical Technology", 1988, MARCEL DEK ER
"Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
BANCHEREAU, J.; V. PASCUAL: "Type I interferon in systemic lupus erythematosus and other autoimmune diseases", IMMUNITY, vol. 25, no. 3, 2006, pages 383 - 92
CASANOVA, J.L.; L. ABEL; L. QUINTANA-MURCI: "Human TLRs and IL-lRs in Host Defense: Natural Insights fi om Evolutionary, Epidemiological, and Clinical Genetics", ANNU REV IMMUNOL, 2010
COSTEDOAT-CHALUMEAU N ET AL: "Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 77, no. 1, 1 January 2010 (2010-01-01), pages 4 - 5, XP026832816, ISSN: 1297-319X, [retrieved on 20100101] *
COSTEDOAT-CHALUMEAU, N. ET AL.: "Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus", ARTHRITIS RHEUM, vol. 54, no. 10, 2006, pages 3284 - 90
DEANE, J.A. ET AL.: "Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation", IMMUNITY, vol. 27, no. 5, 2007, pages 801 - 10
DENG, Y. ET AL.: "Micro NA-3 4 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus", PLOS GENETICS, 2013, pages E1003336
FAIRHURST, A.M. ET AL.: "Yaa autoimmune phenotypes are conferred by overexpression of TLR7", EUR J IMMUNOL, vol. 38, no. 7, 2008, pages 1971 - 8
FR6D6RIERIC DE MONTIGNY; GILLES ARGOUARCH; CLAUDE LAPINTE, SYNTHESIS, 2006, pages 293
GORDEN, K.B. ET AL.: "Synthetic TLR agonists reveal functional differences between human TLR7 and TLRB", J IMMUNOL, vol. 174, no. 3, 2005, pages 1259 - 68
HOLM, S.: "A simple sequentially rejective multiple test procedure", SCANDINAVIAN JOURNAL OF STATISTICS, vol. 6, no. 2, 1979, pages 65 - 70
KIROU, K.A. ET AL.: "Activation of the inter/eron-alpha at way identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease", ARTHRITIS RHEUM, vol. 52, no. 5, 2005, pages 1491 - 503
KONO, H.; K.L. ROCK: "How dying cells alert the immune system to danger", NAT REV IMMUNOL, vol. 8, no. 4, 2008, pages 279 - 89
LAFYATIS, R.; M. YORK; A. MARSHAK-ROTHSTEIN: "Antimalarial agents: closing the gate on Toll-like receptors?", ARTHRITIS RHEUM, vol. 54, no. 10, 2006, pages 3068 - 70
MEANS, T.K. ET AL.: "Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9", J CLIN INVEST, vol. 115, no. 2, 2005, pages 407 - 17
NICKERSON, K.M. ET AL.: "TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus", J IMMUNOL, vol. 184, no. 4, 2010, pages 1840 - 8
SAVARESE, E. ET AL.: "Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis", ARTHRITIS RHEUM, vol. 58, no. 4, 2008, pages 1107 - 15
SAVARESE, E. ET AL.: "Ul small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7", BLOOD, vol. 107, no. 8, 2006, pages 3229 - 34
SHEN, N. ET AL.: "Sexspecific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus", PROC NATL ACAD SCI U S A, vol. 107, no. 36, 2010, pages 15838 - 43
TSUZUKI, TETRAHEDRON ASYMMETRY, vol. 12, 2001, pages 29891
VOLLMER, J. ET AL.: "Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8", J EXP MED, vol. 202, no. 11, 2005, pages 1575 - 85

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087174B2 (en) 2013-10-14 2018-10-02 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
USRE47193E1 (en) 2013-10-14 2019-01-08 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
TWI736566B (en) * 2015-12-17 2021-08-21 德商默克專利有限公司 Tlr7/8 antagonists and uses thereof
CN108699032B (en) * 2015-12-17 2022-07-22 默克专利有限公司 Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders
JP2018537501A (en) * 2015-12-17 2018-12-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Polycyclic TLR7 / 8 antagonists and their use in the treatment of immune disorders
EP3889146A1 (en) * 2015-12-17 2021-10-06 Merck Patent GmbH Polyheterocyclic tlr7/8 antagonists and their uses for treating immune disorders
EP3889145A1 (en) * 2015-12-17 2021-10-06 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
WO2017106607A1 (en) * 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
US10947213B1 (en) 2015-12-17 2021-03-16 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN108699032A (en) * 2015-12-17 2018-10-23 默克专利有限公司 Polycyclic TLR7/8 antagonists and its purposes in treating immune disorder
CN113603675A (en) * 2015-12-17 2021-11-05 默克专利有限公司 Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders
RU2783748C2 (en) * 2015-12-17 2022-11-16 Мерк Патент Гмбх Polycyclic antagonists of tlr7/8 and their use in treatment of immune disorders
US10399957B2 (en) 2015-12-17 2019-09-03 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
US10696649B2 (en) 2015-12-17 2020-06-30 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
US11629134B2 (en) 2015-12-17 2023-04-18 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
TWI804003B (en) * 2015-12-17 2023-06-01 德商默克專利有限公司 Tlr7/8 antagonists and uses thereof
AU2021218041B2 (en) * 2015-12-17 2023-10-05 Merck Patent Gmbh Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
US10544122B2 (en) 2015-12-17 2020-01-28 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN109563075B (en) * 2016-08-08 2022-09-30 默克专利股份公司 TLR7/8 antagonists and uses thereof
US11512069B2 (en) 2016-08-08 2022-11-29 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN109563075A (en) * 2016-08-08 2019-04-02 默克专利股份公司 TLR7/8 antagonist and application thereof
JP7028861B2 (en) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー Indole compound with pyridyl substitution
KR20190045301A (en) * 2016-09-09 2019-05-02 브리스톨-마이어스 스큅 컴퍼니 Pyridyl substituted indole compounds
CN109923108B (en) * 2016-09-09 2022-04-29 百时美施贵宝公司 Pyridyl-substituted indole compounds
CN109923108A (en) * 2016-09-09 2019-06-21 百时美施贵宝公司 The benzazolyl compounds that pyridyl group replaces
KR102519535B1 (en) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 Pyridyl substituted indole compounds
JP2019530667A (en) * 2016-09-09 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Pyridyl-substituted indole compounds
US11274285B2 (en) 2016-10-14 2022-03-15 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
IL272016B (en) * 2017-07-18 2022-10-01 Merck Patent Gmbh Pyrrolidine derivatives and their use as tlr7/8 antagonists
EP4248968A3 (en) * 2017-07-18 2023-12-06 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
WO2019018354A1 (en) * 2017-07-18 2019-01-24 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US10793553B2 (en) 2017-07-18 2020-10-06 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
IL272016B2 (en) * 2017-07-18 2023-02-01 Merck Patent Gmbh Pyrrolidine derivatives and their use as tlr7/8 antagonists
US10836750B1 (en) 2017-07-18 2020-11-17 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
WO2019125849A1 (en) * 2017-12-19 2019-06-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN108101860A (en) * 2018-02-08 2018-06-01 苏州敬业医药化工有限公司 The preparation method of cis -2,6- thebaines
US11220502B2 (en) 2018-02-12 2022-01-11 Hoffmann-La Roche, Inc. Sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11788077B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
WO2020048595A1 (en) * 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel cyclic amidine compounds for the treatment of autoimmune disease
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
WO2020052738A1 (en) * 2018-09-11 2020-03-19 F. Hoffmann-La Roche Ag Pyrazolopyridine amine compounds for the treatment of autoimmune disease
US20210395239A1 (en) * 2018-09-27 2021-12-23 Hoffmann-La Roche Inc. Heterocyclyl compounds for the treatment of autoimmune disease
WO2020064792A1 (en) * 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease
EP4371987A1 (en) 2018-10-31 2024-05-22 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
CN114728988A (en) * 2019-11-20 2022-07-08 豪夫迈·罗氏有限公司 Spiro (isobenzofuran azetidine) compounds for the treatment of autoimmune diseases
WO2021099406A1 (en) * 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds

Also Published As

Publication number Publication date
SG11201602818TA (en) 2016-05-30
IL245131B (en) 2018-11-29
SG10202103278TA (en) 2021-04-29
MD20160052A2 (en) 2016-09-30
RU2679622C2 (en) 2019-02-12
JP6420878B2 (en) 2018-11-07
TWI702218B (en) 2020-08-21
ZA201905393B (en) 2020-11-25
UA120039C2 (en) 2019-09-25
CA2927510C (en) 2022-03-01
KR20160068949A (en) 2016-06-15
LT3057964T (en) 2020-02-25
CN110105346A (en) 2019-08-09
US20180030045A1 (en) 2018-02-01
CY1122776T1 (en) 2021-05-05
EP3057964B1 (en) 2019-12-04
JP2016535003A (en) 2016-11-10
PL3057964T3 (en) 2020-05-18
MD4635C1 (en) 2020-01-31
SI3057964T1 (en) 2020-03-31
CL2016000662A1 (en) 2016-12-16
PH12016500642B1 (en) 2016-05-30
US9428495B2 (en) 2016-08-30
BR112016008359B1 (en) 2022-07-19
MX2019005192A (en) 2019-10-21
KR20180011874A (en) 2018-02-02
RS59911B1 (en) 2020-03-31
PE20160608A1 (en) 2016-07-08
CN110105346B (en) 2023-03-10
MX2016004632A (en) 2016-10-26
ES2773303T3 (en) 2020-07-10
MX364657B (en) 2019-05-03
AU2018264036B2 (en) 2020-07-16
RU2016118619A (en) 2017-11-22
TW201838988A (en) 2018-11-01
EP3995495A1 (en) 2022-05-11
MA39034A1 (en) 2018-01-31
JP2019023220A (en) 2019-02-14
US20180354939A1 (en) 2018-12-13
CN106414432A (en) 2017-02-15
MY192489A (en) 2022-08-23
US20150105370A1 (en) 2015-04-16
HK1223092A1 (en) 2017-07-21
EP3626717A1 (en) 2020-03-25
SG10201704327RA (en) 2017-06-29
MD4635B1 (en) 2019-06-30
MA39034B1 (en) 2018-09-28
IL262970A (en) 2018-12-31
BR112016008359A2 (en) 2017-10-03
CN106414432B (en) 2019-06-14
JO3554B1 (en) 2020-07-05
AR098014A1 (en) 2016-04-27
IL245131A0 (en) 2016-06-30
PT3057964T (en) 2020-02-25
TWI624467B (en) 2018-05-21
DK3057964T3 (en) 2020-02-24
ZA201801112B (en) 2020-10-28
RU2016118619A3 (en) 2018-05-23
AU2014334554A1 (en) 2016-06-02
AU2018264036A1 (en) 2018-12-06
KR101823488B1 (en) 2018-01-30
USRE47193E1 (en) 2019-01-08
TW201602100A (en) 2016-01-16
NZ720129A (en) 2021-03-26
HUE048706T2 (en) 2020-08-28
ZA201601882B (en) 2019-09-25
HRP20200147T1 (en) 2020-05-01
AU2014334554B2 (en) 2018-12-06
ZA201608132B (en) 2019-01-30
US20160326161A1 (en) 2016-11-10
CA2927510A1 (en) 2015-04-23
US10087174B2 (en) 2018-10-02
IL262970B (en) 2019-10-31
JP6223563B2 (en) 2017-11-01
JP2017226700A (en) 2017-12-28
KR102103256B1 (en) 2020-04-23
PH12016500642A1 (en) 2016-05-30
JP6639607B2 (en) 2020-02-05
EP3057964A1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
USRE47193E1 (en) Selectively substituted quinoline compounds
AU2017204586B2 (en) Tetrahydropyrazolopyrimidine compounds
CA3098585A1 (en) Pyridazinones as parp7 inhibitors
KR20220109401A (en) Pyridazinone as a PARP7 inhibitor
KR20180094939A (en) Polycyclic TLR7 / 8 antagonists and their use in the treatment of immune disorders
JP2021527100A (en) Piridinyl heterocyclyl compounds for the treatment of autoimmune diseases
CA3204318A1 (en) N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
AU2019313199B2 (en) CDK8/19 inhibitors
TW202317106A (en) Substituted aminopyridine compounds as egfr inhibitors
JP2023502238A (en) Triazatricycle compounds for the treatment of autoimmune diseases
CA3176957A1 (en) Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
JP2023500639A (en) Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14790937

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 000393-2016

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 12016500642

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/004632

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2927510

Country of ref document: CA

Ref document number: 2016523329

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 245131

Country of ref document: IL

Ref document number: IDP00201602502

Country of ref document: ID

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016008359

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2014790937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014790937

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20160052

Country of ref document: MD

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A 2016 0052

Country of ref document: MD

ENP Entry into the national phase

Ref document number: 20167012593

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201605195

Country of ref document: UA

Ref document number: 16126159

Country of ref document: CO

Ref document number: 39034

Country of ref document: MA

ENP Entry into the national phase

Ref document number: 2016118619

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014334554

Country of ref document: AU

Date of ref document: 20141014

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016008359

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160414